5

May 2024 Volume 31
Editors:
Kaye Wilson & Ayeshah Khan
email: enquiry@pharmac.govt.nz
Telephone +64 4 460 4990
Level 9, 40 Mercer Street
PO Box 10 254 Wellington
Freenhone Information Line

Freephone Information Line 0800 66 00 50 (9am - 5pm weekdays)

Circulation

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month by subscribing at pharmac.govt.nz/subscribe.

Production

Typeset automatically from XML and TFX. XML version of the Schedule available from schedule.pharmac.govt.nz/pub/schedule

Programmers

Anrik Drenth

CC

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency

BY

ISSN 1179-3686 (i)

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/. Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

	Index	308
Section I	National Immunisation Schedule	294
Section D	Special Foods	271
Section C	Extemporaneous Compounds (ECPs)	268
	Various	265
	Sensory Organs	260
	Respiratory System & Allergies	249
	choology rigonio a minanocappicocanio	

Section A General Rules

Section B	Alimentary Tract & Metabolism	6
	Blood & Blood Forming Organs	36
	Cardiovascular System	46
	Dermatologicals	68
	Genito Urinary System	77
	Hormone Preparations – Systemic	84
	Infections – Agents For Systemic Use	95
	Musculoskeletal System	116
	Nervous System	123
	Oncology Agents & Immunosuppressants	153
	Respiratory System & Allergies	249
	Sensory Organs	260
	Various	265
Section C	Extemporaneous Compounds (ECPs)	268
Section D	Special Foods	271
Section I	National Immunisation Schedule	294

Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list.

Pharmac's role:

"to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided."

Pae Ora (Healthy Futures) Act 2022

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at https://pharmac.govt.nz/about.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in Health NZ Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in Health NZ Hospitals for which national prices have been negotiated by Pharmac.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to Health NZ Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements Pharmac has with the supplier and, for Pharmaceuticals used in Health NZ Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in Health NZ Hospitals. Section H lists the Pharmaceuticals that that can be used in Health NZ Hospitals and is a separate publication.


The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gram g	
kilogram kg	
international unit iu	

Abbreviations

Capsule Cream Device Dispersible Effervescent Emulsion	Amp Cap Crm Dev Disp Eff Emul EC
Enteric Coated	EC

microgram me	cg
milligramn	ng
millilitreı	ml

millimole	mmol
unit	u

Gelatinous	Gel	SolutionSoln
Granules	Gran	SuppositorySupp
Infusion	Inf	TabletTab
Injection	Inj	Tincture Tinc
Liquid	Liq	Trans Dermal Delivery
Long Acting	LA	SystemTDDS
Ointment	Oint	-
Sachet	Sach	

Read the General Rules : https://pharmac.govt.nz/section-a.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price)		Fully ubsidised	Brand or Generic
	\$	Per		Manufacturer
Antacids and Antiflatulents				
Antacids and Reflux Barrier Agents				
LGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg p sachet		30	1	Gaviscon Infant
ODIUM ALGINATE				
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80	60		
0 1 11	(13.61)			Gaviscon Extra Strength
 Oral liq 500 mg with sodium bicarbonate 267 mg and calcium 	n			Strength
carbonate 160 mg per 10 ml	1.50 (7.50)	500 ml		Acidex
Dhaan hata Dinding Aganta	(1.00)			
Phosphate Binding Agents				
LUMINIUM HYDROXIDE € Tab 600 mg		100	1	Alu-Tab
ALCIUM CARBONATE				
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement	39.00	500 ml	1	Roxane
	47.30	473 ml		Calcium carbonate PAI S29
Only when prescribed for patients unable to swallow calor inappropriate and the prescription is endorsed according Antidiarrhoeals	cium carbonate table		1	PAI S29
inappropriate and the prescription is endorsed according	cium carbonate table		1	PAI S29
inappropriate and the prescription is endorsed according Antidiarrhoeals	cium carbonate table		✔ ere calci	PAI 329 um carbonate tablets ar
inappropriate and the prescription is endorsed according Anticliarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a Tab 2 mg	cium carbonate table ly. a PSO 	ts or wh	✓ ere calci	PAI 529 um carbonate tablets ar Nodia
inappropriate and the prescription is endorsed according Antidiarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a Tab 2 mg	cium carbonate table ly. a PSO 	ts or wh	✓ ere calci	PAI 329 um carbonate tablets ar
inappropriate and the prescription is endorsed according Antidiarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a Cap 2 mg Rectal and Colonic Anti-inflammatories	cium carbonate table ly. a PSO 	ts or wh	✓ ere calci	PAI 529 um carbonate tablets ar Nodia
inappropriate and the prescription is endorsed according Antidiarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a Cap 2 mg Cap 2 mg Rectal and Colonic Anti-inflammatories UDESONIDE	a PSO 	ts or wh	✓ ere calci	PAI 529 um carbonate tablets ar Nodia
inappropriate and the prescription is endorsed according Antidiarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a Cap 2 mg Rectal and Colonic Anti-inflammatories	a PSO 	ts or wh	✓ ere calci	PAI 529 um carbonate tablets ar Nodia
inappropriate and the prescription is endorsed according Antidiarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a	cium carbonate table ily. a PSO 10.75 7.25	400 400 90	vere calci	PAI 529 um carbonate tablets ar Nodia <u>Diamide Relief</u> Budesonide Te Arai
inappropriate and the prescription is endorsed according Antidiarrhoeals Agents Which Reduce Motility OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a	cium carbonate table ily. a PSO 	400 400 90	vere calci	PAI 529 um carbonate tablets ar Nodia <u>Diamide Relief</u> Budesonide Te Arai

continued...

Subsidy	Full	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🖌	Manufacturer	

continued...

- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Initial application — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:

- 3.1 Diabetes; or
- 3.2 Cushingoid habitus; or
- 3.3 Osteoporosis where there is significant risk of fracture; or
- 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
- 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).
- Note: Indication marked with * is an unapproved indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

HYDROCORTISONE AGETATE			
Rectal foam 10%, CFC-Free (14 applications)		15 g OP	 Colifoam
HYDROCORTISONE ACETATE WITH PRAMOXINE HYDR	ROCHLORIDE		
Topical aerosol foam, 1% with pramoxine hydrochloride	e 1%26.55	10 g OP	Proctofoam S29
MESALAZINE			
Tab 400 mg		100	Asacol
Tab long-acting 500 mg		100	Pentasa
Tab 800 mg		90	Asacol
-			Asacol S29 S29
Modified release granules, 1 g	118.10	100 OP	Pentasa
Enema 1 g per 100 ml		7	Pentasa
Suppos 500 mg		20	Asacol
Suppos 1 g		28	 Pentasa

	Subsidy		Fully	
	(Manufacturer's Price) \$	Per	Subsidised	I Generic Manufacturer
OLSALAZINE				
Tab 500 mg	56.02	60	1	Atnahs Olsalazine S29
	93.37	100	1	Dipentum
Cap 250 mg		100		Dipentum
PREDNISOLONE SODIUM				
Rectal foam 20 mg per dose (14 applications)	74.10	1 OP		Essential
				Prednisolone S29
SODIUM CROMOGLICATE Cap 100 mg	112.25	100		Ralicrom
SULFASALAZINE	113.35	100	v	Railcroin
SULFASALAZINE ★ Tab 500 mg	16.52	100	1	Salazopyrin
* Tab EC 500 mg		100		Salazopyrin EN
Local preparations for Anal and Rectal Disorde	*0			
Local preparations for Anal and Rectal Disorde	15			
Antihaemorrhoidal Preparations				
LUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PI	ALATE AND CINCH	OCAI	NE	
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and				
cinchocaine hydrochloride 5 mg per g		30 g C	P 🗸	Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg	7 20	12	1	Ultraproct
HYDROCORTISONE WITH CINCHOCAINE		12	•	onapioer
Oint 5 mg with cinchocaine hydrochloride 5 mg per g		30 g O	P 🗸	Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		12	1	Proctosedyl
Management of Anal Fissures				
GLYCERYL TRINITRATE - Special Authority see SA1329 below	w – Retail pharmacy			
* Oint 0.2%		30 g O	P 🗸	Rectogesic
SA1329 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals vali		ewal u	nless notif	fied where the patient has
chronic anal fissure that has persisted for longer than three week	(S.			
Antispasmodics and Other Agents Altering Gui	t Motility			
GLYCOPYRRONIUM BROMIDE				
Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available or	na			
PSO		5	1	Robinul
HYOSCINE BUTYLBROMIDE				
* Tab 10 mg		100		Buscopan
Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	1.91	5	~	Spazmol
MEBEVERINE HYDROCHLORIDE	8 50	90	1	Colofac
		50	•	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antiulcerants				
Antisecretory and Cytoprotective				
MISOPROSTOL – Wastage claimable * Tab 200 mcg – Up to 120 tab available on a PSO	47.73	120	√ (Cytotec
Helicobacter Pylori Eradication				
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement a) Maximum of 28 tab per prescription b) Subsidised only if prescribed for helicobacter pylori en Note: the prescription is considered endorsed if clarit inhibitor and either amoxicillin or metronidazole.	radication and presc		is endorse	
H2 Antagonists				
FAMOTIDINE – Only on a prescription * Tab 20 mg	4.91	100	√ I	Famotidine Hovid ©29
* Tab 40 mg	10.32	100	√ i	Famotidine Hovid S29
Inj 10 mg per ml, 4 ml – Subsidy by endorsement Subsidy by endorsement – Subsidised for patients received		10 t of pa		Mylan ^{S29} Ə.
Proton Pump Inhibitors				
LANSOPRAZOLE * Cap 15 mg * Cap 30 mg OMEPRAZOLE For omeprazole suspension refer Standard Formulae, page 2	5.26	100 100	-	<u>Lanzol Relief</u> Lanzol Relief
Cap 10 mg	2.06	90	✓ <u>(</u>	<u>Omeprazole actavis</u> 10
Cap 20 mg	2.02	90	✓ <u>(</u>	Omeprazole actavis 20
Cap 40 mg	3.18	90	✓ <u>(</u>	<u>Omeprazole actavis</u> 40
 Powder – Only in combination Only in extemporaneously compounded omeprazole suspansion 		5 g	√ I	Midwest
 Inj 40 mg ampoule with diluent 		5	-	<u>Dr Reddy's</u> <u>Omeprazole</u> Dcicure s29
PANTOPRAZOLE * Tab EC 20 mg * Tab EC 40 mg		90 90		Panzop Relief Panzop Relief
Site Protective Agents				
COLLOIDAL BISMUTH SUBCITRATE Tab 120 mg	14.51	50	v (Gastrodenol S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
SUCRALFATE Tab 1 g		120		Carafate

Bile and Liver Therapy

⇒SA1461 Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

56

✓ Xifaxan

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Diabetes

Hyperglycaemic Agents

DIAZOXIDE - Special Authority see SA1320 below - Retail pl	harmacy		
Cap 25 mg		100	 Proglicem S29
Cap 100 mg		100	Proglicem S29
Oral liq 50 mg per ml	620.00	30 ml OP	 Proglycem S29
			e5 Pharma S29

⇒SA1320 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains

appropriate and the patient is benefiting from treatment.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit – Up to 5 kit available on a PSO	1	 Glucagen Hypokit
Insulin - Short-acting Preparations		
INSULIN NEUTRAL ▲ Inj human 100 u per ml25.26	10 ml OP	 ✓ Actrapid ✓ Humulin B
▲ Ini human 100 u per ml. 3 ml	5	 Actrapid Penfill

Insulin - Intermediate-acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE		
▲ Inj 100 iu per ml, 3 ml prefilled pen	5	 NovoMix 30 FlexPen
INSULIN ISOPHANE ▲ Inj human 100 u per ml17.68	10 ml OP	✓ Humulin NPH
,		 Protaphane
▲ Inj human 100 u per ml, 3 ml	5	 Humulin NPH
		 Protaphane Penfill

✓ Humulin R

	Cubaidu		Fully Brand ar
	Subsidy	() () () () () ()	Fully Brand or
	(Manufacturer's F \$	Price) Subs	sidised Generic Manufacturer
	ψ	Fei	
NSULIN ISOPHANE WITH INSULIN NEUTRAL			
Inj human with neutral insulin 100 u per ml		10 ml OP	 Humulin 30/70
] · · · · · · · · · · · · · · · · · · ·			 Mixtard 30
Inj human with neutral insulin 100 u per ml, 3 ml	12 66	5	✓ Humulin 30/70
	42.00	5	
			PenMix 30
			PenMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj lispro 25% with insulin lispro protamine 75% 100 u per n	nl		
3 ml		5	 Humalog Mix 25
		5	
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per n		_	• • • • • • • • • •
3 ml		5	 Humalog Mix 50
Insulin - Long-acting Preparations			
NSULIN GLARGINE			
Inj 100 u per ml, 10 ml	63.00	1	 Lantus
Inj 100 u per ml, 3 ml		5	✓ Lantus
Inj 100 u per ml, 3 ml disposable pen		5	✓ Lantus SoloStar
		5	
Insulin - Rapid Acting Preparations			
NSULIN ASPART			A N A N N
Inj 100 u per ml, 10 ml		1	 NovoRapid
Inj 100 u per ml, 3 ml		5	NovoRapid Penfill
Inj 100 u per ml, 3 ml syringe	51.19	5	NovoRapid FlexPen
NSULIN GLULISINE			
Inj 100 u per ml, 10 ml	27.02	1	🖌 Anidra
			✓ Apidra
Inj 100 u per ml, 3 ml		5	✓ Apidra
Inj 100 u per ml, 3 ml disposable pen		5	Apidra SoloStar
NSULIN LISPRO			
Inj 100 u per ml, 10 ml	34 92	10 ml OP	 Humalog
Inj 100 u per ml, 3 ml		5	✓ Humalog
		5	• Humaiog
Alpha Glucosidase Inhibitors			
CARBOSE			
	0.05	00	Accest
€ Tab 50 mg		90	✓ <u>Accarb</u>
F Tab 100 mg		90	Accarb
Oral Hypoglycaemic Agents			
LIBENCLAMIDE			
€ Tab 5 mg	7.50	100	Daonil
LICLAZIDE			
← Tab 80 mg	20.10	500	 Glizide
-	20.10		<u></u>
LIPIZIDE			
		100	Minidiab
🗧 Tab 5 mg	4.58		
-	4.58		
IETFORMIN HYDROCHLORIDE			 Metformin Viatris
Tab 5 mg IETFORMIN HYDROCHLORIDE Tab immediate-release 500 mg Tab immediate-release 850 mg	14.74	1,000 500	✓ <u>Metformin Viatris</u> ✓ Metformin Viatris

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	_	Subsidised	
	\$	Per		Manufacturer
PIOGLITAZONE				
* Tab 15 mg	6.80	90	✓	Vexazone
* Tab 30 mg	7.30	90		Vexazone
* Tab 45 mg		90	~	Vexazone
VILDAGLIPTIN				
Tab 50 mg		60	✓	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE				
Tab 50 mg with 1,000 mg metformin hydrochloride		60	✓	Galvumet
Tab 50 mg with 850 mg metformin hydrochloride		60	✓	Galvumet
GLP-1 Agonists				
DULAGLUTIDE - Special Authority see SA2338 below - Retai	l pharmacy			
Note: Not to be given in combination with a funded SGLT-2	2 inhibitor or other GLP	-1 ag	jonist.	
Inj 1.5mg per 0.5 ml prefilled pen		4	✓	Trulicity
► SA2338 Special Authority for Subsidy				
Note: Subsidy for patients with existing approvals prior to 1 Ma	y 2024. Approvals vali	d wit	hout furthe	r renewal unless notified.
No new patients will be granted from 1 May 2024 until further no				
LIRAGLUTIDE - Special Authority see SA2339 below - Retail	pharmacy			
a) Maximum of 9 inj per prescription				
b)				
a) Not to be given in combination with a funded SGL	T-2 inhibitor or other GI	_P-1	agonist.	
b) Maximum of 1 pack of 3 (6 mg per ml, 3 ml) prefille	ed pens will be funded	per n	nonth.	
Inj 6 mg per ml, 3 ml prefilled pen		3	✓	Victoza

⇒SA2339 Special Authority for Subsidy

Note: Subsidy for patients with existing approvals prior to 1 May 2024. Approvals valid without further renewal unless notified. No new patients will be granted from 1 May 2024 until further notice.

SGLT2 Inhibitors

⇒SA2068 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has previously received an initial approval for a GLP-1 agonist; or
- 2 All of the following:
 - 2.1 Patient has type 2 diabetes; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 2.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 2.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 2.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 2.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 2.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.

EMPAGLIFLOZIN - Special Authority see SA2068 on the previous page - Retail pharmacy

Note: Not to be given in combination with a funded GLP-1 agonisi	i.
 T 1 10	

*	Tab 10 mg	58.56	30	 Jardiance
*	Tab 25 mg	58.56	30	 Jardiance

EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE – Special Authority see SA2068 on the previous page – Retail pharmacy

	Note: Not to be given in combination with a funded GLP-1 ac	jonist.		
*	Tab 5 mg with 1,000 mg metformin hydrochloride		60	 Jardiamet
*	Tab 5 mg with 500 mg metformin hydrochloride		60	 Jardiamet
*	Tab 12.5 mg with 1,000 mg metformin hydrochloride		60	 Jardiamet
*	Tab 12.5 mg with 500 mg metformin hydrochloride		60	 Jardiamet

Diabetes Management

Ketone Testing

BLOOD KETONE DIAGNOSTIC TEST STRIP - Subsidy by endorsement

- a) Not on a BSO
- b) Maximum of 20 strip per prescription
- c) Up to 10 strip available on a PSO
- d) Patient has any of the following:
 - 1) type 1 diabetes; or
 - 2) permanent neonatal diabetes; or
 - 3) undergone a pancreatectomy; or
 - 4) cystic fibrosis-related diabetes; or

5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly.

Test strips......15.50

.15.50 10 strip OP

KetoSens

	Subsidy (Manufacturer's Price) \$		Fully lised	Brand or Generic Manufacturer
Dual Blood Glucose and Blood Ketone Testing				
 UAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A dual blood glucose and blood ketone diagnostic test m 1) type 1 diabetes; or 2) permanent neonatal diabetes; or 3) undergone a pancreatectomy; or 4) cystic fibrosis-related diabetes; or 5) metabolic disease or epilepsy under the care of a p The prescription must be endorsed accordingly. Only 1 	eter is subsidised for paediatrician, neurolog meter per patient will	a patient wh gist or metal be subsidise	no has: polic sp ed (no i	ecialist. 'epeat prescriptions). Fo
the avoidance of doubt patients who have previously rec funded CareSens meter.		, other than	Careo	ens, are eligible for a
Meter with 50 lancets, a lancing device and 10 blood glucos diagnostic test strips		1 OP	/ C:	areSens Dual
5		101	• •	
Blood Glucose Testing				
 LOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a is receiving insulin or sulphonylurea therapy; or is pregnant with diabetes; or is on home TPN at risk of hypoglycaemia or hyperg has a genetic or an acquired disorder of glucose he syndrome. The prescription must be endorsed accordingly. Only or prescriptions). Patients already using the CareSens N F meter, unless they have: 	patient who: Jlycaemia; or omeostasis, excluding ne CareSens meter pe	er patient wi	I be su	bsidised (no repeat

	Subsidy	<u> </u>	Fully	Brand or
	(Manufacturer's Pri \$	ce) Subs Per	idised	Generic Manufacturer
	et eveileble en e DO		-	
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 te The number of test strips available on a prescription is res)		
 Prescribed for a patient on insulin or a sulphonylurea 		rdinaly Phar	maciete	may annotate the
prescription as endorsed where there exists a record				
 Prescribed on the same prescription as insulin or a s endorsed; or 				
3) Prescribed for a pregnant woman with diabetes and				
Prescribed for a patient on home TPN at risk of hypo				
5) Prescribed for a patient with a genetic or an acquired		homeostasis	excludin	ng type 1 or type
2 diabetes and metabolic syndrome and endorsed ad	ccordingly.			
Test strips		50 test OP		reSens N reSens PRO
			• 04	
LOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED) The number of test strips available on a prescription is res	tricted to 50 unless:			
 Prescribed for a patient on insulin or a sulphonylurea 		rdingly. Phar	macists	may annotate the
prescription as endorsed where there exists a record				
 Prescribed on the same prescription as insulin or a s endorsed; or 	ulphonylurea in whic	h case the pr	escriptio	n is deemed to be
3) Prescribed for a pregnant woman with diabetes and	endorsed accordingl	y; or		
4) Prescribed for a patient on home TPN at risk of hypo				
5) Prescribed for a patient with a genetic or an acquired		homeostasis	excludin	ng type 1 or type
2 diabetes and metabolic syndrome and endorsed ad	coraingly.			
Blood glucose test strips		50 test OP	✔ Se	ensoCard
Insulin Syringes and Needles				
Subsidy is available for disposable insulin syringes, needles, a	nd pen needles if pre	escribed on th	ne same	form as the one used fo
he supply of insulin or liraglutide or when prescribed for a patie				
annotate the prescription as endorsed where there exists a rec	ord of prior dispensi	ng of insulin c	or liraglut	ide.
NSULIN PEN NEEDLES – Maximum of 200 dev per prescript	ion			
₭ 29 g × 12.7 mm		100		D Micro-Fine
₩ 31 g × 5 mm		100		D Micro-Fine
₩ 31 g × 6 mm	9.50	100	🗸 Be	erpu

100

100

- ✓ B-D Micro-Fine
 - ✓ B-D Micro-Fine

* 31 g × 8 mm 10.95

	Subsidy (Manufacturer's Price)	Der	Fully Subsidised	Generic			
	\$	Per	<i>.</i>	Manufacturer			
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 200 dev per prescription							
* Syringe 0.3 ml with 29 g × 12.7 mm needle		100	1	B-D Ultra Fine			
	1.36	10					
	(1.99)			B-D Ultra Fine			
* Syringe 0.3 ml with 31 g × 8 mm needle		100	1	B-D Ultra Fine II			
	1.30	10					
	(1.99)			B-D Ultra Fine II			
* Syringe 0.5 ml with 29 g x 12.7 mm needle		100	1	B-D Ultra Fine			
	1.36	10					
	(1.99)			B-D Ultra Fine			
* Syringe 0.5 ml with 31 g × 8 mm needle	()	100	1	B-D Ultra Fine II			
-, , , , , , , , , , , , , , , , , , ,	1.36	10					
	(1.99)			B-D Ultra Fine II			
* Syringe 1 ml with 29 g × 12.7 mm needle	· · /	100	1	B-D Ultra Fine			
	1.36	10					
	(1.99)			B-D Ultra Fine			
* Syringe 1 ml with 31 g × 8 mm needle	()	100	1	B-D Ultra Fine II			
	1.36	10					
	(1.99)	.0		B-D Ultra Fine II			
Insulin Pumps							

Insulin Pumps

INSULIN PUMP - Special Authority see SA1603 below - Retail pharmacy

a)	Maximum of 1 dev per prescription
b)	Only on a prescription

C)	Maximum of T insulin pump per patient each four yea	ar period.		
Mi	in basal rate 0.025 U/h		1	 MiniMed 770G
Mi	in basal rate 0.1 U/h		1	 Tandem t:slim
				X2 with Basal-IQ

⇒SA1603 Special Authority for Subsidy

data and a factor of the second

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes; and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and

.

- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Either:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

16

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 It has been at least 4 years since the last insulin pump received by the patient or, in the case of patients qualifying under previous pump therapy for the initial application; the pump is due for replacement; and

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	Ibsidised	Generic
\$	Per	1	Manufacturer

continued...

4 Either:

4.1 Applicant is a relevant specialist; or

4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and

8 Either:

- 8.1 Applicant is a relevant specialist; or
- 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or

Subsidy		Fully	Brand or	
(Manufacturer's Price	e)	Subsidised	Generic	
\$	Per	· · ·	Manufacturer	

continued...

9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 8.2 The pump is due for replacement; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol; and
- 2 The patient's HbA1c has not deteriorated more than 5 mmol/mol from the time of commencing pump treatment; and
- 3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and
- 4 Either:
 - 4.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 4.2 The pump is due for replacement; and
- 5 Either:
 - 5.1 Applicant is a relevant specialist; or
 - 5.2 Applicant is a nurse practitioner working within their vocational scope.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufact

ic Manufacturer

Insulin Pump Consumables

⇒SA1985 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes: and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Fither:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the followina:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 Either:
 - 3.1 Applicant is a relevant specialist; or
 - 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application - (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person): and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol: and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 8 Fither:
 - 8.1 Applicant is a relevant specialist: or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 2 vears for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events: and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Fither:
 - 3.1 Applicant is a relevant specialist; or

Subs	sidy	Fully	Brand or
(Manufactu	rer's Price) Subsid	lised	Generic
\$	B Per	1	Manufacturer

continued...

3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 Applicant is a relevant specialist; or
 - 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 Applicant is a relevant specialist; or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

20

1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully osidised	Brand or Generic Manufacturer
continued				
than 80 mmol/mol; and				
 2 The patient's HbA1c has not deteriorated more than 5 mm 3 The patient has not had an increase in severe unexplained 4 Either: 				ne; and
4.1 Applicant is a relevant specialist; or4.2 Applicant is a nurse practitioner working within their	r vocational scope.			
INSULIN PUMP CARTRIDGE – Special Authority see SA1985 o a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 packs of cartridge sets will be funded per Cartridge 300 U, t:lock × 10	year.	narmacy 1 OP	✓ т	andem Cartridge
INSULIN PUMP INFUSION SET (STEEL CANNULA) - Special	Authority see SA1988	5 on page	e 19 – Re	etail pharmacy
a) Maximum of 3 set per prescription	,	1.0		, ,
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.			<i>.</i>	
10 mm steel needle; 60 cm tubing × 10		1 OP	✓ N	IiniMed Sure-T MMT-884A
10 mm steel needle; 80 cm tubing × 10	130.00	1 OP	✓ N	/iniMed Sure-T MMT-886A
6 mm steel needle; 60 cm tubing × 10	130.00	1 OP	✓ N	/iniMed Sure-T MMT-864A
6 mm steel needle; 80 cm tubing × 10	130.00	1 OP	✓ N	/iniMed Sure-T MMT-866A
8 mm steel needle; 60 cm tubing × 10	130.00	1 OP	✓ N	/iniMed Sure-T MMT-874A
8 mm steel needle; 80 cm tubing × 10	130.00	1 OP	✓ N	/iniMed Sure-T MMT-876A
(MiniMed Sure-T MMT-884A 10 mm steel needle; 60 cm tubing ×	10 to be delisted 1	luly 2024)	
(MiniMed Sure-T MMT-886A 10 mm steel needle; 80 cm tubing ×	10 to be delisted 1	luly 2024 _,)	
INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT Retail pharmacy	INSERTION) – Spe	cial Auth	ority see	SA1985 on page 19 -
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm steel cannula; straight insertion; 80 cm line × 10 with 10 needles	130.00	1 OP	✓ т	ruSteel
8 mm steel cannula: straight insertion: 80 cm line x 10 with				

8 mm steel cannula; straight insertion; 80 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel
6 mm steel cannula; straight insertion; 60 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel
8 mm steel cannula; straight insertion; 60 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
NSULIN PUMP INFUSION SET (TEFLON CANNULA) – Spec a) Maximum of 3 set per prescription	cial Authority see SA19	85 on	page 19 -	- Retail pharmacy
 b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 10 mm toffice needle, 110 cm toffice u 10. 	100.00	1 OP		MiniMed Citherrothe
13 mm teflon needle, 110 cm tubing × 10	130.00	TOP	v	MiniMed Silhouette MMT-382A
13 mm teflon needle, 45 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-368A
13 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	~	MiniMed Silhouette MMT-381A
13 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-383A
17 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-377A
17 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-378A
17 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MiniMed Silhouette MMT-384A
6 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-398A
6 mm teflon needle, 45 cm blue tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-941A
6 mm teflon needle, 45 cm pink tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-921A
6 mm teflon needle, 60 cm blue tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-943A
6 mm teflon needle, 60 cm pink tubing × 10	130.00	1 OP	1	MiniMed Mio MMT-923A
6 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MiniMed Quick-Set MMT-399A
6 mm teflon needle, 80 cm blue tubing	130.00	1 OP	1	MiniMed Mio MMT-945A
6 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	1	MiniMed Mio
6 mm teflon needle, 80 cm pink tubing × 10	130.00	1 OP	1	MMT-965A MiniMed Mio
6 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	1	MMT-925A MiniMed Quick-Set
9 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	1	MMT-387A MiniMed Quick-Set
9 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	1	MMT-396A MiniMed Quick-Set
9 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	1	MMT-397A MiniMed Mio MMT-975A

	Subsidy) Out	Fully Brand or
	(Manufacturer's Pri \$	ce) Subs Per	sidised Generic Manufacturer
9 mm teflon needle, 80 cm tubing × 10		1 OP	 MiniMed Quick-Set MMT-386A
(MiniMed Silhouette MMT-382A 13 mm teflon needle, 110 cm tubi	na x 10 to be de	listed 1 July 2	
(MiniMed Silhouette MMT-368A 13 mm teflon needle, 45 cm tubin			
(MiniMed Silhouette MMT-383A 13 mm teflon needle, 80 cm tubin			
MiniMed Silhouette MMT-384A 17 mm teflon needle, 80 cm tubin			
(MiniMed Quick-Set MMT-387A 6 mm teflon needle, 80 cm tubing			
MiniMed Quick-Set MMT-386A 9 mm teflon needle, 80 cm tubing			
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN SA1985 on page 19 – Retail pharmacy	SERTION WITH	INSERTION	DEVICE) - Special Authority see
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
13 mm teflon cannula; angle insertion; insertion device; 110 cr	m		
line × 10 with 10 needles		1 OP	 AutoSoft 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm			
line × 10 with 10 needles		1 OP	✓ AutoSoft 30
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT		-	
see SA1985 on page 19 – Retail pharmacy			ON DEVICE) - Special Authority
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
6 mm teflon cannula; straight insertion; insertion device;			
110 cm line × 10 with 10 needles	140.00	1 OP	✓ AutoSoft 90
		TOP	 Autosoft 90
6 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles		1.00	✓ AutoSoft 90
	140.00	1 OP	V AutoSoft 90
9 mm teflon cannula; straight insertion; insertion device;	140.00	1.00	Auto Coff 00
110 cm line × 10 with 10 needles		1 OP	 AutoSoft 90
9 mm teflon cannula; straight insertion; insertion device; 60 cm		4.00	(Auto 0 - # 00
line × 10 with 10 needles		1 OP	 AutoSoft 90
NSULIN PUMP RESERVOIR – Special Authority see SA1985 on	page 19 - Retai	l pharmacy	
 Maximum of 3 sets per prescription 			
 b) Only on a prescription 			
c) Maximum of 13 packs of reservoir sets will be funded per y	/ear.		
10 × luer lock conversion cartridges 1.8 ml for Paradigm pump	s50.00	1 OP	 ADR Cartridge 1.8
Cartridge for 7 series pump; 3.0 ml × 10	50.00	1 OP	 MiniMed
			3.0 Reservoir
			MMT-332A
Discritional Industrian Documents			
Digestives Including Enzymes			
PANCREATIC ENZYME			
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase			
10,000 Ph Eur U, total protease 600 Ph Eur U)	34 93	100	 Creon 10000
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase		100	
25,000 Ph Eur U, total protease 1,000 Ph Eur U)	04 28	100	 <u>Creon 25000</u>
		100	• <u>01601123000</u>
Modified release granules pancreatin 60.12 mg (amylase			
3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph	24.02	20 a OP	 Creon Micro
Eur U)		20 g OP	
URSODEOXYCHOLIC ACID - Special Authority see SA1739 on t			
Cap 250 mg		100	✓ Ursosan

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Si	Fully	Brand or
(Manufacturer's Price)		ubsidised	Generic
`\$´´	Per	1	Manufacturer

⇒SA1739 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln20.00	500 g OP	✓ Konsyl-D
Faecal Softeners		
DOCUSATE SODIUM - Only on a prescription * Tab 50 mg	100 100	✓ <u>Coloxyl</u> ✓ <u>Coloxyl</u>

24	🗸 fully subsidised
24	Principal Supply

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

	Subsidy		Fully Brand or
	(Manufacturer's Pr		idised Generic
	\$	Per	 Manufacturer
DOCUSATE SODIUM WITH SENNOSIDES			
Tab 50 mg with sennosides 8 mg	3.50	200	✓ Laxsol
POLOXAMER – Only on a prescription			
Not funded for use in the ear.			
* Oral drops 10%	4.17	30 ml OP	✓ Coloxyl
Opioid Receptor Antagonists - Peripheral			
	CO1 holew Det	il nhormoou	
METHYLNALTREXONE BROMIDE – Special Authority see SA1 Inj 12 mg per 0.6 ml vial			✓ Relistor
	246.00	7	 ✓ Relistor
	240.00	1	• Heliston
SA1691 Special Authority for Subsidy Initial application — (Opioid induced constipation) from any unless notified for applications meeting the following criteria: Both:	relevant practitior	ner. Approvals	s valid without further renewal
1 The patient is receiving palliative care; and 2 Either:			
2.1 Oral and rectal treatments for opioid induced cons	tination are ineffe	ctive: or	
2.1 Oral and rectal treatments for opioid induced cons 2.2 Oral and rectal treatments for opioid induced cons			ed.
	apadon are anabi		
Osmotic Laxatives			
GLYCEROL			
Suppos 2.8/4.0 g – Only on a prescription	10.39	20	 Lax-suppositories
			Glycerol
LACTULOSE – Only on a prescription			
* Oral liq 10 g per 15 ml	3.61	500 ml	✓ Laevolac
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BI	CARBONATE AN	ID SODIUM C	HLORIDE
Powder for oral soln 13.125 g with potassium chloride 46.6 n			-
sodium bicarbonate 178.5 mg and sodium chloride 350.		30	 Molaxole
SODIUM ACID PHOSPHATE – Only on a prescription			
Enema 16% with sodium phosphate 8%	2 50	1	 Fleet Phosphate
	2.00		Enema
		optintion	Enoma
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	• •	scription	
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml		50	Missiste
5 ml		50	Micolette
			✓ Micolette-S29 S29
(Micolette-S29 S29 Enema 90 mg with sodium lauryl sulphoace	tate 9 mg per ml,	5 ml to be del	isted 1 August 2024)
Stimulant Laxatives			
BISACODYL – Only on a prescription * Tab 5 mg	E 90	200	 Bisacodyl Viatris
		200 10	✓ Lax-Suppositories
		10	
SENNA – Only on a prescription	0.17	100	
* Tab, standardised		100	Constrat
	(8.21)	00	Senokot
	0.43	20	Senokot
	(2.06)		JEHUKUL

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		,	Brand or
	(Manufacturer's Price \$	e) Sub Per		Generic Manufacturer
ODIUM PICOSULFATE - Special Authority see SA2053 be				
Oral soln 7.5 mg per ml	7.40	30 ml OP	🗸 Du	Icolax SP Drop
SA2053 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals Both:	valid for 6 months for a	pplications	meeting th	ne following criteria:
 The patient is a child with problematic constipation de macrogol where practicable; and The patient would otherwise require a high-volume bo 				
tenewal from any relevant practitioner. Approvals valid for benefiting from treatment.	• • •			
Metabolic Disorder Agents				
LGLUCOSIDASE ALFA – Special Authority see SA1986 be	elow – Retail pharmacy			
Inj 50 mg vial	1,142.60	1	🖌 My	ozyme
SA1986 Special Authority for Subsidy				
nitial application only from a metabolic physician. Approva II of the following:	ils valid for 12 months fo	or application	ons meetir	ng the following criteria:
 The patient is aged up to 24 months at the time of initi and 	al application and has b	een diagno	osed with i	infantile Pompe disease
2 Any of the following:				
 Diagnosis confirmed by documented deficiency villus biopsies and/or cultured amniotic cells; or 		ase by prer	natal diagr	nosis using chorionic
2.2 Documented deficiency of acid alpha-glucoside		ccharide te	sting indic	ating a diagnostic
elevation of glucose tetrasaccharides; or 2.3 Documented deficiency of acid alpha-glucosid			enetic testi	ng indicating a
disease-causing mutation in the acid alpha-glu 2.4 Documented urinary tetrasaccharide testing in			lucose tet	rasaccharides, and
molecular genetic testing indicating a disease-	causing mutation in the	GAA gene	; and	
 Patient has not required long-term invasive ventilation (ERT); and 	for respiratory failure p	rior to start	ing enzym	e replacement therapy
4 Patient does not have another life-threatening or seve or might be reasonably expected to compromise a res	ponse to ERT; and	-	-	be influenced by ERT
5 Alglucosidase alfa to be administered at doses no gre tenewal only from a metabolic physician. Approvals valid for				owing criteria:
Il of the following:			ing the foll	owing chicha.
1 The treatment remains appropriate for the patient and				
 2 Alglucosidase alfa to be administered at doses no gre 3 Patient has not had severe infusion-related adverse re 				opriate pre-medication
and/or adjustment of infusion rates; and	eactions which were not	preventab	ie by appi	ophate pre-medication
4 Patient has not developed another life threatening or s influenced by ERT; and	severe disease where the	ne long tern	n prognos	is is unlikely to be
 5 Patient has not developed another medical condition t ERT; and 	hat might reasonably be	e expected	to compro	omise a response to
 6 There is no evidence of life threatening progression of invasive ventilation; and 	f respiratory disease as	evidenced	by the nee	eded for > 14 days of
7 There is no evidence of new or progressive cardiomy	opathy.			
	– Rotail nharmaov			
RGININE – Special Authority see SA2042 on the next page	- netali phannacy			
Tab 1,000 mg	CBS	90 50	✓ Clin✓ Sol	nicians

	Subsidy acturer's Price) \$	F Subsid Per	ised (Brand or Generic Manufacturer
■SA2042 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals valid for 6 metabolism that may respond to arginine supplementation.	3 months where	e patient ha	as a sus	pected inborn error of
Renewal only from a metabolic physician. Approvals valid for 24 months Both:	s for applicatior	ns meeting	the follo	owing criteria:
 The patient has a confirmed diagnosis of an inborn error of metable The treatment remains appropriate and the patient is benefiting from the patient is benefiti		onds to ar	ginine s	upplementation; and
BETAINE – Special Authority see SA1987 below – Retail pharmacy Powder for oral soln	75.00 180) g OP	🗸 Cys	stadane
 SA1987 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals valid for 1 All of the following: 1 The patient has a confirmed diagnosis of homocystinuria; and 	12 months for a	pplications	meetin	g the following criteria:
 2 Any of the following: 2.1 A cystathionine beta-synthase (CBS) deficiency; or 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) de 2.3 A disorder of intracellular cobalamin metabolism; and 	ficiency; or			
3 An appropriate homocysteine level has not been achieved despite Renewal only from a metabolic physician. Approvals valid for 12 months patient is benefiting from treatment.				
COENZYME Q10 – Special Authority see SA2039 below – Retail pharm Cap 120 mg Cap 160 mg	CBS	30 60	✔ Sol ✔ Go	gar Healthy
SA2039 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals valid for € metabolism that may respond to coenzyme Q10 supplementation. Renewal only from a metabolic physician. Approvals valid for 24 months				
Both: 1 The patient has a confirmed diagnosis of an inborn error of metab and 2 The treatment remains appropriate and the patient is benefiting fr		onds to co	enzyme	e Q10 supplementation;
GALSULFASE – Special Authority see SA1988 below – Retail pharmac Inj 1 mg per ml, 5 ml vial2,23	y	1	🗸 Nag	glazyme
SA1988 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals valid for 1 Both:	12 months for a	pplications	meetin	g the following criteria:
 The patient has been diagnosed with mucopolysaccharidosis VI; Either: 				
 2.1 Diagnosis confirmed by demonstration of N-acetyl-galacto enzyme activity assay in leukocytes or skin fibroblasts; or 2.2 Detection of two disease causing mutations and patient ha VI. 				, , , ,
Renewal only from a metabolic physician. Approvals valid for 12 months All of the following:	s for applicatior	ns meeting	the follo	owing criteria:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy		Fully	Brand or
	(Manufacturer's Price		Subsidised	Generic
	\$	Per	v	Manufacturer
continued and/or adjustment of infusion rates; and				
3 Patient has not developed another life threatening or sev	ara disaasa whara th	a long	term progn	osis is unlikely to be
influenced by Enzyme Replacement Therapy (ERT); and		ic long	term progra	
4 Patient has not developed another medical condition that		expec	ted to com	promise a response to
ERT.			···· ·	
IDURSULFASE - Special Authority see SA1623 below - Retail	pharmacy			
Inj 2 mg per ml, 3 ml vial		1	✓ E	laprase
➡SA1623 Special Authority for Subsidy				
Initial application only from a metabolic physician. Approvals v	alid for 24 weeks for	applic	ations meet	ing the following criteria:
All of the following:				
 The patient has been diagnosed with Hunter Syndrome (Either: 	mucopolysaccharido	sis II); a	and	
2.1 Diagnosis confirmed by demonstration of iduronal assay in cultured skin fibroblasts; or	e 2-sulfatase deficie	ncy in v	white blood	cells by either enzyme
2.2 Detection of a disease causing mutation in the idu	ironate 2-sulfatase g	ene; ar	nd	
3 Patient is going to proceed with a haematopoietic stem c idursulfase would be bridging treatment to transplant; and		within	the next 3 r	months and treatment with
4 Patient has not required long-term invasive ventilation for (ERT); and		rior to s	starting Enzy	vme Replacement Therapy
5 Idursulfase to be administered for a total of 24 weeks (eq	uivalent to 12 weeks	pre- a	nd 12 week	s post-HSCT) at doses no
greater than 0.5 mg/kg every week.				
LARONIDASE - Special Authority see SA1695 below - Retail p				
Inj 100 U per ml, 5 ml vial	1,335.16	1	✓ A	Idurazyme
SA1695 Special Authority for Subsidy				
Initial application only from a metabolic physician. Approvals v All of the following:	valid for 24 weeks for	applic	ations meet	ing the following criteria:
 The patient has been diagnosed with Hurler Syndrome (r Either: 	nucopolysacchardos	is I-H);	and	
2.1 Diagnosis confirmed by demonstration of alpha-L- assay in cultured skin fibroblasts; or	iduronidase deficien	cy in w	hite blood c	ells by either enzyme
2.2 Detection of two disease causing mutations in the to have Hurler syndrome; and	alpha-L-iduronidase	gene a	and patient	has a sibling who is known
3 Patient is going to proceed with a haematopoietic stem c laronidase would be bridging treatment to transplant; and		within	the next 3 r	months and treatment with
4 Patient has not required long-term invasive ventilation for		rior to s	starting Enzy	me Replacement Therapy
(ERT); and				
5 Laronidase to be administered for a total of 24 weeks (eq than 100 units/kg every week.	uivalent to 12 weeks	pre- a	nd 12 post-l	HSCT) at doses no greater
LEVOCARNITINE - Special Authority see SA2040 on the next	page – Retail pharma	acv		
Tab 500 mg	•	30	✓ s	olgar
Cap 250 mg		30		olgar
Cap 500 mg	CBS	60	🖌 E	Balance
Oral liq 1 g per 10 ml	CBS	118 m	I ∕ C	Carnitor S29
			🗸 N	lovitium Sugar
				Free S29
Oral liq 500 mg per 10 ml	CBS	300 m	I	Balance

Subsidy	Fu		
(Manufacturer's Price)	Subsidise	ed Generic	
 \$	Per	 Manufacturer 	

⇒SA2040 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to carnitine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to carnitine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

RIBOFLAVIN – Special Authority see SA2041 below – Retail pharmacy

Tab 100 mg	CBS	100	 ✓ Country Life ✓ Puritan's Pride Vitamin B-2 100 mg ^{S29}
Cap 100 mg	CBS	100	✓ Solgar

⇒SA2041 Special Authority for Subsidy

Initial application only from a metabolic physician or neurologist. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation.

Renewal only from a metabolic physician or neurologist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

➡SA1989 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 1 month for applications meeting the following criteria: All of the following:

- 1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
- 2 Treatment with sapropterin is required to support management of PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Renewal only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
 - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:
 - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
 - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
 - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and

				2
	Subsidy (Manufacturer's Price	e) Subsi	Fully	Brand or Generic
	\$	Per	1	Manufacturer
continued				
 Sapropterin to be administered at doses no greater than a Sapropterin to be used alone or in combination with PKU Total treatment duration with sapropterin will not exceed 2 becoming pregnant) and treatment will be stopped after de 	dietary managemer 2 months for each	it; and		s time for planning and
SODIUM BENZOATE – Special Authority see SA1599 below – F Soln 100 mg per ml		100 ml	🗸 A	mzoate S29
SA1599 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals va cycle disorder. Renewal only from a metabolic physician. Approvals valid for 12	alid for 12 months w	here the pat	tient ha	s a diagnosis of a urea
patient is benefiting from treatment.				
SODIUM PHENYLBUTYRATE – Special Authority see SA1990 I Grans 483 mg per g		nacy 174 g OP	✓ P	heburane
► SA1990 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals va cycle disorder involving a deficiency of carbamylphosphate synth synthetase. Renewal only from a metabolic physician. Approvals valid for 12 patient is benefiting from treatment.	etase, ornithine trar	nscarbamyla	se or a	rgininosuccinate
TAURINE – Special Authority see SA2043 below – Retail pharm	асу			
Cap 500 mg Cap 1,000 mg Powder	CBS	50 90 300 g	🗸 L	olgar ife Extension ife Extension
 SA2043 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals variation metabolic physician is a provided with the second term of ter	months for applica ndrial disorder whic	tions meetin h responds t	g the fo	bllowing criteria:
TRIENTINE – Special Authority see SA2324 below – Retail phar	U U			
Cap 250 mg	2,022.00	100	🗸 Т	rientine Waymade
 SA2324 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals value the following criteria: All of the following: 1 Patient has confirmed Wilson disease; and 2 Treatment with D-penicillamine has been trialled and disco effects or has not received sufficient benefit; and 	ontinued because th	ne person ha	is expe	rienced intolerable side
3 Treatment with zinc has been trailled and discontinued be not received sufficient benefit, or zinc is considered clinica and requires copper chelation.				
Gaucher's Disease				
TALIGLUCERASE ALFA – Special Authority see SA2137 on the Inj 200 unit vial		pharmacy 1	✔ E	lelyso

Subsidy	Fully		Brand or	
(Manufacturer's Price)	Subsidised		Generic	
\$	Per	1	Manufacturer	

➡SA2137 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT; and
- 3 Any of the following:
 - 3.1 Patient has haematological complications of Gaucher disease; or
 - 3.2 Patient has skeletal complications of Gaucher disease; or
 - 3.3 Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
 - 3.4 Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
 - 3.5 Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period; and
- 4 Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).
- Note: Indication marked with * is an unapproved indication

Renewal only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started; and
- 2 Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3 Radiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 5 Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE

Soln 0.15% - Higher subsidy of \$22.60 per 500 ml with		500 1	
Endorsement	9.00 (22.60)	500 ml	Difflam
Additional subsidy by endorsement for a patient who has	· · · ·	s a result of tre	Billian
prescription is endorsed accordingly.			
CARMELLOSE SODIUM WITH GELATIN AND PECTIN			
Paste	17.20	56 g OP	 Stomahesive
	4.55	15 g OP	
	(7.90)		Orabase
	1.52	5 g OP	
	(3.60)		Orabase
Powder		28 g OP	o
	(10.95)		Stomahesive

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pr \$	rice) Subs Per	Fully Brand or idised Generic ✔ Manufacturer
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE * Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06 (6.00)	15 g OP	Bonjela
TRIAMCINOLONE ACETONIDE Paste 0.1%	5.49	5 g OP	✓ Kenalog in Orabase
Oropharyngeal Anti-infectives			
AMPHOTERICIN B Lozenges 10 mg	5.86	20	🗸 Fungilin
MICONAZOLE Oral gel 20 mg per g	4.74	40 g OP	✓ <u>Decozol</u>
NYSTATIN Oral liq 100,000 u per ml	2.22	24 ml OP	✓ <u>Nilstat</u>
Vitamins			
Vitamin B			
HYDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a F	2SO2.46	3	 ✓ Cobal-B12 5299 ✓ <u>Hydroxocobalamin</u> <u>Panpharma</u> ✓ Vita-B12
	4.10	5	 Vita-B12 Cobalin-H \$29 Neo-Cytamen \$29 \$29
	8.20	10	 Vitarubin Depot Injection \$29
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription			
 * Tab 25 mg – No patient co-payment payable * Tab 50 mg 		90 500	 ✓ <u>Vitamin B6 25</u> ✓ Pyridoxine multichem
THIAMINE HYDROCHLORIDE – Only on a prescription * Tab 50 mg	4.65	100	✓ Thiamine multichem
VITAMIN B COMPLEX * Tab, strong, BPC	11.25	500	✓ Bplex
Vitamin C			
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription			
* Tab 100 mg		500	✓ <u>Cvite</u>

	Subsidy (Manufacturer's P	rice) Subs	Fully	Brand or Generic
	\$	Per	1	Manufacturer
Vitamin D				
ALFACALCIDOL				
* Cap 0.25 mcg		100	✓ 0	ne-Alpha
			✓ 0	ne-Alpha S29 S29
* Cap 1 mcg	87.98	100		ne-Alpha
	co.co	00 00		one-Alpha S29 S29
* Oral drops 2 mcg per ml	00.08	20 ml OP	v (ne-Alpha
CALCITRIOL * Cap 0.25 mcg	7 90	100		alcitriol-AFT
* Cap 0.25 mcg		100 100	-	alcitriol-AFT
		100	• •	
COLECALCIFEROL * Cap 1.25 mg (50,000 iu) - Maximum of 12 cap per preso	ription 3.65	12	1 V	ït.D3
Vit.D3 to be Principal Supply on 1 June 2024		12	• •	11.00
* Oral liq 188 mcg per ml (7,500 iu per ml)	9.00	5 ml OP	✓ 0	linicians
Multivitamin Preparations				
MULTIVITAMIN RENAL - Special Authority see SA1546 below	w – Retail pharmac	y		
* Сар	7.28	30	✓ 0	linicians Renal Vit
■ SA1546 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals the following criteria: Either:				
 The patient has chronic kidney disease and is receivin The patient has chronic kidney disease grade 5, define 15 ml/min/1.73 m² body surface area (BSA). 				
MULTIVITAMINS – Special Authority see SA1036 below – R	etail pharmacy			
* Powder	74.88	200 g OP	🗸 P	aediatric Seravit
SA1036 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals	valid without further i	renewal unless	s notifie	d where the patient has
inborn errors of metabolism. Renewal from any relevant practitioner. Approvals valid with	out further repowel u	place petified	whore r	ationt has had a proviou
approval for multivitamins.		niess nouneu	where p	allent has had a previot
VITAMINS				
* Tab (BPC cap strength)	18.50	1,000	🗸 N	lvite
 Cap (fat soluble vitamins A, D, E, K) – Special Authority 		1,000	• •	
SA1720 below – Retail pharmacy		60	🗸 V	itabdeck
SA1720 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals	valid without further i	renewal unless	s notifie	d for applications meetir
the following criteria:				
Any of the following:				
1 Patient has cystic fibrosis with pancreatic insufficiency				
2 Patient is an infant or child with liver disease or short g	jut syndrome; or			

2 Patient is an infant or child with liver disease or short gut syndrome; or

3 Patient has severe malabsorption syndrome.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Minerals				
Calcium				
CALCIUM CARBONATE * Tab 1.25 g (500 mg elemental) * Tab eff 1.25 g (500 mg elemental) – Subsidy by endorseme	nt260.00	250 100	1	Calci-Tab 500 Calcium 500 mg Hexal 529
Subsidy by endorsement – Only when prescribed for pa considered unsuitable.	ediatric patients (< 5	years) where ca	lcium carbonate oral liquid is
CALCIUM GLUCONATE * Inj 10%, 10 ml ampoule		10	1	Max Health - Hameln 829
	64.00	20	1	Max Health \$29
lodine				
POTASSIUM IODATE * Tab 253 mcg (150 mcg elemental iodine)	5.99	90	1	<u>NeuroTabs</u>
Iron				
FERROUS FUMARATE * Tab 200 mg (65 mg elemental) FERROUS FUMARATE WITH FOLIC ACID	3.04	100	v	Ferro-tab
* Tab 310 mg (100 mg elemental) with folic acid 350 mcg FERROUS SULFATE	5.98	100	1	Ferro-F-Tabs
 * Tab long-acting 325 mg (105 mg elemental) * Oral liq 30 mg (6 mg elemental) per 1 ml 	9.25	30 250 n 500 n	nl 🖌	<u>Ferrograd</u> Ferro-Liquid <u>Ferodan</u>
IRON (AS FERRIC CARBOXYMALTOSE) – Special Authority s Inj 50 mg per ml, 10 ml vial		Retail 1		Ferinject

Initial application — (serum ferritin less than or equal to 20 mcg/L) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and

- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Rapid correction of anaemia is required.

Renewal — (serum ferritin less than or equal to 20 mcg/L) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and
- 2 A re-trial with oral iron is clinically inappropriate.

Initial application - (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist,

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 Patient has been diagnosed with iron-deficiency anaemia; and

- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or
 - 2.4 Rapid correction of anaemia is required.

Renewal — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient continues to have iron-deficiency anaemia; and
- 2 A re-trial with oral iron is clinically inappropriate.

IRON POLYMALTOSE

* Inj 50 mg per ml, 2 ml ampoule	5	✓ Ferrosig
Magnesium		
MAGNESIUM HYDROXIDE Suspension 8%33.60	355 ml	 Phillips Milk of Magnesia 529
MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml ampoule	10	 Martindale
* Inj 2 mmol per ml, 10 ml ampoule75.06 Zinc	10	✓ Inresa S29
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental)11.00	100	✓ Zincaps

Subsidy		Fully	Brand or
(Manufacturer's Price)	5	Subsidised	Generic
\$	Per	✓	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

► SA2266 Special Authority for Subsidy

Initial application — (chronic renal failure) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.
- Note: Indication marked with * is an unapproved indication

Renewal — (chronic renal failure) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

EPOETIN ALFA - Special Authority see SA2266 above - Retail pharmacy

Wastage claimable

Tuotago olamabio		
Inj 1,000 iu in 0.5 ml, syringe	 6	 Binocrit
Inj 2,000 iu in 1 ml, syringe	6	 Binocrit
Inj 3,000 iu in 0.3 ml, syringe	6	 Binocrit
Inj 4,000 iu in 0.4 ml, syringe	6	 Binocrit
Inj 5,000 iu in 0.5 ml, syringe	6	 Binocrit
Inj 6,000 iu in 0.6 ml, syringe	6	 Binocrit
Inj 8,000 iu in 0.8 ml, syringe	6	 Binocrit
Inj 10,000 iu in 1 ml, syringe	6	 Binocrit
Inj 40,000 iu in 1 ml, syringe	1	 Binocrit

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully osidised	Brand or Generic Manufacturer
Megaloblastic				
FOLIC ACID				
* Tab 0.8 mg	26.60	1,000	✓ F	Folic Acid multichem
* Tab 5 mg	5.82	100	✓ <u>F</u>	Folic Acid Viatris
Oral liq 50 mcg per ml	30.26	25 ml OP	✓ E	Biomed
Antifibringlytics, Hasmostatics and Losal Solar	oconto			
Antifibrinolytics, Haemostatics and Local Sclere	USams			
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha	arm]			
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm	arm] ent. Access to fund		ent is ma	anaged by the Haemophili
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia	arm] ent. Access to fund Management grou			
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial	arm] ent. Access to fund Management grou 612.50		√ µ	Alprolix
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial Inj 500 iu vial	arm] ent. Access to fund Management grou 612.50 1,225.00		✓ ✓	Alprolix Alprolix
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	arm] ent. Access to fund Management grou 612.50 1,225.00 2,450.00		✓ ✓ ✓	Alprolix Alprolix Alprolix
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial	arm] ent. Access to fund Management grou 612.50 1,225.00 2,450.00 4,900.00		I	Alprolix Alprolix Alprolix Alprolix Alprolix
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	arm] Management grou 612.50 2,450.00 4,900.00 7,350.00		✓ ✓ ✓ ✓	Alprolix Alprolix Alprolix
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial Inj 4,000 iu vial ELTROMBOPAG – Special Authority see SA1743 below – Retai	arm] ent. Access to fund Management group 612.50 2,450.00 2,450.00 4,900.00 7,350.00 9,800.00		✓ ✓ ✓ ✓	Alprolix Alprolix Alprolix Alprolix Alprolix Alprolix
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha For patients with haemophilia B receiving prophylaxis treatm Treaters Group in conjunction with the National Haemophilia Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial Inj 4,000 iu vial	arm] Management group 612.50 2,450.00 4,900.00 7,350.00 9,800.00 I pharmacy			Alprolix Alprolix Alprolix Alprolix Alprolix Alprolix

➡SA1743 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	1	Manufacturer	

and significant mucocutaneous bleeding.

Initial application — (severe aplastic anaemia) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and

- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Renewal — (severe aplastic anaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EMICIZUMAB - [Xpharm] - Special Authority see SA2272 below

Inj 30 mg in 1 ml vial		1	 Hemlibra
Inj 60 mg in 0.4 ml vial	7,138.00	1	 Hemlibra
Inj 105 mg in 0.7 ml vial		1	 Hemlibra
Inj 150 mg in 1 ml vial		1	 Hemlibra

⇒SA2272 Special Authority for Subsidy

Initial application — (Severe Haemophilia A with or without FVIII inhibitors) only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

38

- 1 Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%); and
- 2 Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

Inj 1 mg syringe	1	NovoSeven RT
Inj 2 mg syringe2,356.60	1	NovoSeven RT
Inj 5 mg syringe	1	NovoSeven RT
Inj 8 mg syringe	1	NovoSeven RT

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	ç	Fully Subsidised	Generic
	\$	Per	 ✓ 	Manufacturer
FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xph	arml			
For patients with haemophilia. Preferred Brand of bypassi		oredict	ted use A	ccess to funded treatment
is managed by the Haemophilia Treaters Group in conjunc				
Inj 500 U		1		EIBANF
Inj 1,000 U		1		
Inj 2,500 U		1		EIBANF
MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xp				
For patients with haemophilia. Rare Clinical Circumstance		a rocor	mhinant far	stor VIII Access to funder
treatment is managed by the Haemophilia Treaters Group	in conjunction with the	Vation	al Haamon	hilia Management Group
subject to criteria.		Valion	arnaemop	mila management oroup,
Inj 250 iu prefilled syringe	287 50	1	✓ X	(yntha
Inj 500 iu prefilled syringe		1		(yntha
Inj 1,000 iu prefilled syringe		1		(yntha
Inj 2,000 iu prefilled syringe		1		lyntha
Inj 3,000 iu prefilled syringe		1		lyntha
, , , ,			- /	, yn dia
NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xphar		la		
For patients with haemophilia. Access to funded treatmen	t is managed by the Ha	emopr	illa i reate	rs Group in conjunction
with the National Haemophilia Management Group.	105.00			
Inj 500 iu vial		1		RIXUBIS
Inj 1,000 iu vial		1	-	RIXUBIS
Inj 2,000 iu vial		1		RIXUBIS
Inj 3,000 iu vial	,	1	• •	RIXUBIS
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE)				
For patients with haemophilia. Preferred Brand of short ha				
managed by the Haemophilia Treaters Group in conjunction		•		
Inj 250 iu vial		1		dvate
Inj 500 iu vial		1		dvate
Inj 1,000 iu vial		1	-	dvate
Inj 1,500 iu vial		1		dvate
Inj 2,000 iu vial		1		dvate
Inj 3,000 iu vial		1	✓ µ	Advate
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENAT				
For patients with haemophilia. Rare Clinical Circumstance	es Brand of short half-life	e recor	mbinant fac	ctor VIII. Access to funded
treatment is managed by the Haemophilia Treaters Group	in conjunction with the	Vation	al Haemop	hilia Management Group,
subject to criteria.				
Inj 250 iu vial		1	🗸 k	Cogenate FS
Inj 500 iu vial		1	🗸 k	Cogenate FS
Inj 1,000 iu vial		1	🗸 k	Cogenate FS
Inj 2,000 iu vial	1,900.00	1		Cogenate FS
Inj 3,000 iu vial	2,850.00	1	🗸 k	Cogenate FS
RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VI	II] – [Xpharm]			
For patients with haemophilia A receiving prophylaxis treat		d treat	ment is ma	anaged by the Haemophilia
Treaters Group in conjunction with the National Haemophi				
Inj 250 iu vial	0 0 1	1	🗸 A	Adynovate
Inj 500 iu vial		1		Adynovate
Inj 1,000 iu vial		1		Adynovate
Inj 2,000 iu vial		1		Adynovate
SODIUM TETRADECYL SULPHATE	,		-	
* Inj 3% 2 ml	28 50	5		
小 IIJ ∪ /0 ∠ III	(73.00)	5	-	ibro-vein
	(73.00)		Г	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

(Subsidy Manufacturer's Price) \$	Per	Fully Subsidised	Generic
TRANEXAMIC ACID				
Tab 500 mg	10.45 45.68	60 100		<u>Mercury Pharma</u> Cyklokapron
Vitamin K				
PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		5 5		Konakion MM Konakion MM
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN * Tab 100 mg Ethics Aspirin EC to be Principal Supply on 1 June 2024	12.65	990	1	Ethics Aspirin EC
CLOPIDOGREL				
* Tab 75 mg	5.07	84	~	Arrow - Clopid
DIPYRIDAMOLE * Tab long-acting 150 mg	13.93	60	1	Pytazen SR
TICAGRELOR – Special Authority see SA1955 below – Retail pha * Tab 90 mg	•	56		<u>Ticagrelor Sandoz</u> Brilinta
(Brilinta Tab 90 mg to be delisted 1 July 2024)				

(Brilinta Tab 90 mg to be delisted 1 July 2024)

⇒SA1955 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Initial application — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

40

- 1 Either:
 - 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
 - 1.2 Patient is about to have a neurological stenting procedure performed*; and

2 Either:

- 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
- 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

Initial application — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initial application — (Stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Renewal — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.
- Notes: indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM - Special Authority see SA2152 b	elow – Retail pharmacy		
Inj 20 mg in 0.2 ml syringe		10	 Clexane
Inj 40 mg in 0.4 ml syringe		10	 Clexane
Inj 60 mg in 0.6 ml syringe		10	 Clexane
Inj 80 mg in 0.8 ml syringe		10	 Clexane
Inj 100 mg in 1 ml syringe		10	 Clexane
Inj 120 mg in 0.8 ml syringe		10	 Clexane Forte
Inj 150 mg in 1 ml syringe	143.86	10	 Clexane Forte

⇒SA2152 Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		ully	Brand or
()	Manufacturer's Price)	Subsid	sed	Generic
	\$	Per	✓	Manufacturer

continued...

treatment; or

- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Initial application — (Short-term use during treatment of COVID-19 with nirmatrelvir with ritonavir) from any relevant practitioner. Approvals valid for 2 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is receiving an anticoagulation treatment that has drug/drug interactions with ritonavir that increases risk of bleeding; and
- 2 Patient meets the Access Criteria for COVID-19 antivirals published on the Pharmac website*; and
- 3 Other antiviral treatments for COVID-19 have been considered and are not clinically suitable options.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

HEPARIN SODILIM

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

Inj 1,000 iu per ml, 5 ml ampoule86.11	50	 Pfizer
Inj 5,000 iu per ml, 5 ml vial83.00	10	✓ <u>Heparin Sodium</u> Panpharma
Inj 5,000 iu per ml, 1 ml32.66	5	✓ DBL Heparin Sodium S29
70.33		✓ Hospira
Inj 25,000 iu per ml, 0.2 ml22.42	5	 Hospira
42.40		 Heparin DBL S29
482.20	50	✓ Heparin DBL S29
HEPARINISED SALINE Inj 10 iu per ml, 5 ml	50	✓ Pfizer
Oral Anticoagulants		
DABIGATRAN		
Cap 75 mg – No more than 2 cap per day27.99 Pradaxa to be Principal Supply on 1 July 2024	60	 Pradaxa
Cap 110 mg27.99 Pradaxa to be Principal Supply on 1 July 2024	60	 Pradaxa
Cap 150 mg27.99 Pradaxa to be Principal Supply on 1 July 2024	60	 Pradaxa
RIVAROXABAN		
Tab 10 mg – No more than 1 tab per day	30	✓ Xarelto
Tab 15 mg – Up to 14 tab available on a PSO	28	✓ Xarelto
Tab 20 mg	28	✓ Xarelto
1 ab 20 mg 14.00	20	

42

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per	1	Manufacturer
WARFARIN SODIUM				
Note: Marevan and Coumadin are not interchangeable.				
* Tab 1 mg	3.46	50	✓	Coumadin
v	7.50	100	✓	Marevan
* Tab 2 mg	4.31	50	✓	Coumadin
* Tab 3 mg		100	✓	Marevan
* Tab 5 mg		50	✓	Coumadin
v	13.50	100	✓	Marevan
Blood Colony-stimulating Factors				
FILGRASTIM – Special Authority see SA1259 below – Retail p	harmacv			
Ini 300 mcg per 0.5 ml prefilled svringe	06.00	10	1	Nivestim

Inj 300 mcg per 0.5 ml prefilled syringe	 10	 Nivestim
Inj 480 mcg per 0.5 ml prefilled syringe	 10	 Nivestim

➡SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^{9} /L).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM – Special Authority see SA1912 below – Retail pharmacy

Inj 6 mg per 0.6 ml syringe	65.00	1	 Ziextenzo
-----------------------------	-------	---	-------------------------------

► SA1912 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*). Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

GLUCOSE [DEXTROSE]		
* Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO	5	 Biomed
✤ Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO17.50	1	 Biomed
POTASSIUM CHLORIDE		
* Inj 75 mg per ml, 10 ml65.00	50	🗸 Juno

	Subsidy		Fully	Brand or
	(Manufacturer's Pric		sidised	Generic
	\$	Per	/	Manufacturer
	00.50			
Inj 8.4%, 50 ml	23.52	1	✓ B	iomed
a) Up to 5 inj available on a PSO				
b) Not in combination	04.40			· · · · · · · ·
Inj 8.4%, 100 ml		1	• 8	iomed
a) Up to 5 inj available on a PSOb) Not in combination				
ODIUM CHLORIDE				
Not funded for use as a nasal drop. Not funded for nebulise for nebuliser use.	er use except when	used in conji	unction	with an antibiotic intende
Inj 0.9%, bag – Up to 2000 ml available on a PSO	1.33	500 ml	✓ B	axter
	1.36	1,000 ml	🗸 В	axter
Only if prescribed on a prescription for renal dialysis, ma	aternity or post-nata	al care in the	home of	of the patient, or on a PS
for emergency use. (500 ml and 1,000 ml packs)				
Inj 23.4% (4 mmol/ml), 20 ml ampoule		5	✓ B	iomed
For Sodium chloride oral liquid formulation refer Standa				
Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO		20		resenius Kabi
Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO		50	_	resenius Kabi
Inj 0.9%, 20 ml ampoule	5.00	20	✓ F	resenius Kabi
OTAL PARENTERAL NUTRITION (TPN)				
Infusion	CBS	1 OP	🗸 I	PN
VATER				
 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of e 4) When used for the dilution of sodium chloride soln 7% 		atients only.		
Inj 10 ml ampoule – Up to 5 inj available on a PSO Inj 20 ml ampoule – Up to 5 inj available on a PSO		50 20	_	<u>lultichem</u> resenius Kabi
Oral Administration				
ALCIUM POLYSTYRENE SULPHONATE				
Powder		300 g OP	✓ 0	alcium Resonium
COMPOUND ELECTROLYTES		•		
Powder for oral soln – Up to 5 sach available on a PSO		50	✓ E	lectral
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE			_	<u></u>
Soln with electrolytes	-	,000 ml OP	✓ н	ydralyte -
	0.00	,000 mi Oi	• 1	Lemonade
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82 50	100	/ P	hosphate Phebra
	02.00	100	• F	noophate i nebia
POTASSIUM CHLORIDE		60		
	E 00			
Fab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)		60	~	blancasant
	(17.10)		-	hlorvescent
K Tab long-acting 600 mg (8 mmol)	(17.10)	200	-	hlorvescent pan-K
₭ Tab long-acting 600 mg (8 mmol) SODIUM BICARBONATE	(17.10) 15.35	200	✓ S	pan-K
K Tab long-acting 600 mg (8 mmol)	(17.10) 15.35		✓ s	

	Subsidy (Manufacturer's Price)						Brand or Generic	
	\$	Per	1	Manufacturer				
SODIUM POLYSTYRENE SULPHONATE								
Powder		454 g OP	🗸 🗸 R	Resonium-A				

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Alpha-Adrenoceptor Blockers				
Alpha Adrenoceptor Blockers				
DOXAZOSIN				
* Tab 2 mg		500		Doxazosin Clinect
* Tab 4 mg	20.94	500	~	Doxazosin Clinect
PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg		30		BNM S29
	216.67	100	-	Dibenzyline S29
PRAZOSIN			-	
* Tab 1 mg	5.53	100	~	Arrotex-Prazosin
				S29 S29
W. Tab O are	9.98	400		Minipress S29
* Tab 2 mg		100	~	Arrotex-Prazosin
	10.00			S29 S29
* Tab 5 mg	13.29	100		Minipress ^{©29} Arrotex-Prazosin
* Tab 5 mg		100	•	S29 S29
	22.00		1	Minipress S29
* Cap 1 mg		100		Prazosin Mylan S29
* Cap 2 mg		100		Prazosin Mylan S29
* Cap 5 mg		100		Prazosin Mylan S29
				,
Agents Affecting the Renin-Angiotensin Syste	m			
ACE Inhibitors				
CAPTOPRIL				
 Oral liq 5 mg per ml Oral liquid restricted to children under 12 years of age. 		00 ml (OP 🗸	DP-Captopril
CILAZAPRIL – Subsidy by endorsement				
Subsidy by endorsement – Subsidised for patients who we endorsed accordingly. Pharmacists may annotate the pres				
dispensing of cilazapril.				
* Tab 0.5 mg		90		Zapril
* Tab 2.5 mg		90	-	Zapril Zopril
		90	•	Zapril
	1 75	90		Acotoo
 * Tab 5 mg * Tab 10 mg 		90 90	-	<u>Acetec</u> Acetec
* Tab 10 mg		90 90	-	Acetec
LISINOPRIL				
* Tab 5 mg		90	1	Ethics Lisinopril
				Teva Lisinopril
* Tab 10 mg	11.67	90		Ethics Lisinopril
				Teva Lisinopril
* Tab 20 mg	14.69	90		Ethics Lisinopril Teva Lisinopril

	Subsidy		Fully Brand or
	(Manufacturer's Price)	Subsi	
	\$	Per	 Manufacturer
PERINDOPRIL			
* Tab 2 mg	1.58	30	 <u>Coversyl</u>
* Tab 4 mg	2.95	30	 Coversyl
* Tab 8 mg		30	✓ Coversyl
· · · · · · · · · · · · · · · · · · ·		00	e eereisyi
QUINAPRIL			
* Tab 5 mg	5.97	90	 Arrow-Quinapril 5
* Tab 10 mg		90	✓ Arrow-Quinapril 10
* Tab 20 mg		90	Arrow-Quinapril 20
RAMIPRIL			
* Cap 1.25 mg	6 90	90	🗸 Tryzan
* Cap 2.5 mg		90	✓ <u>Tryzan</u>
* Cap 5 mg		90	 <u>Tryzan</u>
* Cap 10 mg	7.05	90	 Tryzan
1 5			
ACE Inhibitors with Diuretics			
ACE Inhibitors with Diuretics			
	• •		
QUINAPRIL WITH HYDROCHLOROTHIAZIDE – Subsidy by er			
Subsidy by endorsement – Subsidised for patients who were	e taking guinapril with	hydrochlor	othiazide prior to 1 May
2022 and the prescription is endorsed accordingly. Pharma			
exists a record of prior dispensing of quinapril with hydroch		procompa	
Tab 10 mg with hydrochlorothiazide 12.5 mg	4.10	30	 Accuretic 10
Tab 20 mg with hydrochlorothiazide 12.5 mg	5.25	30	 Accuretic 20
Angiotensin II Antagonists			
Angiotensin il Antagonists			
CANDESARTAN CILEXETIL			
* Tab 4 mg	2.00	90	 <u>Candestar</u>
* Tab 8 mg	2.28	90	 Candestar
* Tab 16 mg	3 31	90	✓ Candestar
* Tab 32 mg		90	✓ Candestar
* Tab 52 Tily		90	
LOSARTAN POTASSIUM			
* Tab 12.5 mg	2 00	84	 Losartan Actavis
5		• ·	
* Tab 25 mg		84	 Losartan Actavis
* Tab 50 mg	2.86	84	 Losartan Actavis
* Tab 100 mg	4.57	84	 Losartan Actavis
J.			
Angiotensin II Antagonists with Diuretics			
Anyiotensin ii Antayonists with Diuretics			
CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE			_
* Tab 16 mg with hydrochlorothiazide 12.5 mg	4.10	30	 APO-Candesartan
- · · ·			HCTZ 16/12.5
* Tab 22 ma with hydrochlorothia-ida 12 5 ma	5.05	20	✓ APO-Candesartan
 Tab 32 mg with hydrochlorothiazide 12.5 mg 		30	
			HCTZ 32/12.5
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
	4.00	00	A Museu Lesenten O
* Tab 50 mg with hydrochlorothiazide 12.5 mg	4.00	30	 Arrow-Losartan &
			Hydrochlorothiazide

	Subsidy (Manufacturer's Price)		Fully sidised	Brand or Generic
	\$	Per	1	Manufacturer
Angiotensin II Antagonists with Neprilysin Inhib	oitors			
SACUBITRIL WITH VALSARTAN - Special Authority see SA230	02 below – Retail pha	armacy		
Tab 24.3 mg with valsartan 25.7 mg		56		ntresto 24/26
Tab 48.6 mg with valsartan 51.4 mg		56		ntresto 49/51
Tab 97.2 mg with valsartan 102.8 mg		56	✓ E	ntresto 97/103
▶ SA2302 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals value the following criteria:	d without further rene	ewal unles	ss notifie	d for applications meeting
All of the following:				
 Patient has heart failure; and Any of the following: 				
2.1 Patient is in NYHA/WHO functional class II; or				
2.2 Patient is in NYHA/WHO functional class III; or				
2.3 Patient is in NYHA/WHO functional class IV; and				
3 Either:				
3.1 Patient has a documented left ventricular ejection 13.2 An ECHO is not reasonably practical, and in the operation of the				
treatment; and				
4 Patient is receiving concomitant optimal standard chronic	heart failure treatme	nts.		
Antiarrhythmics				
For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaes	sthetics Local page	123		
AMIODARONE HYDROCHLORIDE	Salouoo, Looda, pago	120		
Tab 100 mg	2 40	30	1 A	ratac
▲ Tab 100 mg		30	_	ratac
Inj 50 mg per ml, 3 ml ampoule – Up to 10 inj available on a		6	_	ordarone-X
	15.22	10		lax Health
ATROPINE SULPHATE	10122			
 * Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a 				
* Inj 600 micg per mi, 1 mi ampoule – Op to 5 mj available on a PSO		10	~ N	lartindale
		10	• <u>II</u>	
DIGOXIN	7 90	240		anavin BC
 Tab 62.5 mcg – Up to 30 tab available on a PSO Tab 250 mcg – Up to 30 tab available on a PSO 		240 240	_	anoxin PG anoxin
 * Tab 250 mcg – Op to 30 tab available on a PSO * Oral lig 50 mcg per ml 		240 60 ml		anoxin
		00 111		anoxin Paediatric Elixir
			🗸 L	anoxin S29 S29
DISOPYRAMIDE PHOSPHATE			_	
▲ Cap 100 mg	20.05	84	✔ R	ythmodan - Cheplafarm S29
	23.87	100	✓ R	ythmodan

48

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
FLECAINIDE ACETATE				
▲ Tab 50 mg		60		Flecainide BNM Flecatab S29
Cap long-acting 100 mg		90		Flecainide Controlled
▲ Cap long-acting 200 mg	54.28	90	1	Release Teva Flecainide Controlled Release Teva
Inj 10 mg per ml, 15 ml ampoule MEXILETINE HYDROCHLORIDE	108.16	5	1	Tambocor
▲ Cap 150 mg	162.00	100	1	Teva S29
Cap 250 mg		100	1	Teva S29
Tab 150 mg	40.90	50	✓	Rytmonorm
Antihypotensives				
MIDODRINE - Special Authority see SA1474 below - Retail phare	macy			
Tab 2.5 mg		100		MAR-Midodrine S29 Midodrine Medsurge
Tab 5 mg	59.98	100	1	Midodrine Medsurge

SA1474 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta-Adrenoceptor Blockers

Beta Adrenoceptor Blockers

ATENOLOL		
* Tab 50 mg9.33	500	 Viatris
* Tab 100 mg14.20	500	 ✓ Atenolol Viatris ✓ Mylan Atenolol
* Oral liq 25 mg per 5 ml21.25	300 ml OP	✓ Atenolol AFT S29 S29
38.20		 Essential Generics (\$29)
49.85		 Atenolol AFT
Restricted to children under 12 years of age.		
(Mylan Atenolol Tab 100 mg to be delisted 1 July 2024)		
(Atenolol AFT S29 S29 Oral liq 25 mg per 5 ml to be delisted 1 August 2024)		
BISOPROLOL FUMARATE		
* Tab 2.5 mg	90	Ipca-Bisoprolol
* Tab 5 mg	90	Ipca-Bisoprolol
* Tab 10 mg2.71	90	 Ipca-Bisoprolol

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

_		Subsidy		Fully	
		(Manufacturer's Price) \$	Per	Subsidised	
CAF	RVEDILOL				
*	Tab 6.25 mg	2.24	60	1	Carvedilol Sandoz
*	Tab 12.5 mg	2.30	60	1	Carvedilol Sandoz
*	Tab 25 mg	2.95	60	✓	Carvedilol Sandoz
_AE	BETALOL				
*	Tab 100 mg		100	1	Trandate
*	Tab 200 mg		100	1	Trandate
₭	Inj 5 mg per ml, 20 ml ampoule		5		
		(88.60)			Trandate
ŧ	inj 5 mg per ml, 20 ml vial		1		
		(48.20)			Alvogen S29
١E.	TOPROLOL SUCCINATE				-
*	Tab long-acting 23.75 mg	4.20	90	1	Myloc CR
ŧ	Tab long-acting 47.5 mg	3.65	90	1	Myloc CR
ŧ	Tab long-acting 95 mg	5.24	90	1	Myloc CR
*	Tab long-acting 190 mg	9.76	90	1	Myloc CR
٨E.	TOPROLOL TARTRATE				
*	Tab 50 mg	5.66	100	✓	IPCA-Metoprolol
*	Tab 100 mg	7.55	60	✓	IPCA-Metoprolol
*	Tab long-acting 200 mg	23.40	28	✓	Slow-Lopresor
¥	Inj 1 mg per ml, 5 ml vial		5	✓	Metoprolol IV Mylan
				✓	Metoprolol IV Viatris
JAI	DOLOL				
*	Tab 40 mg	19.19	100		Nadolol BNM
*	Tab 80 mg		100	1	Nadolol BNM
R	DPRANOLOL				
*	Tab 10 mg	7.04	100	1	Drofate
¥	Tab 40 mg	8.75	100	1	IPCA-Propranolol
*	Cap long-acting 160 mg		100	1	Cardinol LA
¥	Oral liq 4 mg per ml - Special Authority see SA1327 below -	-			
	Retail pharmacy	CBS !	500 m	nl 🗸	Roxane-
					Propranolol S29

⇒SA1327 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

SOTALOL

*	Tab 80 mg	500	🗸 <u>Mylan</u>
	Tab 160 mg14.00	100	🗸 <u>Mylan</u>

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per	1	Manufacturer
Calcium Channel Blockers				
Dihydropyridine Calcium Channel Blockers				
AMLODIPINE				
* Tab 2.5 mg	1 45	90	1	Vasorex
		90 90		Vasorex
			-	
* Tab 10 mg		90	•	Vasorex
FELODIPINE			_	
* Tab long-acting 2.5 mg	1.45	30	✓	Plendil ER
* Tab long-acting 5 mg	4.07	90	✓	Felo 5 ER
* Tab long-acting 10 mg		90	✓	Felo 10 ER
NIFEDIPINE				
 Tab long-acting 10 mg – Subsidy by endorsement 	10.40	56	1	Tensipine MR10 S29
* Tab long-acting to mg - Subsidy by endorsement		50	•	
Subsidised for patients who were taking nifedipine tab	long-acting 10 mg prior	r to 1	July 2023	and the prescription is
endorsed accordingly. Pharmacists may annotate the				
dispensing of nifedipine tab long-acting 10 mg.		JU 11		
 Tab long-acting 20 mg 	17 72	100	1	Nyefax Retard
		14		Mylan Italy (24 hr
* Tab long-acting 30 mg		14	•	
			_	release) S29
	10.24	30	~	Nifedipine
				Viatris S29
	34.10	100	✓	Mylan (24 hr
				release) S29
* Tab long-acting 60 mg	EO 01	100		•
* Tab long-acting 60 mg		100	•	Mylan (24 hr
				release) S29
Other Calcium Channel Blockers				
other Galcium Ghanner Diockers				
DILTIAZEM HYDROCHLORIDE				
* Cap long-acting 120 mg	65.35	500	✓	Diltiazem CD Clinect
* Cap long-acting 180 mg		30	✓	Cardizem CD
* Cap long-acting 240 mg		30	-	Cardizem CD
PERHEXILINE MALEATE				
	62.00	100		Dovoia
* Tab 100 mg	02.90	100	•	Pexsig
VERAPAMIL HYDROCHLORIDE			_	
* Tab 40 mg	7.01	100	✓	Isoptin
* Tab 80 mg	11.74	100	✓	Isoptin
* Tab long-acting 120 mg		100	✓	Isoptin Retard S29
				Isoptin SR
* Tab long-acting 240 mg		30	-	Isoptin SR
 Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on 				
PSO		5	1	Isoptin
		5	•	loopull
Centrally-Acting Agents				
oonaany-Adang Agento				
CLONIDINE				
* Patch 2.5 mg, 100 mcg per day - Only on a prescription	11.70	4	✓	<u>Mylan</u>
 Patch 5 mg, 200 mcg per day – Only on a prescription 		4		Mylan
 Patch 7.5 mg, 300 mcg per day – Only on a prescription 		4		Mylan
and the may bee may be day to any on a problem.		•	•	<u>,</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	
	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
CLONIDINE HYDROCHLORIDE				
* Tab 25 mcg		112	✓	Clonidine Teva
* Tab 150 mcg		100	1	Catapres
* Inj 150 mcg per ml, 1 ml ampoule		10	✓	Medsurge
METHYLDOPA				
* Tab 250 mg		100	✓	Methyldopa Mylan
0				Methyldopa Viatris
	52.85	500		Methyldopa Mylan
				S29 S29
(Methyldopa Mylan Tab 250 mg to be delisted 1 September 2024	1)			
(Methyldopa Mylan S29 S29) Tab 250 mg to be delisted 1 Septe	,			

Diuretics

Loop Diuretics

BUMETANIDE			
* Tab 1 mg	4.91	30	 Burinex S29 S29
	16.36	100	 Burinex
* Inj 500 mcg per ml, 4 ml vial	7.95	5	 Burinex
(Burinex S29 S29) Tab 1 mg to be delisted 1 August 2024)			
FUROSEMIDE [FRUSEMIDE]			
Tab 40 mg – Up to 30 tab available on a PSO	8.00	1,000	IPCA-Frusemide
* Tab 500 mg	25.00	50	 Urex Forte
	89.48		 Furosemid-
			Ratiopharm S29
	169.96	100	✓ Furosemid-
			Ratiopharm S29
* Oral liq 10 mg per ml		30 ml OP	✓ Lasix
* Inj 10 mg per ml, 25 ml ampoule	60.65	6	🗸 Lasix
* Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a	PSO2.40	5	 Furosemide-Baxter

Potassium Sparing Diuretics

AMILORIDE HYDROCHLORIDE			
Oral liq 1 mg per ml		25 ml OP	 Biomed
EPLERENONE - Special Authority see SA1728 below	 Retail pharmacy 		
Tab 25 mg		30	 Inspra
Tab 50 mg	25.00	30	 Inspra

► SA1728 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1 Patient has heart failure with ejection fraction less than 40%; and

- 2 Either:
 - 2.1 Patient is intolerant to optimal dosing of spironolactone; or

2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

CARDIOVASCUL	AR SYSTEM
--------------	-----------

Subsidy (Manufacturer's Pri \$	ce) S Per	Fully Subsidised	Brand or Generic Manufacturer
	100 100	✓	<u>Spiractin</u> <u>Spiractin</u> Biomed
	28	•	Frumil
	50	✓	Moduretic
51.50	500	•	<u>Arrow-</u> Bendrofluazide
• •	500	•	<u>Arrow-</u> Bendrofluazide
29.21	25 ml O	P 🖌	Biomed
6.95	50	✓]	Hygroton
16.00	90	•	Dapa-Tabs
CBS	1 50		Metolazone ^{S29} Zaroxolyn ^{S29}
	28 OP 56 OP 56 OP		Jinarc Jinarc Jinarc Jinarc Jinarc
	(Manufacturer's Pri	(Manufacturer's Price) S Per	(Manufacturer's Price) Subsidised 3.68 100 •

► SA2166 Special Authority for Subsidy

Initial application — (autosomal dominant polycystic kidney disease) only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease; and
- 2 Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 ml/min/1.73 m² at treatment initiation; and
- 3 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price) 8	Subsidised	Generic	
\$	Per	1	Manufacturer	

- 3.1 Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m² within one-year; or
- 3.2 Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period.

Renewal — (autosomal dominant polycystic kidney disease) only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m²; and
- 2 Patient has not undergone a kidney transplant.

Lipid-Modifying Agents

Fibrates		
BEZAFIBRATE * Tab 200 mg		 ✓ <u>Bezalip</u> ✓ <u>Bezalip</u> Retard
Other Lipid-Modifying Agents		
ACIPIMOX * Cap 250 mg	.56 30 5.44	 ✓ Olbetam S29 \$29 ✓ Olbetam
Resins		
COLESTIPOL HYDROCHLORIDE Grans for oral liq 5 g	2.89 30	✓ Colestid
Powder for oral suspension 4 g sachet	.50 50	 Colestyramine - Mylan \$299 Quantalan sugar free \$299
HMG CoA Reductase Inhibitors (Statins)		
ATORVASTATIN * Tab 10 mg	0.24 500 0.92 500 0.54 500 7.16 100	 Lorstat Lorstat Lorstat Lorstat Clinect Clinect

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
ROSUVASTATIN – Special Authority see SA2093 below – Reta	il pharmacy		
* Tab 5 mg	1.29	30	 Rosuvastatin Viatris
Rosuvastatin Viatris to be Principal Supply on 1 Octobe	r 2024		
* Tab 10 mg	1.69	30	 Rosuvastatin Viatris
Rosuvastatin Viatris to be Principal Supply on 1 Octobe	r 2024		
* Tab 20 mg	2.71	30	Rosuvastatin Viatris
* Tab 40 mg		30	 Rosuvastatin Viatris

⇒SA2093 Special Authority for Subsidy

Initial application — (cardiovascular disease risk) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Patient is considered to be at risk of cardiovascular disease; and
- 1.2 Patient is Māori or any Pacific ethnicity; or

2 Both:

- 2.1 Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
- 2.2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (familial hypercholesterolemia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
- 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (established cardiovascular disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

1 Any of the following:

- 1.1 Patient has proven coronary artery disease (CAD); or
- 1.2 Patient has proven peripheral artery disease (PAD); or
- 1.3 Patient has experienced an ischaemic stroke; and
- 2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (recurrent major cardiovascular events) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke,
- coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
- 2 LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

(Ma	Subsidy anufacturer's Price	e)	Fully Subsidised	
	\$	Per	1	Manufacturer
SIMVASTATIN				
* Tab 10 mg	1.68	90	1	Simvastatin Mylan
				Simvastatin Viatris
₭ Tab 20 mg	2.54	90		Simvastatin Viatris
🖌 Tab 40 mg	4.11	90		Simvastatin Mylan
			1	Simvastatin Viatris
Simvastatin Viatris to be Principal Supply on 1 June 2024				• · · · •
₭ Tab 80 mg	8.81	90		Simvastatin Mylan
Oliverse table Mistic to be Driveled Orentz and these 0004			~	Simvastatin Viatris
Simvastatin Viatris to be Principal Supply on 1 June 2024				
Simvastatin Mylan Tab 40 mg to be delisted 1 December 2024)				
Simvastatin Mylan Tab 80 mg to be delisted 1 September 2024)				
Selective Cholesterol Absorption Inhibitors				
ZETIMIBE				
₭ Tab 10 mg	1 76	30	1	Ezemibe Viatris
		00		Ezetimibe Sandoz
			•	
				-
Tab 10 mg with simvastatin 10 mg		30		Zimybe
Tab 10 mg with simvastatin 20 mg		30		Zimybe
Tab 10 mg with simulatatin 40 mg		30		Zimybe
Tab 10 mg with simvastatin 80 mg	8.15	30	•	Zimybe
Nitrates				
GLYCERYL TRINITRATE				
Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO	7 40 05	i0 dose		Nitrolingual Pump
		o uose	Ur •	•
C Datab 05 mg 5 mg par day	15 70	30		Spray Nitroderm TTS
Patch 25 mg, 5 mg per day Datch 50 mg, 10 mg per day				
Patch 50 mg, 10 mg per day	18.62	30	•	Nitroderm TTS
SOSORBIDE MONONITRATE				
₭ Tab 20 mg		100		Ismo 20
K Tab long-acting 40 mg		30		Ismo 40 Retard
Fab long-acting 60 mg	13.50	90	~	Duride
Sympathomimetics				
ADRENALINE	4.00	-		Aanan Advanatin-
Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO		5		Aspen Adrenaline
	12.65	-		DBL Adrenaline
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO .	27.00 49.00	5 10	-	Hospira
			~	Aspen Adrenaline

56

 Tab 25 mg - Special Authority see SA1321 below - Retail pharmacy		Subsidy		Fully	Brand or
Vasodilators HYDRALAZINE HYDROCHLORIDE * Tab 25 mg - Special Authority see SA1321 below - Retail pharmacy		· · · · · · · · · · · · · · · · · · ·	_		
HYDRALAZINE HYDROCHLORIDE * Tab 25 mg - Special Authority see SA1321 below - Retail pharmacy		\$	Per		Manufacturer
HYDRALAZINE HYDROCHLORIDE * Tab 25 mg - Special Authority see SA1321 below - Retail pharmacy	Vasodilators				
 Tab 25 mg - Special Authority see SA1321 below - Retail pharmacy	Vasoullators				
pharmacy	HYDRALAZINE HYDROCHLORIDE				
56 ✓ Onelink S™ 84 ✓ AMDIPHARM S™ 100 ✓ Camber S™ 100 ✓ Camber S™ >SA1321 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meetir he following criteria: Either: 1 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to AG inhibitors and/or angiotensin receptor blockers. WINOXIDIL Tab 10 mg Tab 10 mg 47.04 60 ✓ Minoxidil Roma S™ 78.40 100 ✓ Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details Tab 20 mg 21.73 60 ✓ Max Health PAPAVERINE HYDROCHLORIDE 21.73 60 ✓ Max Health PAPAVERINE HYDROCHLORIDE 25.712 5 ✓ Hospira PENTOXIFYLLINE [OXPENTIFYLLINE] 42.26 50 ✓ Trental 400 Endothelin Receptor Antagonists 200.00 30 ✓ Ambrisentan Viatris	* Tab 25 mg – Special Authority see SA1321 below – Retail				
84 ✓ AMDIPHARM 529 100 ✓ Camber 529 >SA1321 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meetir he following criteria: Either: 1 For the treatment of refractory hypertension; or 2 For the treatment of neart failure in combination with a nitrate, in patients who are intolerant or have not responded to AG inhibitors and/or angiotensin receptor blockers. WINOXIDIL 47.04 60 ✓ Minoxidil Roma 529 1 Tab 10 mg 47.04 60 ✓ Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details 4 100 ✓ Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details 4 100 ✓ Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details 4 100 ✓ Loniten ATab 20 mg 21.73 60 ✓ Max Health 4 PAPAVERINE HYDROCHLORIDE 4 4 4 4 4 * Inj 12 mg per ml, 10 ml ampoule 257.12 5 ✓ Hospira *ENTOXIFYLLINE [OXPENTIFYLLINE] 42.26 50 ✓ Trental 400	pharmacy	CBS	1	✓ Н	ydralazine
100 Camber 329 ** Inj 20 mg ampoule 25.90 ** SA1321 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meetir the following criteria: Either: 1 2 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to Ad inhibitors and/or angiotensin receptor blockers. VIIOXIDIL Tab 10 mg * Tab 10 mg 47.04 60 * Tab 10 mg 21.73 60 * Tab 20 mg 27.44 60 * Tab 20 mg 257.12 5 * Hospira 257.12 5 * Hospira 257.12 5 * Tab 400 mg 42.26 50 * Trental 400 Candber Mill 92 92 * Hospira * Particular Experimentary 42.26 50 * Trental 400 * Tab 400 mg 200			56	√ 0	nelink S29
 Inj 20 mg ampoule			84	🗸 A	MDIPHARM S29
 SA1321 Special Authority for Subsidy mitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to Ad inhibitors and/or angiotensin receptor blockers. VINOXIDIL Tab 10 mg 47.04 60 / Minoxidil Roma ^{\$29} 78.40 100 / Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details Tab 10 mg 21.73 60 / Max Health Tab 20 mg 27.44 60 / Max Health PAPAVERINE HYDROCHLORIDE * Inj 12 mg per ml, 10 ml ampoule 257.12 5 / Hospira PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg 42.26 50 / Trental 400 Endothelin Receptor Antagonists 			100	✓ C	amber S29
nitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to AC inhibitors and/or angiotensin receptor blockers. WINOXIDIL ▲ Tab 10 mg	* Inj 20 mg ampoule		5	🗸 A	presoline
nitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to AC inhibitors and/or angiotensin receptor blockers. WINOXIDIL ▲ Tab 10 mg	SA1321 Special Authority for Subsidy				
he following criteria: Either: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to AC inhibitors and/or angiotensin receptor blockers. WINOXIDIL ▲ Tab 10 mg		d without further rene	wal u	Inless notified	d for applications meeting
1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to AG inhibitors and/or angiotensin receptor blockers. WINOXIDIL Tab 10 mg 47.04 60 ✓ Minoxidil Roma 🐲 Tab 10 mg 78.40 100 ✓ Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details ✓ Loniten Tab 10 mg 21.73 60 ✓ Max Health Tab 20 mg 27.44 60 ✓ Max Health PAPAVERINE HYDROCHLORIDE 27.44 60 ✓ Max Health * Inj 12 mg per ml, 10 ml ampoule 257.12 5 ✓ Hospira PENTOXIFYLLINE [OXPENTIFYLLINE] 42.26 50 ✓ Trental 400 Endothelin Receptor Antagonists 200.00 30 ✓ Ambrisentan Viatris AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy 200.00 30 ✓ Ambrisentan Viatris Tab 10 mg 200.00 30 ✓ Ambrisentan Viatris	the following criteria:				
2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to Ad inhibitors and/or angiotensin receptor blockers. VIINOXIDIL Tab 10 mg 47.04 60 ✓ Minoxidil Roma 🖘 A Tab 10 mg 78.40 100 ✓ Loniten VICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details ✓ Max Health A Tab 10 mg 21.73 60 ✓ Max Health A Tab 20 mg 27.44 60 ✓ Max Health PAPAVERINE HYDROCHLORIDE 27.44 60 ✓ Max Health * Inj 12 mg per ml, 10 ml ampoule 257.12 5 ✓ Hospira PENTOXIFYLLINE [OXPENTIFYLLINE] 42.26 50 ✓ Trental 400 Endothelin Receptor Antagonists AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy 200.00 30 ✓ Ambrisentan Viatris Tab 10 mg 200.00 30 ✓ Ambrisentan Viatris	Either:				
inhibitors and/or angiotensin receptor blockers. WINOXIDIL ▲ Tab 10 mg	1 For the treatment of refractory hypertension; or				
inhibitors and/or angiotensin receptor blockers. WINOXIDIL ▲ Tab 10 mg	2 For the treatment of heart failure in combination with a nit	rate, in patients who a	are in	tolerant or ha	ave not responded to ACE
Tab 10 mg					
78.40 100 ✓ Loniten NICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details ✓ Tab 10 mg 21.73 60 ✓ Tab 20 mg 27.44 60 ✓ PAPAVERINE HYDROCHLORIDE ✓ Max Health * Inj 12 mg per ml, 10 ml ampoule .257.12 5 ✓ PENTOXIFYLLINE [OXPENTIFYLLINE] .42.26 50 ✓ Trental 400 Endothelin Receptor Antagonists AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy Tab 5 mg .200.00 30 ✓ Ambrisentan Viatris Tab 10 mg .200.00 30 ✓ Ambrisentan Viatris	MINOXIDIL				
78.40 100 ✓ Loniten NICORANDIL – Brand switch fee payable (Pharmacode 2677903) - see page 265 for details ✓ Tab 10 mg 21.73 60 ✓ Tab 20 mg 27.44 60 ✓ PAPAVERINE HYDROCHLORIDE ✓ Max Health * Inj 12 mg per ml, 10 ml ampoule .257.12 5 ✓ PENTOXIFYLLINE [OXPENTIFYLLINE] .42.26 50 ✓ Trental 400 Endothelin Receptor Antagonists AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy Tab 5 mg .200.00 30 ✓ Ambrisentan Viatris Tab 10 mg .200.00 30 ✓ Ambrisentan Viatris	▲ Tab 10 mg	47 04	60	🖌 M	inoxidil Roma S29
▲ Tab 10 mg					
▲ Tab 10 mg	NICORANDII - Brand switch fee payable (Pharmacode 267790	3) - see nage 265 for	dota	ile –	
▲ Tab 20 mg					ax Health
PAPAVERINE HyDROCHLORIDE ** Inj 12 mg per ml, 10 ml ampoule	5				
 * Inj 12 mg per ml, 10 ml ampoule	-				
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg Endothelin Receptor Antagonists AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy Tab 5 mg Tab 10 mg 200.00 30 ✓ Ambrisentan Viatris Ambrisentan Viatris		257 10	5	/ u	ocnira
Tab 400 mg 42.26 50 Trental 400 Endothelin Receptor Antagonists AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy 30 <u>Ambrisentan Viatris</u> Tab 5 mg 200.00 30 <u>Ambrisentan Viatris</u> Tab 10 mg 200.00 30 <u>Ambrisentan Viatris</u>			5	• 1	ospila
Endothelin Receptor Antagonists AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy Tab 5 mg		40.00		<i>.</i>	
AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy Tab 5 mg	l ab 400 mg		50	✓ 1	rental 400
AMBRISENTAN – Special Authority see SA2253 below – Retail pharmacy Tab 5 mg	Endethelin Decenter Antegoniste				
Tab 5 mg30✓Ambrisentan ViatrisTab 10 mg30✓Ambrisentan Viatris	Endothelin Receptor Antagonists				
Tab 5 mg30✓Ambrisentan ViatrisTab 10 mg30✓Ambrisentan Viatris	AMBRISENTAN - Special Authority see SA2253 below - Retail	pharmacy			
5			30	🗸 A	mbrisentan Viatris
xxCA2252 Special Authority for Subcidy	Tab 10 mg		30	🗸 🖌	mbrisentan Viatris
TOMACON DURING MULTURING DUDSION	➡SA2253 Special Authority for Subsidy				

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and

4 Any of the following:

4.1 All of the following:

- 4.1.1 PAH has been confirmed by right heart catheterisation; and
- 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
- 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
- 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	F	ully Brand or	
(Manufacturer's	S Price) Subsidi	sed Generic	
\$	Per	 Manufacture 	er

cm⁻⁵); and

- 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Ambrisentan is to be used as PAH monotherapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects with both sildenafil and bosentan; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 All of the following:
 - 5.1 Ambrisentan is to be used as PAH dual therapy; and
 - 5.2 Either:

continued...

58

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 5.2.1 Patient has tried a PAH monotherapy (sildenafil or bosentan) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; or
- 5.2.2 Patient has tried PAH dual therapy including bosentan and has experienced intolerable side effects on bosentan; and
- 5.3 Both:
 - 5.3.1 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy; and
 - 5.3.2 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease).

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Ambrisentan is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Both:
 - 5.2.2.1 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.2.2.2 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

continued...

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	1	Manufacturer	

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where the patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and</u> treatment of pulmonary hypertension PAH

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Tab 62.5 mg	 60	✓ Bosentan Dr Reddy's
Tab 125 mg	 60	✓ <u>Bosentan Dr</u> <u>Reddy's</u>

SA2254 Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

- 5.1 Bosentan is to be used as PAH monotherapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil; or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	ubsidised	Generic
\$	Per	✓	Manufacturer

applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Bosentan is to be used as part of PAH dual therapy; and
- 6 Either:
 - 6.1 Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool**; or
 - 6.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	✓	Manufacturer	

- 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

- 5.1 Bosentan is to be used as part of PAH triple therapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from bosentan treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and</u> treatment of pulmonary hypertension PAH

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL - Special Authority see SA2255 below - Retail pharmacy

Tab 25 mg	4	🗸 Vedafil
Tab 50 mg1.70	4	🗸 Vedafil
•	12	✓ Vedafil

➡SA2255 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Initial application — (Pulmonary arterial hypertension*) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following:

1 Patient has pulmonary arterial hypertension (PAH)*; and

continued...

62

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	1	Manufacturer	

- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH is confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg; and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance (PVR) of at least 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures.

Initial application — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has a documented history of traumatic or non-traumatic spinal cord injury; and
- 2 Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment.

Renewal — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Note: Indications marked with * are Unapproved Indications.

† The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of</u> pulmonary hypertension PAH

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Prostacyclin Analogues

EPOPROSTENOL - Special Authority see SA2256 below - Re	etail pharmacy		
Inj 500 mcg vial		1	 Veletri
Inj 1.5 mg vial	73.21	1	🗸 Veletri

⇒SA2256 Special Authority for Subsidy

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- $2\;$ PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:

		ully Br	and or
(Manufac	cturer's Price) Subsidi	sed Ge	eneric
	\$ Per	 Ma 	anufacturer

- 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵): and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these auidelines) + : or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 All of the following:
 - 5.1 Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.3 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool.

Initial application - (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV: and
- 4 Any of the following:
 - 4.1 All of the following:

Principal Supply

- 4.1.1 PAH has been confirmed by right heart catheterisation; and
- 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
- 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
- 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
- 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these quidelines) † ; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and

- 5 Both:
 - 5.1 Epoprostenol is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from epoprostenol treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and</u> treatment of pulmonary hypertension PAH

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

ILOPROST – Special Authority see SA2257 below – Retail pharmacy

🗸 Vebulis

30

⇒SA2257 Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

Subsidy	y Fu	ly Brand or
(Manufacturer'	s Price) Subsidise	d Generic
\$	Per	Manufacturer

5 Both:

- 5.1 Iloprost is to be used as PAH monotherapy; and
- 5.2 Either:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan); or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 All of the following:
 - 5.1 Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Either:
 - 5.2.1 Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist; and
 - 5.3 Either:
 - 5.3.1 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; or
 - 5.3.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

66

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Iloprost is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</u>

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

	Subsidy (Manufacturer's Price \$) Sub Per	Fully osidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterial	s, page 95			
ADAPALENE				
a) Maximum of 30 g per prescription				
b) Only on a prescription				
Gel 0.1%		30 g OP	✓ [Differin
ISOTRETINOIN - Special Authority see SA2023 below - Retai	l pharmacy			
Cap 5 mg		60	✓ (Dratane
Cap 10 mg		120	✓	Dratane
Cap 20 mg		120	 	Dratane

➡SA2023 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Either:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
- 2 Patient is not of child bearing potential.

TRETINOIN

Crm 0.5 mg per g $-$ Maximum of 50 g per prescription .	15.57	50 g OP	✓ <u>ReTrieve</u>	
Antibacterials Topical				
For systemic antibacterials, refer to INFECTIONS, Antibacter	erials, page 95			
HYDROGEN PEROXIDE * Crm 1%	8 56	10 g OP	✓ Crystaderm	
MUPIROCIN		10 9 01	• Orystaderin	
Oint 2%		15 g OP		
	(13.00)		Bactroban	
 a) Only on a prescription 				

b) Not in combination

68

DERMATOLOGICALS

	Qubaidu			—
	Subsidy (Manufacturer's I	Price) Subs	Fully Brand or sidised Generic	
	\$	Per	 Manufacturer 	
SODIUM FUSIDATE [FUSIDIC ACID]				_
Crm 2%	1.59	5 g OP	 Foban 	
a) Maximum of 5 g per prescription		- 5 -		
b) Only on a prescription				
c) Not in combination				
Oint 2%	1.59	5 g OP	 Foban 	
a) Maximum of 5 g per prescription				
b) Only on a prescription				
c) Not in combination				
SULFADIAZINE SILVER	40.00			
Crm 1%		50 g OP	 Flamazine 	
a) Up to 250 g available on a PSO				
b) Not in combination				
Antifungals Topical				
For systemic antifungals, refer to INFECTIONS, Antifungals,	page 102			
AMOROLFINE				
a) Only on a prescription				
b) Not in combination				
Nail soln 5%	21.87	5 ml OP	✓ MycoNail	
CLOTRIMAZOLE				
* Crm 1%	1.10	20 g OP	 Clomazol 	
a) Only on a prescription				
b) Not in combination	4.00			
* Soln 1%		20 ml OP	Conastan	
a) Only on a proparintian	(7.55)		Canesten	
a) Only on a prescriptionb) Not in combination				
,				
ECONAZOLE NITRATE Crm 1%	1.00	20 g OP		
0111176	(8.09)	20 9 01	Pevaryl	
a) Only on a prescription	(0.00)		i ovalji	
b) Not in combination				
Foaming soln 1%, 10 ml sachets	9.89	3		
	(18.64)		Pevaryl	
a) Only on a prescription				
b) Not in combination				
MICONAZOLE NITRATE			_	
* Crm 2%	0.90	15 g OP	Multichem	
a) Only on a prescription				
b) Not in combination	4.00			
* Lotn 2%	4.36 (10.03)	30 ml OP	Daktarin	
a) Only on a prescription	(10.03)		Dariann	
b) Not in combination				
* Tinct 2%	4.36	30 ml OP		
	(12.10)	-	Daktarin	
a) Only on a prescription				
b) Not in combination				

	Subsidy (Manufacturer's P \$	rice) Sub: Per	Fully Brand or sidised Generic ✓ Manufacturer
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination			
Crm, aqueous, BP	3.45	100 g	 healthE Calamine Aqueous
ROTAMITON			
a) Only on a prescription			
b) Not in combination			4
Crm 10%	3.29	20 g OP	✓ <u>Itch-Soothe</u>
ENTHOL – Only in combination			
 Only in combination with a dermatological base or p With or without other dermatological galenicals. 	roprietary Topical C	orticosteriod –	Plain
Crystals	6.92	25 g	✓ MidWest
	29.60	100 g	 MidWest
Corticosteroids Topical			
or systemic corticosteroids, refer to CORTICOSTEROIDS A	ND RELATED AGE	NTS, page 85	
Corticosteroids - Plain			
ETAMETHASONE DIPROPIONATE			
Crm 0.05%		15 g OP	 Diprosone
	36.00	50 g OP	 Diprosone
Diprosone to be Principal Supply on 1 July 2024	0.00		
Oint 0.05%	2.96 36.00	15 g OP 50 g OP	 Diprosone Diprosone
Diprosone to be Principal Supply on 1 July 2024	30.00	50 y OF	
Oint 0.05% in propylene glycol base		30 g OP	 Diprosone OV
ETAMETHASONE VALERATE		J -	
Crm 0.1%	4.53	50 g OP	 Beta Cream
Cont 0.1%		50 g OP	✓ Beta Ointment
€ Lotn 0.1%		50 ml OP	✓ Betnovate
LOBETASOL PROPIONATE			
€ Cm 0.05%		30 g OP	 Dermol
€ Oint 0.05%		30 g OP	✓ Dermol
LOBETASONE BUTYRATE			
Crm 0.05%	5 38	30 g OP	
	(10.00)	50 g O.	Eumovate
YDROCORTISONE	()		· · ···•
Crm 1% – Only on a prescription	1 78	30 g OP	 Ethics
	20.40	500 g	✓ <u>Lunes</u> ✓ Noumed
 Powder – Only in combination 		25 g	✓ ABM
Up to 5% in a dermatological base (not proprietary To		0	
galenicals	-	,	0

70

DERMATOLOGICALS

	Subsidy		Fully	Brand or
	(Manufacturer's I \$	Price) Subs Per	sidised ✓	Generic Manufacturer
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN				
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% - Only	on			
a prescription		250 ml	 I 	DP Lotn HC
DP Lotn HC to be Principal Supply on 1 June 2024				
HYDROCORTISONE BUTYRATE				
Lipocream 0.1%		100 g OP		Locoid Lipocream
Oint 0.1%		100 g OP		Locoid
Milky emul 0.1%	12.33	100 ml OP	✓	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE			-	
Crm 0.1%		15 g OP	-	Advantan
Oint 0.1%	4.95	15 g OP		Advantan
MOMETASONE FUROATE			-	
Crm 0.1%		15 g OP		Elocon Alcohol Free
Oint 0.19/	3.10	50 g OP		Elocon Alcohol Free
Oint 0.1%	1.95 2.90	15 g OP 50 g OP		<u>Elocon</u> Elocon
Lotn 0.1%		30 g OP 30 ml OP		Elocon
	4.50	30 111 01	• !	
TRIAMCINOLONE ACETONIDE Crm 0.02%	6 40	100 g OP	1	Aristocort
Oint 0.02%		100 g OP		Aristocort
	0.01	100 g 01		
Corticosteroids - Combination				
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FL	JSIDIC ACIDI			
Crm 0.1% with sodium fusidate (fusidic acid) 2%		15 g OP		
	(10.45)	-	I	Fucicort
 a) Maximum of 15 g per prescription 				
 b) Only on a prescription 				
HYDROCORTISONE WITH MICONAZOLE - Only on a prescri	otion			
* Crm 1% with miconazole nitrate 2%	1.89	15 g OP	✓]	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - C	Only on a prescri	ption		
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	 I 	Pimafucort
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYC	IN AND NYSTA	TIN		
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 m	g			
and gramicidin 250 mcg per g – Only on a prescription		15 g OP		
	(9.28)		`	/iaderm KC
Parrier Creame and Emellionte				
Barrier Creams and Emollients				
Barrier Creams				
DIMETHICONE				
* Crm 5% pump bottle	4.30	500 ml OP	~ 1	nealthE
			• !	Dimethicone 5%
* Crm 10% pump bottle		500 ml OP	✓ 1	nealthE
				Dimethicone 10%
ZINC AND CASTOR OIL				
* Oint	4.25	500 g	 I 	Evara

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

DERMATOLOGICALS

	Subsidy (Manufacturer's Pr	rice) Subsi	Fully Brand or dised Generic
		Per	Manufacturer
Emollients			
AQUEOUS CREAM			
Crm	1.30	100 g	 healthE Aqueous Cream SLS Free
	1.73	500 g	 ✓ Evara ✓ <u>GEM Aqueous</u> <u>Cream</u>
CETOMACROGOL			
* Crm BP	1.99	500 g	 Cetomacrogol-AFT
CETOMACROGOL WITH GLYCEROL			
Crm 90% with glycerol 10%	2.13	500 ml OP	✓ Evara
	3.50	1,000 ml OP	✓ Evara
EMULSIFYING OINTMENT			
* Oint BP	3.13	500 g	✓ Emulsifying Ointment ADE
DIL IN WATER EMULSION			_
* Crm	2.04	500 g	 Fatty Cream AFT
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%	4.94	500 g OP	✓ White Soft Liquid Paraffin AFT
JREA			
* Crm 10%	1.37	100 g OP	 healthE Urea Cream
NOOL FAT WITH MINERAL OIL – Only on a prescription			
* Lotn hydrous 3% with mineral oil	5.60	1,000 ml	
	(14.96)		DP Lotion
	(20.53)		Alpha-Keri Lotion
	1.40	250 ml OP	
	(5.87)	4 000	DP Lotion
	5.60	1,000 ml	DIC Lation
	(23.91)		BK Lotion
	1.40	250 ml OP	BK Lotion
	(7.73)		
Other Dermatological Bases			
PARAFFIN			
White soft – Only in combination	4.74	450 g	 EVARA White Soft Paraffin
	4.99		 healthE
	19.00	2,500 g	 EVARA White Soft Paraffin
	19.99		healthE

(healthE White soft to be delisted 1 June 2024) (healthE White soft to be delisted 1 June 2024)

DERMATOLOGICALS

	Subsidy		Fully	Brand or
	(Manufacturer's Pric	e) Subs Per	sidised	Generic Manufacturer
	Ψ		-	Manulacturer
Minor Skin Infections				
POVIDONE IODINE				
Oint 10%	7.40	65 g OP	🗸 E	Betadine
a) Maximum of 130 g per prescriptionb) Only on a prescription				
Antiseptic Solution 10%	4.15	100 ml	✓ <u>F</u>	Riodine
Antiseptic soln 10%	3.83	15 ml	-	Riodine
	6.99	500 ml	✓ F	Riodine
Skin preparation, povidone iodine 10% with 30% alcohol		100 ml	_	
	(3.48)		E	Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol	1.63 (7.78)	100 ml	F	Pfizer
Parasiticidal Preparations				
DIMETHICONE				
* Lotn 4%	4.25	200 ml OP	✓ <u>ł</u>	<u>nealthE</u> Dimethicone 4% Lotion
IVERMECTIN - Special Authority see SA2294 below - Retail p	harmacy			
Tab 3 mg – Up to 100 tab available on a PSO		4	√ 9	Stromectol
1) PSO for institutional use only. Must be endorsed	with the name of the	e institution f	or whic	h the PSO is required an

- PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.
- 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.
- For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.

➡SA2294 Special Authority for Subsidy

Initial application — (Scables) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Either:

1 The person has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or

2 Both:

2.1 The person has a confirmed diagnosis of scabies or is a close contact of a scabies case; and

2.2 Either:

- 2.2.1 The person is unable to complete topical therapy; or
- 2.2.2 Previous treatment with topical therapy has been tried and not cleared the infestation.

Initial application — (Other parasitic infections) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 filariasis; or
- 2 cutaneous larva migrans (creeping eruption); or
- 3 strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Either:

1 The person has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or

2 Both:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price)	Sub	Fully sidised	Brand or Generic
	(Manulacturer 3 1 1106) \$	Per		Manufacturer
continued				
2.1 The person has a confirmed diagnosis of scable	s or is a close contact	of a scabie	es case;	and
2.2 Either:	th a wanter want			
2.2.1 The person is unable to complete topical 2.2.2 Previous treatment with topical therapy h		leared the	infesta	tion
Renewal — (Other parasitic infections) from any relevant problem ollowing criteria: Any of the following: 1 1 filariasis; or 2 cutaneous larva migrans (creeping eruption); or 3 strongyloidiasis. 1				
PERMETHRIN				
Lotn 5%	4.28 3	0 ml OP	✓ <u>F</u>	A-Scabies
Psoriasis and Eczema Preparations				
ACITRETIN – Special Authority see SA2024 below – Retail ph	armacy			
Cap 10 mg	•	60	I N I	lovatretin
Novatretin to be Principal Supply on 1 July 2024				
Cap 25 mg	57.37	60	🗸 N	lovatretin

Novatretin to be Principal Supply on 1 July 2024

⇒SA2024 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and 3 Either:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
- 2 Patient is not of child bearing potential.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Foam spray 500 mcg with calcipotriol 50 mcg per g Gel 500 mcg with calcipotriol 50 mcg per g Oint 500 mcg with calcipotriol 50 mcg per g	39.35	60 g OP 60 g OP 30 g OP	 Enstilar <u>Daivobet</u> <u>Daivobet</u>
CALCIPOTRIOL Oint 50 mcg per g	40.00	120 g OP	 Daivonex

	Subsidy		Fully Brand or
	(Manufacturer's Pi \$	rice) Sub Per	sidised Generic Manufacturer
COAL TAR	Ŷ		manaratian
Soln BP – Only in combination	36.25	200 ml	✓ Midwest
1) Up to 10% only in combination with a dermatologic			
2) With or without other dermatological galenicals.	a base of proprie	elary ropicary	
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SUL	PHUR		
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% an	d		
allantoin crm 2.5%	6.59	75 g OP	
	(8.00)		Egopsoryl TA
	3.43	30 g OP	
	(4.35)		Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Soln 12% with salicylic acid 2% and sulphur 4% oint	4.97	25 g OP	 Coco-Scalp
	7.95	40 g OP	 Coco-Scalp
PIMECROLIMUS – Special Authority see SA1970 below – Reta	il pharmacy		
 Maximum of 15 g per prescription 			
b) Note: a maximum of 15 g per prescription and no more t		tion per 12 we	
Cream 1%		15 g OP	 <u>Elidel</u>
SA1970 Special Authority for Subsidy			
nitial application only from a dermatologist, paediatrician, opht of a dermatologist, paediatrician or ophthalmologist. Approvals w			
neeting the following criteria:			
Both:			
 Both: Patient has atopic dermatitis on the eyelid; and Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to 			prificial dermatitis, rosacea,
 Patient has atopic dermatitis on the eyelid; and Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. 	pical corticosteroi	ds, cataracts,	prificial dermatitis, rosacea, glaucoma, or raised intraocular
 Both: Patient has atopic dermatitis on the eyelid; and Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE 	pical corticosteroi SCEIN – Only or	ids, cataracts, n a prescriptio	prificial dermatitis, rosacea, glaucoma, or raised intraoculai n
 Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ₭ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium 	pical corticosteroi SCEIN – Only or	ds, cataracts,	prificial dermatitis, rosacea, glaucoma, or raised intraocula
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ₭ Soln 2.3% with trolamine laurilsulfate and fluorescein sodiun SALICYLIC ACID	pical corticosteroi SCEIN – Only or 15.41	ids, cataracts, n a prescriptio 500 ml	prificial dermatitis, rosacea, glaucoma, or raised intraocular n Ý <u>Pinetarsol</u>
 Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodiun SALICYLIC ACID Powder – Only in combination 	pical corticosteroi SCEIN – Only or 15.41	ids, cataracts, n a prescriptio 500 ml 250 g	prificial dermatitis, rosacea, glaucoma, or raised intraocular n <u>✓ Pinetarsol</u> ✓ Midwest
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ₭ Soln 2.3% with trolamine laurilsulfate and fluorescein sodiun SALICYLIC ACID	pical corticosteroi SCEIN – Only or 15.41	ids, cataracts, n a prescriptio 500 ml 250 g	prificial dermatitis, rosacea, glaucoma, or raised intraocula n ✓ <u>Pinetarsol</u> ✓ Midwest
 Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination	pical corticosteroi SCEIN – Only or 15.41	ids, cataracts, n a prescriptio 500 ml 250 g	prificial dermatitis, rosacea, glaucoma, or raised intraocula n ✓ <u>Pinetarsol</u> ✓ Midwest
 Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g	prificial dermatitis, rosacea, glaucoma, or raised intraocula n ✓ <u>Pinetarsol</u> ✓ Midwest
 Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder – Only in combination 1) Only in combination with a dermatological base or 2) With or without other dermatological galenicals. 	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g al Corticoster 100 g	 prificial dermatitis, rosacea, glaucoma, or raised intraocula n Pinetarsol Midwest oid – Plain or collodion flexible Midwest
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination 1) Only in combination with a dermatological base or 2) With or without other dermatological galenicals. SULPHUR Precipitated - Only in combination with a dermatological base or 1) Only in combination 1) Only in combination	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g al Corticoster 100 g	 prificial dermatitis, rosacea, glaucoma, or raised intraocula n Pinetarsol Midwest oid – Plain or collodion flexible Midwest
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g al Corticoster 100 g	 prificial dermatitis, rosacea, glaucoma, or raised intraocula n Pinetarsol Midwest oid – Plain or collodion flexible Midwest
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g al Corticoster 100 g al Corticoster	prificial dermatitis, rosacea, glaucoma, or raised intraocula n <u>Y Pinetarsol</u> <u>Y Midwest</u> oid – Plain or collodion flexible Midwest oid – Plain
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination 1) Only in combination with a dermatological base or 2) With or without other dermatological galenicals. SULPHUR Precipitated - Only in combination with a dermatological base or 1) Only in combination adermatological base or 2) With or without other dermatological galenicals.	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g al Corticoster 100 g	 prificial dermatitis, rosacea, glaucoma, or raised intraocula n Pinetarsol Midwest oid – Plain or collodion flexible Midwest
Both: 1 Patient has atopic dermatitis on the eyelid; and 2 Patient has at least one of the following contraindications documented epidermal atrophy, documented allergy to to pressure. PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE ★ Soln 2.3% with trolamine laurilsulfate and fluorescein sodium SALICYLIC ACID Powder - Only in combination	pical corticosteroi SCEIN – Only or 1	ids, cataracts, n a prescriptio 500 ml 250 g al Corticoster 100 g al Corticoster 30 g OP	orificial dermatitis, rosacea, glaucoma, or raised intraocula n <u>Pinetarsol</u> <u>Midwest</u> oid – Plain or collodion flexible <u>Midwest</u> oid – Plain

DERMATOLOGICALS

(Manufacturer's Price) Subsidised Generic \$ Per ✔ Manufacturer
--

SA2074 Special Authority for Subsidy

Initial application only from a dermatologist, paediatrician or any relevant practitioner on the recommendation of a dermatologist, paediatrician, . Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Patient has atopic dermatitis on the face; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids.

Scalp Preparations			
BETAMETHASONE VALERATE			
* Scalp app 0.1%	9.84	100 ml OP	 <u>Beta Scalp</u>
CLOBETASOL PROPIONATE * Scalp app 0.05%	6.26	30 ml OP	✓ Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	6.57	100 ml OP	✓ Locoid
KETOCONAZOLE	0.00		
Shampoo 2%	3.23 4.09	100 ml OP	 ✓ <u>Sebizole</u> ✓ Sebizole
a) Maximum of 100 ml per prescription			
b) Only on a prescription			
Sunscreens			
SUNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity s endorsed accordingly.	econdary to a de	fined clinical co	ndition and the prescription is
Lotn,	6.50	200 g OP	✓ Marine Blue Lotion SPF 50+
Wart Preparations			
For salicylic acid preparations refer to PSORIASIS AND ECZEM	A PREPARATIO	NS, page 74	
PODOPHYLLOTOXIN			_
Soln 0.5%a) Maximum of 3.5 ml per prescription		3.5 ml OP	 Condyline
b) Only on a prescription			
Other Skin Preparations			
Antineoplastics			
FLUOROURACIL SODIUM	0.05	00 × 00	
		20 g OP	Efudix
IMIQUIMOD Crm 5%, 250 mg sachet	21.72	24	🗸 Perrigo

Per ✓ Manufacturer

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Con	traceptives - Non-hormonal				
Con	doms				
COND	OMS				
* 49	mm - Up to 144 dev available on a PSO	11.42	144	✓	Moments
₭ 53	mm	0.95	10	✓	Moments
		11.64	144	✓	Moments
	 Maximum of 60 dev per prescription 				
	 b) Up to 60 dev available on a PSO 				
₭ 53	mm, 0.05 mm thickness	0.95	10		Moments
		11.42	144	✓	Moments
	 a) Up to 60 dev available on a PSO 				
	 b) Maximum of 60 dev per prescription 				
€ 53	mm, chocolate, brown		10		Moments
		11.64	144	1	Moments
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription				
€ 53	mm, strawberry, red		10		Moments
		11.64	144	1	Moments
	 a) Up to 60 dev available on a PSO 				
	 b) Maximum of 60 dev per prescription 				
€ 56	mm		10		Moments
		11.64	144	1	Moments
	a) Maximum of 60 dev per prescription				
	 b) Up to 60 dev available on a PSO 				
€ 56	mm, 0.05 mm thickness		12		Gold Knight
		24.10	144	1	Gold Knight
	 a) Up to 60 dev available on a PSO 				
	 Maximum of 60 dev per prescription 				
€ 56	mm, 0.05mm thickness (bulk pack)	20.17	144	1	Gold Knight
	 Maximum of 60 dev per prescription 				
	 b) Up to 60 dev available on a PSO 				
€ 56	mm, 0.08 mm thickness	0.97	10		Moments
		11.64	144	✓	Moments
	 a) Up to 60 dev available on a PSO 				
	b) Maximum of 60 dev per prescription				
€ 56	mm, 0.08 mm thickness, red		10		Moments
		11.64	144	~	Moments
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription			-	
₭ 56	mm, chocolate		12	-	Gold Knight
		21.45	144	1	Gold Knight
	a) Up to 60 dev available on a PSO				
	b) Maximum of 60 dev per prescription			-	
€ 56	mm, strawberry		12		Gold Knight
		21.45	144	~	Gold Knight
	a) Up to 60 dev available on a PSO				
	 Maximum of 60 dev per prescription 			-	.
₭ 60	mm		12		Gold Knight XL
		21.89	144	~	Gold Knight XL
	a) Maximum of 60 dev per prescription				
70	b) Uprim 69 destance lable on a PSO	S29 Unapproved	d med	icine supplie	ed under Section 29
e 60	mm_khillsparst.ppiy	Sole Sebsidised	slabb	ly 🗸	Gold Knight XL

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
a) Maximum of 60 dev per prescriptionb) Up to 60 dev available on a PSO				
Contraceptive Devices				
INTRA-UTERINE DEVICE a) Up to 40 dev available on a PSO b) Only on a PSO ★ IUD 29.1 mm length × 23.2 mm width	29.80	1	✓ (MED NSHA Silver/ Copper Short Choice 380 7med Nsha Silver/ copper Short Choice TT380 Short
# IUD 33.6 mm length × 29.9 mm width	29.80	1		Choice TT380 Standard
₭ IUD 35.5 mm length × 19.6 mm width		1	√ <u>(</u>	Choice Load 375

Contraceptives - Hormonal

Combined Oral Contraceptives

⇒SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 mcg with desogestrel 150 mcg and 7 inert tab - Up	to		
	84 tab available on a PSO	10.00	84	 Mercilon 28

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets ·	-			
Up to 84 tab available on a PSO	1.50	84	✓	Lo-Oralcon 20 ED
* Tab 30 mcg with levonorgestrel 150 mcg	6.62	63		
	(16.50)			Microgynon 30
 a) Higher subsidy of \$15.00 per 63 tab with Special Auth b) Up to 63 tab available on a PSO * Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets Up to 84 tab available on a PSO ETHINYLOESTRADIOL WITH NORETHISTERONE 	-	the 84		ige Oralcon 30 ED
 Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 				
84 tab available on a PSO		84 112	✓	Brevinor 1/28 Brevinor-1 28 Day Norimin-1 28 Day
Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – U	р			•
to 84 tab available on a PSO		84	1	Norimin
(Brevinor-1 28 Day Tab 35 mcg with norethisterone 1 mg and 7 ir (Norimin 1 28 Day Tab 35 mcg with parathistorone 1 mg and 7 in				,

(Norimin-1 28 Day Tab 35 mcg with norethisterone 1 mg and 7 inert tab to be delisted 1 December 2024)

Progestogen-only Contraceptives

⇒SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

80

* Tab 30 mcg – Up to 84 tab available on a PSO	16.50	84	 Microlut
	22.00	112	 Microlut
✤ Subdermal implant (2 × 75 mg rods) – Up to 3 pack available			
on a PSO	106.92	1	✓ Jadelle
MEDROXYPROGESTERONE ACETATE			
Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO	9.18	1	 Depo-Provera
			•

	Subsidy (Manufacturer's Price) \$	Subsi Per	Fully dised	Brand or Generic Manufacturer
NORETHISTERONE Tab 350 mcg – Up to 84 tab available on a PSO		84	✓ <u>N</u>	oriday 28
Emergency Contraceptives				
LEVONORGESTREL * Tab 1.5 mg a) Maximum of 2 tab per prescription b) Up to 5 tab available on a PSO c) Note: Direct Provision by a pharmacist permitted under		1 Part I of Se	_	<u>evonorgestrel</u> <u>BNM</u>
Antiandrogen Oral Contraceptives				
Prescribers may code prescriptions "contraceptive" (code "O") whe and prescription charge will be as per other contraceptives, as follo • A maximum \$5.00 prescription charge (patient co-payment) r • prescription may be written for up to six months supply	ows:	for contrac	ception	. The period of supply

• prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to any non contraceptive prescription charges that apply, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

* Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs - Up

to 168 tab available on a PSO	5.08 168	✓ Ginet	
-------------------------------	----------	---------	--

Gynaecological Anti-infectives

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID

Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator8.43 (24.87)	100 g OP	Aci-Jel
CLOTRIMAZOLE		
* Vaginal crm 1% with applicators	35 g OP	 Clomazol
* Vaginal crm 2% with applicators	20 g OP	 Clomazol
MICONAZOLE NITRATE		
* Vaginal crm 2% with applicator	40 g OP	 Micreme
NYSTATIN	0	
Vaginal crm 100,000 u per 5 g with applicator(s)	75 g OP	✓ <u>Nilstat</u>

Myometrial and Vaginal Hormone Preparations

ERGOMETRINE MALEATE

Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	160.00	5	✓ DBL Ergometrine
OESTRIOL			
* Crm 1 mg per g with applicator	6.95	15 g OP	 Ovestin
* Pessaries 500 mcg	7.55	15	 Ovestin

	Subsidy		Fully Brand or
	(Manufacturer's Pric	e) Sub	sidised Generic
	\$	Per	 Manufacturer
	Ŧ		
OXYTOCIN – Up to 5 inj available on a PSO			
Inj 5 iu per ml, 1 ml ampoule		5	 Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule	5.98	5	 Oxytocin BNM
			✓ Oxytocin GH \$29
	11.00	10	✓ Oxytocin
	11.96	10	•
			Panpharma
(Oxytocin GH S29) Inj 10 iu per ml, 1 ml ampoule to be delis	ted 1 August 2024)		
OXYTOCIN WITH ERGOMETRINE MALEATE - Up to 5 inj	available on a PSO		
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml a		5	 Syntometrine
ing 5 id with ergometrine maleate 500 meg per mi, 1 mi a	inpoule	5	• Syntometrine
December 7. de 100 libre			
Pregnancy Tests - hCG Urine			
PREGNANCY TESTS - HCG URINE			
 a) Up to 200 test available on a PSO 			
b) Only on a PSO			
Cassette		40 test OP	 Smith BioMed Rapid
			Pregnancy Test
	10.00		• •
	16.00		 David One Step
			Cassette
			Pregnancy Test
Urinary Agents			
For urinary tract Infections refer to INFECTIONS, Antibacteria	als, page 113		
E Almha Daduatasa Inhihitara			
5-Alpha Reductase Inhibitors			
FINACTERIDE Creation Authority and CA0000 holowy Bot	ail pharmany		
FINASTERIDE – Special Authority see SA0928 below – Ret		400	
* Tab 5 mg	4.79	100	✓ <u>Ricit</u>
SA0928 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals	valid without further re	newal unles	s notified for applications meeting
the following criteria:			
Both:			
 Patient has symptomatic benign prostatic hyperplasia 	; and		
2 Either:			
2.1 The patient is intolerant of non-selective alpha	blockers or these are o	ontraindicat	ted; or
2.2 Symptoms are not adequately controlled with r			
Alpha-1A Adrenoreceptor Blockers			
Alpha-TA Autenoreceptor Diockers			
TAMSULOSIN HYDROCHLORIDE - Special Authority see	SA1022 bolow Dotail	nharmaou	
			Tomoulogin Day
* Cap 400 mcg		100	Tamsulosin-Rex
SA1032 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals	valid without further re-	newal unles	s notified for applications meeting
the following criteria:			and the second second second second
Both:			
 Patient has symptomatic benign prostatic hyperplasia 			
2. The patient is intelerant of nen calenting alpha blocks	ra ar thaga are contrain	diagtad	

2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

82

	Subsidy (Manufacturer's Pr \$	rice) Subsi Per	Fully dised	Brand or Generic Manufacturer
Other Urinary Agents				
OXYBUTYNIN * Tab 5 mg	5.42	100		lchemy Oxybutynin
POTASSIUM CITRATE Oral lig 3 mmol per ml – Special Authority see SA1083 belov	v —			
Retail pharmacy		200 ml OP	✔ В	iomed
SA1083 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both:	I for 12 months fo	or applications	meetin	g the following criteria:
 The patient has recurrent calcium oxalate urolithiasis; and The patient has had more than two renal calculi in the two 	vears prior to the	annlication		
Renewal from any relevant practitioner. Approvals valid for 2 yea benefitting from the treatment.			appro	priate and the patient is
SODIUM CITRO-TARTRATE * Grans eff 4 g sachets	3 50	28	✓ U	ral
SOLIFENACIN SUCCINATE			_	<u> </u>
Tab 5 mg Tab 10 mg		30 30		olifenacin Viatris olifenacin Viatris
Detection of Substances in Urine				
ORTHO-TOLIDINE				
* Compound diagnostic sticks	7.50 (8.25)	50 test OP	H	emastix
TETRABROMOPHENOL * Blue diagnostic strips		100 test OP	🗸 A	Ibustix
Obstetric Preparations				
Antiprogesterones				
MIFEPRISTONE Tab 200 mg – Up to 15 tab available on a PSO	79.90 180.00	1 3		ifegyne ifegyne

	Subsidy Manufacturer's Price)	ę	Fully Subsidised	Brand or Generic
	\$	Per	1	Manufacturer
Calcium Homeostasis				
CALCITONIN				
* Inj 100 iu per ml, 1 ml ampoule	121.00	5	🗸 M	liacalcic
CINACALCET - Special Authority see SA2170 below - Retail pha	irmacy			
Tab 30 mg – Wastage claimable		28	√ <u>C</u>	inacalet Devatis
Tab 60 mg – Wastage claimable		28	✓ C	inacalet Devatis
► SA2170 Special Authority for Subsidy				
Initial application — (parathyroid carcinoma or calciphylaxis)	only from a nephrol	ogist c	or endocrino	ologist. Approvals valid for
6 months for applications meeting the following criteria:	-			

Either:

1 All of the following:

- 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
- 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
- 1.3 The patient is symptomatic; or

2 All of the following:

- 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
- 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
- 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

Renewal — (parathyroid carcinoma or calciphylaxis) only from a nephrologist or endocrinologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.
- Note: This does not include parathyroid adenomas unless these have become malignant.

Initial application — (primary hyperparathyroidism) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has primary hyperparathyroidism; and
- 2 Either:
 - 2.1 Patient has hypercalcaemia of more than 3 mmol/L with or without symptoms; or
 - 2.2 Patient has hypercalcaemia of more than 2.85 mmol/L with symptoms; and
- 3 Surgery is not feasible or has failed; and
- 4 Patient has other comorbidities, severe bone pain, or calciphylaxis.

Initial application — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Patient has tertiary hyperparathyroidism and markedly elevated parathyroid hormone (PTH) with hypercalcaemia; or
- 1.2 Patient has symptomatic secondary hyperparathyroidism and elevated PTH; and
- 2 Patient is on renal replacement therapy; and
- 3 Any of the following:

fully subsidised

Principal Supply

3.1 Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations; or

continued 3.2 Parathyroid tissue is surgically inaccessible; or 3.3 Parathyroid surgery is not feasible. Renewal — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 12 months fo applications meeting the following citeria: Either: 1 The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically accept parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate. ZOLEDRONIC ACID In 4 mg per 5 ml, vial		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
3.3 Parathyroid surgery is not feasible. Renewal — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 12 months fo applications meeting the tollowing orteria: The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically accept parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate. ZOLEDRONIC ACID 1 ✓ Zoledronic acid Viatris In J am gp er 5 ml, vial 18.00 1 ✓ Zoledronic acid Viatris Corticosteroids and Related Agents for Systemic Use 5 Celestone BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE * 19.20 5 * Tab 0.5 mg – Up to 60 tab available on a PSO 2.65 30 ✓ Dexmethaone Oral liq 1 mg per ml. 19.20 5 Celestone Chronodose DEXAMETHASONE PHOSPHATE Examethasone phosphate injection will not be funded for oral use. * Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	continued				
applications meeting the following criteria: Ether: 1 The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically accept parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate. ZOLEDRONIC ACID Inj 4 mg per 5 ml, vial					
parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate. ZOLEDRONIC ACID Inj 4 mg per 5 ml, vial EXAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE ** Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml	applications meeting the following criteria:	any relevant practiti	ioner.	Approvals	valid for 12 months for
Inj 4 mg per 5 ml, vial 1 ✓ Zoledronic acid Viatris Corticosteroids and Related Agents for Systemic Use DETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml 19.20 5 (36.96) Celestone Chronodose DEXAMETHASONE * 1.50 30 ✓ Dexmethsone Chronodose DEXAMETHASONE * 1.50 30 ✓ Dexmethsone Chronodose DEXAMETHASONE * 1.50 30 ✓ Dexmethsone Chronodose DEXAMETHASONE PHOSPHATE Dexamethasone phosphate injection will not be funded for oral use. * Biomed VEXAMETHASONE ACETATE * 10 ✓ HameIn PLOPCORTISONE ACETATE * 11.46 100 ✓ Horinef * Inj 4 mg per ml, 1 mampoule – Up to 5 inj available on a PSO	parathyroid hormone (PTH) level to support ongoing cessal	tion of treatment ha	s not b	een reache	d; or
Viatris Viatris Viatris Orticosteroids and Related Agents for Systemic Use BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml 19.20 5 (36.96) Celestone Chronodose DEXAMETHASONE * Tab 4 mg - Up to 60 tab available on a PSO 2.65 30 ✓ Dexmethsone Oral liq 1 mg per ml mg per ml 52.80 25 ml OP ✓ Biomed DEXAMETHASONE PHOSPHATE Dexamethasone phosphate injection will not be funded for oral use. * Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO 7.86 10 ✓ HameIn FLUDRCCORTISONE ACETATE * Tab 100 mg 20 mg 20.32 100 ✓ Douglas * Tab 5 mg 8.10 100 ✓ Elorinef HYDROCORTISONE * Tab 5 mg 8.10 100 ✓ Douglas * Tab 2 mg 20.32 100 ✓ <td>ZOLEDRONIC ACID</td> <td></td> <td></td> <td></td> <td></td>	ZOLEDRONIC ACID				
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml	Inj 4 mg per 5 ml, vial		1	✓ <u>Z</u>	
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE ** Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml	Corticosteroids and Related Agents for Systemic	c Use			
* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml 19.20 (36.96) 5 Celestone Chronodose Celestone Chronodose DEXAMETHASONE * Tab 4 mg - Up to 80 tab available on a PSO 1.50 2.65 30 30 ✓ Dexmethsone Dexmethsone * Tab 4 mg - Up to 30 tab available on a PSO 2.65 30 30 ✓ Dexmethsone Dexmethasone phosphate injection will not be funded for oral use. * Inj 4 mg per ml, 1 ml ampoule - Up to 5 inj available on a PSO 7.86 10 10 ✓ Hamein Hamein * Tab 100 mcg. 11 46 100 100 ✓ Elorinef *YDROCORTISONE * Tab 20 mg 8.10 100 100 ✓ Douglas * Tab 20 mg 8.10 100 100 ✓ Douglas * Tab 20 mg 20.32 100 100 ✓ Douglas * Tab 20 mg 23.10 20 ✓ Medrol * Tab 20 mg 23.10 20 ✓ Medrol * Tab 20 mg 223.10 100 ✓ Douglas * Tab 100 mg vial 4.38 1 1 ✓ Solu-Cortef a) Not on a BSO b) Up to 5 inj available on a PSO 112.00 100 ✓ Medrol * Tab 100 mg CAS SODIUM SUCCINATE) Inj 40 mg vial 1 ✓ Solu-Medrol-Act- O-Vial In					
(36.96) Celestone Chronodose DEXAMETHASONE 30 ✓ Dexmethsone * Tab 0.5 mg - Up to 30 tab available on a PSO			5		
DEXAMETHASONE 30 ✓ Dexmethsone ** Tab 0.5 mg - Up to 60 tab available on a PSO			U	C	elestone
** Tab 0.5 mg - Up to 60 tab available on a PSO 1.50 30 ✓ Dexmethsone ** Tab 4 mg - Up to 30 tab available on a PSO 2.65 30 ✓ Dexmethsone Oral liq 1 mg per ml 52.80 25 ml OP ✓ Biomed DEXAMETHASONE PHOSPHATE 25 ml OP ✓ Biomed Dexamethasone phosphate injection will not be funded for oral use. * 10 ✓ HameIn * Inj 4 mg per ml, 1 ml ampoule - Up to 5 inj available on a PSO 7.86 10 ✓ HameIn * Inj 4 mg per ml, 2 ml ampoule - Up to 5 inj available on a PSO 13.10 10 ✓ HameIn FLUDROCORTISONE ACETATE 11.46 100 ✓ Elorinef HYDROCORTISONE 8.10 100 ✓ Douglas * Tab 2 0 mg 20.32 100 ✓ Douglas * Tab 2 0 mg 4.38 1 ✓ Solu-Cortef a) Not on a BSO 4.38 1 ✓ Solu-Cortef b) Up to 5 inj available on a PSO 223.10 100 ✓ Medrol WETHYLPREDNISOLONE 112.00 100 ✓ Medrol WETHYLPREDNISOLONE (AS SODIUM SUCCINATE) 11 1 ✓ Solu-Medrol-Act-O-Vial Inj 125 mg vial		()			Chronodose
* Tab 4 mg - Up to 30 tab available on a PSO 2.65 30 ✓ Dexmethsone Oral liq 1 mg per ml		4 50		1	
Oral liq 1 mg per ml .52.80 25 ml OP ✓ Biomed DEXAMETHASONE PHOSPHATE Dexamethasone phosphate injection will not be funded for oral use. 10 ✓ HameIn Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO .7.86 10 ✓ HameIn * Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO .13.10 10 ✓ HameIn FLUDROCORTISONE ACETATE * 10 ✓ Florinef HYDROCORTISONE .11.46 100 ✓ Florinef HYDROCORTISONE .20.32 100 ✓ Douglas * Tab 5 mg .20.32 100 ✓ Douglas * Tab 20 mg .20.32 100 ✓ Douglas * Tab 20 mg .20.32 100 ✓ Douglas * Tab 4 ng .20.31 .20.22 100 ✓ Solu-Cortef * Tab 4 mg .112.00 100 ✓ Medrol ✓ Solu-Medrol-Act-O-Vial Inj 125 mg vial .22.30 1 ✓ Solu-Medrol-Act-O-Vial O-Vial Inj 500 mg vial .26.88 1 ✓ Solu-Medrol-Act-O-Vial					
DEXAMETHASONE PHOSPHATE Dexamethasone phosphate injection will not be funded for oral use. Inj 4 mg per ml, 1 ml ampoule - Up to 5 inj available on a PSO7.86 10 ✓ HameIn Hinj 4 mg per ml, 2 ml ampoule - Up to 5 inj available on a PSO13.10 10 ✓ HameIn StuDROCORTISONE ACETATE 10 ✓ Florinef YDROCORTISONE 11.46 100 ✓ Elorinef YDROCORTISONE 8.10 100 ✓ Douglas K Tab 5 mg 8.10 100 ✓ Douglas K Tab 20 mg 20.32 100 ✓ Douglas K Tab 20 mg vial 4.38 1 ✓ Solu-Cortef a) Not on a BSO b) Up to 5 inj available on a PSO ✓ Medrol ✓ Medrol K Tab 4 mg 112.00 100 ✓ Medrol ✓ Medrol K Tab 4 mg 223.10 20 ✓ Medrol ✓ Solu-Medrol-Act-O-Vial Inj 125 mg vial 24 34.10 1 ✓ Solu-Medrol-Act-O-Vial Inj 500 mg vial 26.88 1 ✓ Solu-Medrol-Act-O-Vial					
** Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO7.86 10 - Hameln ** Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO13.10 10 - Hameln ** Tab 100 mcg	DEXAMETHASONE PHOSPHATE		5 111 01		loned
 * Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO13.10 10 Hameln FLUDROCORTISONE ACETATE * Tab 100 mcg			10	🗸 н	ameln
FLUDROCORTISONE ACETATE * Tab 100 mcg				_	
* Tab 100 mcg				_	
* Tab 5 mg 8.10 100 ✓ Douglas * Tab 20 mg 20.32 100 ✓ Douglas * Inj 100 mg vial 4.38 1 ✓ Solu-Cortef a) Not on a BSO b) Up to 5 inj available on a PSO 112.00 100 ✓ Medrol * Tab 4 mg 112.00 100 ✓ Medrol ✓ Medrol * Tab 100 mg 223.10 20 ✓ Medrol METHYLPREDNISOLONE 223.10 20 ✓ Medrol METHYLPREDNISOLONE (AS SODIUM SUCCINATE) 1 ✓ Solu-Medrol-Act-O-Vial Inj 40 mg vial 34.10 1 ✓ Solu-Medrol-Act-O-Vial Inj 500 mg vial 26.88 1 ✓ Solu-Medrol-Act-O-Vial		11.46	100	✓ <u>F</u>	lorinef
 * Tab 20 mg	HYDROCORTISONE				
 k Inj 100 mg vial	* Tab 5 mg	8.10	100	🗸 D	ouglas
a) Not on a BSO b) Up to 5 inj available on a PSO METHYLPREDNISOLONE * Tab 4 mg					
b) Up to 5 inj available on a PSO METHYLPREDNISOLONE * Tab 4 mg		4.38	1	✓ <u>s</u>	olu-Cortef
METHYLPREDNISOLONE * Tab 4 mg * Tab 4 mg * Tab 100 mg * Tab 100 mg 223.10 20 * Medrol METHYLPREDNISOLONE (AS SODIUM SUCCINATE) Inj 40 mg vial Inj 125 mg vial Inj 500 mg vial 20 21 223.10 20 * Solu-Medrol-Act-O-Vial 1 1 * Solu-Medrol-Act-O-Vial 1 1 * Solu-Medrol-Act-O-Vial 1 1 * Solu-Medrol-Act-O-Vial					
* Tab 4 mg 112.00 100 ✓ Medrol * Tab 100 mg 223.10 20 ✓ Medrol METHYLPREDNISOLONE (AS SODIUM SUCCINATE) 1 ✓ Solu-Medrol-Act-O-Vial Inj 40 mg vial					
* Tab 100 mg 20 ✓ Medrol METHYLPREDNISOLONE (AS SODIUM SUCCINATE) 1 ✓ Solu-Medrol-Act- O-Vial Inj 40 mg vial 34.10 1 ✓ Solu-Medrol-Act- O-Vial Inj 125 mg vial 34.10 1 ✓ Solu-Medrol-Act- O-Vial Inj 500 mg vial 26.88 1 ✓ Solu-Medrol-Act- O-Vial		110.00	400		• •
METHYLPREDNISOLONE (AS SODIUM SUCCINATE) 1 ✓ Solu-Medrol-Act-O-Vial Inj 40 mg vial 34.10 1 ✓ Solu-Medrol-Act-O-Vial Inj 500 mg vial 26.88 1 ✓ Solu-Medrol-Act-O-Vial					
Inj 40 mg vial 22.30 1 ✓ Solu-Medrol-Act-O-Vial Inj 125 mg vial 34.10 1 ✓ Solu-Medrol-Act-O-Vial Inj 500 mg vial 26.88 1 ✓ Solu-Medrol-Act-O-Vial	-	223.10	20	♥ IV	leuror
O-Vial Inj 125 mg vial 1 ✓ Solu-Medrol-Act- O-Vial Inj 500 mg vial 26.88 1 ✓ Solu-Medrol-Act- O-Vial		22.20	1	10	olu-Medrol-Act-
O-Vial Inj 500 mg vial	וון די ווע יומו		1	* 3	
O-Vial	Inj 125 mg vial	34.10	1	√ S	
	Inj 500 mg vial		1	√ S	
inj 1 g viai	Inj 1 g vial		1	√ S	olu-Medrol

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$	e) Per	Full Subsidise	/
METHYLPREDNISOLONE ACETATE				
Inj 40 mg per ml, 1 ml vial	47.06	5	~	Depo-Medrol
PREDNISOLONE				
 Oral liq 5 mg per ml – Up to 30 ml available on a PSO Restricted to children under 12 years of age. 	6.00	30 ml O	P 🗸	Redipred
PREDNISONE				
* Tab 1 mg		500	✓	Prednisone Clinect
* Tab 2.5 mg		500	✓	Prednisone Clinect
* Tab 5 mg – Up to 30 tab available on a PSO		500		Prednisone Clinect
* Tab 20 mg – Up to 30 tab available on a PSO	50.51	500	~	Prednisone Clinect
TETRACOSACTRIN				
* Inj 250 mcg per ml, 1 ml ampoule		1	1	Synacthen
Jee She year				UK Synacthen
* Inj 1 mg per ml, 1 ml ampoule		1		Synacthen Depot
			-	Synacthene
				Retard S29
FRIAMCINOLONE ACETONIDE				
Ini 10 mg per ml, 1 ml ampoule	21 42	5		Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule		5		Kenacort-A 40
Sex Hormones Non Contraceptive Androgen Agonists and Antagonists				
CYPROTERONE ACETATE				
Tab 50 mg		50		Siterone
Tab 100 mg		50	~	Siterone
ESTOSTERONE				
Gel (transdermal) 16.2 mg per g	52.00	88 g Ol	> √	Testogel
Testogel to be Principal Supply on 1 July 2024				
Patch 5 mg per day		30	~	Androderm
ESTOSTERONE CIPIONATE				
Inj 100 mg per ml, 10 ml vial		1	~	Depo-Testosterone
	393.00		✓	Taro-
				Testosterone S29
ESTOSTERONE ESTERS				
Inj 250 mg per ml, 1 ml	10 08	1		Sustanon Ampoules
	12.30	I	•	Sustanon Ampoules
ESTOSTERONE UNDECANOATE				
Cap 40 mg – Subsidy by endorsement		100		Steril-Gene S29
Subsidy by endorsement – subsidised for patients who				
1 November 2021 and the prescription is endorsed ac				
where there exists a record of prior dispensing of testo		•		
Inj 250 mg per ml, 4 ml vial	86.00	1	v	Reandron 1000

86

	Subsidy	Fu	ully Brand or
	(Manufacturer's Price)	Subsidis	ed Generic
	\$	Per	 Manufacturer
Hormone Replacement Therapy -	Systemic		
Oestrogens	·		
OESTRADIOL			
* Tab 1 mg		28 OP	-
W. Tab O and	(11.10)	~~~~	Estrofem
* Tab 2 mg		28 OP	F atura fa un
Datah 50 mag par 04 haura	(11.10)	4	Estrofem ✓ Climara
Patch 50 mcg per 24 hours		4	
a) No more than 1 patch per week			
b) Only on a prescription	0.05	0	
Patch 25 mcg per day			 Estradiol TDP Mylan
	13.50		Estraderm MX S29
	14.50		 Estradot
a) No more than 2 patch per week			
b) Only on a prescription			
Patch 50 mcg per day			 Estradiol TDP Mylan
			 Estradiol Viatris
	14.50		 Estraderm MX S29
			 Estradiol
			Sandoz S29
			 Estradot
a) No more than 2 patch per week			
b) Only on a prescription			
Patch 75 mcg per day		8	 Estradiol TDP Mylan
		,	 Estradiol Viatris
	14.50		 Estradiol
			Sandoz S29
			 Estradot
a) No more than 2 patch per week			
b) Only on a prescription			
Patch 100 mcg per day		8	 Estradiol TDP Mylan
·			 Estradiol Viatris
	14.50		 Estradiol
			Sandoz S29
			✓ Estradot
	15.50		 Estraderm MX \$29
a) No more than 2 patch per week	10.00		Estruction mix de
b) Only on a prescription			
· · · ·			
OESTRADIOL VALERATE			<i>.</i> -
Tab 1 mg			 Progynova
* Tab 2 mg		84	 Progynova
OESTROGENS			
* Conjugated, equine tab 300 mcg		28	
	(17.50)		Premarin
* Conjugated, equine tab 625 mcg	4.12	28	
-	(17.50)		Premarin

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Pubaidu		Eully	Brand or
	Subsidy (Manufacturer's Price) Sut	Fully osidised	Brand or Generic
	\$	Per	~	Manufacturer
Progestogens				
riogestogens				
MEDROXYPROGESTERONE ACETATE				
* Tab 2.5 mg		30		rovera
W. Tab Casa	8.75	56	-	rovera
* Tab 5 mg	9.80 17.50	56 100		Provera Provera
* Tab 10 mg		100 30	-	Provera
Progestogen and Oestrogen Combined Prep				
r rogestogen and bestrogen bombined r rep				
OESTRADIOL WITH NORETHISTERONE				
* Tab 1 mg with 0.5 mg norethisterone acetate	· · - · - ·	28 OP		
Mr. Tab O man the dama and the transmission of the	(18.10)	00.05	K	lliovance
* Tab 2 mg with 1 mg norethisterone acetate		28 OP		11:
	(18.10)		K	liogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg with 1 mg norethisterone acetate (10).		00 O D		
oestradiol tab (12) and 1 mg oestradiol tab (6)	· · - · - ·	28 OP	т	-
	(18.10)		1	risequens
Other Oestrogen Preparations				
Chief Coolicgen Proparations				
OESTRIOL				
* Tab 2 mg	7.70	30	✓ <u>c</u>	Vestin
Other Dregesteren Drenerstiene				
Other Progestogen Preparations				
LEVONORGESTREL				
* Intra-uterine device 52 mg		1	🗸 N	lirena
* Intra-uterine device 13.5 mg		1	🗸 🗸	aydess
MEDROXYPROGESTERONE ACETATE				
Tab 100 mg	116.15	100	🗸 P	Provera HD
NORETHISTERONE				
* Tab 5 mg – Up to 30 tab available on a PSO	5.49	30	🗸 P	Primolut N
PROGESTERONE				
* Cap 100 mg		30	🗸 U	Itrogestan
			_	3
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg	7 56	100	🖌 N	leo-Mercazole
-		100	• 1	
LEVOTHYROXINE	E EE	00		unthroid
* Tab 25 mcg * Tab 50 mcg		90 28		Synthroid Jercury Pharma
* 1 ab 50 mcg	5.79	28 90		lercury Pharma
	12.86	200		ltroxin
	64.28	1.000		Itroxin
* Tab 100 mcg		28		lercury Pharma
Ŭ	6.01	90		synthroid
	13.36	200		ltroxin
	66.78	1,000	✓ E	Itroxin

	Subsidy (Manufacturer's Price) \$	S Per	Fully Subsidised	Brand or Generic Manufacturer
PROPYLTHIOURACIL – Special Authority see SA1199 below – I	Retail pharmacy			
Tab 50 mg		100	🗸 P	TU \$29

➡SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

SOMATROPIN (OMNITROPE) - Special Authority see	SA2032 below – Retail pharmacy	
* Inj 5 mg cartridge		 Omnitrope
		 Omnitrope S29 S29
* Inj 10 mg cartridge		 Omnitrope
		 Omnitrope S29 S29
* Inj 15 mg cartridge		 Omnitrope
		✓ Omnitrope S29 S29

► SA2032 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or</p>
- 2 All of the following:
 - Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and</p>
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under ; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

90

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l)) × 40 = corrected GFR (ml/min/1.73m²) in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised		Generic	
\$	Per	✓	Manufacturer	

continued...

- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or
- 3 All of the following:
 - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
 - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
 - 3.3 The patient has severe growth hormone deficiency (see notes); and
 - 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and

	Subsidy	F	ully	Brand or
(1	Manufacturer's Price)	Subsid	sed	Generic
	\$	Per	1	Manufacturer

continued...

3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

GnRH Analogues

GOSERELIN

GOSERELIN			
Implant 3.6 mg, syringe		1	✓ <u>Zoladex</u>
Implant 10.8 mg, syringe	138.23	1	 Zoladex
LEUPRORELIN			
Additional subsidy by endorsement where the patient is a child	or adolescent	and is unable	to tolerate administration of
goserelin and the prescription is endorsed accordingly.			
Inj 3.75 mg prefilled dual chamber syringe – Higher subsidy of			
\$221.60 per 1 inj with Endorsement		1	
• •• •• • • • • • • •	(221.60)		Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy	(,		
of \$591.68 per 1 inj with Endorsement	177.50	1	
· · · · · · · · · · · · · · · · · · ·	(591.68)		Lucrin Depot 3-month
	(,		,
Vasopressin Agonists			
DESMOPRESSIN			_
Wafer 120 mcg	47.00	30	 Minirin Melt
DESMOPRESSIN ACETATE			
Tab 100 mcg	25.00	30	 Minirin
Tab 200 mcg	54.45	30	🗸 Minirin
▲ Nasal spray 10 mcg per dose	34.95	6 ml OP	 Desmopressin-
			PH&T
			4 • • • • •
Inj 4 mcg per ml, 1 ml	67.18	10	 Minirin
Other Friday in America			
Other Endocrine Agents			
CABERGOLINE			
Tab 0.5 mg – Maximum of 2 tab per prescription; can be			
waived by Special Authority see SA2070 on the next page	4 43	2	✓ Dostinex
warrow by openial nationaly see OA2070 on the next page		8	✓ Dostinex
	17.54	0	Dodinex

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Sul Per	Fully osidised	Brand or Generic Manufacturer
 SA2070 Special Authority for Waiver of Rule Initial application from any relevant practitioner. Approvals value the following: Hyperprolactinemia; or Acromegaly*; or Inhibition of lactation. Renewal — (for patients who have previously been funded up practitioner. Approvals valid without further renewal unless notifie which has expired and the treatment remains appropriate and the Note: Indication marked with * is an unapproved indication. 	nder Special Author	ity form has prev	SA1031 iously he) from any relevant
CLOMIFENE CITRATE Tab 50 mg	29.84	10	✓ N	lylan Clomiphen S29

Cap 250 mg	558.00	50	 Metopirone
------------	--------	----	--------------------------------

94

METYRAPONE

	Subsidy		Fully	Brand or
	(Manufacturer's Price)			Generic
	(Manalactarer 3 1 1100) \$	Per	1000 1	Manufacturer
	φ	Fei		Wanulaciulei
Anthelmintics				
ALBENDAZOLE - Special Authority see SA1318 below - Retain	il pharmacy			
Tab 400 mg		60	✓ E	skazole S29
► SA1318 Special Authority for Subsidy				
Initial application only from an infectious disease specialist or the second	olinical microbiologist	Approvale	valid f	for 6 months whore the
	cilinical microbiologist.	Approvais	vallu i	
patient has hydatids.				
Renewal only from an infectious disease specialist or clinical mi	icrobiologist. Approva	als valid for 6	6 mont	ths where the treatment
remains appropriate and the patient is benefitting from the treat	ment.			
MEBENDAZOLE – Only on a prescription				
Tab 100 mg	7.97	6	✓ V	/ermox
Oral lig 100 mg per 5 ml	2.18	15 ml		
	(7.83)		V	/ermox
	(1.00)		•	onnox
PRAZIQUANTEL				
Tab 600 mg		8	✓ E	Biltricide
		-		
Antibacterials				
Antibacteriais				
a) For topical antibacterials, refer to DERMATOLOGICALS, pa	ao 68			
b) For anti-infective eye preparations, refer to SENSORY ORG	ANS, page 260			
Conheleenevine and Conhemusine				
Cephalosporins and Cephamycins				
CEFACLOR MONOHYDRATE				
Cap 250 mg		100		anbaxy-Cefaclor
Grans for oral lig 125 mg per 5 ml – Wastage claimable	3.75	100 ml	🗸 F	anbaxy-Cefaclor
CEFALEXIN				-
	0.05			
Cap 250 mg		20		ephalexin ABM
Cap 500 mg	5.85	20	✓ 0	ephalexin ABM
Grans for oral lig 25 mg per ml - Wastage claimable		100 ml	✓ F	lynn
Grans for oral lig 50 mg per ml – Wastage claimable		100 ml		lynn
		100 111		Cefalexin Sandoz
	11.75		• (eralexin Sandoz
CEFAZOLIN – Subsidy by endorsement				
Only if prescribed for dialysis or cellulitis in accordance with	a Health NZ Hospital	annroved n	rotocc	and the prescription is
		approved p	101000	
endorsed accordingly.		_		
Inj 500 mg vial		5		Cefazolin-AFT
Inj 1 g vial	3.59	5	✓ 0	efazolin-AFT
Inj 2 g vial	7.09	5	√ 0	efazolin-AFT
			-	
CEFTRIAXONE – Subsidy by endorsement				
 a) Up to 10 inj available on a PSO 				
b) Subsidised only if prescribed for a dialysis or cystic fibro	sis patient, or the trea	tment of gor	orrho	ea. or the treatment of
pelvic inflammatory disease, or the treatment of suspect				
	eu meningococcar uis			
endorsed accordingly.				
Inj 500 mg vial	0.79	1	_	Ceftriaxone-AFT
Inj 1 g vial	3.59	5	√ 0	Ceftriaxone-AFT
, .			_	
CEFUROXIME AXETIL – Subsidy by endorsement				
Only if prescribed for prophylaxis of endocarditis and the pr				
Tab 250 mg	CBS	20	🗸 A	scend-
				Cefuroxime S29

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

 $\ensuremath{\textbf{\#}}$ Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
ystic fibrosis bronchi	•	ll be sul	
	2		ithromax
	15 ml	✓ Z	ithromax
	(Manufacturer's Price) \$ n; can be waived by ystic fibrosis bronchi 8.19 	(Manufacturer's Price) Subs \$ Per h; can be waived by Special Au ystic fibrosis bronchiectasis wi 	(Manufacturer's Price) \$ Per ✓ h; can be waived by Special Authority ystic fibrosis bronchiectasis will be sul 8.19 30 ✓ A

Initial application — (bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
- 2 Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
- 3 Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram negative organisms*; or
- 4 Patient has an atypical Mycobacterium infection.
- Note: Indications marked with * are unapproved indications.

Initial application — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
- 2 Patient is aged 18 and under; and
- 3 Either:
 - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
 - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

Renewal — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).
- The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

Tab 250 mg	8.53	14	Klacid
Grans for oral lig 250 mg per 5 ml - Wastage claimable		50 ml	Klacid

► SA1857 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price	e) -	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

1 Atypical mycobacterial infection; or

2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents. Initial application — (Helicobacter pylori eradication) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 For the eradication of helicobacter pylori in a patient unable to swallow tablets; and

2 For use only in combination with omeprazole and amoxicillin as part of a triple therapy regimen.

Initial application — (Prophylaxis of infective endocarditis) from any relevant practitioner. Approvals valid for 3 months where prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated. Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ERYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial	10.00	1	 Erythrocin IV
ERYTHROMYCIN ETHYL SUCCINATE			
Tab 400 mg		100	🗸 E-Mycin
 a) Up to 20 tab available on a PSO 			
b) Up to 2 x the maximum PSO quantity for RFPP			
Grans for oral liq 200 mg per 5 ml	5.00	100 ml	 E-Mycin
 a) Up to 300 ml available on a PSO 			
b) Up to 2 x the maximum PSO quantity for RFPP			
c) Wastage claimable			
Grans for oral liq 400 mg per 5 ml	6.77	100 ml	 E-Mycin
 a) Up to 200 ml available on a PSO 			
b) Wastage claimable			
ROXITHROMYCIN			
Tab 150 mg		50	Arrow-
ő			Roxithromycin
Tab 300 mg	25.00	50	✓ Arrow-
			Roxithromycin

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully Brand or idised Generic Manufacturer
Penicillins	Ŷ		
AMOXICILLIN			
Cap 250 mg	27.50	500	 Miro-Amoxicillin
	43.45		 Alphamox
 a) Up to 30 cap available on a PSO 			
b) Up to 10 x the maximum PSO quantity for RFPP			
c) Miro-Amoxicillin to be Principal Supply on 1 September			· · · · · · · · · · · · · · · · · · ·
Cap 500 mg		500	 Miro-Amoxicillin
	66.44		 Alphamox
a) Up to 30 cap available on a PSO			
 b) Up to 10 x the maximum PSO quantity for RFPP a) Mine Amazini III in to be Dringing Lower to Amazini III in the Amazini III	0.4		
c) Miro-Amoxicillin to be Principal Supply on 1 August 20		100 ml	 Alphamox 125
Grans for oral liq 125 mg per 5 ml.		100 111	 Alphamox 125
a) Up to 200 ml available on a PSOb) Wastage claimable			
Grans for oral lig 250 mg per 5 ml	2.81	100 ml	 Alphamox 250
a) Up to 300 ml available on a PSO	2.01	100 111	 Alphaniox 250
b) Up to 10 x the maximum PSO guantity for RFPP			
c) Wastage claimable			
Inj 250 mg vial	15.97	10	 Ibiamox
Inj 500 mg vial		10	✓ Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO		10	✓ Ibiamox
Alphamox Cap 250 mg to be delisted 1 September 2024)			
Alphamox Cap 500 mg to be delisted 1 August 2024)			
AMOXICILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab			
available on a PSO	1.59	10	 Curam Duo 500/125
Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 n			<u></u>
per ml		100 ml	 Augmentin
a) Up to 200 ml available on a PSO			Ū
b) Wastage claimable			
Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 n	ng		
per ml – Up to 200 ml available on a PSO		100 ml OP	 Curam
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj			
available on a PSO		10	 Bicillin LA
BENZYLPENICILLIN SODIUM [PENICILLIN G]			
Inj 600 mg (1 million units) vial – Up to 5 inj available on a PS	SO 16.50	10	✓ Sandoz
		10	Candoz

98

	Subsidy (Manufacturer's Price		Fully sidised	
	\$	Per	-	Manufacturer
FLUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO		250		Flucloxacillin-AFT
Cap 500 mg – Up to 30 cap available on a PSO		500		Flucloxacillin-AFT
Grans for oral liq 25 mg per ml	3.29	100 ml	1	AFT
a) Up to 200 ml available on a PSOb) Wastage claimable				
Grans for oral liq 50 mg per ml	3.68	100 ml	1	AFT
 a) Up to 200 ml available on a PSO b) Wastage claimable 				
Inj 250 mg vial		10	1	Flucloxin
Flucloxin to be Principal Supply on 1 July 2024				
Inj 500 mg vial		10	1	Flucloxin
Flucloxin to be Principal Supply on 1 July 2024				
Inj 1 g vial – Up to 5 inj available on a PSO	6.00	5	-	Flucil
PHENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap 250 mg – Up to 30 cap available on a PSO	3 84	50	1	Cilicaine VK
Cap 500 mg		50		Cilicaine VK
a) Up to 20 cap available on a PSO		00	•	<u>omounic vit</u>
b) Up to 2 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	3.40	100 ml	1	AFT
a) Up to 200 ml available on a PSO	0.+0	100 111	•	
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml	4 24	100 ml	1	AFT
a) Up to 300 ml available on a PSO		100 111	•	
b) Up to 2 x the maximum PSO quantity for RFPP				
c) Wastage claimable				
Tetracyclines				
•				
DOXYCYCLINE X Tab 100 mg Line to 20 tab available on a DSO	64.40	500		Doxine
* Tab 100 mg – Up to 30 tab available on a PSO		500	•	Doxine
MINOCYCLINE HYDROCHLORIDE				
* Tab 50 mg – Additional subsidy by Special Authority see				
SA1355 below – Retail pharmacy	5.79	60		
	(12.05)			Mino-tabs
* Cap 100 mg	19.32	100		
	(52.04)			Minomycin
➡SA1355 Special Authority for Manufacturers Price				
Initial application from any relevant practitioner. Approvals va	lid without further rer	newal unles	s notif	ied where the patient has
rosacea.				
TETRACYCLINE - Special Authority see SA1332 below - Reta	ail pharmacy			
Tab 250 mg		28	1	Accord S29
SA1332 Special Authority for Subsidy		-		
Initial application from any relevant practitioner. Approvals va	lid for 2 months for a	nnligations	mooti	an the following criterie:
Both:	ing for 3 months for a	pplications	meetii	ng the following chiefla:
1 For the eradication of helicobacter pylori following unsuc	cossful treatment wit	h annronria	to fire	t line thereby: and

1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and

2 For use only in combination with bismuth as part of a quadruple therapy regimen.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Other Antibiotics				
For topical antibiotics, refer to DERMATOLOGICALS, page 68				
CIPROFLOXACIN Recommended for patients with any of the following: i) microbiologically confirmed and clinically significant pse ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea.	eudomonas infection;	or		
Tab 250 mg – Up to 5 tab available on a PSO	2.42	28	1	Cipflox
	3.85	10	1	Ciprofloxacin - Torrent ©29
Tab 500 mg – Up to 5 tab available on a PSO	4.25	10	1	Ciprofloxacin - Torrent S29
Tab 750 mg	5.95	28	~	Cipflox
CLINDAMYCIN				
Cap hydrochloride 150 mg Inj 150 mg per ml, 4 ml ampoule		24 10		Dalacin C Hameln
COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – S Only if prescribed for dialysis or cystic fibrosis patient and the Inj 150 mg	e prescription is endo			∕. Colistin-Link
GENTAMICIN SULPHATE Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient of endorsed accordingly.		5 / trac		DBL Gentamicin and the prescription is
Inj 10 mg per ml, 2 ml ampoule - Subsidy by endorsement	91.00	5	~	Wockhardt S29
	182.00	10		Teligent \$29
Only if prescribed for a dialysis or cystic fibrosis patient of endorsed accordingly.	or complicated urinary	/ trac	t infection a	and the prescription is
Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement		10		Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient	87.50 or complicated urinan	50 / trac		Pfizer and the prescription is
endorsed accordingly.	or complicated unitary			
MOXIFLOXACIN – Special Authority see SA1740 below – Retai No patient co-payment payable	l pharmacy			
Tab 400 mg		5	~	Avelox
 SA1740 Special Authority for Subsidy Initial application — (Tuberculosis) only from a respiratory sp for applications meeting the following criteria: Any of the following: Both: 	ecialist or infectious d	iseas	e specialis	t. Approvals valid for 1 year
 Active tuberculosis*; and Any of the following: 				
1.2.1 Documented resistance to one or more firs 1.2.2 Suspected resistance to one or more first-li	,	rculos	sis assume	d to be contracted in an

Subsidy		Fully	Brand or
Manufacturer's Price)	Subs	idised	Generic
 \$	Per	1	Manufacturer

continued...

area with known resistance), as part of regimen containing other second-line agents; or

- 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
- 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
- 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or
- 3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria: All of the following:

1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and

2 Either:

- 2.1 Has tried and failed to clear infection using azithromycin; or
- 2.2 Has laboratory confirmed azithromycin resistance; and

3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only. Note: Indications marked with * are unapproved indications.

PAROMOMYCIN - Special Authority see SA1689 below - Retail pharmacy

➡SA1689 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria: Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolyica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolyica carriage.

PYRIMETHAMINE - Special Authority see SA1328 below - Retail pharmacy

⇒SA1328 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

30

✓ Daraprim S29

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

SODIUM FUSIDATE [FUSI	36	 Fucidin
Ũ	 	
Tab 500 mg	 56	✓ Wockhardt S29

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$) Sub: Per	Fully sidised	Brand or Generic Manufacturer
■ SA1331 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valic the following criteria: Any of the following:	l without further ren	ewal unles	s notified	d for applications meeting
 For the treatment of toxoplasmosis in patients with HIV for For pregnant patients for the term of the pregnancy; or For infants with congenital toxoplasmosis until 12 months 		ns; or		
TOBRAMYCIN Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and		5 endorsed a		obramycin (Viatris) gly.
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by endorsementa) Wastage claimable		56 dose	✓ <u>T</u>	obramycin BNM
b) Only if prescribed for a cystic fibrosis patient and the TRIMETHOPRIM	prescription is endo	rsed accor	dingly.	
* Tab 300 mg – Up to 30 tab available on a PSO		50	✓ <u>⊺</u>	MP
 TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOX/ * Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – L to 30 tab available on a PSO	lp 64.80 nl	500 100 ml	✓ <u>⊺</u>	risul eprim
VANCOMYCIN – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or for difficile following metronidazole failure and the prescription is Inj 500 mg vial	endorsed according		for treat ✓ M	
Antifungals				
 a) For topical antifungals refer to DERMATOLOGICALS, page 65 b) For topical antifungals refer to GENITO URINARY, page 81 FLUCONAZOLE)			
Cap 50 mg		28	✓ <u>M</u>	
Cap 150 mg Cap 200 mg		1 28	✓ <u>M</u> ✓ M	
Powder for oral suspension 10 mg per ml – Special Authority see SA1359 below – Retail pharmacy Wastage claimable		35 ml		iflucan
SA1359 Special Authority for Subsidy Initial application — (Systemic candidiasis) from any relevant meeting the following criteria: Both:	practitioner. Appro	ovals valid f	or 6 wee	eks for applications
 Patient requires prophylaxis for, or treatment of systemic of Patient is unable to swallow capsules. 	andidiasis; and			
Initial application	t practitioner. Appr	ovals valid	for 6 mc	onths for applications

meeting the following criteria: All of the following:

	Subsidy		Fully	Brand or
	(Manufacturer's Price \$	e) Sub Per	osidised	Generic Manufacturer
continued				
 Patient is immunocompromised; and Patient is at moderate to high risk of invasive fungal infecti Patient is unable to swallow capsules. 	on; and			
Renewal — (Systemic candidiasis) from any relevant practition following criteria: Both:	er. Approvals valio	d for 6 wee	ks for a	pplications meeting the
 Patient requires prophylaxis for, or treatment of systemic c Patient is unable to swallow capsules. 				
Renewal — (Immunocompromised) from any relevant practition following criteria: All of the following:	ner. Approvals vali	id for 6 moi	nths for	applications meeting the
 Patient remains immunocompromised; and Patient remains at moderate to high risk of invasive fungal Patient is unable to swallow capsules. 	infection; and			
TRACONAZOLE				
Cap 100 mg Oral liq 10 mg per ml – Special Authority see SA1322 below		15	•	Itrazole
Retail pharmacy		50 ml OP	1	Sporanox
SA1322] Special Authority for Subsidy Initial application only from an infectious disease specialist, clinic practitioner on the recommendation of a infectious disease physic valid for 6 months where the patient has a congenital immune def Renewal from any relevant practitioner. Approvals valid for 6 mo benefitting from the treatment.	ian, clinical microb iciency.	iologist or o	clinical i	mmunologist. Approvals
KETOCONAZOLE				
Tab 200 mg – PCT	CBS	30 100	1 : 1 :	Burel S29 Strides Shasun S29 Taro S29 Teva- Ketoconazole S29
NYSTATIN				
Tab 500,000 u	(17.09)	50	I	Nilstat
Cap 500,000 u	12.81 (15.47)	50	I	Nilstat
POSACONAZOLE - Special Authority see SA1285 below - Reta				
Tab modified-release 100 mg Oral liq 40 mg per ml		24 05 ml OP		Posaconazole Juno Devatis
SA1285 Special Authority for Subsidy Initial application only from a haematologist or infectious disease	e specialist. Appro	vals valid f	or 6 we	eks for applications

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria: Either:

1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Si	ubsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

* Tab 250 mg	4.48	42	✓ Apo-Terbinafine S29
	8.97	84	✓ Deolate
VORICONAZOLE - Special Authority see SA1273 below	 Retail pharmacy 		
Tab 50 mg		56	✓ Vttack
Tab 200 mg		56	 Vttack
Powder for oral suspension 40 mg per ml - Wastage			
claimable		70 ml	 Vfend

⇒SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

1 Detient is immerse

- Patient is immunocompromised; and
 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Antimalarials

104

PRIMAQUINE - Special Authority see SA1684 on	the next page – Retail pharmacy
Tab 15 mg	

Sanofi
 Primaguine S29

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

100

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

■ SA1684 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaguine is to be given for a maximum of 21 days.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has relapsed vivax or ovale malaria: and
- 2 Primaguine is to be given for a maximum of 21 days.

Antitrichomonal Agents			
METRONIDAZOLE			
Tab 200 mg – Up to 30 tab available on a PSO		250	 Metrogyl
Tab 400 mg – Up to 15 tab available on a PSO	5.23	21	 Metrogyl
Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	 Flagyl-S
Suppos 500 mg	24.48	10	🗸 Flagyl
ORNIDAZOLE			
Tab 500 mg		10	 Arrow-Ornidazole
-			
Antituberculotics and Antileprotics			
Note: There is no co-payment charge for all pharmaceuticals I immigration status.	isted in the Antitube	erculotics and	Antileprotics group regardless of
BEDAQUILINE – Special Authority see SA2244 below – Retai No patient co-payment payable			
Tab 100mg	3,084.51	24 OP	 Sirturo
► SA2244 Special Authority for Subsidy Initial application — (multi-drug resistant tuberculosis) fro applications meeting the following criteria: Both:	om any relevant prac	ctitioner. App	rovals valid for 6 months for
 The person has multi-drug resistant tuberculosis (MDR- 2 Ministry of Health's Tuberculosis Clinical Network has n of the treatment regimen. 	<i>,,</i>	ual case and r	ecommends bedaquiline as part

CLOFAZIMINE - Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist. 100 Lamprene S29

CYCLOSERINE - Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.

Cap 250 mg		60	Cyclorin S29
------------	--	----	--------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Pri \$	ice) Sub Per	Fully Brand or sidised Generic ✓ Manufacturer	
DAPSONE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommodermatologist		is disease ph	iysician, clinical microbi	ologist o
Tab 25 mg		100	 Dapsone 	
Tab 100 mg		100	 Dapsone 	
THAMBUTOL HYDROCHLORIDE – Retail pharmacy-S	pecialist			
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommendation	nendation of, an infectiou	ıs disease ph	iysician, clinical microbi	ologist c
respiratory physician				Ū
Tab 100 mg	85.73	100	EMB Fatol \$29	
Tab 400 mg	49.34	56	 Myambutol \$29 	
ONIAZID – Retail pharmacy-Specialist				
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommendation	nendation of, an internal	medicine phy	/sician, paediatrician, cl	inical
microbiologist, dermatologist or public health phys				
F Tab 100 mg	23.00	100	✓ <u>PSM</u>	
ONIAZID WITH RIFAMPICIN - Retail pharmacy-Specia	alist			
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommicrobiologist, dermatologist or public health phys	nendation of, an internal ician	medicine phy	/sician, paediatrician, cl	inical
Tab 100 mg with rifampicin 150 mg		100	 <u>Rifinah</u> 	
Tab 150 mg with rifampicin 300 mg	179.13	100	 <u>Rifinah</u> 	
NEZOLID – Special Authority see SA2234 below – Reta	ail pharmacy			
No patient co-payment payable				
Tab 600 mg	276.89	10	🗸 Zyvox	
Oral liq 20 mg per ml	1,879.00	150 ml	 Zyvox 	
 Special Authority for Subsidy itial application — (multi-drug resistant tuberculosis pplications meeting the following criteria: oth: 1 The person has multi-drug resistant tuberculosis (N 2 Ministry of Health's Tuberculosis Clinical Network I the treatment regimen. 	MDR-TB); and			
Ũ	: aliat			
ARA-AMINO SALICYLIC ACID – Retail pharmacy-Spec	alist			
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommondation	nendation of an infectiou	is disease sn	ecialist clinical microbi	ntonist o
respiratory physician		io diocuoc op	colaist, chindar microsi	ologiot
Grans for oral liq 4 g sachet		30	Paser S29	
ROTIONAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
 b) Prescriptions must be written by, or on the recommendation of the second seco	nendation of, an infectiou	ıs disease sp	ecialist, clinical microbi	ologist
Tab 250 mg		100	 Peteha S29 	
RAZINAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
 b) Prescriptions must be written by, or on the recommon respiratory physician 	nendation of, an infectiou	is disease ph	iysician, clinical microbi	ologist
Tab 500 mg	64.95	100	 AFT-Pyrazinam 	ide
06 V fully subsidised Principal Supply	S29 Unappro		supplied under Section 29	

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Sub Per	sidised Generic Manufacturer
IFABUTIN – Retail pharmacy-Specialist	.		
a) No patient co-payment payable			
b) Prescriptions must be written by, or on the recomm gastroenterologist	endation of, an infectio	ous disease ph	ysician, respiratory physician o
🖌 Cap 150 mg		30	 Mycobutin
IFAMPICIN – Subsidy by endorsement			
a) No patient co-payment payable			
b) For confirmed recurrent Staphylococcus aureus infe antimicrobial based on susceptibilities and the pres			1 2
Retail pharmacy - Specialist. Specialist must be an	•	0.7	
paediatrician, or public health physician.		,	
₭ Cap 150 mg		100	✓ <u>Rifadin</u>
€ Cap 300 mg		100	✓ <u>Rifadin</u>
• Oral lig 100 mg per 5 ml	12.60	60 ml	 ✓ Rifadin Sanofi ✓ Rifadin
	12.00	00 111	
Antivirals			
ar ava proparations rafer to Eva Proparations. Anti Infacti	vo Proparations, page	260	
or eye preparations refer to Eye Preparations, Anti-Infecti	ve Freparations, page	200	
Hepatitis B Treatment			
NTECAVIR			
 Tab 0.5 mg 		30	Entecavir (Rex)
AMIVUDINE – Special Authority see SA1685 below – Re		~~	
Tab 100 mg Oral lig 5 mg per ml		28 240 ml OP	✓ <u>Zetlam</u> ✓ Zeffix
■SA1685 Special Authority for Subsidy		240 111 01	♥ Zellix
nitial application only from a relevant specialist or medica	al practitioner on the re	commendatio	n of a relevant specialist.
, .			· · · · · · · · · · · · · · · · · · ·
pprovais valid for a year where used for the treatment of t	Jievention of hepatitis	υ.	
			nt or prevention of hepatitis B.
enewal from any relevant practitioner. Approvals valid fo ENOFOVIR DISOPROXIL	r 2 years where used f	or the treatme	
enewal from any relevant practitioner. Approvals valid fo ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for	r 2 years where used f	or the treatme	
enewal from any relevant practitioner. Approvals valid fo ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA:	r 2 years where used f the treatment of HIV is 2139., page 110	for the treatme s included in th	e count of up to 4 subsidised
enewal from any relevant practitioner. Approvals valid fo ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA	r 2 years where used f the treatment of HIV is 2139., page 110	or the treatme	
enewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA Tab 245 mg (300 mg as a maleate)	r 2 years where used f the treatment of HIV is 2139., page 110	for the treatme s included in th	e count of up to 4 subsidised Tenofovir Disoproxil
enewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA Tab 245 mg (300 mg as a maleate)	r 2 years where used f the treatment of HIV is 2139., page 110	for the treatme s included in th	e count of up to 4 subsidised Tenofovir Disoproxil
antiretrovirals for the purposes of Special Authority SA Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme s included in th 30	e count of up to 4 subsidised <u>Tenofovir Disoproxil</u> <u>Viatris</u>
 Itenewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR Tab dispersible 200 mg 	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme s included in th 30 25	e count of up to 4 subsidised
tenewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate)	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme s included in th 30 25 56	e count of up to 4 subsidised
enewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR Tab dispersible 200 mg Tab dispersible 400 mg Tab dispersible 800 mg	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme s included in th 30 25	e count of up to 4 subsidised
tenewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR E Tab dispersible 200 mg Tab dispersible 400 mg Tab dispersible 800 mg ALACICLOVIR	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme s included in th 30 25 56 35	e count of up to 4 subsidised
enewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR Tab dispersible 200 mg Tab dispersible 400 mg ALACICLOVIR Tab 500 mg	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme s included in th 30 25 56	 Count of up to 4 subsidised <u>Tenofovir Disoproxil</u> <u>Viatris</u> <u>Lovir</u> <u>Lovir</u> <u>Lovir</u> <u>Lovir</u> <u>Vaclovir</u>
enewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR Tab dispersible 200 mg	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme is included in th 30 25 56 35 30 30 30	e count of up to 4 subsidised
enewal from any relevant practitioner. Approvals valid for ENOFOVIR DISOPROXIL Tenofovir disoproxil prescribed under endorsement for antiretrovirals for the purposes of Special Authority SA: Tab 245 mg (300 mg as a maleate) Herpesvirus Treatments CICLOVIR Tab dispersible 200 mg Tab dispersible 400 mg ALACICLOVIR Tab 500 mg	r 2 years where used f the treatment of HIV is 2139., page 110 	ior the treatme is included in th 30 25 56 35 30 30 30	 Count of up to 4 subsidised <u>Tenofovir Disoproxil</u> <u>Viatris</u> <u>Lovir</u> <u>Lovir</u> <u>Lovir</u> <u>Lovir</u> <u>Vaclovir</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Pric	e)	Subsidised	Generic
\$	Per	✓	Manufacturer

⇒SA1993 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or

2 Both:

- 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and
- 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Hepatitis C Treatment				
GLECAPREVIR WITH PIBRENTASVIR – [Xpharm] Note the supply of treatment is via Pharmac's approved dire website <u>https://pharmac.govt.nz/maviret</u> Tab 100 mg with pibrentasvir 40 mg		Furth		an be found on Pharmac's /laviret
 LEDIPASVIR WITH SOFOSBUVIR – [Xpharm] – Special Author No patient co-payment payable Tab 90 mg with sofosbuvir 400 mg	rity see SA1605 belo 24,363.46 HepCTP) CTP). ct to confirmation of e	w 28 ligibilit	√ ⊦ y.	larvoni

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see SA2138 below

- a) Funding for emtricitabine with tenofovir disoproxil for use as PrEP, should be applied using Special Authority SA2138.
- b) Endorsement for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV and percutaneous exposure): Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA2139 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement, for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV and percutaneous exposure), is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA2139, page 110 There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the Pharmac website.

➡SA2138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Notes: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:

https://ashm.org.au/HIV/PrEP/

Renewal from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria: Both:

	Subsidy	Fully	Brand or
	(Manufacturer's Price)	Subsidised	Generic
	\$	Per 🗸	Manufacturer
continued			
 Patient has tested HIV negative, does not have signs of seroconversion; and 	or symptoms of acute HIV	infection and ha	as been assessed for HIV
2 The Practitioner considers the patient is at elevated ris	sk of HIV exposure and us	se of PrEP is clin	ically appropriate.
Notes: Refer to local health pathways or the Australasian So guidelines:	ciety for HIV, Viral Hepati	tis and Sexual H	ealth Medicine clinical
https://ashm.org.au/HIV/PrEP/			
COVID-19 Treatments			
 MOLNUPIRAVIR – [Xpharm] – Subsidy by endorsement a) No patient co-payment payable b) Treatment is funded only if patient meets access crite and has been endorsed accordingly by the prescriber process. Refer to the Pharmac website for more infor Cap 200 mg 	. The supply of treatment rmation about this and sto	t is via Pharmac' ock availability.	·
NIRMATRELVIR WITH RITONAVIR - [Xpharm] - Subsidy by	y endorsement		
a) No patient co-payment payable			
b) Treatment is funded only if patient meets access crite and has been endorsed accordingly by the prescriber process. Refer to the Pharmac website for more infor	. The supply of treatment	t is via Pharmac'	
Tab 150 mg with ritonavir 100 mg		30 V	Davlavid

Tab 150 mg with ritonavir 100 mg0.00 30 V Paxlovid

Antiretrovirals

⇒SA2139 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following exposure to HIV) from any relevant practitioner. Approvals valid

	Subsidy	Fully	Brand or
(Manu	ufacturer's Price)	Subsidised	Generic
	\$ Per	<i>✓</i>	Manufacturer

continued...

for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/).

Renewal — (second or subsequent post-exposure prophylaxis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see SA2139 on the previous p Tab 200 mg Tab 600 mg	 acy 90 30	 ✓ Stocrin ✓ Stocrin ✓ Efavirenz Milpharm [©]29
ETRAVIRINE – Special Authority see SA2139 on the previous Tab 200 mg	 nacy 60	✓ Intelence

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully Brand or idised Generic ✓ Manufacturer
VEVIRAPINE – Special Authority see SA2139 on page 110 – F Tab 200 mg	• •	60	✓ <u>Nevirapine</u> <u>Alphapharm</u>
Oral suspension 10 mg per ml	203.55	240 ml OP	 Nevirapine Viatris Viramune Suspension
Nevirapine Alphapharm Tab 200 mg to be delisted 1 July 2024)		·
Nucleosides Reverse Transcriptase Inhibitors			
BACAVIR SULPHATE - Special Authority see SA2139 on page	ge 110 – Retail pl	harmacy	
Tab 300 mg		60	 Ziagen
Oral liq 20 mg per ml	256.31	240 ml OP	 Ziagen
Ziagen Oral liq 20 mg per ml to be delisted 1 July 2024)			
BACAVIR SULPHATE WITH LAMIVUDINE – Special Authorit Note: abacavir with lamivudine (combination tablets) count acti retraviral Special Authority.			
anti-retroviral Special Authority. Tab 600 mg with lamivudine 300 mg	29.50	30	✓ <u>Abacavir/</u> Lamivudine Viatris
FAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOF	PROXII – Snecia	l Authority see	
harmacy		i / tutilonty bee	one too on page the thetail
Note: Efavirenz with emtricitabine and tenofovir disoproxil of anti-retroviral Special Authority	counts as three a	nti-retroviral me	dications for the purposes of th
Tab 600 mg with emtricitabine 200 mg and tenofovir disopro 245 mg (300 mg as a maleate)		30	✓ Viatris
MTRICITABINE – Special Authority see SA2139 on page 110 Cap 200 mg		су 30	 Emtriva
AMIVUDINE – Special Authority see SA2139 on page 110 – F	Retail pharmacy		
Tab 150 mg		60	Lamivudine Viatris
Oral liq 10 mg per ml		240 ml OP	✓ 3TC
IDOVUDINE [AZT] - Special Authority see SA2139 on page 1	10 – Retail pharn	nacy	
		100	 Retrovir
Cap 100 mg Oral liq 10 mg per ml			✓ Retrovir✓ Retrovir
Cap 100 mg Oral liq 10 mg per ml	152.25 30.45 ee SA2139 on pag	100 200 ml OP ge 110 – Retail	 Retrovir pharmacy
Cap 100 mg Oral liq 10 mg per ml IDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablet		100 200 ml OP ge 110 – Retail	 Retrovir pharmacy
Cap 100 mg Oral liq 10 mg per ml IDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination table the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg		100 200 ml OP ge 110 – Retail anti-retroviral m	 Retrovir pharmacy nedications for the purposes of Alphapharm Lamivudine/
Cap 100 mg Oral liq 10 mg per ml IDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablet the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg		100 200 ml OP ge 110 – Retail anti-retroviral m	 Retrovir pharmacy nedications for the purposes of Alphapharm Lamivudine/
Cap 100 mg Oral liq 10 mg per ml CIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablet the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg Alphapharm Tab 300 mg with lamivudine 150 mg to be delisted Protease Inhibitors		100 200 ml OP ge 110 – Retail anti-retroviral m 60	 Retrovir pharmacy nedications for the purposes of Alphapharm Lamivudine/
Cap 100 mg Oral liq 10 mg per ml CIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablet the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg		100 200 ml OP ge 110 – Retail anti-retroviral m 60	 Retrovir pharmacy nedications for the purposes of Alphapharm Lamivudine/ Zidovudine Viatris <u>Atazanavir Mylan</u> <u>Atazanavir Mylan</u>
Cap 100 mg Oral liq 10 mg per ml IDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablet the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg Alphapharm Tab 300 mg with lamivudine 150 mg to be delisted Protease Inhibitors TAZANAVIR SULPHATE – Special Authority see SA2139 on Cap 150 mg		100 200 ml OP ge 110 – Retail anti-retroviral m 60 I pharmacy 60	 Retrovir pharmacy nedications for the purposes of Alphapharm Lamivudine/ Zidovudine Viatris

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Subs	idised	Generic Manufacturer
	Ŧ	1.61		
DARUNAVIR – Special Authority see SA2139 on page 110 –				-
Tab 400 mg		60 60		Darunavir Viatris
Tab 600 mg		60		Darunavir Viatris
LOPINAVIR WITH RITONAVIR - Special Authority see SA21				
Tab 100 mg with ritonavir 25 mg	150.00	60	~	Lopinavir/Ritonavir
	005.00	100		<u>Mylan</u> Lemineuin/Ditemeuin
Tab 200 mg with ritonavir 50 mg	295.00	120	v	Lopinavir/Ritonavir Mylan
				wyian
RITONAVIR – Special Authority see SA2139 on page 110 – F		00		Norvir
Tab 100 mg		30	v	NOTVIE
Strand Transfer Inhibitors				
DOLUTEGRAVIR - Special Authority see SA2139 on page 11	0 – Retail pharmacy			
Tab 50 mg		30	1	Tivicay
DOLUTEGRAVIR WITH LAMIVUDINE - Special Authority see	SA2139 on page 110	- Retail pł	arma	CV
Tab 50 mg with lamivudine 300 mg		30		Dovato
RALTEGRAVIR POTASSIUM – Special Authority see SA2139	on page 110 – Retail r	harmacy		
Tab 400 mg		60	1	Isentress
Tab 600 mg		60	1	Isentress HD
Immune Modulators				
	SA2034 below - Retai	Inharman	v	
PEGYLATED INTERFERON ALFA-2A – Special Authority see			,	eed for ribavirin and meet
PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small	group of patients who l	nave a clir	ical n	
PEGYLATED INTERFERON ALFA-2A – Special Authority see	l group of patients who l Coordinator at Pharmac	nave a clir	, ical n)23-58	
PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0	l group of patients who l Coordinator at Pharmac	nave a clir on 0800-0	, ical n)23-58	8 option 4.
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	l group of patients who l Coordinator at Pharmac 748.50	nave a clir on 0800-(4	iical n 123-58 ✓	8 option 4. Pegasys
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	l group of patients who l Coordinator at Pharmac 	nave a clir on 0800-0 4 fection w	iical no 23-58 V th HIV	8 option 4. Pegasys / or genotype 2 or 3 post
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	l group of patients who l Coordinator at Pharmac 	nave a clir on 0800-0 4 fection w	iical no 23-58 V th HIV	8 option 4. Pegasys / or genotype 2 or 3 post
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C (Inj 180 mcg prefilled syringe	I group of patients who l Coordinator at Pharmac 748.50 or 6 infection or co-in nonths for applications r	nave a clir on 0800-0 4 fection w	iical no 23-58 V th HIV	8 option 4. Pegasys / or genotype 2 or 3 post
 PEGYLATED INTERFERON ALFA-2A - Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C (Inj 180 mcg prefilled syringe	I group of patients who l Coordinator at Pharmac 	nave a clir on 0800-0 4 fection w	iical no 23-58 V th HIV	8 option 4. Pegasys / or genotype 2 or 3 post
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C (Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 748.50 or 6 infection or co-in nonths for applications r or 6 infection; or d with HIV; or	nave a clir on 0800-0 4 fection w neeting th	th HIV	8 option 4. Pegasys / or genotype 2 or 3 post
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C (Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 748.50 or 6 infection or co-in nonths for applications r or 6 infection; or d with HIV; or	nave a clir on 0800-0 4 fection w neeting th	th HIV	8 option 4. Pegasys / or genotype 2 or 3 post
 PEGYLATED INTERFERON ALFA-2A - Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C (Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	nave a clir on 0800-(4 fection w neeting th transplan	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0 Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A - Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C C Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0 Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0 Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0 Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0 Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	th HIV th HIV th and	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria:
 PEGYLATED INTERFERON ALFA-2A – Special Authority see Note: Pharmac will consider funding ribavirin for the small Special Authority criteria. Please contact the Hepatitis C 0 Inj 180 mcg prefilled syringe	I group of patients who I Coordinator at Pharmac 	ave a clir on 0800-(4 fection w neeting th transplan ogist, infec	tical nu 123-58 th HIN e follo t; and tious o	8 option 4. Pegasys / or genotype 2 or 3 post wing criteria: disease specialist or genera

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Initial application — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:
 - 2.1 Patient has a myeloproliferative disorder*; and
 - 2.2 Patient is intolerant of hydroxyurea; and
 - 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:
 - 3.1 Patient has a myeloproliferative disorder; and
 - 3.2 Patient is pregnant, planning pregnancy or lactating.

Renewal — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 No evidence of disease progression; and

Subsidy (Manufacturer's Price)	Fully Subsidised	
\$	Per 🗸	Manufacturer

continued...

- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:
 - 3.1 Patient has a cutaneous T cell lymphoma*; or
 - 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with * are unapproved indications.

Initial application — (post-allogenic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse.

Renewal — (post-allogenic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with * are unapproved indications.

Urinary Tract Infections

METHENAMINE (HEXAMINE) HIPPURATE			
* Tab 1 g	19.95	100	✓ <u>Hiprex</u>
NITROFURANTOIN			
* Tab 50 mg – Up to 30 tab available on a PSO		100	 Nifuran
* Tab 100 mg	37.50	100	✓ Nifuran
* Cap modified-release 100 mg – Up to 15 cap available on a			
PSO		100	✓ Macrobid
NORFLOXACIN			
Tab 400 mg – Subsidy by endorsement	245.00	100	Arrow-Norfloxacin

Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.

	Subsidy		Fully Brand or
	(Manufacturer's Price) \$	Per	Subsidised Generic Manufacturer
Anticholinesterases			
EOSTIGMINE METILSULFATE			
Inj 2.5 mg per ml, 1 ml ampoule		10	 Max Health
YRIDOSTIGMINE BROMIDE			
Tab 60 mg	50.28	100	 Mestinon
Non-Steroidal Anti-Inflammatory Drugs			
ICLOFENAC SODIUM			
F Tab EC 25 mg	1.99	50	 Diclofenac Sandoz
Tab 50 mg dispersible	1.50	20	 Voltaren D
• Tab EC 50 mg	1.99	50	 Diclofenac Sandoz
Tab long-acting 75 mg		100	 Voltaren SR
Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a	PSO 13.20	5	 Voltaren
Suppos 12.5 mg		10	✓ Voltaren
Suppos 25 mg		10	 Voltaren
Suppos 50 mg – Up to 10 supp available on a PSO		10	✓ Voltaren
· Suppos 100 mg	7.00	10	 Voltaren
UPROFEN			
Tab 200 mg		1,000	
Tab long-acting 800 mg		30	Brufen SR
Oral liq 20 mg per ml		200 m	
	11.29		 Fenpaed 100 mg per 5 ml
ETOPROFEN	40.07	~~	
Cap long-acting 200 mg	12.07	28	 Oruvail SR
EFENAMIC ACID			
Cap 250 mg	1.25	50	
	(10.82)		Ponstan
	0.50	20	
	(7.50)		Ponstan
APROXEN			
F Tab 250 mg		500	 Noflam 250
• Tab 500 mg		250	 Noflam 500
Tab long-acting 750 mg	6.47	28	 Naprosyn SR 750
Tab long-acting 1 g	8.62	28	 Naprosyn SR 1000
ENOXICAM			
F Tab 20 mg		100	✓ <u>Tilcotil</u>
Inj 20 mg vial	9.95	1	✓ AFT
NSAIDs Other			
ELECOXIB			
Cap 100 mg	3.45	60	 Celebrex
			 Celecoxib Pfizer
0 000	2.00	30	✓ Celebrex
Cap 200 mg	3.20	30	• Celebrex

	Subsidy (Manufacturer's Pric \$	e) Sul Per	Fully Brand or bsidised Generic ✓ Manufacturer
Topical Products for Joint and Muscular Pain	ψ	Fei	
CAPSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail			
pharmacy		45 g OP	 Zostrix
	13.00	60 g OP	 Rugby Capsaicin
			Topical Cream ^{S29}
SA1289 Special Authority for Subsidy			Urcall a
itial application from any relevant practitioner. Approvals valid	d without further re	newal unles	ss notified where the patient has
steoarthritis that is not responsive to paracetamol and oral non-s			
Antirheumatoid Agents			
IYDROXYCHLOROQUINE – Subsidy by endorsement			
Subsidised only if prescribed for rheumatoid arthritis, systemi			-
suppression, relevant dermatological conditions (cutaneous f mucosal ulceration)*, sarcoidosis (pulmonary and non-pulmo			
Pharmacists may annotate the prescription as endorsed whe			
hydroxychloroquine. Note: Indication marked with a * is an			
F Tab 200 mg		100	 Plaquenil
EFLUNOMIDE			
F Tab 10 mg	6.00	30	✓ <u>Arava</u>
F Tab 20 mg	6.00	30	✓ Arava
ENICILLAMINE			
Tab 125 mg		100	 D-Penamine D-Penamine
Tab 250 mg		100	 D-Penamine
Drugs Affecting Bone Metabolism			
Alendronate for Osteoporosis			
LENDRONATE SODIUM			
← Tab 70 mg	3.10	4	 Fosamax
Fosamax to be Principal Supply on 1 July 2024			
LENDRONATE SODIUM WITH COLECALCIFEROL			
 Tab 70 mg with colecalciferol 5,600 iu 	1.99	4	 Fosamax Plus
Fosamax Plus to be Principal Supply on 1 July 2024			
Other Treatments			
ENOSUMAB - Special Authority see SA1777 below - Retail ph			
Inj 60 mg prefilled syringe		1	 Prolia
SA1777 Special Authority for Subsidy			
nitial application from any relevant practitioner. Approvals valid	d without further re	newal unles	ss notified for applications meeting
ne following criteria:			

All of the following:

1 The patient has severe, established osteoporosis; and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

(Subsidy (Manufacturer's Price)			Brand or Generic
	\$	Per	1	Manufacturer

continued...

- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
 - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 10 ml vial	32.49	1	 Pamisol
Inj 6 mg per ml, 10 ml vial	88.11	1	 Pamisol
Inj 9 mg per ml, 10 ml vial		1	 Pamisol
RALOXIFENE HYDROCHLORIDE - Special Authority see SA1779	on the next page	– Retail pł	narmacy
* Tab 60 mg	53.76	28	 Evista

 Subsidy (Manufacturer's Price)	Sub	Fully sidised	Brand or Generic
 \$	Per	~	Manufacturer

⇒SA1779 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score less than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg	2.50	4	 <u>Risedronate Sandoz</u>
TERIPARATIDE - Special Authority see SA1139 below - Ret	ail pharmacy		
Inj 250 mcg per ml, 2.4 ml		1	🗸 Teriparatide - Teva
	490.00		 Forteo
Tavinavatida – Tava ta ka Dvinainal Oversky an 1 Ivez (2004		

Teriparatide - Teva to be Principal Supply on 1 June 2024 (Forteo Inj 250 mcg per ml, 2.4 ml to be delisted 1 June 2024)

⇒SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price)	Subs	Fully sidised	Brand or Generic
(Manulactarer 3 Theo)	Per	√	Manufacturer

continued...

absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable

- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID Inj 0.05 mg per ml, 100 ml, bag	22.53	100 ml OP	✓ <u>Zoledronic Acid</u> <u>Viatris</u>
Hyperuricaemia and Antigout			
ALLOPURINOL			
* Tab 100 mg	11.47	500	 DP-Allopurinol
	17.99	1,000	 Ipca-Allopurinol
Ipca-Allopurinol to be Principal Supply on 1 June 2024			
* Tab 300 mg	22.50	500	 Ipca-Allopurinol
	28.57		 DP-Allopurinol
Ipca-Allopurinol to be Principal Supply on 1 June 2024			
(DP-Allopurinol Tab 100 mg to be delisted 1 June 2024)			
(DP-Allopurinol Tab 300 mg to be delisted 1 June 2024)			
BENZBROMARONE - Special Authority see SA1963 below - Ret	ail pharmacy		
Tab 50 mg		100	 Narcaricin mite S29
Tab 100 mg		30	 Desuric S29
			 Urinorm S29
	45.00	100	 Benzbromaron AL
			100 S29

⇒SA1963 Special Authority for Subsidy

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefitting from the treatment; and

2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

COLCHICINE

* Tab 500 mcg......6.00

100

Colgout

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
FEBUXOSTAT – Special Authority see SA2054 below – Retail p	pharmacy			
Tab 80 mg		28	🖌 F	ebuxostat (Teva)
	20.00		✓ F	ebuxostat multichem
Febuxostat (Teva) to be Principal Supply on 1 June 202	4			
Tab 120 mg	11.78	28	🖌 F	ebuxostat (Teva)
-	20.00		✓ F	ebuxostat multichem

Febuxostat (Teva) to be Principal Supply on 1 June 2024 (Febuxostat multichem Tab 80 mg to be delisted 1 June 2024) (Febuxostat multichem Tab 120 mg to be delisted 1 June 2024)

⇒SA2054 Special Authority for Subsidy

Initial application — (Gout) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout..

Initial application — (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and
- 2 Patient has a documented history of allopurinol intolerance.

Renewal — (Gout) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Renewal — (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks where the treatment remains appropriate and the patient is benefitting from treatment.

	DBENECID Tab 500 mg	66.95	100	✓ Probenecid-AFT
N	uscle Relaxants			
ΒA	CLOFEN			
*	Tab 10 mg	4.20	100	 Pacifen
	Inj 0.05 mg per ml, 1 ml ampoule - Subsidy by endorsement	11.55	1	 Lioresal Intrathecal
	Subsidised only for use in a programmable pump in patient caused intolerable side effects and the prescription is endo		1 0	ents have been ineffective or have
	Inj 2 mg per ml, 5 ml ampoule - Subsidy by endorsement	306.82	5	 Medsurge
	Subsidised only for use in a programmable pump in patient caused intolerable side effects and the prescription is endo			ents have been ineffective or have
DA	NTROLENE			
	Cap 25 mg	112.13	100	 Dantrium
				 Dantrium S29 S29
	Cap 50 mg	77.00	100	 Dantrium

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
ORPHENADRINE CITRATE Tab 100 mg	20.76	100	✓ N	lorflex	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disord	ers			
Dopamine Agonists and Related Agents				
AMANTADINE HYDROCHLORIDE				
Cap 100 mg		60		Symmetrel
	63.73	100		Symmetrel
POMORPHINE HYDROCHLORIDE				
Inj 10 mg per ml, 2 ml ampoule		5	-	Movapo
Inj 10 mg per ml, 5 ml ampoule	121.84	5	✓	Movapo
NTACAPONE				_
Tab 200 mg		100		Comtan
EVODOPA WITH BENSERAZIDE				
 Tab dispersible 50 mg with benserazide 12.5 mg 		100	-	Madopar Rapid
 Cap 50 mg with benserazide 12.5 mg 		100	-	Madopar 62.5
Cap 100 mg with benserazide 25 mg		100	-	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100		Madopar HBS
Cap 200 mg with benserazide 50 mg		100	✓	Madopar 250
EVODOPA WITH CARBIDOPA				
 Tab 100 mg with carbidopa 25 mg 		100		Sinemet
Tab long-acting 200 mg with carbidopa 50 mg		100		Sinemet CR
Tab 250 mg with carbidopa 25 mg		100	v :	Sinemet
RAMIPEXOLE HYDROCHLORIDE				
Tab 0.25 mg		100		Ramipex
Tab 1 mg		100	v	Ramipex
ASAGILINE				
🗧 Tab 1 mg	53.50	30	✓ .	Azilect S29
OPINIROLE HYDROCHLORIDE				
Tab 0.25 mg	4.05	84	✓	Ropin
Tab 1 mg	4.95	84	✓	Ropin
Tab 2 mg	6.48	84	✓]	Ropin
Tab 5 mg	14.50	84	✓ [<u>Ropin</u>
OLCAPONE				
Tab 100 mg	152.38	100	 Image: A second s	Tasmar
Anticholinergics				
ENZATROPINE MESYLATE				
Tab 2 mg	9.59	60	✓	Benztrop
Inj 1 mg per ml, 2 ml		5	-	Phebra
a) Up to 10 inj available on a PSO		-		
b) Only on a PSO				
ROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	✓	Kemadrin
Agents for Essential Tremor, Chorea and Rel				
ILUZOLE – Special Authority see SA1403 on the next page Wastage claimable				
Tab 50 mg	130.00	56	1	Rilutek
		00	•	inutor

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

NERVOUS SYSTEM

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$ Pe	er ✓	Manufacturer

► SA1403 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limbs; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg106.59	112	✓ Motetis	

Anaesthetics

Local

IDOCAINE [LIGNOCAINE] Gel 2%, tube – Subsidy by endorsement	14.50	30 ml	 Xylocaine 2% Jelly
a) Up to 150 ml available on a PSO		00111	
b) Subsidised only if prescribed for urethral or cervical a	dministration an	d the prescript	tion is endorsed accordingly
Gel 2%, 11 ml urethral syringe – Subsidy by endorsement			 Instillagel Lido
a) Up to 5 each available on a PSO			_
 b) Subsidised only if prescribed for urethral, cervical or i 	rectal administra	tion and the p	rescription is endorsed
accordingly.			
IDOCAINE [LIGNOCAINE] HYDROCHLORIDE			
Oral (gel) soln 2%		200 ml	 Mucosoothe
Inj 1%, 5 ml ampoule - Up to 25 inj available on a PSO		25	 Lidocaine-Baxter
	17.50	50	
	(35.00)		Xylocaine
Inj 2%, 5 ml ampoule - Up to 5 inj available on a PSO	9.00	25	 Lidocaine-Baxter
Inj 1%, 20 ml ampoule - Up to 5 inj available on a PSO		5	
	(20.00)		Xylocaine
Inj 1%, 20 ml vial – Up to 5 inj available on a PSO	6.85	5	 Lidocaine-Baxter
Inj 2%, 20 ml vial – Up to 5 inj available on a PSO	7.15	5	 Lidocaine-Baxter
Inj 10%, 5 ml ampoule - Subsidy by endorsement	CBS	10	Xylocard 500 S29
Subsidised only for people receiving palliative care service	ces where other	analgesic age	nts haven't been effective.

				V003 3131EM
	Subsidy (Manufacturer's Prio \$	ce) Per	Fully Subsidised	Brand or Generic Manufacturer
Topical Local Anaesthetics				
 SA0906 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid condition requiring frequent injections or venepuncture. Renewal from any relevant practitioner. Approvals valid for 2 yea benefiting from treatment. IDOCAINE [LIGNOCAINE] – Special Authority see SA0906 abor Crm 4%. 	rs where the trea	tment rei	mains appro	
	27.00	30 g O		MX4
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Autho Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes)		above – 1 30 g O 5	Р 🧹 Е	nacy MLA MLA
Analgesics				
or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pa	ge 116			
Non-opioid Analgesics				
ASPIRIN 券 Tab dispersible 300 mg − Up to 30 tab available on a PSO CAPSAICIN − Subsidy by endorsement	5.65	100	✓ <u>E</u>	thics Aspirin
Subsidised only if prescribed for post-herpetic neuralgia or dia accordingly.	abetic peripheral r	neuropat	hy and the p	prescription is endorsed
accolungy. Crm 0.075%	11.95 15.14	45 g O 57 g O		ostrix HP ugby Capsaicin Topical Cream S29
NEFOPAM HYDROCHLORIDE Tab 30 mg	23 40	90	۷ ۵	cupan
1 ub 00 mg		50		oupuil

	Subsidy		Fully Brand or	
	(Manufacturer's Pr		sidised Generic	
	\$	Per	 Manufacturer 	
PARACETAMOL				
Tab 500 mg - blister pack		1,000	 Pacimol 	
a) Maximum of 300 tab per prescription; can be	waived by endorsement			
b) Up to 30 tab available on a PSO				
c)				
 Subsidy by endorsement for higher qua 	intities is available for pat	tients with long	g term conditions who r	equire
regular daily dosing for one month or gr				cists may
annotate the prescription as endorsed w				
Maximum of 100 tab per dispensing for				
(for non-endorsed patients), then disper		s not exceedin	g 100 tab per dispensi	ng.
Tab 500 mg - bottle pack – Maximum of 300 tab per			*	
prescription; can be waived by endorsement		1,000	Noumed	
			Paracetamol	
 Subsidy by endorsement for higher quantit 	ies is available for patient	ts with long ter	rm conditions who requ	ire regular
daily dosing for one month or greater, and				innotate th
prescription as endorsed where dispensing				
Maximum of 100 tab per dispensing for nor				0 tabs (for
non-endorsed patients), then dispense in re	epeat dispensings not ex	ceeding 100 ta	ab per dispensing.	
			_	
Oral liq 120 mg per 5 ml		200 ml	Paracetamol	
			(Ethics)	
	10.50	200 ml OP	 Avallon 	
 a) Maximum of 600 ml per prescription; can be 	waived by endorsement			
b) Up to 200 ml available on a PSO				
c) Not in combination				
d)				
1) Maximum of 200 ml per dispensing for				nl (for
non-endorsed patients), then dispense				
Subsidy by endorsement for higher qua transfer to the second sec				
regular daily dosing for one month or gr				
Pharmacists may annotate the prescrip	tion as endorsed where c	dispensing his	tory supports a long-ter	rm
condition.			O to a Manalantan (alla	
 Note: 200 ml presentations of paraceta 		ipplied on BS	J to a vaccinator (othe	er than a
Pharmacist) under the provisions in Par				
 Note: Direct Provision by a pharmacist approximation with immunication of a shift 				
conjunction with immunisation of a chilo Oral liq 250 mg per 5 ml		200 ml	✓ Pamol	vaccine.
		200 111		
 a) Maximum of 600 ml per prescription; can be b) Up to 200 ml available on a PSO 	walved by endorsement			
c) Not in combination				
d)1) Maximum of 200 ml per dispensing for the second se	non-endorsed nationte	f auantities or	escribed exceed 200 m	nl (for
non-endorsed patients), then dispense				
 Subsidy by endorsement for higher qua 				equire
regular daily dosing for one month or gr				
Pharmacists may annotate the prescrip				
condition.			,,	
 Note: 200 ml presentations of paraceta 	amol oral liquid mav be su	upplied on BS	O to a Vaccinator (othe	r than a
Pharmacist) under the provisions in Par				
4) Note: Direct Provision by a pharmacist		d under the pro	ovisions in Part I of Sec	ction A in
conjunction with immunisation of a child				
··· ;· ··· · ·························	,			

		Subsidy		Fully	
		(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
	Suppos 125 mg	4.29	10	1	Gacet
	Suppos 250 mg		10		Gacet
	Suppos 500 mg		50		Gacet
)	pioid Analgesics				
C	DEINE PHOSPHATE – Safety medicine; prescriber may d	etermine dispensina fre	auen	cv	
	Tab 15 mg		100		Noumed
	Tab 30 mg		100		Aspen
	5			✓	Noumed
	Tab 60 mg		100	1	Noumed
Н	IYDROCODEINE TARTRATE				
	Tab long-acting 60 mg	8.60	60	1	DHC Continus
- 1	NTANYL				
••	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	c) Safety medicine; prescriber may determine dispensing	frequency			
	Inj 50 mcg per ml, 2 ml ampoule		10	1	Boucher and Muir
	Inj 50 mcg per ml, 10 ml ampoule		10		Boucher and Muir
	Patch 12.5 mcg per hour		5	✓	Fentanyl Sandoz
	Patch 25 mcg per hour	7.99	5	✓	Fentanyl Sandoz
	Patch 50 mcg per hour	9.49	5	✓	Fentanyl Sandoz
	Patch 75 mcg per hour		5	✓	Fentanyl Sandoz
	Patch 100 mcg per hour		5	1	Fentanyl Sandoz
Ε	THADONE HYDROCHLORIDE				
	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	c) Safety medicine; prescriber may determine dispensing	frequency			
	d) Extemporaneously compounded methadone will only b		e of th	ne cheapes	st form available
	(methadone powder, not methadone tablets).				
	e) For methadone hydrochloride oral liquid refer Standard	Formulae, page 268			
	Tab 5 mg		10	1	Methadone BNM
	Oral liq 2 mg per ml		200 m	nl 🗸	Biodone
	Oral liq 5 mg per ml	6.40	200 m	nl 🗸	Biodone Forte
	Oral liq 10 mg per ml		200 m	nl 🗸	Biodone Extra Forte
	Inj 10 mg per ml, 1 ml		10	1	AFT
C	RPHINE HYDROCHLORIDE				
1	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	c) Safety medicine; prescriber may determine dispensing	frequency			
	Oral lig 1 mg per ml		200 m	nl 🗸	RA-Morph
	Oral lig 2 mg per ml		200 m		RA-Morph
	Oral liq 5 mg per ml		200 m		Ordine S29
					RA-Morph
					•
	Oral liq 10 mg per ml	27.74	200 m	11 v	Ordine S29

(Ordine S29 Oral liq 10 mg per ml to be delisted 1 July 2024)

NERVOUS SYSTEM

(N)	Subsidy Ianufacturer's Price)	Fully Subsidised	
(14	\$	Per		
ORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequ	ency			
Tab immediate-release 10 mg		10	1	Sevredol
Tab immediate-release 20 mg	5.52	10	1	Sevredol
Cap long-acting 10 mg	3.00	10	✓	m-Eslon
Cap long-acting 30 mg	4.30	10	✓	m-Eslon
Cap long-acting 60 mg	9.00	10	1	m-Eslon
Cap long-acting 100 mg	10.50	10	✓	m-Eslon
Oral liq 2 mg per ml – Brand switch fee payable (Pharmacode				
2669986) - see page 265 for details	16.31	100 m	l 🗸	Wockhardt S29
	29.80		✓	Oramorph
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	5.38	5	1	Medsurge
Inj 10 mg per ml, 1 ml ampoule - Up to 5 inj available on a PSC		5		Medsurge
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC		5		Medsurge
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC	D6.28	5	1	Medsurge
YCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequ	encv			
Tab controlled-release 5 mg		20	1	Oxycodone Sandoz
5	3.77	28		Oxycodone Sandoz
				S29 S29
	4.04	30	1	OxyContin S29
Tab controlled-release 10 mg		20		Oxycodone Sandoz
	3.77	28		Oxycodone Sandoz
	••••			S29 S29
Tab controlled-release 20 mg	3 49	20	1	Oxycodone Sandoz
Tab controlled-release 40 mg.		20		Oxycodone Sandoz
Tab controlled-release 80 mg		20		Oxycodone Sandoz
Cap immediate-release 5 mg		20		OxyNorm
Cap immediate-release 10 mg		20		OxyNorm
Cap immediate-release 20 mg		20		OxyNorm
Oral lig 5 mg per 5 ml		250 m		OxyNorm
Inj 10 mg per ml, 1 ml ampoule		5		Hameln
Inj 10 mg per ml, 2 ml ampoule		5	1	HameIn
Inj 50 mg per ml, 1 ml ampoule		5	1	HameIn
RACETAMOL WITH CODEINE – Safety medicine; prescriber ma	av determine disr	ensin	n frequenc	 V
Tab paracetamol 500 mg with codeine phosphate 8 mg		1.000		Paracetamol +
		.,000	2	Codeine (Relieve)
THIDINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payablec) Safety medicine; prescriber may determine dispensing frequ	opov			
c) Safety medicine; prescriber may determine dispensing frequ Tab 50 mg		10		Noumed Pethidine
Inj 50 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC		10 5		DBL Pethidine
	23.00	5	•	Hydrochloride
Ini 50 ma normi. O mi omnovilo — Lin to 5 ini ovalishis sa a DOC	00 70	F		•
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSC	130.72	5	•	DBL Pethidine
				Hydrochloride

	Subsidy		Fully	
	(Manufacturer's Price)	Per	Subsidised	Generic Manufacturer
	\$	rei		INIGITUIACIUTEI
TRAMADOL HYDROCHLORIDE	4.05	~~		Turnel OD 400
Tab sustained-release 100 mg		20		Tramal SR 100
Tab sustained-release 150 mg		20		Tramal SR 150
Tab sustained-release 200 mg		20 100		Tramal SR 200 Arrow-Tramadol
Cap 50 mg		100	v	Arrow-Tramadol
Antidepressants				
Cyclic and Related Agents				
AMITRIPTYLINE - Safety medicine; prescriber may determine	e dispensina frequency			
Tab 10 mg		100	1	Arrow-Amitriptyline
Tab 25 mg		100		Arrow-Amitriptyline
Tab 50 mg		100		Arrow-Amitriptyline
CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; pres	criber may determine d	isner	nsina freau	ency
Tab 10 mg		30		Clomipramine Teva
Tab 25 mg		30		Clomipramine Teva
0	39.97	100	1	Anafranil S29
Cap 10 mg		28	1	Clomipramine -
				Teva S29
Cap 25 mg	11.19	28	1	Clomipramine
				Teva S29
				1010
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by				
 a) Safety medicine; prescriber may determine dispensing b) Subsidy by endorsement – Subsidised for patients who 		[dath	ionin1 hudr	achlarida prior to 1 lupa
, , , , , , , , , , , , , , , , , , , ,	were taking uusulepin	luouii		
2019 and the prescription is endorsed accordingly Ph	armacists may annotate	•	nrecorintia	
2019 and the prescription is endorsed accordingly. Ph exists a record of prior dispensing of dosulenin (dothier		•	prescriptio	
exists a record of prior dispensing of dosulepin [dothier	oin] hydrochloride.	the		n as endorsed where there
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg	bin] hydrochloride. 3.85	•	· · · ·	n as endorsed where there Dosulepin Viatris
exists a record of prior dispensing of dosulepin [dothier	bin] hydrochloride. 3.85	the 30	· · · ·	n as endorsed where there Dosulepin Viatris Dosulepin
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg	bin] hydrochloride. 3.85	the 30	1	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁶²⁹
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg	bin] hydrochloride. 3.85	the 30	1	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁵²⁹ Dosulepin
exists a record of prior dispensing of dosulepin [dothie Tab 75 mg Cap 25 mg	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	the 30	1	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁶²⁹
exists a record of prior dispensing of dosulepin [dothie Tab 75 mg Cap 25 mg (Dosulepin Mylan 329) Cap 25 mg to be delisted 1 October 20	oin] hydrochloride. 3.85 7.83	30 50	J J	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁶²⁹ Dosulepin Viatris ⁶²⁹
exists a record of prior dispensing of dosulepin [dothiep Tab 75 mg Cap 25 mg (Dosulepin Mylan 529) Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib	bin] hydrochloride. 	the 30 50	g frequency	n as endorsed where there Dosulepin Viatris Dosulepin Mylan 529 Dosulepin Viatris 529
exists a record of prior dispensing of dosulepin [dothie Tab 75 mg Cap 25 mg (Dosulepin Mylan 329) Cap 25 mg to be delisted 1 October 20	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	the 30 50 nsing 50	g frequency	n as endorsed where there Dosulepin Mylan ⁶²⁹ Dosulepin Viatris ⁶²⁹
exists a record of prior dispensing of dosulepin [dothiep Tab 75 mg Cap 25 mg (Dosulepin Mylan ^{sze} Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg	224) er may determine dispe 10.000 10.000 10.000 10.000 10.000 10.000	the 30 50 nsing 50 100	g frequency	n as endorsed where there Dosulepin Mylan ⁶²⁹ Dosulepin Viatris ⁶²⁹ Tofranil Tofranil
exists a record of prior dispensing of dosulepin [dothiep Tab 75 mg Cap 25 mg (Dosulepin Mylan 329) Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib	224) er may determine dispe 10.000 10.000 10.000 10.000 10.000 10.000	the 30 50 nsing 50	g frequency	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁶²⁹ Dosulepin Viatris ⁶²⁹ Tofranil Tofranil Imipramine
exists a record of prior dispensing of dosulepin [dothiep Tab 75 mg Cap 25 mg (Dosulepin Mylan ^{sze} Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg	224) er may determine dispe 	nsing 50 100 28	g frequency	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁶²⁹ Dosulepin Viatris ⁶²⁹ Tofranil Tofranil Imipramine Crescent ⁶²⁹
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg Cap 25 mg (Dosulepin Mylan 529 Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg Tab 25 mg	224) er may determine dispe 	the 30 50 50 100 28 50	g frequenc:	n as endorsed where there Dosulepin Viatris Dosulepin Mylan ⁸²⁹ Dosulepin Viatris ⁸²⁹ Tofranil Tofranil Imipramine Crescent ⁸²⁹ Tofranil
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg Cap 25 mg (Dosulepin Mylan 200 Cap 25 mg to be delisted 1 October 200 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg Tab 25 mg NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pre	224) er may determine dispe 	the 30 50 50 100 28 50 100 28	g frequence	n as endorsed where there Dosulepin Viatris Dosulepin Mylan \$29 Dosulepin Viatris \$29 Tofranil Tofranil Imipramine Crescent \$29 Tofranil Imipramil Infranil
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg Cap 25 mg (Dosulepin Mylan 329) Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pre Tab 10 mg	224) er may determine dispe 	the 30 50 50 100 28 50 100 100 100	g frequence	n as endorsed where there Dosulepin Viatris Dosulepin Mylan \$29 Dosulepin Viatris \$29 Tofranil Tofranil Imipramine Crescent \$29 Tofranil Imipramine Crescent \$29 Tofranil
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg Cap 25 mg (Dosulepin Mylan 329) Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg Tab 25 mg NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pre	224) er may determine dispe 	the 30 50 50 100 28 50 100 28	g frequence	n as endorsed where there Dosulepin Viatris Dosulepin Mylan \$29 Dosulepin Viatris \$29 Tofranil Tofranil Imipramine Crescent \$29 Tofranil Imipramil Infranil
exists a record of prior dispensing of dosulepin [dothien Tab 75 mg Cap 25 mg (Dosulepin Mylan 329) Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pre Tab 10 mg	224) er may determine dispe 	the 30 50 50 100 28 50 100 100 100	g frequence	n as endorsed where there Dosulepin Viatris Dosulepin Mylan \$29 Dosulepin Viatris \$29 Tofranil Tofranil Imipramine Crescent \$29 Tofranil Imipramine Crescent \$29 Tofranil
exists a record of prior dispensing of dosulepin [dothier Tab 75 mg Cap 25 mg (Dosulepin Mylan 200 Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg Tab 25 mg NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pre Tab 10 mg Tab 25 mg Monoamine-Oxidase Inhibitors (MAOIs) - Non	224) er may determine dispe 	the 30 50 50 100 28 50 100 100 100	g frequence	n as endorsed where there Dosulepin Viatris Dosulepin Mylan \$29 Dosulepin Viatris \$29 Tofranil Tofranil Imipramine Crescent \$29 Tofranil Imipramine Crescent \$29 Tofranil
exists a record of prior dispensing of dosulepin [dothier Tab 75 mg Cap 25 mg (Dosulepin Mylan ⁶²⁹ Cap 25 mg to be delisted 1 October 20 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescrib Tab 10 mg Tab 25 mg NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pre Tab 10 mg Tab 25 mg	bin] hydrochloride. 	the 30 50 50 100 28 50 100 100 100	g frequency	n as endorsed where there Dosulepin Viatris Dosulepin Mylan \$29 Dosulepin Viatris \$29 Tofranil Tofranil Imipramine Crescent \$29 Tofranil Imipramine Crescent \$29 Tofranil

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Monoamine-Oxidase Type A Inhibitors				
MOCLOBEMIDE				
* Tab 150 mg		60		Aurorix
* Tab 300 mg		60	1	Aurorix
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE				
* Tab 20 mg	2.86	84	1	Celapram
ESCITALOPRAM				
* Tab 10 mg		28		Ipca-Escitalopram
	1.07		~	Escitalopram (Ethics)
* Tab 20 mg	1.49	28	1	Ipca-Escitalopram
FLUOXETINE HYDROCHLORIDE				· · · ·
 Tab dispersible 20 mg, scored – Subsidy by endorsement Subsidised by endorsement 	2.50	28	1	<u>Fluox</u>
 When prescribed for a patient who cannot swallow accordingly; or 	·			
1) When prescribed for a patient who cannot swallow	ple of 20 mg in which	case	the presci	iption is deemed to be
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multij endorsed. Note: Tablets should be combined with 	ple of 20 mg in which h capsules to facilitate	case	the presci emental 10	iption is deemed to be
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multij 	ple of 20 mg in which h capsules to facilitate	case incr	the presci emental 10	iption is deemed to be) mg doses.
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multi endorsed. Note: Tablets should be combined with Cap 20 mg 	ple of 20 mg in which h capsules to facilitate	case incr 30	the presci emental 10	iption is deemed to be) mg doses. Brown & Burk 529
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multij endorsed. Note: Tablets should be combined with 	ple of 20 mg in which h capsules to facilitate 2.22 3.13	case incr 30	the prescr emental 10	iption is deemed to be) mg doses. Brown & Burk 529
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multi endorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg 	ple of 20 mg in which h capsules to facilitate 2.22 3.13	case incr 30 90	the prescr emental 10	iption is deemed to be o mg doses. Brown & Burk 529 <u>Arrow-Fluoxetine</u>
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multipendorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE 	ple of 20 mg in which h capsules to facilitate 2.22 3.13 4.11	case incr 30 90	the prescr emental 10	iption is deemed to be o mg doses. Brown & Burk 529 <u>Arrow-Fluoxetine</u>
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multij endorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg 	ple of 20 mg in which h capsules to facilitate 	case incr 30 90 90	the prescr emental 10	iption is deemed to be o mg doses. Brown & Burk 529 <u>Arrow-Fluoxetine</u> Loxamine
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multij endorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg 	ple of 20 mg in which h capsules to facilitate 	case incr 30 90 90 30	the prescr emental 10	iption is deemed to be mg doses. Brown & Burk 529 <u>Arrow-Fluoxetine</u> Loxamine Setrona
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multi endorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg * Tab 100 mg Other Antidepressants 	ple of 20 mg in which h capsules to facilitate 	case incr 30 90 90 30	the prescr emental 10	iption is deemed to be mg doses. Brown & Burk 529 <u>Arrow-Fluoxetine</u> Loxamine Setrona
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multi endorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg * Tab 100 mg Other Antidepressants 	ple of 20 mg in which h capsules to facilitate 2.22 3.13 4.11 0.99 1.74	case incr 30 90 90 30	the prescience of the prescien	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multipendorsed. Note: Tablets should be combined with Cap 20 mg Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg * Tab 100 mg MIRTAZAPINE Tab 30 mg 	ble of 20 mg in which h capsules to facilitate 	28 30	the prescuence of the prescuen	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed Noumed
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multi endorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg * Tab 100 mg Other Antidepressants WIRTAZAPINE 	ble of 20 mg in which h capsules to facilitate 	288 30 28 30 28	the prescuence of the prescuen	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed Noumed Noumed
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multi endorsed. Note: Tablets should be combined with Cap 20 mg Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg * Tab 100 mg Other Antidepressants WIRTAZAPINE Tab 30 mg Tab 45 mg Tab 45 mg 	ble of 20 mg in which h capsules to facilitate 	28 30	the prescuence of the prescuen	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed Noumed
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multipendorsed. Note: Tablets should be combined with Cap 20 mg. Cap 20 mg. PAROXETINE Tab 20 mg. SERTRALINE Tab 50 mg. Tab 100 mg. Other Antidepressants WIRTAZAPINE Tab 30 mg. Tab 45 mg. VENLAFAXINE 	ble of 20 mg in which h capsules to facilitate 2.22 3.13 4.11 0.99 1.74 2.60 2.60 	case incr 30 90 90 30 30 30 28 30 28 30	the prescuence of the prescuen	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed Noumed Noumed Noumed
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multipendorsed. Note: Tablets should be combined with Cap 20 mg. PAROXETINE Tab 20 mg. SERTRALINE Tab 50 mg. Tab 100 mg. Other Antidepressants MIRTAZAPINE Tab 45 mg. VENLAFAXINE Cap 37.5 mg. 	ple of 20 mg in which h capsules to facilitate 2.22 3.13 4.11 0.99 1.74 2.60 	case incr 30 90 90 30 30 28 30 28 30 28 30 28 30 84	the prescuence of the prescuen	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed Noumed Noumed Noumed Noumed Noumed Noumed
 When prescribed for a patient who cannot swallow accordingly; or When prescribed in a daily dose that is not a multipendorsed. Note: Tablets should be combined with Cap 20 mg PAROXETINE * Tab 20 mg SERTRALINE * Tab 50 mg * Tab 100 mg MIRTAZAPINE Tab 30 mg 	ble of 20 mg in which h capsules to facilitate 2.22 3.13 4.11 0.99 1.74 2.60 	case incr 30 90 90 30 30 30 28 30 28 30	the prescuence of the prescuen	iption is deemed to be o mg doses. Brown & Burk 529 Arrow-Fluoxetine Loxamine Setrona Setrona Noumed Noumed Noumed Noumed

	Subsidy (Manufacturer's Pric		Fully Brand or sidised Generic
	\$	Per	 Manufacturer
Antiepilepsy Drugs			
Agents for Control of Status Epilepticus			
DIAZEPAM - Safety medicine; prescriber may determine di			
Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorseme	nt27.92	5	 Hospira
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
c) PSO must be endorsed "not for anaesthetic prod		5	Ctopolid
Rectal tubes 5 mg – Up to 5 tube available on a PSO		Э	✓ <u>Stesolid</u>
PHENYTOIN SODIUM			
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available o		_	
PSO		5	 Hospira
Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available o		-	. Ile entire
PSO	154.01	5	 Hospira
Control of Epilepsy			
CARBAMAZEPINE			
* Tab 200 mg	14.53	100	 Tegretol
* Tab long-acting 200 mg		100	 Tegretol CR
	33.96	200	 Tegretol CR
* Tab 400 mg	34.58	100	 Tegretol
* Tab long-acting 400 mg		100	 Tegretol CR
Oral liq 20 mg per ml		250 ml	 Tegretol
CLOBAZAM – Safety medicine; prescriber may determine c			
Tab 10 mg	9.12	50	 Frisium
CLONAZEPAM – Safety medicine; prescriber may determin	e dispensing frequency		
Oral drops 2.5 mg per ml	7.38	10 ml OP	 Rivotril
ETHOSUXIMIDE			
Cap 250 mg		56	 Essential
			Ethosuximide S29
	140.88	100	 Zarontin
Oral liq 250 mg per 5 ml		200 ml	 Zarontin
GABAPENTIN			
Note: Not subsidised in combination with subsidised pro-	egabalin		
₭ Cap 100 mg	•	100	✓ <u>Nupentin</u>
₭ Cap 300 mg	8.45	100	 Nupentin
₭ Cap 400 mg	10.26	100	 Nupentin
ACOSAMIDE - Special Authority see SA2267 on the next		/	
Tab 50 mg		14	 Vimpat
Tab 100 mg	50.06	14	 Vimpat
	200.24	56	 Vimpat
▲ Tab 150 mg		14	 Vimpat
* T 000	300.40	56	Vimpat
▲ Tab 200 mg		56	 Vimpat

Subsidy		Fully	Brand or
(Manufacturer's Price)	9	Subsidised	Generic
\$	Per	✓	Manufacturer

➡SA2267 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has focal epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment.

LAN	NOTRIGINE			
	Tab dispersible 2 mg		30	 Lamictal
	Tab dispersible 5 mg	50.00	30	 Lamictal
*	Tab dispersible 25 mg	4.20	56	 Logem
*	Tab dispersible 50 mg	5.11	56	 Logem
*	Tab dispersible 100 mg	6.75	56	 Logem
LE\	/ETIRACETAM			
	Tab 250 mg	5.84	60	 Everet
	Tab 500 mg		60	 Everet
	Tab 750 mg		60	 Everet
	Tab 1,000 mg		60	 Everet
	Oral liq 100 mg per ml		300 ml OP	 Levetiracetam-AFT
PHI	ENOBARBITONE			
	For phenobarbitone oral liquid refer Standard Formulae, p	age 268		
	Tab 15 mg	•	500	✓ PSM
	· ~ · · · · · · · · · · · · · · · · · ·	248.50		✓ Noumed
				Phenobarbitone
	Tab 30 mg	398 50	500	✓ Noumed
			000	Phenobarbitone
(PS	M Tab 15 mg to be delisted 1 August 2024)			
•	č č <i>j</i>			
	ENYTOIN SODIUM	75.00	200	 Dilantin Infatab
ጥ	Tab 50 mg		200	 Dilantin Dilantin
	Cap 30 mg		200	 ✓ Dilantin
×	Cap 100 mg Oral lig 30 mg per 5 ml		200 500 ml	 Dilantin Dilantin Paediatric
	1 01	22.03	500 mi	
PRI	EGABALIN			
	Note: Not subsidised in combination with subsidised gaba	•	50	
	Cap 25 mg		56	 Pregabalin Pfizer
	•	7.80		 Milpharm S29
*	Cap 75 mg	2.65	56	 Pregabalin Pfizer
		8.10		 Milpharm S29
	Cap 150 mg	4.01	56	 Lyrica
				Pregabalin Pfizer
		12.44		 Milpharm S29
	Cap 300 mg	7.38	56	 Pregabalin Pfizer
PRI	MIDONE			
*	Tab 250 mg		100	 Primidone Clinect
	č			

	Subsidy		Fully	
	(Manufacturer's Price	/	Subsidised	
	\$	Per		Manufacturer
SODIUM VALPROATE				
Tab 100 mg		100	✓	Epilim Crushable
Tab 200 mg EC	27.44	100	✓	Epilim
Tab 500 mg EC		100	✓	Epilim
* Oral liq 200 mg per 5 ml		300 m	nl 🗸	Epilim S/F Liquid
			✓	Epilim Syrup
* Inj 100 mg per ml, 4 ml	41.50	1	✓	Epilim IV
STIRIPENTOL - Special Authority see SA2268 below - Retail ph	armacy			
Cap 250 mg	509.29	60	1	Diacomit
Powder for oral lig 250 mg sachet		60	1	Diacomit

⇒SA2268 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

▲ Tab 25 mg		60	 Arrow-Topiramate
J. J			 Topiramate Actavis
	26.04		 Topamax
▲ Tab 50 mg		60	 Arrow-Topiramate
Ŭ			 Topiramate Actavis
	44.26		 Topamax
▲ Tab 100 mg		60	 Arrow-Topiramate
•			 Topiramate Actavis
	75.25		 Topamax
▲ Tab 200 mg	55.19	60	 Arrow-Topiramate
•			 Topiramate Actavis
	129.85		 Topamax
Sprinkle cap 15 mg	20.84	60	 Topamax
Sprinkle cap 25 mg		60	 Topamax
VIGABATRIN – Special Authority see SA2088 below – Retail pha			
▲ Tab 500 mg		100	 Sabril
 Powder for oral soln 500 mg per sachet 		60	 ✓ Sabril

► SA2088 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
- 1.3 Patient has tuberous sclerosis complex; and

2 Either:

- 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields...

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields...

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 116

Acute Migraine Treatment

Principal Supply

RIZATRIPTAN Tab orodispersible 10 mg	4.84	30	✓ Rizamelt
SUMATRIPTAN			
Tab 50 mg		90 90	✓ <u>Sumagran</u>
Tab 100 mg Inj 12 mg per ml, 0.5 ml prefilled pen – Maximum		90	✓ <u>Sumagran</u>
prescription		2 OP	✓ <u>Clustran</u>
Prophylaxis of Migraine			
For Beta Adrenoceptor Blockers refer to CARDIOVAS	CULAR SYSTEM, page 49		
PIZOTIFEN ₭ Tab 500 mcg	02.01	100	- Condomigron
K Tab 500 mcg	25.21	100	 Sandomigran
Antinausea and Vertigo Agents			
or Antispasmodics refer to ALIMENTARY TRACT, pa	age 8		
PREPITANT - Special Authority see SA0987 below	, ,		
Cap 2 × 80 mg and 1 × 125 mg		3 OP	Emend Tri-Pack
SA0987 Special Authority for Subsidy			
nitial application from any relevant practitioner. App metogenic chemotherapy and/or anthracycline-basec			
Renewal from any relevant practitioner. Approvals va			
hemotherapy and/or anthracycline-based chemothera			acigoing inging chickegoine
BETAHISTINE DIHYDROCHLORIDE	.,	,	
* Tab 16 mg	3.70	100	✓ <u>Serc</u>
fully subsidised	S29 Unappro	oved medicine	e supplied under Section 29
134 Principal Supply	Solo Subsidiend Supply		

Sole Subsidised Supply

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
CYCLIZINE HYDROCHLORIDE Tab 50 mg CYCLIZINE LACTATE	0.49	10	✓ <u>N</u>	ausicalm
Inj 50 mg per ml, 1 ml ampoule – Up to 10 inj available on a PSO		10	√ <u>H</u>	ameln
DOMPERIDONE * Tab 10 mg	4.00	100	✓ <u>D</u>	omperidone <u>Viatris</u>
HYOSCINE HYDROBROMIDE				
Inj 400 mcg per ml, 1 ml ampoule Patch 1 mg per 72 hours – Special Authority see SA1998	93.00	10	🗸 N	artindale S29
below – Retail pharmacy	17.70	2	🗸 S	copoderm TTS
	88.50	10		copolamine - Mylan copolamine - Mylan S29 ^{©29}

➡SA1998 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.

Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

METOCLOPRAMIDE HYDROCHLORIDE		
* Tab 10 mg – Up to 30 tab available on a PSO1.57	100	 Metoclopramide Actavis 10
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO7.00	10	✓ Baxter
ONDANSETRON		
* Tab 4 mg2.27	50	 Periset
Tab disp 4 mg – Up to 10 tab available on a PSO0.56	10	Periset ODT
* Tab 8 mg4.10	50	Periset
Tab disp 8 mg – Up to 10 tab available on a PSO	10	 Periset ODT
PROCHLORPERAZINE		
* Tab 3 mg buccal	50	
(30.00)		Buccastem
(30.00)		Max Health \$29
(30.00)		Prochlorperazine
		Brown & Burk S29
* Tab 5 mg – Up to 30 tab available on a PSO	250	 Nausafix
		✓ Nausafix - S29 S29
✤ Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO25.81	10	 Stemetil

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	Sub	osidised	Generic
	\$	Per	~	Manufacturer
Authorita				
Antipsychotics				
General				
General				
MISULPRIDE - Safety medicine; prescriber may determine c	lispensing frequency			
Tab 100 mg	7.21	30	✓ 9	Sulprix
Tab 200 mg		60	✓ 9	Sulprix
Tab 400 mg		60	✓ 9	Sulprix
RIPIPRAZOLE – Safety medicine; prescriber may determine	dispensing frequency			-
Tab 5 mg		30	1	Aripiprazole Sandoz
		00		Ascend
			• ,	
Tob 10 mg	10 50	20		Aripiprazole S29
Tab 10 mg		30		Aripiprazole Sandoz
Tab 15 mg		30		Aripiprazole Sandoz
Tab 20 mg		30		Aripiprazole Sandoz
Tab 30 mg		30		Aripiprazole Sandoz
HLORPROMAZINE HYDROCHLORIDE – Safety medicine; p	prescriber may determ	ine disper	nsing fre	equency
Tab 25 mg – Up to 30 tab available on a PSO	15.62	100	✓ I	Largactil
Tab 100 mg – Up to 30 tab available on a PSO		100	 ✓ I 	Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO		10	 ✓ I 	Largactil
LOZAPINE – Hospital pharmacy [HP4]				
Safety medicine; prescriber may determine dispensing freq	liency			
Tab 25 mg		50	1	Clopine
	0.00	00		Clozaril
	13.37	100		Clopine
	10.07	100		Clozaril
Tab 50 mg	8 67	50		Clopine
Tab 50 mg	17.33	100		Clopine
Tab 100 mg		50		Clopine
Tab 100 mg		50		Clozaril
	34.65	100		Clopine
	34.05	100		Clozaril
Tab 200 mg	24 65	50		Clopine
Tab 200 mg		50 100		Clopine
Succession E0 mg nor ml		100 ml		Versacloz
Suspension 50 mg per ml		100 mi	•	versacioz
ALOPERIDOL – Safety medicine; prescriber may determine				_
Tab 500 mcg – Up to 30 tab available on a PSO		100		Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100		Serenace
Tab 5 mg – Up to 30 tab available on a PSO		50		Serenace
	29.72	100		Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO		100 ml		Serenace
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a	PSO21.55	10	✓ 9	Serenace
EVOMEPROMAZINE – Safety medicine; prescriber may dete	rmine dispensina frea	uencv		
Tab 25 mg (33.8 mg as a maleate)		100	 I 	Nozinan (Swiss)
Tab 25 mg as a maleate		100		Nozinan
Tab 100 mg (135 mg as a maleate)		100		Nozinan (Swiss)
Tab 100 mg as a maleate		100		Nozinan
	······································			

	Subsidy		Fully	Brand or
	(Manufacturer's Price		Subsidised	
	\$	Per		Manufacturer
EVOMEPROMAZINE HYDROCHLORIDE - Safety medicine; p	orescriber may deter	mine d	spensing	frequency
Inj 25 mg per ml, 1 ml ampoule		5	1	Neuraxpharm S29
			1	Nozinan S29 S29
	24.48	10	1	Wockhardt
Neuraxpharm 🐲 Inj 25 mg per ml, 1 ml ampoule to be delisted	d 1 August 2024)			
Nozinan S29 529 Inj 25 mg per ml, 1 ml ampoule to be delisted	- /			
ITHIUM CARBONATE – Safety medicine; prescriber may deter	v ,	auonov	,	
Tab long-acting 400 mg		100		Priadel
Cap 250 mg		100		Douglas
		100	•	Dougias
DLANZAPINE – Safety medicine; prescriber may determine disp	• • •	20		Zunina
Tab 2.5 mg	1.40	30	•	Zypine
Zypine to be Principal Supply on 1 August 2024 Tab 5 mg	1.02	30		Zypine
Zypine to be Principal Supply on 1 August 2024	1.90	30	•	zypine
Tab orodispersible 5 mg	2 4 2	28	1	Zypine ODT
Tab 10 mg		30		Zypine
Zypine to be Principal Supply on 1 August 2024		00	•	Lypine
Tab orodispersible 10 mg	2 89	28	1	Zypine ODT
		20	-	
PERICYAZINE – Safety medicine; prescriber may determine disp		100		Neulactil
Tab 2.5 mg		100		Neulactil
Tab 10 mg		100	•	Neulacui
QUETIAPINE – Safety medicine; prescriber may determine dispe	0 1 7			.
Tab 25 mg		90		Quetapel
Tab 100 mg		90		Quetapel
Tab 200 mg		90		Quetapel
Tab 300 mg		90	•	Quetapel
RISPERIDONE – Safety medicine; prescriber may determine dis				
Tab 0.5 mg		60		Risperidone (Teva)
Tab 1 mg		60		Risperidone (Teva)
Tab 2 mg		60		Risperidone (Teva)
Tab 3 mg		60		Risperidone (Teva)
Tab 4 mg		60		Risperidone (Teva)
Oral liq 1 mg per ml		30 ml		Risperon
	17.80	100 m	•	Risperon
ZIPRASIDONE – Safety medicine; prescriber may determine dis			-	
Cap 20 mg		60		Zusdone
Cap 40 mg		60		Zusdone
Cap 60 mg		60		Zusdone
Cap 80 mg		60	/	Zusdone
ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; pres	,		0	
Tab 10 mg	31.45	100	~	Clopixol
Depot Injections				
Deportingeotions				

 Safety medicine; prescriber may determine dispensing frequence			
Inj 300 mg vial	273.56	1	 Ability Maintena S29
Inj 400 mg vial	341.96	1	 Abilify Maintena S29

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

⇒SA2312 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 Patient has a current Special Authority approval for olanzapine depot injection, risperidone depot injection or paliperidone depot injection; and
- 1.2 Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with olanzapine depot injection, risperidone depot injection or paliperidone depot injection; or
- 2 Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection (see Note below for the olanzapine Special Authority criteria for new olanzapine depot injection patients prior to 1 April 2024).

Notes: The Olanzapine depot injection Special Authority criteria that apply to criterion 2 in this Aripiprazole Special Authority application are as follows:

- The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- All of the following:
 - The patient has schizophrenia; and
 - The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of aripiprazole depot injection has been associated with fewer days of intensive intervention than prior to the initiation of an atypical antipsychotic depot injection.

FLUPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

PALIPERIDONE - Special Authority see SA1429 on the next page - Retail pharmacy

TEOLENTITIZOE DECANOATE - Salety medicine, prescriber may determine disp	споту печ	ucity
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	 Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO	5	 Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	 Fluanxol
HALOPERIDOL DECANOATE - Safety medicine; prescriber may determine dispe	nsing frequ	iency
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	 Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	 Haldol Concentrate
		 Haldol
		Decanoas S29
OLANZAPINE – Special Authority see SA2313 below – Retail pharmacy		
a) Safety medicine; prescriber may determine dispensing frequency		
b) Note – no new patients to be initiated on olanzapine.		
Inj 210 mg vial	1	 Zyprexa Relprevv
Inj 300 mg vial414.00	1	 Zyprexa Relprevv
lnj 405 mg vial504.00	1	 Zyprexa Relprevv

➡SA2313 Special Authority for Subsidy

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Safety medicine; prescriber may determine dispensing fr	requency		
Inj 25 mg syringe		1	Invega Sustenna
Inj 50 mg syringe		1	 Invega Sustenna
Inj 75 mg syringe		1	 Invega Sustenna
Inj 100 mg syringe		1	 Invega Sustenna
Inj 150 mg syringe		1	🗸 Invega Sustenna

Subsidy (Manufacturer's Pri	,	Fully Subsidised	Brand or Generic	
\$	Pe	r 🖌	Manufacturer	

⇒SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE PALMITATE - Special Authority see SA2167 below - Retail pharmacy

Inj 175 mg syringe		1	🗸 Invega Trinza
Inj 263 mg syringe		1	🗸 Invega Trinza
Inj 350 mg syringe		1	🗸 Invega Trinza
Inj 525 mg syringe	1,305.36	1	🗸 Invega Trinza

⇒SA2167 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 The patient has schizophrenia; and

2 The patient has had an initial Special Authority approval for paliperidone once-monthly depot injection.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

RISPERIDONE - Special Authority see SA1427 below - Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial		1	 Risperdal Consta
Inj 37.5 mg vial	178.71	1	 Risperdal Consta
Inj 50 mg vial	217.56	1	 Risperdal Consta

⇒SA1427 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO 1	19.80 5	 Clopixol
--	---------	------------------------------

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
Anxiolytics				
BUSPIRONE HYDROCHLORIDE				
* Tab 5 mg		100	✓ В	suspirone Viatris
* Tab 10 mg		100	✓ <u>B</u>	uspirone Viatris
CLONAZEPAM - Safety medicine; prescriber may determine dis	spensing frequency			
Tab 500 mcg		100	✓ P	axam
Tab 2 mg	10.78	100	🗸 P	axam
DIAZEPAM - Safety medicine; prescriber may determine disper	sing frequency			
Tab 2 mg	0 1 2	500	🗸 A	rrow-Diazepam
Tab 5 mg	115.00	500	✓ A	rrow-Diazepam
LORAZEPAM - Safety medicine; prescriber may determine disp	ensing frequency			
Tab 1 mg		250	🗸 🗸	tivan
Tab 2.5 mg		100	✓ <u>A</u>	tivan

Multiple Sclerosis Treatments

⇒SA2274 Special Authority for Subsidy

Initial application — (Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
 - 1.2 Patient has an EDSS score between 0 6.0; and
 - 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
 - 1.4 All of the following:
 - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5° C); and
 - 1.4.5 Either:
 - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
 - 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
 - 1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
 - 1.6 Any of the following:
 - 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
continued				
 1.6.2 A sign of that new inflammatory activity is a 1.6.3 A sign of that new inflammatory is a T2 lesion 1.6.4 A sign of that new inflammatory activity is a features of a recent attack that occurred with 1.6.5 A sign of that new inflammatory activity is new inflammatory activity inflammatory activity is new inflammatory activi	n with associated loc prominent T2 lesion t nin the last 2 years; o w T2 lesions compa	cal swelling that clearly or red with a	g; or / is res previo	ponsible for the clinical
Note: Treatment on two or more funded multiple sclerosis treatmer Renewal — (Multiple Sclerosis - dimethyl fumarate, fingolimo beta-1-beta, natalizumab and teriflunomide) from any relevant had an EDSS score of 0 to 6.0 (inclusive) with or without the use of the patient has walked 100 metres or more with or without aids in Note: Treatment on two or more funded multiple sclerosis treatment	d, glatiramer acetat practitioner. Approv of unilateral or bilater the last six months).	e, interfer als valid fo al aids at a	on bei or 12 m any tim	nonths where patient has
DIMETHYL FUMARATE – Special Authority see SA2274 on the p	previous page – Reta	ul pharmad	су	
 a) Wastage claimable b) Note: Treatment on two or more funded multiple coloresis 	traatmanta aimultan		ot nor	mittad
b) Note: Treatment on two or more funded multiple sclerosis Cap 120 mg		14		rinned. Tecfidera
Cap 240 mg		56	-	ecfidera
FINGOLIMOD – Special Authority see SA2274 on the previous p. a) Wastage claimable b) Note: Treatment on two or more funded multiple sclerosis Cap 0.5 mg	treatments simultan		not per	mitted. Silenya
				allellya
GLATIRAMER ACETATE – Special Authority see SA2274 on the Note: Treatment on two or more funded multiple sclerosis tre Inj 40 mg prefilled syringe	atments simultaneou		permitt	ed. Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA2274 of Note: Treatment on two or more funded multiple sclerosis tree Inj 6 million iu prefilled syringe Injection 6 million iu per 0.5 ml pen injector	atments simultaneou		oermitt	
INTERFERON BETA-1-BETA – Special Authority see SA2274 or Note: Treatment on two or more funded multiple sclerosis tre Inj 8 million iu per 1 ml	n the previous page – atments simultaneou		permitt	
NATALIZUMAB – Special Authority see SA2274 on the previous Note: Treatment on two or more funded multiple sclerosis tre Inj 20 mg per ml, 15 ml vial	page – Retail pharma atments simultaneou			ed. 'ysabri
 TERIFLUNOMIDE – Special Authority see SA2274 on the previou a) Wastage claimable b) Note: Treatment on two or more funded multiple sclerosis Tab 14 mg 	treatments simultan			mitted. Aubagio
Multiple Sclerosis Treatments - Other				

OCRELIZUMAB - Special Authority see SA2273 on the	next page – Retail pharmacy	
Note: Treatment on two or more funded multiple scl	erosis treatments simultaneously	is not permitted.
Inj 30 mg per ml, 10 ml vial		 Ocrevus

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	<u> </u>	Manufacturer

⇒SA2273 Special Authority for Subsidy

Initial application — (Multiple Sclerosis - ocrelizumab) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
 - 1.2 Patient has an EDSS score between 0 6.0; and
 - 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
 - 1.4 All of the following:
 - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and
 - 1.4.5 Either:
 - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
 - 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
 - 1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
 - 1.6 Any of the following:
 - 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
 - 1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
 - 1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
 - 1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
 - 1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or
- 2 Patient has an active Special Authority approval for either dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab or teriflunomide.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Renewal — (Multiple Sclerosis - ocrelizumab) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Initial application — (Primary Progressive Multiple Sclerosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Diagnosis of primary progressive multiple sclerosis (PPMS) meets the 2017 McDonald criteria and has been confirmed by a neurologist; and
- 2 Patient has an EDSS 2.0 (score equal to or greater than 2 on pyramidal functions) to EDSS 6.5; and

Viaisom

Subsidy		Fully	Brand or	_
(Manufacturer's Price)	:	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

3 Patient has no history of relapsing remitting multiple sclerosis.

Renewal — (Primary Progressive Multiple Sclerosis) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of less than or equal to 6.5 at any time in the last six months (ie patient has walked 20 metres with bilateral assistance/aids, without rest in the last six months).

30

Sedatives and Hypnotics

MELATONIN – Special Authority see SA1666 below – Retail pharmacy

Restricted to patients aged 18 years or under.

⇒SA1666 Special Authority for Subsidy

Initial application only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)*; and
- 2 Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate; and
- 3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
- 4 Patient is aged 18 years or under*.

Renewal only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is aged 18 years or under*; and
- 2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
- 3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
- 4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Note: Indications marked with * are unapproved indications.

MIDAZOLAM - Safety medicine; prescriber may d	letermine dispensing frequency		
Inj 1 mg per ml, 5 ml ampoule	6.10	10	 Midazolam-Baxter
Inj 1 mg per ml, 5 ml plastic ampoule – Up to	10 inj available		
on a PSO		10	 Pfizer
On a PSO for status epilepticus use only.		epilepticu	us use only.
Inj 5 mg per ml, 3 ml ampoule	5.00	5	 Midazolam-Baxter
Inj 5 mg per ml, 3 ml plastic ampoule – Up to	5 inj available on		
a PSO		5	 Pfizer
On a PSO for status epilepticus use only.	PSO must be endorsed for status	epilepticu	is use only.
PHENOBARBITONE SODIUM - Special Authority	y see <mark>SA1386 below</mark> – Retail pharm	nacy	
Inj 200 mg per ml, 1 ml ampoule		10	 Max Health S29
➡SA1386 Special Authority for Subsidy			
Initial application from any relevant practitioner.	Approvals valid without further rene	ewal unle	ss notified for applications meeting
the following criteria:			
Both:			
 For the treatment of terminal agitation that i 	is unresponsive to other agents; an	d	
2 The applicant is part of a multidisciplinary te	eam working in palliative care.		
TEMAZEPAM - Safety medicine; prescriber may	determine dispensing frequency		
Tab 10 mg	,	25	✓ Normison

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
ZOPICLONE – Safety medicine; prescriber may determine dispe Tab 7.5 mg		500 🗸	Zopiclone Actavis
Spinal Muscular Atrophy			
NUSINERSEN – PCT only – Special Authority see SA2174 below Inj 12 mg per 5 ml vial		1 🗸	Spinraza
Initial application — (spinal muscular atrophy (SMA)) from ar applications meeting the following criteria: All of the following:	ny relevant practitione	r. Approvals va	alid for 12 months for
 Patient has genetic documentation of homozygous SMN1 heterozygous mutation; and Patient is 18 years of age or under; and Either: 	gene deletion, homo:	zygous SMN1 p	oint mutation, or compound
 3.1 Patient has experienced the defined signs and sym 3.2 Both: 3.2.1 Patient is pre-symptomatic; and 3.2.2 Patient has three or less copies of SMN2. 	nptoms of SMA type I	II or IIIa prior to	o three years of age; or
Renewal — (spinal muscular atrophy (SMA)) from any relevar meeting the following criteria: All of the following:	nt practitioner. Approv	vals valid for 12	months for applications
 There has been demonstrated maintenance of motor miles Patient does not require invasive permanent ventilation (a reversible cause while being treated with nusinersen; and Nusinersen not to be administered in combination other SI 	t least 16 hours per d	ay) in the absen	ice of a potentially
RISDIPLAM – [Xpharm] – Special Authority see SA2203 below Note: the supply of risdiplam is via Pharmac's approved dire Pharmac's website https://pharmac.govt.nz/risdiplam Powder for oral soln 750 mcg per ml, 60 mg per bottle			can be found on Evrysdi
► SA2203 Special Authority for Subsidy Initial application — (spinal muscular atrophy (SMA)) from an applications meeting the following criteria: All of the following:	ny relevant practitione	r. Approvals va	alid for 12 months for
 Patient has genetic documentation of homozygous SMN1 heterozygous mutation; and Patient is 18 years of age or under; and Either: 	gene deletion, homo:	zygous SMN1 p	oint mutation, or compound
3.1 Patient has experienced the defined signs and sym3.2 Both:	ptoms of SMA type I	II or IIIa prior to	o three years of age; or
3.2.1 Patient is pre-symptomatic; and3.2.2 Patient has three or less copies of SMN2.			
Renewal — (spinal muscular atrophy (SMA)) from any relevant meeting the following criteria: All of the following:			
 There has been demonstrated maintenance of motor miles 	stone function since to	reatment initiation	on; and

- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam; and
- 3 Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
Stimulants/ADHD Treatments			
ATOMOXETINE			
Cap 10 mg		28	 APO-Atomoxetine S29 S29
			✓ Generic Partners
	43.02		✓ APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202			
Cap 18 mg		28	 Generic Partners
	45.57		APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202			
Cap 25 mg		28	 Generic Partners
	44.30		 APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202			
Cap 40 mg		28	 Generic Partners
	46.21		 APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202		~~	
Cap 60 mg		28	 APO-Atomoxetine S29 S29
			 Generic Partners
	51.31		 APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202			
Cap 80 mg	56.45	28	 APO-Atomoxetine S29 S29
			 Generic Partners
	65.20		 APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202			
Cap 100 mg	58.48	28	 APO-Atomoxetine S29 S29
			 Generic Partners
	65.71		 APO-Atomoxetine
APO-Atomoxetine to be Principal Supply on 1 August 202	<u>2</u> 4		
(APO-Atomoxetine S29 S29 Cap 10 mg to be delisted 1 August 2024) (Generic Partners Cap 10 mg to be delisted 1 August 2024) (Generic Partners Cap 18 mg to be delisted 1 August 2024) (Generic Partners Cap 25 mg to be delisted 1 August 2024) (Generic Partners Cap 40 mg to be delisted 1 August 2024) (APO-Atomoxetine S29 S29 Cap 60 mg to be delisted 1 August 2024)			
(Generic Partners Cap 60 mg to be delisted 1 August 2024) (APO-Atomoxetine S29 S29 Cap 80 mg to be delisted 1 August 2 (Generic Partners Cap 80 mg to be delisted 1 August 2024)			
(APO-Atomoxetine S29 S29 Cap 100 mg to be delisted 1 August 2024) (APO-Atomoxetine S29 S29 Cap 100 mg to be delisted 1 August 2024)	t 2024)		

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
DEXAMFETAMINE SULFATE - Special Authority see SA11	49 below – Retail pharma	су		
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensin	g frequency			
Tab 5 mg - Brand switch fee payable (Pharmacode 267	3886) -			
see page 265 for details		100	🗸 P	SM
	28.50		🗸 A	spen
	29.80		🗸 N	oumed
				Dexamfetamine
Noumed Dexamfetamine to be Principal Supply on 1	June 2024			

Noumed Dexamfetamine to be Principal Supply on 1 June 2024

(PSM Tab 5 mg to be delisted 1 June 2024) (Aspen Tab 5 mg to be delisted 1 June 2024)

► SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

- 2.1 Applicant is a paediatrician or psychiatrist; or
- 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	\$	Per		Manufacturer
METHYLPHENIDATE HYDROCHLORIDE – Special Authority se	e SA1964 below – R	etail p	harmacy	
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing free	quency			
c) Note: Brand Switch Fee applies only to patients who have	e transferred from Co	ncerta	a brand d	ue to an out of stock.
Tab immediate-release 5 mg	3.20	30	✓	Rubifen
Tab immediate-release 10 mg		30	✓	Ritalin
			✓	Rubifen
Tab extended-release 18 mg – Brand switch fee payable				
(Pharmacode 2677822) - see page 265 for details	7.75	30	1	Methylphenidate ER - Teva
Tab immediate-release 20 mg		30	1	Rubifen
Tab sustained-release 20 mg.		30	✓	Rubifen SR
Tab extended-release 27 mg – Brand switch fee payable				
(Pharmacode 2677822) - see page 265 for details	11.45	30	1	Methylphenidate ER - Teva
Tab extended-release 36 mg – Brand switch fee payable				
(Pharmacode 2677822) - see page 265 for details	15.50	30	1	Methylphenidate ER - Teva
Tab extended-release 54 mg – Brand switch fee payable				
(Pharmacode 2677822) - see page 265 for details		30	~	Methylphenidate ER - Teva

⇒SA1964 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Note: *narcolepsy is not a registered indication for Methylphenidate ER - Teva.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been

 e)	Fully Subsidised	Brand or Generic	
\$ Per	1	Manufacturer	

continued...

consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal -- (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: *narcolepsy is not a registered indication for Methylphenidate ER - Teva.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA2305 below - Retail pharmacy

a) Only on a controlled drug form

 b) Safety medicine; prescriber may determine dispension 	sing frequency		
Tab extended-release 18 mg		30	 Concerta
Tab extended-release 27 mg	65.44	30	 Concerta
Tab extended-release 36 mg	71.93	30	 Concerta
Tab extended-release 54 mg		30	 Concerta
Cap modified-release 10 mg		30	 Ritalin LA
Cap modified-release 20 mg		30	 Ritalin LA
Cap modified-release 30 mg		30	 Ritalin LA
Cap modified-release 40 mg		30	 Ritalin LA

SA2305 Special Authority for Subsidy

Initial application - (ADHD) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or difficulties with adherence; ٥r
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal - (ADHD) only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

MODAFINIL - Special Authority see SA1999 on the next page -	- Retail pharmacy		
Tab 100 mg		60	1

Modavigil

Subsidy		Fully	Brand or
(Manufacturer's Price)	Sub	sidised	Generic
	Per	siuiseu	Manufacturer
φ	rei	•	Wanulaclurer

⇒SA1999 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3 Either:

- 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
- 3.2 Methylphenidate and dexamfetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg	3.70	84	Ipca-Donepezil
0	4.34	90	 Donepezil-Rex
Ipca-Donepezil to be Principal Supply on 1 June 2024			
* Tab 10 mg	5.50	84	Ipca-Donepezil
5	6.64	90	 Donepezil-Rex
Ipca-Donepezil to be Principal Supply on 1 June 2024			•
(Donepezil-Rex Tab 5 mg to be delisted 1 June 2024)			
(Donepezil-Rex Tab 10 mg to be delisted 1 June 2024)			
RIVASTIGMINE - Special Authority see SA1488 below - Retail	nharmaov		
1 ,			• - • • • • • • • •
Patch 4.6 mg per 24 hour		30	Rivastigmine Patch
			BNM 5
	90.00		Exelon Patch 5
Patch 9.5 mg per 24 hour		30	Rivastigmine Patch
3			BNM 10
	90.00		Exelon Patch 10
	00.00		

⇒SA1488 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 The patient has been diagnosed with dementia; and

2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
Treatments for Substance Dependence				
BUPRENORPHINE WITH NALOXONE – Special Authority see S a) No patient co-payment payable b) Safety medicine; prescriber may determine dispensing free		il pharma	су	
Tab sublingual 2 mg with naloxone 0.5 mg	11.76	28	✓ <u>B</u>	uprenorphine Naloxone BNM
Tab sublingual 8 mg with naloxone 2 mg		28	✓ <u>B</u>	uprenorphine Naloxone BNM

⇒SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health...

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from

any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	15.00	30	 Zyban
-----------------------------	-------	----	---------------------------

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully Brand or idised Generic Manufacturer
DISULFIRAM Tab 200 mg		100	✓ Antabuse
NALTREXONE HYDROCHLORIDE - Special Authority see SA1	1408 below – Retail p	harmacy	
Tab 50 mg	77.77	28	✓ Naltrexone AOP S29
	83.33	30	✓ <u>Naltraccord</u>

► SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to Health NZ or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

- a) Nicotine will not be funded in amounts less than 4 weeks of treatment.
- b) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

3 11 1 41 1 01 0	COUDIT A.
1 28	 Habitrol
3 7	 Habitrol
5 28	 Habitrol
9 7	 Habitrol
2 28	 Habitrol
9 7	 Habitrol
5 216	 Habitrol
9 36	 Habitrol
5 216	 Habitrol
5 36	 Habitrol
2 204	 Habitrol
7 96	 Habitrol
2 204	 Habitrol
7 96	 Habitrol
7 204	 Habitrol
7 96	 Habitrol
7 204	 Habitrol
7 96	 Habitrol
	3 7 5 28 9 7 2 28 9 7 6 216 9 36 5 216 5 216 5 204 7 96 7 204 7 96 7 204 7 204

VARENICLINE TARTRATE - Special Authority see SA1845 on the next page - Retail pharmacy

- a) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack
- b) Varenicline will not be funded in amounts less than 4 weeks of treatment.

c) The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.

Tab 0.5 mg × 11 and 1 mg × 42 16.67	53 OP	 Varenicline Pfizer
Tab 1 mg17.62	56	✓ Varenicline Pfizer

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price	e)	Subsidised	Generic
\$	Per	1	Manufacturer

➡SA1845 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 It has been 6 months since the patient's previous Special Authority was approved; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

The patient must not have had an approval in the past 6 months.

Notes: a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval.

This includes the 4-week 'starter' pack.

	Subsidy	C	Fully sidised	Brand or Generic
	(Manufacturer's Price) \$	Per		Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BENDAMUSTINE HYDROCHLORIDE - PCT only - Speciali				
Inj 25 mg vial Inj 100 mg vial		1 1		ibomustin ibomustin
Inj 1 mg for ECP		1 mg	-	axter
➡SA2153 Special Authority for Subsidy		•		
Initial application — (treatment naive CLL) only from a rele				he recommendation of a
relevant specialist. Approvals valid for 12 months for applicat All of the following:	ions meeting the followir	ig criteria:		
1 The patient has Binet stage B or C, or progressive stag	ae A chronic lymphocytic	leukaem	ia requir	ing treatment: and
2 The patient is chemotherapy treatment naive; and	5			
3 The patient is unable to tolerate toxicity of full-dose FC	R; and			
 4 Patient has ECOG performance status 0-2; and 5 Patient has a Cumulative Illness Rating Scale (CIRS) : 	score of < 6 ; and			
6 Bendamustine is to be administered at a maximum do		1 and 2	everv 4 v	weeks for a maximum of
6 cycles.	.		,	
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small ly			mothera	py treatment is considered
to comprise a known standard therapeutic chemotherapy regi Initial application — (Indolent, Low-grade lymphomas) or			dical pr	actitionar on the
recommendation of a relevant specialist. Approvals valid for				
All of the following:	· · · · · · · · · · · · · · · ·	5		3
1 The patient has indolent low grade NHL requiring treat	ment; and			
2 Patient has a WHO performance status of 0-2; and				
3 Any of the following: 3.1 Both:				
3.1.1 Patient is treatment naive; and				
3.1.2 Bendamustine is to be administered for	a maximum of 6 cycles (in combir	ation wi	th rituximab when
CD20+); or				
3.2 Both:				
3.2.1 Patient is refractory to or has relapsed v	vithin 12 months of a ritu	ximab cor	ntaining	combined
chemo-immunotherapy regimen; and 3.2.2 Bendamustine is to be administered in c	combination with obinutur	zumab foi	' a maxir	num of 6 cvcles: or
3.3 All of the following:				· · · · · · · · · · · · · · · · · · ·
3.3.1 The patient has not received prior bend	amustine therapy; and			
3.3.2 Bendamustine is to be administered for	a maximum of 6 cycles i	n relapse	d patient	is (in combination with
rituximab when CD20+); and 3.3.3 Patient has had a rituximab treatment-fr	an interval of 12 months	or more.	or	

3.4 Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine; and
 - 1.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

continued...

- 2 Both:
 - 2.1 Patients have not received a bendamustine regimen within the last 12 months; and
 - 2.2 Either:

2.2.1 Both:

- 2.2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
- 2.2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more: or
- 2.2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom's macroglobulinaemia.

Initial application --- (Hodgkin's lymphoma*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has Hodgkin's lymphoma requiring treatment; and
- 2 Patient has a ECOG performance status of 0-2: and
- 3 Patient has received one prior line of chemotherapy; and
- 4 Patient's disease relapsed or was refractory following prior chemotherapy; and

~

5 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles.

Note: Indications marked with * are unapproved indications.

BUSULFAN – PCT – Retail pharmacy-Specialist			
Tab 2 mg		100	 Myleran
CARBOPLATIN – PCT only – Specialist			
Inj 10 mg per ml, 45 ml vial		1	 DBL Carboplatin
	45.20		✓ Carboplatin Ebewe
	48.50		 Carbaccord
Inj 1 mg for ECP	0.10	1 mg	 Baxter
CARMUSTINE – PCT only – Specialist			
Inj 100 mg vial	710.00	1	BiCNU
Inj 100 mg for ECP		100 mg OP	✓ Baxter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist		-	
Tab 2 mg		25	Leukeran FC
CISPLATIN – PCT only – Specialist			
Inj 1 mg per ml, 50 ml vial	15.00	1	 Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial		1	 Cisplatin Ebewe Cisplatin Ebewe
	29.66	1	✓ DBL Cisplatin
Inj 1 mg for ECP		1 mg	✓ Baxter
CYCLOPHOSPHAMIDE			Buxton
Tab 50 mg – PCT – Retail pharmacy-Specialist	145.00	50	 Cyclonex
Inj 1 g vial – PCT – Retail pharmacy-Specialist		1	✓ Endoxan
		6	✓ Cytoxan
Inj 2 g vial – PCT only – Specialist		1	 Endoxan
Inj 1 mg for ECP – PCT only – Specialist		1 mg	✓ Baxter
, , , ,		1 119	Buildi
IFOSFAMIDE – PCT only – Specialist	06.00	4	 Holoxan
lnj 1 g		1	 ✓ Holoxan ✓ Holoxan
Inj 2 g			 ✓ Holoxan ✓ Baxter
Inj 1 mg for ECP	0.10	1 mg	- Daxler

	Subsidy Manufacturer's Price)	Subs	Fully sidised	Brand or Generic
	\$	Per	 ✓ 	Manufacturer
LOMUSTINE – PCT – Retail pharmacy-Specialist				
Cap 10 mg	132.59	20	1	CeeNU
Cap 40 mg	399.15	20	1	CeeNU
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist	40.70	25	1	Alkeran
Inj 50 mg - PCT only - Specialist		1	1	Megval S29
			1	Melpha
	67.80		1	Alkeran
			✓	Alkeran S29 S29
DXALIPLATIN – PCT only – Specialist				
Inj 100 mg vial	25.01	1	•	Oxaliplatin Actavis 100
	110.00		1	Oxaliplatin Ebewe
Inj 5 mg per ml, 20 ml vial		1	1	Alchemy Oxaliplatin
	46.32			Oxaliplatin Accord
Inj 1 mg for ECP	0.35	1 mg	1	Baxter
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	1	Bedford S29
			1	Max Health S29
			1	THIO-TEPA S29
	398.00		✓	Tepadina
Inj 100 mg vial	CBS	1	1	Max Health S29
	1,800.00		1	Tepadina
Antimetabolites				
AZACITIDINE – PCT only – Specialist – Special Authority see SA	2141 below			
Inj 100 mg vial		1	1	Azacitidine Dr Reddy's
Inj 1 mg for ECP	0.83	1 mg	1	Baxter
SA2141 Special Authority for Subsidy		Ŭ		

► SA2141 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

155

	Subsidy (Manufacturer's Pri	ce) Sub	Fully sidised	Brand or Generic
	\$	Per	✓	Manufacturer
LCIUM FOLINATE				
Tab 15 mg – PCT – Retail pharmacy-Specialist		10	1	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml - PCT - Retail pharmacy-Specialist .	17.10	5		Hospira
Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Spec	ialist7.28	1		Calcium Folinate Sandoz
			1	Calcium Folinate Sandoz S29 S29
	36.48	5	✓	Eurofolic S29
Inj 50 mg – PCT – Retail pharmacy-Specialist	72.80	10	•	Leucovorin Pharmacia S29
Inj 10 mg per ml, 10 ml vial - PCT only - Specialist	9.49	1	1	Calcium Folinate Sandoz
	47.45	5	1	Eurofolic S29
Inj 100 mg - PCT only - Specialist	7.33	1	1	Calcium Folinate Ebewe
	94.90	10	✓	Leucovorin Pharmacia S29
Inj 300 mg - PCT only - Specialist	22.51	1	1	Calcium Folinate Ebewe
	25.14		✓	Leucovorin DBL S29
Inj 10 mg per ml, 35 ml vial - PCT only - Specialist	25.14	1	-	Calcium Folinate Sandoz
			1	Calcium Folinate Sandoz S29 S29
Inj 1 g – PCT only – Specialist	67.51	1	1	Calcium Folinate Ebewe
Inj 10 mg per ml, 100 ml vial - PCT only - Specialist	72.00	1	1	Calcium Folinate Sandoz
Inj 1 mg for ECP – PCT only – Specialist	0.06	1 mg	✓	Baxter
PECITABINE – Retail pharmacy-Specialist				
Tab 150 mg	9.80	60	1	Capecitabine Viatris
Tab 500 mg		120	1	Capecitabine Viatris
ADRIBINE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml		1		Litak S29
Inj 1 mg per ml, 10 ml		1		Leustatin
Inj 10 mg for ECP TARABINE	749.96	10 mg OP		Baxter
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Spec Inj 100 mg per ml, 20 ml vial – PCT – Retail	ialist472.00	5	✓	Pfizer
pharmacy-Specialist		1		Pfizer Pfizer S29 S29
Inj 1 mg for ECP – PCT only – Specialist	0.29	10 mg		Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Spec UDARABINE PHOSPHATE		100 mg OP	✓	Baxter
Tab 10 mg - PCT - Retail pharmacy-Specialist	412 00	20	1	Fludara Oral
		20	-	
Inj 50 mg vial – PCT only – Specialist	634.00	5		Fludarabine Ebewe

	Subsidy (Manufacturer's Price)	Fully Subsidised	
	\$	Per	 ✓ 	Manufacturer
LUOROURACIL				
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist		1	1	Fluorouracil Accord
Inj 50 mg per ml, 50 ml vial - PCT only - Specialist	14.72	1	✓	Fluorouracil Accord
Inj 50 mg per ml, 100 ml vial - PCT only - Specialist		1	✓	Fluorouracil Accord
Inj 1 mg for ECP – PCT only – Specialist	0.62	100 mg	g 🗸	Baxter
GEMCITABINE HYDROCHLORIDE – PCT only – Specialist Inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine)	,			
26.3 ml vial		1	1	DBL Gemcitabine
lnj 1 g		1	1	Gemcitabine Ebewe
Inj 1 mg for ECP		1 mg	1	Baxter
RINOTECAN HYDROCHLORIDE – PCT only – Specialist				
Inj 20 mg per ml, 5 ml vial		1	1	Accord
	71.44		~	Irinotecan Actavis 100
	100.00		1	Irinotecan-Rex
Inj 1 mg for ECP	0.54	1 mg	1	Baxter
/ERCAPTOPURINE		•		
Tab 50 mg - PCT - Retail pharmacy-Specialist		25	1	Puri-nethol
Oral suspension 20 mg per ml – Retail pharmacy-Specialist				
Special Authority see SA1725 below		00 ml C	DP 🗸	Allmercap

► SA1725 Special Authority for Subsidy

Initial application only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.

Renewal only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.

	Subsidy (Manufacturer's Price		Fully Subsidised	Generic
	\$	Per		Manufacturer
	0.00	00		T
Tab 2.5 mg – PCT – Retail pharmacy-Specialist		90		Trexate
 Tab 10 mg – PCT – Retail pharmacy-Specialist Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Special 		90 5		Trexate Methotrexate DBL
e inj 2.5 mg per mi, 2 mi – POT – Retail pharmacy-Special	151	5		Methotrexate DBL
			•	S29 S29
k Inj 7.5 mg prefilled syringe		1	1	Methotrexate
				Sandoz
Inj 10 mg prefilled syringe		1	1	Methotrexate
, , , , , ,				Sandoz
Inj 15 mg prefilled syringe	14.77	1	1	Methotrexate
				Sandoz
k Inj 20 mg prefilled syringe	14.88	1	1	Methotrexate
, ., , .				Sandoz
k Inj 25 mg prefilled syringe	14.99	1	1	Methotrexate
				Sandoz
Inj 30 mg prefilled syringe	15.09	1	1	Methotrexate
				Sandoz
Inj 25 mg per ml, 2 ml vial – PCT – Retail pharmacy-Spe	cialist30.00	5	1	Methotrexate DBL
				Onco-Vial
Inj 25 mg per ml, 20 ml vial – PCT – Retail pharmacy-Sp	ecialist45.00	1	1	DBL Methotrexate
				Onco-Vial
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Speci	alist25.00	1	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – PCT – Retail				
pharmacy-Specialist	67.99	1	1	Methotrexate Ebewe
Inj 1 mg for ECP – PCT only – Specialist		1 mg		Baxter
Inj 5 mg intrathecal syringe for ECP – PCT only – Special	list4.73	5 mg O	Р 🗸	Baxter
PEMETREXED – PCT only – Specialist – Special Authority s	ee SA1679 below			
Inj 100 mg vial	60.89	1	1	Juno Pemetrexed
Inj 500 mg vial		1		Juno Pemetrexed
Inj 1 mg for ECP	0.55	1 mg	✓	Baxter

⇒SA1679 Special Authority for Subsidy

Initial application — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with mesothelioma; and
- 2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Renewal — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initial application — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

(Man	Subsidy	Fully		Brand or
	ufacturer's Price)	Subsidised		Generic
· · · · · · · · · · · · · · · · · · ·	\$	Per	1	Manufacturer

continued...

- 1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
- 2 Fither:
 - 2.1 Both:
 - 2.1.1 Patient has chemotherapy-naïve disease; and
 - 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles: or
 - 2.2 All of the following:
 - 2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
 - 2.2.2 Patient has not received prior funded treatment with pemetrexed; and
 - 2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Renewal — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the followina:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

т

THIOGUANINE – PCT – Retail pharmacy-Specialist			
Tab 40 mg	 25	 Lanvis 	

Other Cytotoxic Agents

AMSACRINE - PCT only - Specialist		
Inj 50 mg per ml, 1.5 ml ampoule1,500.00	6	 Amsidine S29
4,736.00		 Amsidine S29
Inj 75 mg1,250.00	5	🗸 AmsaLyo 🖘
ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist		
Cap 0.5 mg1,175.87	100	🗸 Agrylin
ARSENIC TRIOXIDE – PCT only – Specialist		
Inj 1 mg per ml, 10 ml vial4,817.00	10	 Phenasen
Inj 10 mg for ECP481.70	10 mg OP	 Baxter
BLEOMYCIN SULPHATE – PCT only – Specialist		
Inj 15,000 iu, vial	1	 DBL Bleomycin Sulfate
Inj 1,000 iu for ECP14.32	1,000 iu	 Baxter
BORTEZOMIB - PCT only - Specialist - Special Authority see SA1889 below		
Inj 3.5 mg vial	1	 DBL Bortezomib
Inj 1 mg for ECP22.26	1 mg	 Baxter

■ SA1889 Special Authority for Subsidy

Initial application - (multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Fither:

- 1 The patient has symptomatic multiple myeloma; or
- 2 The patient has symptomatic systemic AL amyloidosis *.

Note: Indications marked with * are unapproved indications.

	Subsidy		Fully	Brand or
(Manufacturer's F		idised	
	\$	Per	1	Manufacturer
ACARBAZINE – PCT only – Specialist				
Inj 200 mg vial	72.11	1	1	DBL Dacarbazine
, ,	580.60	10	1	Dacarbazine
				APP S29
Inj 200 mg for ECP	72 11	200 mg OP	1	Baxter
, .		200		
ACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist	055.00	4		Coomoron
Inj 0.5 mg vial		1		Cosmegen
Inj 0.5 mg for ECP	255.00	0.5 mg OP	•	Baxter
UNORUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 10 ml		1		Pfizer
Inj 20 mg vial	1,495.00	10	1	Daunorubicin
				Zentiva S29
Inj 20 mg for ECP	171.93	20 mg OP	✓	Baxter
DCETAXEL - PCT only - Specialist		-		
Inj 20 mg	48 75	1	1	Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial		1		DBL Docetaxel
Inj 20 mg per ml, 4 ml vial		1		Docetaxel
	20.00	I	•	Accord S29
lai 00 ma	105.00			
Inj 80 mg		1		Docetaxel Sandoz
Inj 1 mg for ECP	0.35	1 mg	•	Baxter
XORUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial	10.00	1	1	Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial	11.50	1	1	Doxorubicin Ebewe
	17.00		1	Arrow-Doxorubicin
Inj 2 mg per ml, 50 ml vial	23.00	1		Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial	65.00	1	1	Arrow-Doxorubicin
	69.99		1	Accord S29
			1	Doxorubicin Ebewe
Inj 1 mg for ECP	0.35	1 mg	1	Baxter
IRUBICIN HYDROCHLORIDE - PCT only - Specialist		-		
Inj 2 mg per ml, 5 ml vial	25.00	1	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1		Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial		1		Epirubicin Ebewe
Inj 1 mg for ECP		1 mg		Baxter
		i iiig	-	Builton
OPOSIDE	0.40 70	00		Mana al d
Cap 50 mg – PCT – Retail pharmacy-Specialist		20		Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist		10		Vepesid Dev Medical
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist		1		Rex Medical
Inj 1 mg for ECP – PCT only – Specialist	0.09	1 mg	•	Baxter
OPOSIDE PHOSPHATE – PCT only – Specialist				
Inj 100 mg (of etoposide base)		1		Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	1	Baxter
DROXYUREA [HYDROXYCARBAMIDE] – PCT – Retail pharm	acv-Specialist			
Cap 500 mg		100	1	Devatis
RUTINIB – Special Authority see SA2168 on the next page – Re		20		Imbruvica
Tab 140 mg		30		
Tab 420 mg	9,052.00	30	•	Imbruvica

Subsidy (Manufacturer's Price)	Subsi	Fully dised	Brand or Generic
 \$	Per	1	Manufacturer

⇒SA2168 Special Authority for Subsidy

Initial application — (chronic lymphocytic leukaemia (CLL)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic lymphocytic leukaemia (CLL) requiring therapy; and
- 2 Patient has not previously received funded ibrutinib; and
- 3 Ibrutinib is to be used as monotherapy; and
- 4 Any of the following:
 - 4.1 Both:
 - 4.1.1 There is documentation confirming that patient has 17p deletion or TP53 mutation; and
 - 4.1.2 Patient has experienced intolerable side effects with venetoclax monotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient has received at least one prior immunochemotherapy for CLL; and
 - 4.2.2 Patient's CLL has relapsed within 36 months of previous treatment; and
 - 4.2.3 Patient has experienced intolerable side effects with venetoclax in combination with rituximab regimen; or
 - 4.3 Patient's CLL is refractory to or has relapsed within 36 months of a venetoclax regimen.

Renewal — (chronic lymphocytic leukaemia (CLL)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of clinical disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

IDARUBICIN HYDROCHLORIDE

Inj 5 mg vial – PCT only – Specialist	109.74	1	Zavedos
Inj 10 mg vial – PCT only – Specialist		1	 Zavedos
Inj 1 mg for ECP – PCT only – Specialist		1 mg	 Baxter
LENALIDOMIDE – Retail pharmacy-Specialist – Special Au Wastage claimable	thority see SA2047 be	low	
Cap 5 mg	5,122.76	28	 Revlimid
Cap 10 mg	4,655.25	21	 Revlimid
	6,207.00	28	 Revlimid
Cap 15 mg	5,429.39	21	 Revlimid
	7,239.18	28	 Revlimid
Cap 25 mg	7,627.00	21	 Revlimid

⇒SA2047 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:
 - 3.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 3.2 Both:
 - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

bortezomib or thalidomide that precludes further treatment with either of these treatments; and

4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Initial application — (Maintenance following first-line autologous stem cell transplant (SCT)) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and
- 4 Lenalidomide to be administered at a maximum dose of 15 mg/day.

Renewal — (Relapsed/refractory disease) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Renewal — (Maintenance following first line autologous SCT) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist	.00 50	 Uromitexan
Tab 600 mg - PCT - Retail pharmacy-Specialist	.50 50	 Uromitexan
Inj 100 mg per ml, 4 ml ampoule - PCT only - Specialist	.45 15	 Uromitexan
Inj 100 mg per ml, 10 ml ampoule - PCT only - Specialist	.40 15	 Uromitexan
Inj 1 mg for ECP – PCT only – Specialist	.96 100 mg	 Baxter
MITOMYCIN C – PCT only – Specialist		
Inj 5 mg vial641	.70 1	Accord S29
Inj 20 mg vial	.00 1	Omegapharm S29
, ,		🗸 Teva
Inj 1 mg for ECP269	.85 1 mg	 Baxter
MITOZANTRONE – PCT only – Specialist		
Inj 2 mg per ml, 10 ml vial97	.50 1	 Mitozantrone Ebewe
Inj 1 mg for ECP5	.51 1 mg	 Baxter
NIRAPARIB – Special Authority see SA2325 below – Retail pharmacy		
Wastage claimable		
Cap 100 mg	.84 56	🗸 Zejula
13,393	.50 84	🗸 Zejula

⇒SA2325 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	I Generic	
\$	Per 🗸	Manufacturer	

continued...

- 1 Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 Patient has received at least one line** of treatment with platinum-based chemotherapy; and
- 3 Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy; and
- 4 Patient has not previously received funded treatment with a PARP inhibitor; and
- 5 Either:
 - 5.1 Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen; or
 - 5.2 Patient commenced treatment with niraparib prior to 1 May 2024; and
- 6 Treatment to be administered as maintenance treatment; and
- 7 Treatment not to be administered in combination with other chemotherapy.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 No evidence of progressive disease; and
- 2 Treatment to be administered as maintenance treatment; and
- 3 Treatment not to be administered in combination with other chemotherapy; and

4 Either:

- 4.1 Treatment with niraparib to cease after a total duration of 36 months from commencement; or
- 4.2 Treatment with niraparib is being used in the second-line or later maintenance setting.

Notes: * "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component. **A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments

OLAPARIB - Retail pharmacy-Specialist - Special Authority see SA2163 below

		,	 	,	
🗸 Lynparza	56		 		 Tab 100 mg
 Lynparza 	56		 		 Tab 150 mg

➡SA2163 Special Authority for Subsidy

Initial application — (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and

3 Either:

- 3.1 All of the following:
 - 3.1.1 Patient has newly diagnosed, advanced disease; and
 - 3.1.2 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
 - 3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or
- 3.2 All of the following:
 - 3.2.1 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy; and
 - 3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy; and
 - 3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and
 - 3.2.4 Patient has not previously received funded olaparib treatment; and
- 4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 5 Treatment to be administered as maintenance treatment: and
- 6 Treatment not to be administered in combination with other chemotherapy.

Renewal — (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Treatment remains clinically appropriate and patient is benefitting from treatment: and

2 Either:

- 2.1 No evidence of progressive disease; or
- 2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion: and
- 3 Treatment to be administered as maintenance treatment: and
- 4 Treatment not to be administered in combination with other chemotherapy: and
- 5 Either:

5.1 Both:

- 5.1.1 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
- 5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or
- 5.2 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy.

Notes: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component. **A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

PACLITAXEL – PCT only – Specialist			
Inj 30 mg		5	 Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial		1	Anzatax
	24.00		Paclitaxel Ebewe
	91.67		Paclitaxel Actavis
Inj 150 mg		1	Paclitaxel Ebewe
	137.50		Anzatax
			Paclitaxel Actavis
Inj 6 mg per ml, 50 ml vial		1	Anzatax
	44.00		Paclitaxel Ebewe
	275.00		Paclitaxel Actavis
Inj 1 mg for ECP	0.17	1 mg	 Baxter
PEGASPARGASE - PCT only - Special Authority see SA	1979 below		
Inj 750 iu per ml, 5 ml vial	3,455.00	1	Oncaspar LYO \$29
SA1070 Special Authority for Subsidy			

SA1979 Special Authority for Subsidy

Initial application — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.

Initial application — (Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has lymphoma requiring L-asparaginase containing protocols (e.g. SMILE).

Renewal - (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of

	Subsidy (Manufacturer's Price)	Subsi	Fully dised	Brand or Generic
	\$	Per	1	Manufacturer
continued				
a relevant specialist. Approvals valid for 12 months for application Both:	is meeting the follow	ing criteria	:	
 The patient has relapsed acute lymphoblastic leukaemia; a Pegaspargase to be used with a contemporary intensive m 		apy treatm	ient pro	otocol.
PENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Specialist				
Inj 10 mg	CBS	1	🗸 N	ipent S29
PROCARBAZINE HYDROCHLORIDE - PCT - Retail pharmacy-	Specialist			
Cap 50 mg	980.00	50	🗸 N	atulan S29
TEMOZOLOMIDE - Special Authority see SA2275 below - Retail	pharmacy			
Cap 5 mg	9.13	5	🗸 T	emaccord
Cap 20 mg	16.38	5	-	emaccord
	18.30			po-Temozolomide
Cap 100 mg		5	-	emaccord
	40.20	_		po-Temozolomide
Cap 140 mg		5	-	emaccord
Cap 180 mg		14		ccord S29
Cap 250 mg		5	✓ T	emaccord

⇒SA2275 Special Authority for Subsidy

Initial application — (gliomas) only from a relevant specialist. Approvals valid for 12 months where the patient has a glioma. **Renewal** — (gliomas) only from a relevant specialist. Approvals valid for 12 months where treatment remains appropriate and patient is benefitting from treatment.

Initial application — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Initial application — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing's sarcoma.

Renewal — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

THALIDOMIDE - Retail pharmacy-Specialist - Special A	Authority see SA1124 on the	next page)
Cap 50 mg		28	 Thalomid
Cap 100 mg	756.00	28	 Thalomid

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy	Fu	lly	Brand or
(Man	ufacturer's Price)	Subsidis	ed	Generic
	\$	Per	✓	Manufacturer

⇒SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither

Eitner:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an unapproved indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	479.50	100	 Vesanoid
VENETOCLAX - Retail pharmacy-Specialist - Special Authority s	see SA1868 belo	W	
Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg	1,771.86	42 OP	 Venclexta
Tab 10 mg		2 OP	 Venclexta
Tab 50 mg	239.44	7 OP	 Venclexta
Tab 100 mg - Wastage claimable	8,209.41	120	 Venclexta

► SA1868 Special Authority for Subsidy

Initial application — (relapsed/refractory chronic lymphocytic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and
- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

Renewal — (relapsed/refractory chronic lymphocytic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initial application — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

Renewal — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where the treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

	Subsidy		Fully Brand or
	(Manufacturer's Pr		bsidised Generic
	\$	Per	 Manufacturer
INBLASTINE SULPHATE			
Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Spe	ecialist270.37	5	 Hospira
Inj 1 mg for ECP – PCT only – Specialist	6.00	1 mg	 Baxter
INCRISTINE SULPHATE			
Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Spec	cialist51.37	5	 DBL Vincristine
			Sulfate
Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Spec	cialist 102.73	5	 DBL Vincristine
			Sulfate
Inj 1 mg for ECP – PCT only – Specialist	12.60	1 mg	 Baxter
INORELBINE			
Cap 20 mg		1	Vinorelbine Te Arai
Cap 30 mg	40.00	1	 Vinorelbine Te Arai
Cap 80 mg		1	Vinorelbine Te Arai
Inj 10 mg per ml, 1 ml vial – PCT only – Specialist	12.00	1	 Navelbine
	42.00		 Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml vial – PCT only – Specialist	56.00	1	Navelbine
	168.00		Navelbine S29 S29
	210.00		 Vinorelbine Ebewe
	328.65		 Sagent S29
		1 mg	✓ Baxter
Inj 1 mg for ECP – PCT only – Specialist		i ing	Bunton
Inj 1 mg for ECP – PCT only – Specialist Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe	er 2024)	, ng	
Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe	er 2024)	g	
Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors	er 2024) er 2024)		
Vavelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Vavelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable	er 2024) er 2024) e see SA1870 below		
Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority	er 2024) er 2024) e see SA1870 below	224	✓ Alecensa
Vavelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Vavelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) e see SA1870 below		
Vavelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Vavelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 	224	✓ Alecensa
Vavelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Vavelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria:	224 commendatio	✓ Alecensa on of a relevant specialist.
Avelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Avelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu	224 commendation	Alecensa on of a relevant specialist.
Aveibine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Aveibine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu	224 commendation	Alecensa on of a relevant specialist.
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu	224 commendation	Alecensa on of a relevant specialist.
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria
Vavelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Vavelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin er on the recommend	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin eer on the recommend CIST criteria; and	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin eer on the recommend CIST criteria; and t. ge – Retail pharmacy	224 commendation ng cancer; an ase gene rea dation of a re	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria levant specialist. Approvals va
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin eer on the recommend CIST criteria; and t. ge – Retail pharmacy 	224 commendation ng cancer; an ase gene rea	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria levant specialist. Approvals va
 Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 Octobe Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 Octobe Protein-tyrosine Kinase Inhibitors LECTINIB – Retail pharmacy-Specialist – Special Authority Wastage claimable Cap 150 mg	er 2024) er 2024) r see SA1870 below 7,935.00 practitioner on the re owing criteria: able, non-small cell lu s an ALK tyrosine kin er on the recommend CIST criteria; and t. ge – Retail pharmacy 	224 commendation ng cancer; au ase gene rea dation of a re 60	✓ Alecensa on of a relevant specialist. nd arrangement using an appropria levant specialist. Approvals va

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fu) Subsidis Per		
---	-------------------------	--	--

⇒SA1805 Special Authority for Subsidy

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
 - 1.2 Maximum dose of 140 mg/day; or
- 2 Both:
 - 2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
 - 2.2 Maximum dose of 140 mg/day; or

3 All of the following:

- 3.1 The patient has a diagnosis of CML in chronic phase; and
- 3.2 Maximum dose of 100 mg/day; and
- 3.3 Any of the following:
 - 3.3.1 Patient has documented treatment failure* with imatinib; or
 - 3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - 3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
 - 3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on dasatinib*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

ERLOTINIB - Retai	pharmacy-Specia	list - Special Authority	y see SA2115 below
-------------------	-----------------	--------------------------	--------------------

Tab 100 mg	 30	 Alchemy
Tab 150 mg	 30	 Alchemy

➡SA2115 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
- 3 Either:
 - 3.1 Patient is treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient has discontinued gefitinib due to intolerance; and
 - 3.2.2 The cancer did not progress while on gefitinib; and
- 4 Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully osidised	Brand or Generic Manufacturer
continued				
 All of the following: 1 The patient is clinically benefiting from treatment and con 2 Erlotinib to be discontinued at progression; and 3 The regular Special Authority renewal requirements cann 				
GEFITINIB – Retail pharmacy-Specialist – Special Authority see Tab 250 mg		30	✓ II	ressa
► SA2116 Special Authority for Subsidy Initial application only from a relevant specialist or medical prace Approvals valid for 4 months for applications meeting the following All of the following:	ng criteria:			·
 Patient has locally advanced, or metastatic, unresectable Either: Patient is treatment naive; or Both: 		Small Ce	aii Lung (Lancer (NSULU); and
2.2.1 The patient has discontinued erlotinib due 2.2.2 The cancer did not progress whilst on erlot	inib; and			
3 There is documentation confirming that disease expresse4 Gefitinib is to be given for a maximum of 3 months.	es activating mutations	s of EGFI	R tyrosin	e kinase; and
Renewal only from a relevant specialist or medical practitioner of for 6 months where radiological assessment (preferably including Renewal — (pandemic circumstances) from any relevant prac- the following criteria: All of the following:	g CT scan) indicates N	SCLC h	as not p	rogressed.
 The patient is clinically benefiting from treatment and con Gefitinib to be discontinued at progression; and The regular Special Authority renewal requirements cann 			•	
IMATINIB MESILATE				
* Cap 100 mg * Cap 400 mg		60 30		<u>matinib-Rex</u> matinib-Rex
NILOTINIB – Special Authority see SA2301 below – Retail phar Wastage claimable	macy			
Cap 150 mg Cap 200 mg		120 120		asigna asigna
► SA2301 Special Authority for Subsidy Initial application only from a haematologist. Approvals valid for All of the following:	or 6 months for applica	ations me	eting the	e following criteria:
 Patient has a diagnosis of chronic myeloid leukaemia (CM and Either: 	/IL) in blast crisis, high	n risk chro	onic pha	se, or in chronic phase;
2.1 Patient has documented CML treatment failure* w2.2 Patient has experienced treatment limiting toxicity and				ecluding further treatment;
3 Maximum nilotinib dose of 800 mg/day; and4 Subsidised for use as monotherapy only.				
Note: *treatment failure as defined by Leukaemia Net Guideline	S.			

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's P	rice) S	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PALBOCICLIB - Retail pharmacy-Specialist - Special Authority see SA1894 below

Wastage claimable

Tab 75 mg4,000.00	21	 Ibrance
Tab 100 mg4,000.00	21	 Ibrance
Tab 125 mg4,000.00	21	 Ibrance

⇒SA1894 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a Medical oncologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has unresectable locally advanced or metastatic breast cancer; and
- 2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 Either:

second or subsequent line setting

- 4.1 Disease has relapsed or progressed during prior endocrine therapy; or
- 4.2 Both:

first line setting

- 4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
- 4.2.2 Either:
 - 4.2.2.1 Patient has not received prior systemic treatment for metastatic disease; or
 - 4.2.2.2 All of the following:
 - 4.2.2.2.1 Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020; and
 - 4.2.2.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and
 - 4.2.2.2.3 There is no evidence of progressive disease; and
- 5 Treatment must be used in combination with an endocrine partner.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a Medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains appropriate and the patient is benefitting from treatment.

PAZOPANIB - Special Authority see SA1190 below - Retail pharmacy

Tab 200 mg	1,334.70	30	 Votrient
Tab 400 mg	2,669.40	30	 Votrient

⇒SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and

The patient has intermediate or poor prognosis defined as:

- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB - Special Authority see SA1890 below - Retail pharmacy

Wastage claimable

Tab 5 mg2,500.00	56	🖌 Jakavi
Tab 10mg5,000.00	56	🖌 Jakavi
Tab 15 mg	56	🖌 Jakavi
Tab 20 mg	56	🗸 Jakavi

⇒SA1890 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and

Subsidy		Fully	Brand or	
(Manufacturer's Price	e)	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

3 A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB - Special Authority see SA2117 below - Retail pharmacy

Cap 12.5 mg	 28	Sunitinib Pfizer
Cap 25 mg	 28	 Sunitinib Pfizer
Cap 50 mg	 28	 Sunitinib Pfizer

⇒SA2117 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- Both:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy	Fu	lly	Brand or
(Ma	nufacturer's Price)	Subsidis	ed	Generic
	\$	Per	/	Manufacturer

continued...

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Renewal — (GIST pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal (GIST); and
- 2 The patient is clinically benifiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Endocrine Therapy

For GnRH ANALOGUES - refer to HORMONE PREPARATIONS, Trophic Hormones, page 89

ABIRATERONE ACETATE - Retail pharmacy-Specialist - Special Authority see SA2118 below

Wastage claimable

➡SA2118 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Pr	ice)	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

BICALUTAMIDE

Tab 50 mg	4.18	28	✓ Apo- Bicalutamide S23
			✓ Binarex
FLUTAMIDE			
Tab 250 mg	107.55	90	Prostacur S29
ů –	119.50	100	 Flutamin
FULVESTRANT - Retail pharmacy-Specialist - Special Authority	see SA1895 belo	w	
Inj 50 mg per ml, 5 ml prefilled syringe		2	 Faslodex

➡SA1895 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and
- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and
- 3 Treatment to be given at a dose of 500 mg monthly following loading doses; and
- 4 Treatment to be discontinued at disease progression.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains appropriate and patient is benefitting from treatment; and
- 2 Treatment to be given at a dose of 500 mg monthly; and
- 3 There is no evidence of disease progression.

()	Subsidy /anufacturer's Price) \$	Sul Per	Fully osidised	Brand or Generic Manufacturer
OCTREOTIDE				
Inj 50 mcg per ml, 1 ml ampoule	27.58	5	✓ <u>N</u>	lax Health
			✓ 0	Octreotide GH S29
Inj 100 mcg per ml, 1 ml ampoule	32.71	5	🗸 <u>N</u>	lax Health
			✓ 0	Ctreotide GH S29
			✓ s	Sun Pharma S29
Inj 500 mcg per ml, 1 ml ampoule	113.10	5	🗸 N	lax Health
			✓ 0	Ctreotide GH S29
			✓ s	un Pharma S29
OCTREOTIDE LONG-ACTING - Special Authority see SA2119 be	low – Retail pharma	acv		
Inj depot 10 mg prefilled syringe		1	✓ <u>0</u>	<u>)ctreotide Depot</u> Teva
	1,152.00		✓ s	andostatin LAR
Inj depot 20 mg prefilled syringe	647.03	1	✓ 0	Ctreotide Depot
			_	Teva
	1,539.00		🗸 S	andostatin LAR
Inj depot 30 mg prefilled syringe	718.55	1	✓ 0	Octreotide Depot
				Teva

➡SA2119 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Renewal — (Acromegaly - pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for

Subsidy		Fully	Brand or	
(Manufacturer's Price	e)	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

applications meeting the following criteria:

All of the following:

- 1 Patient has acromegaly; and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

3 Both:

- 3.1 Insulinomas; and
- 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:

- 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
- 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Initial application — (pre-operative acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient has acromegaly; and
- 2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
- 3 Patient is scheduled to undergo pituitary surgery in the next six months.

TAMOXIFEN CITRATE

* Tab 10 mg	60 60	 ✓ <u>Tamoxifen Sandoz</u> ✓ <u>Tamoxifen Sandoz</u>
Aromatase Inhibitors		
ANASTROZOLE * Tab 1 mg4.39	30	✓ <u>Anatrole</u>
EXEMESTANE * Tab 25 mg	30	✓ Pfizer Exemestane
LETROZOLE * Tab 2.5 mg5.84	30	✓ Letrole

(Subsidy Manufacturer's Price \$) Subs Per	Fully sidised	Brand or Generic Manufacturer
Immunosuppressants				
Cytotoxic Immunosuppressants				
AZATHIOPRINE				
* Tab 25 mg	7.36	60	1	Azamun
* Tab 50 mg	8.10	100	1	Azamun
MYCOPHENOLATE MOFETIL				
Tab 500 mg	35.90	50	✓ (Cellcept
Cap 250 mg		100	✓ (Cellcept
Powder for oral lig 1 g per 5 ml - Subsidy by endorsement	187.25 1	65 ml OP	✓ (Cellcept
Mycophenolate powder for oral liquid is subsidised only for the prescription is endorsed accordingly.	r patients unable to	o swallow ta	ablets	and capsules, and when

Fusion Proteins

ETANERCEPT - Special Authority see SA2103 below - R	etail pharmacy		
Inj 25 mg		4	 Enbrel
Inj 25 mg autoinjector		4	 Enbrel
Inj 50 mg autoinjector	1,050.00	4	 Enbrel
Inj 50 mg prefilled syringe	1,050.00	4	 Enbrel

⇒SA2103 Special Authority for Subsidy

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either: 1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Ful	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per •	Manufacturer	

continued...

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application - (polyarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist.

S	Subsidy	Fully	Brand or
(Manufa	acturer's Price) Subsid	lised	Generic
	\$ Per	1	Manufacturer

continued...

Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (polyarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Fither:

1 Both:

- The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or
- 2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

Renewal — (oligoarticular course juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or secukinumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (Arthritis - rheumatoid) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects; or
- 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

Renewal — (Arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

1 Dott

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Either:
 - 2.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.
- Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
 - 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
 - 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.
- Note: Indications marked with * are unapproved indications.

Renewal — (undifferentiated spondyloarthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

(M	Subsidy anufacturer's Price)	Subs	Fully idised	Brand or Generic
·	\$	Per	~	Manufacturer

continued...

- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist		
Inj 50 mg per ml, 5 ml2,774.48	5	🗸 ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE - PCT only - Specialist		
Subsidised only for bladder cancer.		
Inj 2-8 × 100 million CFU149.37	1	 OncoTICE
Inj 40 mg per ml, vial176.90	3	 SII-Onco-BCG \$29

Monoclonal Antibodies

ADALIMUMAB (AMGEVITA) - Special Authority see SA2178 b	elow – Retail pharn	nacy	
Inj 20 mg per 0.4 ml prefilled syringe		1	 Amgevita
Inj 40 mg per 0.8 ml prefilled pen		2	 Amgevita
Inj 40 mg per 0.8 ml prefilled syringe		2	 Amgevita

► SA2178 Special Authority for Subsidy

Initial application — (Behcet's disease - severe) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has severe Behcet's disease* that is significantly impacting the patient's quality of life; and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s); or
 - 2.2 The patient has severe gastrointestinal, rheumatological, and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s).

Note: Indications marked with * are unapproved indications.

Initial application — (Hidradenitis suppurativa) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 Patient has 3 or more active lesions; and
- 4 The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application.

Renewal — (Hidradenitis suppurativa) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a DLQI improvement of 4 or more from baseline.

Initial application — (Plaque psoriasis - severe chronic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:

2.1 Either:

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a PASI score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.

Renewal — (Plaque psoriasis - severe chronic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.2 Either:
 - 1.2.1 The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre treatment baseline value; or
 - 1.2.2 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 2 Both:
 - 2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2 Either:
 - 2.2.1 The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2 The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre treatment baseline value.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Both:
 - 1 Patient has pyoderma gangrenosum*; and
 - 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and has not received an adequate response.

Note: Indications marked with * are unapproved indications.

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy		Fully	Brand or	
(Manufacturer's Pri	ce)	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 2.1 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
- 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
- 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
- 2.4 Patient has an ileostomy or colostomy and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on adalimumab; or
- 2 CDAI score is 150 or less, or HBI is 4 or less; or
- 3 The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed.

Initial application — (Crohn's disease - children) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease - children) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 2 PCDAI score is 15 or less; or
- 3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed.

Initial application — (Crohn's disease - fistulising) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complex peri-anal fistula; and

3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application.

Renewal — (Crohn's disease - fistulising) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initial application — (Ocular inflammation - chronic) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

	Subsidy	F	ully	Brand or
(Ma	anufacturer's Price)	Subsid	ised	Generic
	\$	Per	✓	Manufacturer

continued...

- 1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (Ocular inflammation - chronic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 12 weeks' initial treatment; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initial application — (Ocular inflammation - severe) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (Ocular inflammation - severe) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

1 Both:

1.1 Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by radiology imaging; and
 - 2.4 Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and
 - 2.6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application.

Renewal — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (Arthritis - oligoarticular course juvenile idiopathic) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Either:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose).

Renewal — (Arthritis - oligoarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Fither:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (Arthritis - polyarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - psoriatic) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects; or

1.2.2 The patient has received insufficient benefit from to meet the renewal criteria for psoriatic arthritis; or

- 2 All of the following:
 - 2.1 Patient has had active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an ESR greater than 25 mm per hour; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (Arthritis - psoriatic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initial application — (Arthritis - rheumatoid) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is CCP antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Renewal — (Arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Initial application — (Still's disease - adult-onset (AOSD)) only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 Both:

Subsidy	Fully	Brand or	
(Manufacturer's	Price) Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

- 1.1 The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for AOSD; and 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
 - 2.1 Patient's SCCAI score is greater than or equal to 4; or
 - 2.2 Patient's PUCAI score is greater than or equal to 20; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from prior therapy with immunomodulators and systemic corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy; or
- 2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiation on biologic therapy.

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of each of methotrexate, sulfasalazine and leflunomide, at maximum tolerated doses (unless contraindicated); and
- 3 Any of the following:
 - 3.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 3.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications

Renewal — (undifferentiated spondyloarthritis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initial application — (inflammatory bowel arthritis – axial) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Renewal — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (inflammatory bowel arthritis – peripheral) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate, or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
 - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) - Special Authority see SA2157 below - Retail pharmacy

Inj 20 mg per 0.2 ml prefilled syringe1,599.96	2	🗸 Humira
Inj 40 mg per 0.4 ml prefilled pen1,599.96	2	 HumiraPen
Inj 40 mg per 0.4 ml prefilled syringe1,599.96	2	 Humira

⇒SA2157 Special Authority for Subsidy

Initial application — (Behcet's disease – severe) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

All of the followina:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amaevita) following a minimum of 4 weeks treatment: or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Behcet's disease - severe) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has had a good clinical response to treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment: or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 7 days. Fortnightly dosing has been considered.

Renewal — (Hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- - 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline: and
 - 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and

3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered. Initial application - (Psoriasis - severe chronic plaque) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the followina:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment: or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amoevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita: and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Psoriasis - severe chronic plaque) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Fither

Subsidy	Ful	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Pyoderma gangrenosum) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
 - 2 Patient has received a maximum of 6 months treatment with Amgevita; and
 - 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
 - 4 A maximum of 8 doses.

Renewal — (Pyoderma gangrenosum) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated clinical improvement and continues to require treatment; and
- 2 A maximum of 8 doses.

Initial application — (Crohn's disease - adult) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevitat; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - adult) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Any of the following:

- 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
- 1.2 CDAI score is 150 or less; or
- 1.3 The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - fistulising) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - fistulising) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fu	lly Brand or	
(Manufacturer's Price)	Subsidis	ed Generic	
\$	Per	 Manufacturer 	

continued...

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Ocular inflammation – chronic) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
- Renewal (Ocular inflammation chronic) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Ocular inflammation – severe) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Ocular inflammation – severe) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita); and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Arthritis – oligoarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Arthritis – oligoarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months where the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
 - 2 Patient has received a maximum of 6 months treatment with Amgevita; and
 - 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Renewal — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months where the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - psoriatic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Arthritis - psoriatic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Arthritis – rheumatoid) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Arthritis – rheumatoid) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Either:
 - 2.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 2.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initial application — (Still's disease – adult-onset (AOSD)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Pri	ice) Si	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Still's disease – adult-onset (AOSD)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has demonstrated a sustained improvement in inflammatory markers and functional status.

AFLIBERCEPT – Special Authority see SA1772 below – Retail pharmacy

Inj 40 mg per ml, 0.1 ml vial......1,250.00 1 🖌 Eylea

⇒SA1772 Special Authority for Subsidy

Initial application — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
 - 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
 - 1.3 There is no structural damage to the central fovea of the treated eye; and
 - 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Initial application — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Renewal — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

3 There is no structural damage to the central fovea of the treated eye.

Renewal — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with (2nd line anti-VEGF agent), patient has retrialled with at least one injection of bevacizumab and had no response.

BENRALIZUMAB - Special Authority see SA2151 on the next page - Retail pharmacy

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per	1	Manufacturer	

⇒SA2151 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5 × 10°9 cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised mepolizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
 - 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
 - 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

BRENTUXIMAB VEDOTIN – PCT only – Special Authority see SA2289 below

Inj 50 mg vial	5,275.18	1	Adcetris
----------------	----------	---	----------

⇒SA2289 Special Authority for Subsidy

Initial application — (relapsed/refractory Hodgkin lymphoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy; and

Sub	bsidy F	ully	Brand or
(Manufacti	urer's Price) Subsid	sed	Generic
	\$ Per	1	Manufacturer

continued...

- 1.1.2 Patient is ineligible for autologous stem cell transplant; or
- 1.2 Both:
 - 1.2.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma; and
 - 1.2.2 Patient has previously undergone autologous stem cell transplant; and
- 2 Patient has not previously received funded brentuximab vedotin; and
- 3 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
- 4 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Renewal — (relapsed/refractory Hodgkin lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
- 2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and 3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

Initial application — (anaplastic large cell lymphoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma; and
- 2 Patient has an ECOG performance status of 0-1; and
- 3 Patient has not previously received brentuximab vedotin; and
- 4 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
- 5 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Renewal — (anaplastic large cell lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
- 2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
- 3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

CASIRIVIMAB AND IMDEVIMAB - [Xpharm] - Special Authority see SA2096 below

- Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg
 - per ml imdevimab, 11.1 ml vial (1)......0.00 1 OP 🖌 Ronapreve

⇒SA2096 Special Authority for Subsidy

Initial application — (Treatment of profoundly immunocompromised patients) from any relevant practitioner. Approvals valid for 2 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 The patient is in the community with mild to moderate disease severity*; and
- 3 Patient is profoundly immunocompromised** and is at risk of not having mounted an adequate response to vaccination against COVID-19 or is unvaccinated; and
- 4 Patient's symptoms started within the last 10 days; and
- 5 Patient is not receiving high flow oxygen or assisted/mechanical ventilation; and
- 6 Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg.

Notes: * Mild to moderate disease severity as described on the Ministry of Health Website

** Examples include B-cell depletive illnesses or patients receiving treatment that is B-Cell depleting.

CETUXIMAB - PCT only - Specialist - Special Authority see SA1697 on the next page

lnj 5 mg per ml,	20 ml vial	 	364.00	1	 Erbitux
lni 5 ma per ml.	100 ml vial		1.820.00	1	 Erbitux
, , ,			,	1 mg	 Baxter
, ,				•	

	Subsidy (Manufacturer's Price) \$		Illy Brand or ed Generic Manufacturer
 SA1697 Special Authority for Subsidy Initial application only from a medical oncologist or medical p Approvals valid for 6 months for applications meeting the follow All of the following: Patient has locally advanced, non-metastatic, squamou Patient is contraindicated to, or is intolerant of, cisplatin Patient has good performance status; and To be administered in combination with radiation therap 	ving criteria: s cell cancer of the hea ; and		
GEMTUZUMAB OZOGAMICIN – PCT only – Specialist – Spe Inj 5 mg vial	cial Authority see SA22		✓ Mylotarg
 SA2269 Special Authority for Subsidy Initial application only from a haematologist, paediatric haema applications meeting the following criteria: All of the following: Patient has not received prior chemotherapy for this cor Patient has de novo CD33-positive acute myeloid leuka Patient does not have acute promyelocytic leukaemia; a Gemtuzumab ozogamicin will be used in combination w Patient's disease risk has been assessed by cytogeneti Patient must be considered eligible for standard intensity and cytarabine (AraC); and Gemtuzumab ozogamicin to be funded for one course of 5 mg as separate doses). Note: Acute myeloid leukaemia excludes acute promyelocytic another haematological disorder (eg myelodysplasia or myelop 	ndition; and emia; and and ith standard anthracycl c testing to be good or ve remission induction of only (one dose at 3 mg leukaemia and acute m	ine and cytara intermediate; chemotherapy per m ² body s	abine (AraC); and and with standard anthracycline urface area or up to 2 vials of
INFLIXIMAB – PCT only – Special Authority see SA2179 below Inj 100 mg	w 428.00		Remicade
Inj 1 mg for ECP	levant practitioner. App al to 300 or HBI score of ecting more than 50 cm	provals valid for of greater than of the small i	or equal to 10; or intestine; or

- 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease (adults)) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Any of the following:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	9	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 1.1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab; or
- 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
- 1.3 The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Crohn's disease (children)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease (children)) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Graft vs host disease) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has steroid-refractory acute graft vs. host disease of the gut.

Initial application — (Pulmonary sarcoidosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has life-threatening pulmonary sarcoidosis diagnosed by a multidisciplinary team that is refractory to other treatments.

Initial application — (acute fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 weeks for applications meeting the following criteria:

- Both:
 - 1 Patient has acute, fulminant ulcerative colitis; and
 - 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Initial application — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Subsidy	F	ully	Brand or
(Manufacturer's Price) Subsid	ised	Generic
\$	Per	✓	Manufacturer

continued...

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initial application — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (fistulising Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patent has complex peri-anal fistula.

Renewal - (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	F	ully	Brand or	Ī
(Manufacturer's Price)	Subsidi	sed	Generic	
\$	Per	✓	Manufacturer	

continued...

gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
 - 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
 - 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with neurosarcoiosis by a multidisciplinary team; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Renewal — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months for applications meeting the following criteria: Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initial application — (plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 3 months for applications meeting the following criteria: Either:

itner:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

(Mai	Subsidy	F	ully	Brand or
	nufacturer's Price)	Subsidis	sed	Generic
	\$	Per	✓	Manufacturer

continued...

- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

1.2 Both:

- 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with infliximab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 Rheumatoid arthritis; or
 - 2.2 Ankylosing spondylitis; or
 - 2.3 Psoriatic arthritis; or
 - 2.4 Severe ocular inflammation; or
 - 2.5 Chronic ocular inflammation; or
 - 2.6 Crohn's disease (adults); or
 - 2.7 Crohn's disease (children); or
 - 2.8 Fistulising Crohn's disease; or
 - 2.9 Severe fulminant ulcerative colitis; or
 - 2.10 Severe ulcerative colitis; or
 - 2.11 Plaque psoriasis; or

continued...

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsid	ised	Generic
\$	Per	1	Manufacturer

continued...

- 2.12 Neurosarcoidosis; or
- 2.13 Severe Behcet's disease.

Initial application — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept and/or secukinumab; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
- 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes: Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.

Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Renewal — (fulminant ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:

2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

2.2 Any of the following:

- 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
- 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
- 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

1 The patient has had a good clinical response following 3 initial doses; or

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Ful	ly Brand or	
(Manufacturer's F	Price) Subsidise	d Generic	
\$	Per	 Manufacturer 	

continued...

- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
 - 2.1 Patients SCCAI is greater than or equal to 4; or
 - 2.2 Patients PUCAI score is greater than or equal to 20; and
- 3 Patient has tried but has experienced an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has had axial inflammatory pain for six months or more; and

Subsidy	Ful	y Brand or
(Manufacturer's Pric	e) Subsidise	d Generic
\$	Per 🔹	Manufacturer

continued...

- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient's disease has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 Patient has a BASDAI of at least 6 on a 0 10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment .

Renewal — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
 - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

MEPOLIZUMAB - Special Authority see SA2331 below - Retail pharmacy

Inj 100 mg prefilled pen	1,638.00	1	Nucala
Inj 100 mg vial	1,638.00	1	 Nucala

(Nucala Inj 100 mg vial to be delisted 1 August 2024)

⇒SA2331 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than $0.5 \times 10^{\circ}9$ cells/L in the last 12 months; and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy	F	ully	Brand or
(Manu	facturer's Price)	Subsidi	sed	Generic
	\$	Per	✓	Manufacturer

- continued...
 - 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
 - 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
 - 7 Treatment is not to be used in combination with subsidised benralizumab; and
 - 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
 - 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

Initial application — (eosinophilic granulomatosis with polyangiitis) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has eosinophilic granulomatosis with polyangiitis; and
- 2 The patient has trialled and not received adequate benefit from at least one of the following for at least three months (unless contraindicated to all): azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate, or rituximab; and
- 3 Either:
 - 3.1 The patient has trialled prednisone for a minimum of three months and is unable to maintain disease control at doses below 7.5 mg per day; or
 - 3.2 Corticosteroids are contraindicated.

Renewal — (eosinophilic granulomatosis with polyangiitis) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where patient has no evidence of clinical disease progression.

OBINUTUZUMAB - PCT only - Specialist - Special Authority	see SA2155 on the	next page	
Inj 25 mg per ml, 40 ml vial	5,910.00	1	🖌 Gazyva
Inj 1 mg for ECP	6.21	1 mg	 Baxter

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	I Generic	
\$	Per 🗸	Manufacturer	

⇒SA2155 Special Authority for Subsidy

Initial application — (chronic lymphocytic leukaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to 1.5×10^{9} /L and platelets greater than or equal to 75×10^{9} /L.

Initial application — (follicular / marginal zone lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has follicular lymphoma; or
 - 1.2 Patient has marginal zone lymphoma; and
- 2 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen*; and
- 3 Patient has an ECOG performance status of 0-2; and
- 4 Patient has been previously treated with no more than four chemotherapy regimens; and
- 5 Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy*.

Note: * includes unapproved indications

Renewal — (follicular / marginal zone lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 Patient has no evidence of disease progression following obinutuzumab induction therapy; and
- 2 Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and
- 3 Obinutuzumab to be discontinued at disease progression.

OMALIZUMAB - Special Authority see SA1744 below - Retail pharmacy

Inj 150 mg prefilled syringe	450.00	1	🗸 Xolair
Inj 150 mg vial	450.00	1	 Xolair

► SA1744 Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 6 years or older; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and

continued...

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
 - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or
 - 2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and

2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient has previously adequately responded* to 6 doses of omalizumab; or

2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer	
PERTUZUMAB – PCT only – Specialist – Special Authority see SA2276 below					
Inj 30 mg per ml, 14 ml vial	3,927.00	1	✓ P	erjeta	
Ini 420 mg for ECP	3.927.00 42	0 ma OP	🗸 В	axter	

► SA2276 Special Authority for Subsidy

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 Patient is chemotherapy treatment naïve; or
 - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pertuzumab and trastuzumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pertuzumab and trastuzumab.

RITUXIMAB (MABTHERA) - PCT only - Specialist - Special Authority see SA1976 below

Inj 100 mg per 10 ml vial		2	 Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	 Mabthera
Inj 1 mg for ECP	5.64	1 mg	🗸 Baxter (Mabthera)

► SA1976 Special Authority for Subsidy

Initial application — (rheumatoid arthritis - TNF inhibitors contraindicated) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	9	Subsidised	Generic
\$	Per	1	Manufacturer

continued...

- the maximum tolerated dose of ciclosporin; or
- 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
- 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6 Either:

- 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:

- 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:

- 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and 9 Maximum of two 1.000 mg infusions of rituximab given two weeks apart.

Initial application — (rheumatoid arthritis - prior TNF inhibitor use) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

3 Maximum of two 1,000 mg infusions of ntuximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'partial responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

RITUXIMAB (RIXIMYO) - PCT only - Specialist - Special Authority see SA2233 below

Inj 100 mg per 10 ml vial		2	Riximyo
Inj 500 mg per 50 ml vial	688.20	1	Riximyo
Inj 1 mg for ECP	1.38	1 mg	 Baxter (Riximyo)

► SA2233 Special Authority for Subsidy

Initial application — (ABO-incompatible organ transplant) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initial application — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or
 - 3.4 Patient is a female of child-bearing potential; or
 - 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of

Subsid	ly Fu	ully Brand or
(Manufacturer	r's Price) Subsidise	ed Generic
\$	Per	 Manufacturer

continued...

4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Antibody-mediated organ transplant rejection) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has been diagnosed with antibody-mediated organ transplant rejection*. Note: Indications marked with * are unapproved indications.

Initial application — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or

2.2.2 Both:

- 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
- 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
- 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and

4 Either:

- 4.1 The patient does not have chromosome 17p deletion CLL; or
- 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2. **Renewal — (Chronic lymphocytic leukaemia)** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
- 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and

Subsidy		Fully	Brand or
(Manufacturer's Price)) Si	ubsidised	Generic
\$	Per	1	Manufacturer

continued...

2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (Neuromyelitis Optica Spectrum Disorder(NMOSD)) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Renewal — (Neuromyelitis Optica Spectrum Disorder) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initial application — (Post-transplant) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.
- Note: Indications marked with * are unapproved indications.

Initial application — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
 - 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

2 Either:

2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or

2.2 Both:

2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Renewal — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

- All of the following:
 - 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
 - 2 An initial response lasting at least 12 months was demonstrated; and
 - 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initial application — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS))

only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only

from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

- 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initial application — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

1 Either:

1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)) 5	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: Fither:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initial application — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia*

Subsidy		Fully	Brand or
(Manufacturer's Price)) 5	Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Renewal — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.
- Note: Indications marked with * are unapproved indications.

Renewal — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initial application — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria: Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.
- Note: Indications marked with * are unapproved indications.

Initial application — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
 - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
 - 3.2 Rapid treatment is required due to life threatening complications; and
- 4 Maximum of four 1,000mg infusions of rituximab.

Renewal — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2 The patient has not received rituximab in the previous 6 months; and
- 3 Maximum of two cycles of 2 × 1,000mg infusions of rituximab given two weeks apart.

Initial application — (graft versus host disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initial application — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

Subsidy		Fully	Brand or	_
(Manufacturer's Price)	Su	Ibsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and
- 4 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria: Fither:

1 Both:

- 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Renewal — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles).

Initial application — (Membranous nephropathy) only from a nephrologist or any relevant practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy*; or
 - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m2; and
- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note); and
- 3 The total rituximab dose would not exceed the equivalent of 375mg/m2 of body surface area per week for a total of 4 weeks.

Renewal — (Membranous nephropathy) only from a nephrologist or any relevant practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for membranous nephropathy*; and
- 2 Either:
 - 2.1 Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; or
 - 2.2 Patient achieved partial response to treatment and requires repeat treatment (see Note); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Notes:

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsidi	sed	Generic
\$	Per	✓	Manufacturer

continued...

experienced intolerable side effects.

d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

Initial application — (B-cell acute lymphoblastic leukaemia/lymphoma*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses.

Note: Indications marked with * are unapproved indications.

Initial application — (desensisation prior to transplant) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant*; and
- 2 Patient would receive no more than two doses at 375 mg/m2 of body-surface area.

Note: Indications marked with * are unapproved indications.

Initial application — (pemiphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has severe rapidly progressive pemphigus; and
 - 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
 - 1.3 Any of the following:
 - 1.3.1 Skin involvement is at least 5% body surface area; or
 - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
 - 1.3.3 Involvement of two or more mucosal sites; or
- 2 Both:
 - 2.1 Patient has pemphigus; and
 - 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.

Note: Indications marked with * are unapproved indications.

Renewal — (pemiphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement; and
- 2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with * are unapproved indications.

Initial application — (immunoglobulin G4-related disease (IgG4-RD*)) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed diagnosis of IgG4-RD*; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse; or

Subsidy		Fully	Brand or	
(Manufacturer's Pr	rice)	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

2.2 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance; and

3 Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart. Note: Indications marked with * are unapproved indications.

Renewal — (immunoglobulin G4-related disease (IgG4-RD*)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed; or
 - 1.2 Patient is receiving maintenance treatment for IgG4-RD*; and
- 2 Rituximab re-treatment not to be given within 6 months of previous course of treatment; and

3 Maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with * are unapproved indications.

	Special Authority	1 coo \$12094 b	elow – Retail pharmacy	
SECUNINUMAD	- Special Authonity	/ see SA2084 D	elow – Retail pharmacy	

		······································	
Cosentyx	1	prefilled syringe799.50	Inj 150 mg per ml, 1 ml prefilled syringe
 Cosentyx 	2	1,599.00	

⇒SA2084 Special Authority for Subsidy

Initial application — (severe chronic plaque psoriasis – second-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a Health NZ Hospital, for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Initial application — (severe chronic plaque psoriasis – first-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole

Subsidy	Fu	Illy Brand or	
(Manufacturer's	Price) Subsidis	ed Generic	
\$	Per	 Manufacturer 	

continued...

body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis – first and second-line biologic) only from a dermatologist or medical practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initial application — (ankylosing spondylitis – second-line biologic) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and

- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis – second-line biologic) only from a rheumatologist or medical practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate; and
- 3 Secukinumab to be administered at doses no greater than 150 mg monthly.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:

Subsidy		Fully	Brand or
(Manufacturer's	Price)	Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

- 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician; and
- 2 Secukinumab to be administered at doses no greater than 300 mg monthly.

SILTUXIMAB – Special Authority see SA1596 below – Retail pharmacy

Note: Siltuximab is to be administered at doses no gre	ater than 11 mg/kg every 3	3 weeks.	
Inj 100 mg vial	770.57	1	 Sylvant
Inj 400 mg vial		1	 Sylvant

⇒SA1596 Special Authority for Subsidy

Initial application only from a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Renewal only from a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TIXAGEVIMAB WITH CILGAVIMAB - [Xpharm] - Subsidy by endorsement

- a) No patient co-payment payable
- b) Treatment is funded only if patient meets access criteria for tixagevimab with cilgavimab (as per https://pharmac.govt.nz/Evusheld) and has been endorsed accordingly by the prescriber. The supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.
- Inj 100 mg per ml, 1.5 ml vial with cilgavimab 100 mg per

ml,1.5 ml vial	0.00	1	Evusheld
TOCILIZUMAB – PCT only – Special Authority see SA	A2332 on the next page		
Inj 20 mg per ml, 4 ml vial		1	 Actemra
Inj 20 mg per ml, 10 ml vial		1	 Actemra
Inj 20 mg per ml, 20 ml vial	1,100.00	1	 Actemra
Inj 1 mg for ECP		1 mg	 Baxter
, ,		Ũ	

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
 \$	Per 🗸	Manufacturer

⇒SA2332 Special Authority for Subsidy

Initial application — (cytokine release syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research ENABLE trial programme; and
 - 2.2 The patient has developed CRS or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) following CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS or ICANS for CAR T-cell therapy at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initial application — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

Subsidy	y Fi	ully Brand or	
(Manufacturer	s Price) Subsidis	ised Generic	
\$	Per	 Manufacturer 	

continued...

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initial application — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

Subsidy	Full	/ Brand or	_
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.4 Any of the following:
 - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Initial application — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Initial application — (moderate to severe COVID-19) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with barcitinib.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has a sustained improvement in inflammatory markers and functional status. Renewal — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a

	Subsidy	Fully	Brand or
(Manu	facturer's Price)	Subsidised	Generic
	\$ Pe	er 🖌	Manufacturer

continued...

rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB (HERCEPTIN) - PCT only - Specialist - Special Authority see SA2287 below

Inj 150 mg vial	, ,	 	1	 Herceptin
Inj 440 mg vial		 	1	✓ Herceptin
Inj 1 mg for ECP		 9.36	1 mg	 Baxter

(Herceptin Inj 150 mg vial to be delisted 1 June 2024) (Herceptin Inj 440 mg vial to be delisted 1 June 2024) (Baxter Inj 1 mg for ECP to be delisted 1 June 2024)

⇒SA2287 Special Authority for Subsidy

Renewal — (early breast cancer*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or 3.2 Both:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerable side effects; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; or
 - 3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and

4 Either:

- 4.1 Trastuzumab will not be given in combination with pertuzumab; or
- 4.2 All of the following:
 - 4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 4.2.3 The patient has good performance status (ECOG grade 0-1); and
- 5 Trastuzumab not to be given in combination with lapatinib; and
- 6 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting

Subsi	dy Fully E	Brand or
(Manufacture	,	Generic
\$	Per 🖌 I	Manufacturer

continued...

the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB (HERZUMA) – PCT only – Special Authority see SA2293 below

Inj 150 mg vial	100.00	1	🗸 Herzuma
Herzuma to be Principal Supply on 1 June 2024			
Inj 440 mg vial	293.35	1	🗸 Herzuma
Herzuma to be Principal Supply on 1 June 2024			
Inj 1 mg for ECP	0.70	1 mg	 Baxter
		•	

⇒SA2293 Special Authority for Subsidy

Initial application — (early breast cancer) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

- 1 The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment).

Renewal — (early breast cancer*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
 - 1.3 Any of the following:
 - 1.3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 1.3.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; or
 - 1.3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 1.4 Either:
 - 1.4.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 1.4.2 All of the following:
 - 1.4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 1.4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 1.4.2.3 The patient has good performance status (ECOG grade 0-1); and
 - 1.5 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with trastuzumab.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer

Subsidy	F	Fully	Brand or	
(Manufacturer's Price)	Subsid	lised	Generic	
\$	Per	1	Manufacturer	

continued...

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 1.3 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with trastuzumab.

Initial application - (gastric, gastro-oesophageal junction and oesophageal cancer) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology); and
- 2 Patient has an ECOG score of 0-2.

Renewal — (gastric, gastro-oesophageal junction and oesophageal cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 2 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB EMTANSINE - PCT only - Specialist - Special Authority see SA2144 on the next page

Inj 100 mg vial	·····	 2,320.00	1	🖌 Kadcyla
Inj 160 mg vial		 	1	🗸 Kadcyla
Inj 1 mg for ECP		 24.52	1 mg	 Baxter

Subsidy		Fully	Brand or
(Manufacturer's Price)		sidised	Generic
 \$	Per	1	Manufacturer

⇒SA2144 Special Authority for Subsidy

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has early breast cancer expressing HER2 IHC3+ or ISH+; and
- 2 Documentation of pathological invasive residual disease in the breast and/or auxiliary lymph nodes following completion of surgery; and
- 3 Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery; and
- 4 Disease has not progressed during neoadjuvant therapy; and
- 5 Patient has left ventricular ejection fraction of 45% or greater; and
- 6 Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery; and
- 7 Trastuzumab emtansine to be discontinued at disease progression; and
- 8 Total adjuvant treatment duration must not exceed 42 weeks (14 cycles).

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
 - 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
 - 4 Patient has a good performance status (ECOG 0-1); and
 - 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
 - 6 Patient has not received prior funded trastuzumab emtansine treatment; and
 - 7 Treatment to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

USTEKINUMAB – Special Authority see SA2182 below – Retail pharmacy

⇒SA2182 Special Authority for Subsidy

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for Crohn's disease and has experienced

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Pr	ce)	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

intolerable side effects or insufficient benefit to meet renewal criteria; or

2.2.2 Both:

2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and

2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or

2 Both:

- 2.1 Patient has active Crohn's disease; and
- 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and

2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Ustekinumab to administered at a dose no greater than 90 mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or

2 Both:

- 2.1 Patient has active ulcerative colitis; and
- 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

2.2.2 Both:

2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis; and 2.2.2.2 Other biologics for ulcerative colitis are contraindicated.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 Either:

1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or

1.2 PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy*; and

2 Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks.

Note: Criterion marked with * is for an unapproved indication.

VEDOLIZUMAB - PCT only - Special Authority see SA2183 below

► SA2183 Special Authority for Subsidy

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
 - 2.3 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.4 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.5 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Any of the following:

- 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
- 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
- 3.3 Immunomodulators and corticosteroids are contraindicated.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Any of the following:

- 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
- 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
- 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Any of the following:

continued...

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

- 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
- 2.2 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
- 2.3 Patient has extensive small intestine disease; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a SCCAI score is greater than or equal to 4; or
 - 2.3 Patient's PUCAI score is greater than or equal to 20*; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or

1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy *; and 2 Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Programmed Cell Death-1 (PD-1) Inhibitors

ATEZOLIZUMAB - PCT only - Specialist - Special Authority see SA2264 on the next page				
Inj 60 mg per ml, 20 ml vial		1	 Tecentriq 	
Inj 1 mg for ECP	8.08	1 mg	 Baxter 	

	Subsidy	Fully	Brand or
(Mar	nufacturer's Price)	Subsidised	Generic
	\$ P	Per 🗸	Manufacturer

► SA2264 Special Authority for Subsidy

Initial application — (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic non-small cell lung cancer; and
- 2 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 3 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 4 Patient has an ECOG 0-2; and
- 5 Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
- 6 Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 7 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent); and
- 6 Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

DURVALUMAB - PCT only - Specialist - Special Authority see SA2164 below

Inj 50 mg per ml, 10 ml vial	4,700.00	1	🖌 Imfinzi
Inj 50 mg per ml, 2.4 ml vial	1,128.00	1	🗸 Imfinzi
Inj 1 mg for ECP	9.59	1 mg	 Baxter

➡SA2164 Special Authority for Subsidy

Initial application — (Non-small cell lung cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); and
- 2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and
- 3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and
- 4 Patient has a ECOG performance status of 0 or 1; and
- 5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and
- 6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and

7 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
- 7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 8 Treatment with durvalumab to cease upon signs of disease progression.

Renewal — (Non-small cell lung cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and
- 2 Either:
 - 2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
 - 2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 3 Treatment with durvalumab to cease upon signs of disease progression; and
- 4 Total continuous treatment duration must not exceed 12 months.

NIVOLUMAB - PCT only - Specialist - Special Authority see SA2306 below

Inj 10 mg per ml, 4 ml vial1,0	51.98 1	 Opdivo
Inj 10 mg per ml, 10 ml vial2,6	29.96 1	 Opdivo
Inj 1 mg for ECP	27.62 1 mg	✓ Baxter

⇒SA2306 Special Authority for Subsidy

Initial application only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded pembrolizumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

Renewal — (less than 24 months on treatment) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment; or
 - 1.1.2 Patient's disease has had a partial response to treatment; or
 - 1.1.3 Patient has stable disease; and
 - 1.2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
 - 1.3 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with nivolumab.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Renewal — (more than 24 months on treatment) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: Both:

- 1 Patient has been on treatment for more than 24 months; and
- 2 Either:
 - 2.1 All of the following:
 - 2.1.1 Any of the following:
 - 2.1.1.1 Patient's disease has had a complete response to treatment; or
 - 2.1.1.2 Patient's disease has had a partial response to treatment; or
 - 2.1.1.3 Patient has stable disease; and
 - 2.1.2 Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period; and
 - 2.1.3 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
 - 2.2 All of the following:
 - 2.2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
 - 2.2.2 Patient has signs of disease progression; and
 - 2.2.3 Disease has not progressed during previous treatment with nivolumab.

PEMBROLIZUMAB - PCT only - Specialist - Special Authority see SA2307 below

Inj 25 mg per ml, 4 ml vial	4,680.00	1	🗸 Keytruda
Inj 1 mg for ECP	47.74	1 mg	 Baxter

► SA2307 Special Authority for Subsidy

Initial application — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses.

Renewal — (unresectable or metastatic melanoma, less than 24 months on treatment) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment; or
 - 1.1.2 Patient's disease has had a partial response to treatment; or
 - 1.1.3 Patient has stable disease; and
 - 1.2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the

Subsidy		Fully	Brand or	
(Manufacturer's Pri	ce)	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

most recent treatment period; and

- 1.3 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Renewal — (unresectable or metastatic melanoma, more than 24 months on treatment) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient has been on treatment for more than 24 months; and
- 2 Either:
 - 2.1 All of the following:
 - 2.1.1 Any of the following:
 - 2.1.1.1 Patient's disease has had a complete response to treatment; or
 - 2.1.1.2 Patient's disease has had a partial response to treatment; or
 - 2.1.1.3 Patient has stable disease; and
 - 2.1.2 Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period; and
 - 2.1.3 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
 - 2.2 All of the following:
 - 2.2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2.2 Patient has signs of disease progression; and
 - 2.2.3 Disease has not progressed during previous treatment with pembrolizumab.

Initial application — (non-small cell lung cancer first-line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 Patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used as monotherapy; and
- 6 Either:
 - 6.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or
 - 6.2 Both:
 - 6.2.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and
 - 6.2.2 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and
- 7 Patient has an ECOG 0-2; and
- 8 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 9 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Subsidy		Fully	Brand or
(Manufacturer's Price)) Si	ubsidised	Generic
\$	Per	1	Manufacturer

continued...

Renewal — (non-small cell lung cancer first line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (non-small cell lung cancer first-line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 The patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used in combination with platinum-based chemotherapy; and
- 6 Patient has an ECOG 0-2; and
- 7 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 8 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer first line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Other Immunosuppressants

CICL	OSPORIN	

Cap 25 mg	50	Neoral
Cap 50 mg	50	Neoral
Cap 100 mg	50	Neoral
Oral liq 100 mg per ml198.13	50 ml OP	 Neoral

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
EVEROLIMUS – Special Authority see SA2008 below – Retail p Wastage claimable	harmacy			
Tab 10 mg Tab 5 mg		30 30		Afinitor Afinitor

⇒SA2008 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

SIROLIMUS - Special Authority see SA2270 below - Retail pharmacy

Tab 1 mg		100	 Rapamune
Tab 2 mg	1,499.99	100	 Rapamune
Oral liq 1 mg per ml		60 ml OP	 Rapamune

⇒SA2270 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR< 30 ml/min; or
- · Rapidly progressive transplant vasculopathy; or
- · Rapidly progressive obstructive bronchiolitis; or
- · HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

Initial application — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe non-malignant lymphovascular malformation*; and
- 2 Any of the following:
 - 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
 - 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or
 - 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

Renewal — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
 - 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly

	Subsidy	Fully	Brand or
(Manu	ufacturer's Price)	Subsidised	Generic
	\$ Per	✓	Manufacturer

continued...

documents in patient notes; and

- 2 No evidence of progressive disease; and
- 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

Initial application — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) only from a nephrologist or urologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has tuberous sclerosis complex*; and
- 2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

Renewal — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and
- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initial application — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
 - 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or
 - 2.2 Both:
 - 2.2.1 Vigabatrin is contraindicated; and
 - 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on quality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: Those of childbearing age potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.

Renewal — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 12 months where demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment.

Note: Indications marked with * are unapproved indications

TACROLIMUS - Special Authority see SA2271 on the next	t page – Retail pharmad	су	
Cap 0.5 mg		100	 Tacrolimus Sandoz
Cap 0.75 mg		100	 Tacrolimus Sandoz
Cap 1 mg		100	 Tacrolimus Sandoz
Cap 5 mg		50	 Tacrolimus Sandoz

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fu Subsidis Per	ully ed ✔	Brand or Generic Manufacturer
■SA2271 Special Authority for Subsidy Initial application — (organ transplant) only from a relevant si where the patient is an organ transplant recipient. Note: Subsidy applies for either primary or rescue therapy. Initial application — (non-transplant indications*) only from a unless notified for applications meeting the following criteria:				
Both: 1 Patient requires long-term systemic immunosuppression; 2 Either:	and			
 2.1 Ciclosporin has been trialled and discontinued trea clinical response; or 2.2 Patient is a child with nephrotic syndrome*. 	atment because of una	acceptable si	de eff	iects or inadequate
Note: Indications marked with * are unapproved indications				

JAK inhibitors

UPADACITINIB – Special Authority see SA2079 below – Retail pharmacy Tab 15 mg1,271.00

RINVOQ

28

⇒SA2079 Special Authority for Subsidy

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Fither:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic Per Manufacturer \$ Antiallergy Preparations Allergic Emergencies ADRENALINE - Special Authority see SA2185 below - Retail pharmacy a) Maximum of 2 ini per prescription b) Additional prescriptions limited to replacement of up to two devices prior to expiry, or replacement of used device for treatment of anaphylaxis. 1 OP Epipen Jr Inj 0.3 mg per 0.3 ml auto-injector......90.00 1 OP Epipen ⇒SA2185 Special Authority for Subsidy Initial application — (anaphylaxis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Either: 1.1 Patient has experienced an anaphylactic reaction which has resulted in presentation to a hospital or emergency department: or 1.2 Patient has been assessed to be at significant risk of anaphylaxis by a relevant practitioner; and 2 Patient is not to be prescribed more than two devices in initial prescription. ICATIBANT - Special Authority see SA1558 below - Retail pharmacy Ini 10 ma per ml. 3 ml prefilled svringe......2.668.00 1 Firazvr SA1558 Special Authority for Subsidy

Initial application only from a clinical immunologist or relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Supply for anticipated emergency treatment of larvngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
- 2 The patient has undergone product training and has agreed upon an action plan for self-administration.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

■ SA1367 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

BEE VENOM ALLERGY TREATMENT - Special Authority see SA1367 above - Retail pharmacy

05.00	1 OP	VENOX S29
05.00	1 OP	VENOX S29
85.00	1 OP	 Venomil S29
05.00	1 OP	 Albey
05.00	1 OP	✓ Hymenoptera S29
	05.00 85.00 05.00	05.00 1 OP 85.00 1 OP 05.00 1 OP

	Subsidy		Fully	
	(Manufacturer's Price		Subsidised	
	\$	Per		Manufacturer
WASP VENOM ALLERGY TREATMENT - Special Authority see	e SA1367 on the pre	vious p	<mark>age</mark> – Re	tail pharmacy
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze				
dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	1	Albey
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze				•
dried venom, with diluent		1 OP	1	Hymenoptera S29
Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze		-		,
dried venom, with diluent		1 OP	1	Venomil S29
Treatment kit (Yellow Jacket venom) - 1 vial 550 mcg freeze				
dried venom, with diluent	305.00	1 OP	1	Hymenoptera S29
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze		1 01		nymeneptera 😅
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml	305.00	1 OP	1	Albey
Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze		101	•	Albey
		1 OP		Venomil S29
dried venom, with diluent		100	-	VEHOIIIII
Antihistamines				
Antimistanimes				
CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg	1.71	100	1	Zista
* Oral lig 1 mg per ml	2.84	200 ml	1	Histaclear
* Oral liq 2 mg per 5 ml	9.37	500 ml	1	Histafen
(Histafen Oral liq 2 mg per 5 ml to be delisted 1 August 2024)		000 111		Inotation
DEXTROCHLORPHENIRAMINE MALEATE * Tab 2 mg	0.00	40		
* Tab 2 mg		40		Polaramine
	(8.40) 1.01	20		Foldramme
	(5.99)	20		Polaramine
* Oral liq 2 mg per 5 ml		100 ml		FUIdIdITIITE
	(10.29)	100 111		Polaramine
	(10.23)			1 Ularamine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg		20		- <i>v</i> .
	(8.23)			Telfast
* Tab 120 mg		10		T - 16 1
	(8.23)	00		Telfast
	14.22	30		Tolfoot
	(26.44)			Telfast
LORATADINE			-	
* Tab 10 mg		100		Lorafix
* Oral liq 1 mg per ml	1.43	100 ml	1	Haylor syrup
PROMETHAZINE HYDROCHLORIDE				
* Tab 10 mg	1.39	50	✓	Allersoothe
* Tab 25 mg	1.58	50	1	Allersoothe
* Oral liq 1 mg per 1 ml	3.39	100 ml	1	Allersoothe
Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a F	00 01 00	5	1	Hospira

	Subsidy		Fully	
()	Manufacturer's	Price) Per	Subsidised	
	\$	rei		Manulaciulei
Inhaled Corticosteroids				
BECLOMETHASONE DIPROPIONATE				
Aerosol inhaler, 50 mcg per dose	14.01	200 dose		Qvar
Aerosol inhaler, 50 mcg per dose CFC-free		200 dose 200 dose		Beclazone 50
Aerosol inhaler, 100 mcg per dose ch c-nee		200 dose 200 dose	•	Qvar
Aerosol inhaler, 100 mcg per dose CFC-free		200 dose	•	Beclazone 100
		200 dose 200 dose	•	Beclazone 250
Aerosol inhaler, 250 mcg per dose CFC-free	22.07	200 0056	UP V	Deciazone 200
BUDESONIDE				
Powder for inhalation, 100 mcg per dose	17.00	200 dose	OP 🗸	Pulmicort
				Turbuhaler
Powder for inhalation, 200 mcg per dose	19.00	200 dose	OP 🗸	Pulmicort
				Turbuhaler
Powder for inhalation, 400 mcg per dose	32.00	200 dose	OP 🗸	Pulmicort
				Turbuhaler
FLUTICASONE				
Aerosol inhaler, 50 mcg per dose	7.19	120 dose	OP 🗸	Flixotide
Powder for inhalation, 50 mcg per dose	8.61	60 dose	OP 🗸	Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose		60 dose	OP 🗸	Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose		120 dose	OP 🗸	Flixotide
Aerosol inhaler, 250 mcg per dose		120 dose	OP 🗸	Flixotide
Powder for inhalation, 250 mcg per dose		60 dose	OP 🗸	Flixotide Accuhaler
Inhaled Long-acting Beta-adrenoceptor Agonists				
EFORMOTEROL FUMARATE DIHYDRATE				
Powder for inhalation 4.5 mcg per dose, breath activated				
(equivalent to eformoterol fumarate 6 mcg metered dose)		60 dose	OP	
	(16.90)			Oxis Turbuhaler
NDACATEROL				
Powder for inhalation 150 mcg	61.00	30 dose	OP 🗸	Onbrez Breezhaler
Powder for inhalation 300 mcg	61.00	30 dose	OP 🗸	Onbrez Breezhaler
SALMETEROL				
Aerosol inhaler CFC-free, 25 mcg per dose	26.25	120 dose		Serevent
Powder for inhalation, 50 mcg per dose, breath activated		60 dose	•••	Serevent Accuhaler
i owder for inflatation, so meg per dose, breath activated	20.20	ou uuse	Ui⁼ ▼	Serevenit Accunater

	Subsidy (Manufacturer's \$		Fully Brand or dised Generic ✓ Manufacturer		
Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists					
BUDESONIDE WITH EFORMOTEROL Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate per dose (equivalent to 200 mcg budesonide v 6 mcg eformoterol fumarate metered dose) Powder for inhalation 320 mcg with 9 mcg eformoterol fuma per dose (equivalent to 400 mcg budesonide with 12 mc	41.50 Irate	120 dose OP	✓ DuoResp Spiromax		
eformoterol fumarate metered dose) - No more than 2		120 dose OP			
dose per day Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg		120 dose OP 120 dose OP	 ✓ DuoResp Spiromax ✓ Vannair 		
Powder for inhalation 100 mcg with eformoterol fumarate 6		120 dose OP	 Symbicort Turbuhaler 100/6 		
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg	21.40	120 dose OP	🗸 Vannair		
Powder for inhalation 200 mcg with eformoterol fumarate 6	mcg 33.74	120 dose OP	 Symbicort Turbuhaler 200/6 		
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day		60 dose OP	 Symbicort Turbuhaler 400/12 		
LUTICASONE FUROATE WITH VILANTEROL					
Powder for inhalation 100 mcg with vilanterol 25 mcg		30 dose OP	 Breo Ellipta 		
LUTICASONE WITH SALMETEROL					
Aerosol inhaler 50 mcg with salmeterol 25 mcg	25.79	120 dose OP	 Seretide 		
Aerosol inhaler 125 mcg with salmeterol 25 mcg		120 dose OP	 Seretide 		
Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day		60 dose OP	✓ Seretide Accuhaler		
Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day		60 dose OP	 Seretide Accuhaler 		
Beta-Adrenoceptor Agonists					
ALBUTAMOL					
Oral liq 400 mcg per ml		150 ml	✓ Ventolin		
Infusion 1 mg per ml, 5 ml		10	 Ventolin 		

Oral liq 400 mcg per ml	40.00
Infusion 1 mg per ml, 5 ml	130.00
Inj 500 mcg per ml, 1 ml - Up to 5 inj available on a PSO	130.00

5

✓ Ventolin

	Subsidy	Drian) Suba	Fully Brand or idised Generic
	(Manufacturer's \$	Per Per	Manufacturer
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO		200 dose OP	 Respigen
	(6.20)		✓ SalAir Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb	· · ·		
available on a PSO	8.96	20	 ✓ <u>Asthalin</u> ✓ PMS-
			Salbutamol S29
			 Teva-Salbutamol Sterinebs P.F. 629
			✓ Ventolin
	51.11		Vebules s29 ✓ Accord s29
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb		00	
available on a PSO	9.43	20	 ✓ <u>Asthalin</u> ✓ PMS-
			Salbutamol S29
	14.15	30	✓ Salbutamol
(Respigen Aerosol inhaler, 100 mcg per dose CFC free to be del	isted 1 Septem	ber 2024)	Cipla S29
TERBUTALINE SULPHATE			
Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated	22.20	120 dose OP	 Bricanyl Turbuhaler
Anticholinergic Agents			
PRATROPIUM BROMIDE			
Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dos available on a PSO		200 dose OP	✓ Atrovent
Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 ne available on a PSO		20	✓ Univent
	11.73 28.20	20	 Accord \$29
Inhaled Beta-Adrenoceptor Agonists with Antic	holinergic /	Agents	
SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg p dose CFC-free		200 dose OP	✓ Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per			
vial, 2.5 ml ampoule – Up to 20 neb available on a PSO	11.04 33.12	20 60	✓ <u>Duolin</u> ✓ Duolin
			Respules S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
Long-Acting Muscarinic Antagonists				
 GLYCOPYRRONIUM – Subsidy by endorsement a) Inhaled glycopyrronium treatment will not be subsidised i umeclidinium. b) Glycopyrronium powder for inhalation 50 mcg per dose is having COPD using spirometry if spirometry is possible, Powder for inhalation 50 mcg per dose	s subsidised only for and the prescription i 	patients wh s endorsed dose OP nt with sub- as having 0 who had t 30 dose dose OP	io have l accord sidised COPD t totropiu sotropiu sotropiu	been diagnosed as dingly. Seebri Breezhaler inhaled glycopyrronium or using spirometry if m dispensed before Spiriva spiriva Respimat
 a) Umeclidinium will not be subsidised if patient is also rece tiotropium bromide. b) Umeclidinium powder for inhalation 62.5 mcg per dose is COPD using spirometry if spirometry is possible, and the Powder for inhalation 62.5 mcg per dose 	subsidised only for prescription is endo	patients wh	o have lingly.	
Long-Acting Muscarinic Antagonists with Long	-Acting Beta-Ac	drenoce	otor A	gonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

➡SA1584 Special Authority for Subsidy

Initial application from any relevant practitioner.	Approvals valid for 2 years for applications meeting the following criteria:
Both:	

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).
- GLYCOPYRRONIUM WITH INDACATEROL Special Authority see SA1584 above Retail pharmacy Powder for Inhalation 50 mcg with indacaterol 110 mcg......81.00 30 dose OP ✓ Ultibro Breezhaler

UMECLIDINIUM WITH VILANTEROL – Special Authority see SA1584 above – Retail pharmacy

Powder for inhalation 62.5 mcg with vilanterol 25 mcg77.00 30 dose OP 🖌 Anoro Ellipta

Inhaled Corticosteroid with Long-Acting Muscarinic Antagonist and Beta Agonist

FLUTICASONE FUROATE WITH UMECLIDINIUM AND VILANTEROL – Special Authority see SA2326 on the next page – Retail pharmacy

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

⇒SA2326 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and
 - 2.1.2 Any of the following:

Clinical criteria:

- 2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or
- 2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or
- 2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or
- 2.1.2.4 Patient has had an eosinophil count greater than or equal to 0.3×10^{9} cells/L in the previous 12 months; or
- 2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long acting muscarinic antagonist and long acting beta-2 agonist ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler triple therapy.

Antifibrotics

NINTEDANIB - Special Authority see SA2012 below - Retail pharmacy

Note: Nintedanib not subsidised in combination with subsidised pirfenidone.

Cap 100 mg	2,554.00	60 OP	 Ofev
Cap 150 mg	3,870.00	60 OP	 Ofev

⇒SA2012 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic
	\$	Per	1	Manufacturer
PIRFENIDONE - Retail pharmacy-Specialist - Special Authori	ty see SA2013 below			
Note: Pirfenidone is not subsidised in combination with sul	bsidised nintedanib.			
Tab 801 mg		90 OP	🖌 E	sbriet
Tab 267 mg	1,215.00	90	🗸 E	sbriet
►SA2013 Special Authority for Subsidy				

013 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib: or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib: and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Leukotriene Receptor Antagonists

MONTELUKAST

*	Tab 4 mg	28	 Montelukast Viatris
	Tab 5 mg	28	 Montelukast Viatris
*	Tab 10 mg2.90	28	 Montelukast Viatris

Methylxanthines

AMINOPHYLLINE

* Inj 25 mg per ml, 10 ml ampoule - Up to 5 inj available o	na		
PSO		5	 DBL Aminophylline
THEOPHYLLINE			
* Tab long-acting 250 mg	24.90	100	Nuelin-SR
* Oral liq 80 mg per 15 ml	17.95	500 ml	 Nuelin

Mucolytics

DORNASE ALFA - Special Authority see SA1978 below - Reta	il pharmacy
Nebuliser soln. 2.5 mg per 2.5 ml ampoule	

Pulmozvme

SA1978 Special Authority for Subsidy

Initial application - (cystic fibrosis) only from a respiratory physician or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

continued...

6

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

All of the following:

- 1 Patient has a confirmed diagnosis of cystic fibrosis; and
- 2 Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline; and
- 3 Any of the following:
 - 3.1 Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period; or
 - 3.2 Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in the previous 12 month period; or
 - 3.3 Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of < 22/25; or</p>
 - 3.4 Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA).

Renewal — (cystic fibrosis) only from a respiratory physician or paediatrician. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient continues to benefit from treatment.

ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR - PCT only - Special Authority see SA2196 below

Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 3	37.5 mg		
(56) and ivacaftor 75 mg (28)	27,647.39	84 OP	🗸 Trikafta
Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor	75 mg		
(56) and ivacaftor 150 mg (28)	27,647.39	84 OP	🗸 Trikafta

⇒SA2196 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Patient is 6 years of age or older; and
- 3 Either:
 - 3.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
 - 3.2 Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and

4 Either:

- 4.1 Patient has a heterozygous or homozygous F508del mutation; or
- 4.2 Patient has a G551D mutation or other mutation responsive in vitro to elexacaftor/tezacaftor/ivacaftor (see note a); and
- 5 The treatment must be the sole funded CFTR modulator therapy for this condition; and

6 Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.

Notes:

 a) Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf</u>

IVACAFTOR - PCT only - Specialist - Special Authority see SA2017 below

Tab 150 mg		56	Kalydeco
Oral granules 50 mg, sachet		56	Kalydeco
Oral granules 75 mg, sachet	-	56	 Kalydeco

➡SA2017 Special Authority for Subsidy

Initial application only from a respiratory specialist or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

	Subsidy	Fu	Ily Brand o	r
(N	lanufacturer's Price)	Subsidis	ed Generic	:
	\$	Per	 Manufa 	cturer

continued...

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Either:
 - 2.1 Patient must have G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on at least 1 allele; or
 - 2.2 Patient must have other gating (class III) mutation (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) in the CFTR gene on at least 1 allele; and
- 3 Patients must have a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and
- 4 Treatment with ivacaftor must be given concomitantly with standard therapy for this condition; and
- 5 Patient must not have an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing treatment with ivacaftor; and
- 6 The dose of ivacaftor will not exceed one tablet or one sachet twice daily; and
- 7 Applicant has experience and expertise in the management of cystic fibrosis.

SODIUM CHLORIDE

Not funded for use as a nasal drop. Soln 7%	90 ml OP	✓ Biomed
Nasal Preparations		
Allergy Prophylactics		
BUDESONIDE Metered aqueous nasal spray, 50 mcg per dose	200 dose OP 200 dose OP	✓ SteroClear✓ SteroClear
FLUTICASONE PROPIONATE Metered aqueous nasal spray, 50 mcg per dose1.98	120 dose OP	 Flixonase Hayfever <u>& Allergy</u>
IPRATROPIUM BROMIDE Aqueous nasal spray, 0.03%5.23	15 ml OP	✓ Univent
Respiratory Devices		
MASK FOR SPACER DEVICE a) Up to 50 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Small	1	✓ e-chamber Mask
PEAK FLOW METER a) Up to 25 dev available on a PSO b) Only on a PSO		
Low range	1	 Mini-Wright AFS Low Range
Normal range9.54	1	✓ Mini-Wright Standard

	Subsidy (Manufacturer's Price) \$) S Per	Fully ubsidised	Brand or Generic Manufacturer
SPACER DEVICE				
a) Up to 50 dev available on a PSO				
b) Only on a PSO				
220 ml (single patient)	3.65	1	🗸 e	e-chamber Turbo
510 ml (single patient)	5.95	1	√ €	e-chamber La Grande
800 ml	6.50	1	۷ ۱	/olumatic
Respiratory Stimulants				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		5 ml OP	✓ E	Biomed

	Subsidy		Fully Brand or
	(Manufacturer's Pri	ice) Subs	sidised Generic
	\$	Per	 Manufacturer
Ear Preparations			
LUMETASONE PIVALATE Ear drops 0.02% with clioquinol 1%	1 16		I accortan Visform
Ear drops 0.02% with choquinor 1%	4.40	7.5 ml OP	 Locacorten-Viaform ED's
			✓ Locorten-Vioform
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYC	IN AND NYSTATI	N	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate	-		
2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml OP	 Kenacomb
Ear/Evo Droporationa			
Ear/Eye Preparations			
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and			
gramicidin 50 mcg per ml		8 ml OP	Otoday 520
	(9.27) (9.27)		Otodex S29 Sofradex
FRAMYCETIN SULPHATE	(0.27)		Conduck
Ear/Eye drops 0.5%	4.13	8 ml OP	
	(8.65)		Soframycin
Eve Proportions			
Eye Preparations			
Eye preparations are only funded for use in the eye, unless expli	citly stated otherw	ise.	
Anti-Infective Preparations			
ACICLOVIR			
₭ Eye oint 3%	14.88	4.5 g OP	✓ ViruPOS
CHLORAMPHENICOL			
Eye oint 1%	1.09	5 g OP	✓ <u>Devatis</u>
Eye drops 0.5%		10 ml OP	 Chlorsig
Funded for use in the ear*. Indications marked with * a	re unapproved indi	cations.	
CIPROFLOXACIN Eye drops 0.3% – Subsidy by endorsement	9.73	5 ml OP	 Ciprofloxacin Teva
When prescribed for the treatment of bacterial keratitis			
for the second line treatment of chronic suppurative otiti			
Note: Indication marked with a * is an unapproved indic	cation.		
SODIUM FUSIDATE [FUSIDIC ACID]			6
Eye drops 1%	5.29	5 g OP	 Fucithalmic
FOBRAMYCIN	10.45	2 5 a OP	
Eye oint 0.3% Eye drops 0.3%		3.5 g OP 5 ml OP	 ✓ Tobrex ✓ Tobrex
Corticosteroids and Other Anti-Inflammatory P			
DEXAMETHASONE ₩ Eye oint 0.1%	5.86	3.5 g OP	 Maxidex
★ Eye on 0.1%		3.5 g OP 5 ml OP	✓ Maxidex ✓ Maxidex
Ocular implant 700 mcg – Special Authority see SA1680 on		0	
the next page - Retail pharmacy		1	✓ Ozurdex
fully subsidised	S29 Linannr	oved medicine s	supplied under Section 29

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	dised	Generic	
\$	Per	1	Manufacturer	

⇒SA1680 Special Authority for Subsidy

Initial application — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has diabetic macular oedema with pseudophakic lens; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Either:
 - 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
 - 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initial application — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE

* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b		
sulphate 6,000 u per g5.39	3.5 g OP	 Maxitrol
* Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin		
b sulphate 6,000 u per ml 4.50	5 ml OP	 Maxitrol
DICLOFENAC SODIUM		
Eye drops 0.1%	5 ml OP	 Voltaren Ophtha
(Voltaren Ophtha Eye drops 0.1% to be delisted 1 December 2024)		i
FLUOROMETHOLONE		
* Eye drops 0.1%	5 ml OP	🖌 FML
5.20		 Flucon
LEVOCABASTINE		
Eye drops 0.5 mg per ml8.71	4 ml OP	
_); = ==================================)	Livostin
LODOXAMIDE		
Eye drops 0.1%	10 ml OP	 Lomide

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

SENSORY ORGANS

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Subs Per	sidised Generic Manufacturer
IEPAFENAC		101	
Eye drops 0.3%	8.80	3 ml OP	✓ Ilevro
REDNISOLONE ACETATE			
Eye drops 1%	6.92 7.00	10 ml OP 5 ml OP	 Prednisolone-AFT Pred Forte
REDNISOLONE SODIUM PHOSPHATE - Special Authority			
Eye drops 0.5%, single dose (preservative free)	41.20	20 dose	 Minims Prednisolone
SA1715 Special Authority for Subsidy nitial application only from an ophthalmologist or optometrist ollowing criteria: Both:	. Approvals valid f	or 6 months for	r applications meeting the
 Patient has severe inflammation; and Patient has a confirmed allergic reaction to preservative Renewal from any relevant practitioner. Approvals valid for 6 in 	, ,	treatment rema	ins appropriate and the patient
penefiting from treatment.			
SODIUM CROMOGLICATE Eye drops 2%	2.62	10 ml OP	✓ <u>Allerfix</u>
Glaucoma Preparations - Beta Blockers			
ETAXOLOL			
₭ Eye drops 0.25%		5 ml OP	 Betoptic S Betoptic
₭ Eye drops 0.5%	7.50	5 ml OP	 Betoptic
IMOLOL			4 - - - - - - - - - -
 € Eye drops 0.25% € Eye drops 0.5% 		5 ml OP 5 ml OP	 <u>Arrow-Timolol</u> <u>Arrow-Timolol</u>
Glaucoma Preparations - Carbonic Anhydrase	Inhibitors		
NCETAZOLAMIDE ₭ Tab 250 mg	17.03	100	 Diamox
RINZOLAMIDE ∉ Eye drops 1%	7.30	5 ml OP	✓ <u>Azopt</u>
OORZOLAMIDE WITH TIMOLOL ₭ Eye drops 2% with timolol 0.5%	2.73	5 ml OP	✓ Dortimopt
Glaucoma Preparations - Prostaglandin Analo	gues		
BIMATOPROST ≰ Eye drops 0.03%	5.95	3 ml OP	✓ <u>Bimatoprost</u> Multichem
ATANOPROST € Eye drops 0.005%		2.5 ml OP	✓ <u>Teva</u>

SENSORY ORGANS

	Subsidy		Fully	Brand or
	(Manufacturer's P	rice) Subs	idised	Generic
	\$	Per	1	Manufacturer
Glaucoma Preparations - Other				
BRIMONIDINE TARTRATE				
* Eye drops 0.2%	4.29	5 ml OP	✓ <u>P</u>	Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE				
* Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	✓ (Combigan
LATANOPROST WITH TIMOLOL				
* Eye drops 0.005% with timolol 0.5%	4.95	2.5 ml OP	✓ <u>A</u>	Arrow - Lattim
PILOCARPINE HYDROCHLORIDE				
* Eye drops 1%	4.26	15 ml OP	🗸 s	sopto Carpine
* Eye drops 2%	5.35	15 ml OP	✓ s	sopto Carpine
* Eye drops 4%		15 ml OP	✓ Is	sopto Carpine
Subsidised for oral use pursuant to the Standard Formu				
PILOCARPINE NITRATE				
* Eye drops 2% single dose – Special Authority see SA0895				
below – Retail pharmacy		20 dose	🗸 N	linims Pilocarpine
➡ SA0895 Special Authority for Subsidy				

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%	15 ml OP	✓ Atropt
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	15 ml OP	✓ Cyclogyl
 Eye drops 1%, single dose (preservative free) – Only on a prescription	20 dose	 Minims Cyclopentolate
TROPICAMIDE * Eye drops 0.5% * Eye drops 1% 8.66	15 ml OP 15 ml OP	 Mydriacyl Mydriacyl
Preparations for Tear Deficiency		
For acetylcysteine eye drops refer Standard Formulae, page 268 HYPROMELLOSE * Eye drops 0.5%	15 ml OP	✓ Methopt

	Subsidy (Manufacturer's Price \$	Full) Subsidise Per ✔	d Generic
Preservative Free Ocular Lubricants			
SA2134 Special Authority for Subsidy			
nitial application from any relevant practitioner. Approvals va Both:	lid for 12 months for a	applications mee	ing the following criteria:
 Confirmed diagnosis by slit lamp or Schirmer test of seve Either: 	ere secretory dry eye;	and	
2.1 Patient is using eye drops more than four times d 2.2 Patient has had a confirmed allergic reaction to p			
Renewal from any relevant practitioner. Approvals valid for 24 drops and has benefited from treatment.		•	o require lubricating eye
ARBOMER – Special Authority see SA2134 above – Retail pl Ophthalmic gel 0.3%, 0.5 g		30 🖌	' Poly-Gel
OLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL - Eye drops 0.4% and propylene glycol 0.3%, 0.8 ml			e – Retail pharmacy ´ Systane Unit Dose
SODIUM HYALURONATE [HYALURONIC ACID] – Special Au Eye drops 1 mg per ml Hylo-Fresh has a 6 month expiry after opening. The Pl month is not relevant and therefore only the prescribed	13.85 1 harmacy Procedures	0 ml OP	Hylo-Fresh on allowing one bottle per
Other Eye Preparations			
NAPHAZOLINE HYDROCHLORIDE ★ Eye drops 0.1%	4.15 1	5 ml OP 🗸	Naphcon Forte
DLOPATADINE Eye drops 0.1%	2.17	5 ml OP 🖌	Olopatadine Teva
PARAFFIN LIQUID WITH WOOL FAT ₭ Eye oint 3% with wool fat 3%		3.5 g OP 🖌	Poly-Visc

RETINOL PALMITATE

5 g OP 🖌 VitA-POS

VARIOUS

	Outside		Fully Drand an	
	Subsidy (Manufacturer's Price)		Fully Brand or dised Generic	
	\$	Per	 Manufact 	urer
Various				
PHARMACY SERVICES				
Brand switch fee	4 50	1 fee	🗸 BSF Max H	ealth
		1100	✓ BSF	cann
			Methylph	enidate
			ER - Teva	
			 BSF Noum 	ed
			Dexamfe	
			 BSF Wock 	nardt
a) May only be claimed once per patient.				
b) The Pharmacode for BSF Wockhardt is 2669986 - se	e also <mark>page 128</mark>			
c) The Pharmacode for BSF Noumed Dexamfetamine is	2673886 - see also	page 146		
d) The Pharmacode for BSF Methylphenidate ER - Teva		lso page 14	7	
e) The Pharmacode for BSF Max Health is 2677903 - se				
* COVID-19 Services	0.00	1 fee	 After Hours 	
			Mgmt 15	
			✓ After Hours	
			Mgmt 30	
			✓ After Hours	
			Mgmt 45	
			 Antivirals I Review 	Ingromity
			 Complianc Packagir 	
			✓ Med Mgmt	•
			 Med Mgmt Med Mgmt 	
			 Med Mgmt Med Mgmt 	
			✓ Medicine D	
* Immunisation administration fee	0.00	1 fee	 Immunisati 	
			Administ	ration
* Immunisation co-administration fee	0.00	1 fee	 Immunisati 	ion
			Co-admir	nistration
(BSF Max Health Brand switch fee to be delisted 1 August 2024)				
(BSF Methylphenidate ER - Teva Brand switch fee to be delisted				
(BSF Noumed Dexamfetamine Brand switch fee to be delisted 1	June 2024)			
(BSF Wockhardt Brand switch fee to be delisted 1 June 2024)				
Agente Llood in the Treatment of Reisenings				
Agents Used in the Treatment of Poisonings				
Antidotes				
Annuoles				
ACETYLCYSTEINE				
Inj 200 mg per ml, 10 ml ampoule		10	✓ Martindale	Pharma
NALOXONE HYDROCHLORIDE				
a) Up to 10 inj available on a PSO				
b) Only on a PSO				
* Inj 400 mcg per ml, 1 ml ampoule		10	✓ Hameln	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Prio \$	ce) Subs Per	Fully sidised	Brand or Generic Manufacturer
Removal and Elimination				
IARCOAL				
Oral liq 50 g per 250 ml a) Up to 250 ml available on a PSO b) Only on a PSO	43.50	250 ml OP	✓ (Carbosorb-X
FERASIROX – Special Authority see SA1492 below – Ret Wastage claimable	ail pharmacy			
Tab 125 mg dispersible		28	✓ E	xjade
Tab 250 mg dispersible		28	✓ E	xjade
Tab 500 mg dispersible	1,105.00	28	✓ E	xjade
 combination therapy have proven ineffective as 3.2 Treatment with deferiprone has resulted in seve 3.3 Treatment with deferiprone has resulted in arthu 3.4 Treatment with deferiprone is contraindicated d count (ANC) of < 0.5 cells per μL) or recurrent e 0.5 - 1.0 cells per μL). 	ere persistent vomiting itis; or ue to a history of agra	g or diarrhoe	a; or (defined	as an absolute neutrop
newal only from a haematologist. Approvals valid for 2 yea her:	ars for applications m	eeting the fol	lowing	criteria:
 For the first renewal following 2 years of therapy, the tr improvement in all three parameters namely serum fer For subsequent renewals, the treatment has been tole in all three parameters namely serum ferritin, cardiac N 	ritin, cardiac MRI T2* rated and has resulted	and liver MF d in clinical s	l T2* le	vels; or
	ail pharmacy			

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DESFERRIOXAMINE MESILATE

*	Inj 500 mg vial		
---	-----------------	--	--

 ✓ DBL Desferrioxamine Mesylate for Inj BP
 ✓ Deferoxamine Pfizer

10

	Subsidy	Fully	Brand or
	(Manufacturer's Price)	Subsidised	Generic
	\$	Per 🗸	Manufacturer
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml		6	
	(156.71)		Calcium Disodium Versenate

VARIOUS

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs	PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
CODEINE LINCTUS (3 mg per 5 ml) Codeine phosphate Glycerol Preservative Water	60 mg 40 ml qs to 100 ml	PHENOBARBITONE SODIUM PAEDIATRIC ORAL mg per ml) Phenobarbitone Sodium Glycerol BP Water	LIQUID (10 400 mg 4 ml to 40 ml
CODEINE LINCTUS (15 mg per 5 ml) Codeine phosphate Glycerol Preservative Water FOLINIC MOUTHWASH Calcium folinate 15 mg tab	300 mg 40 ml qs to 100 ml 1 tab	PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops Preservative Water (Preservative should be used if quantity supplied is than 5 days.)	qs qs to 500 ml for more
Preservative Water (Preservative should be used if quantity supplied is than 5 days. Maximum 500 ml per prescription.) METHADONE MIXTURE Methadone powder	qs to 500 ml for more qs	SALIVA SUBSTITUTE FORMULA Methylcellulose Preservative Water (Preservative should be used if quantity supplied is than 5 days. Maximum 500 ml per prescription.)	5 g qs to 500 ml for more
Glycerol Water METHYL HYDROXYBENZOATE 10% SOLUTION Methyl hydroxybenzoate Propylene glycol	qs to 100 ml 10 g to 100 ml	SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml Water (Only funded if prescribed for treatment of hyponatr VANCOMYCIN ORAL SOLUTION (25 mg per ml)	
(Use 1 ml of the 10% solution per 100 ml of oral liqu OMEPRAZOLE SUSPENSION Omeprazole capsules or powder Sodium bicarbonate powder BP Water	uid mixture) qs 8.4 g to 100 ml	Vancomycin 500 mg injection Glycerin with sucrose suspension Water (Only funded if prescribed for treatment of Clostridiu following metronidazole failure)	5 vials 37.5 ml to 100 ml um difficile

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or
	(Manufacturer's Pric	e) Sub: Per	sidised Generic Manufacturer
	φ	Per	 Manufacturer
Extemporaneously Compounded Preparations a	nd Galenicals	6	
CODEINE PHOSPHATE - Safety medicine; prescriber may deter	rmine dispensing f	requency	
Powder – Only in combination	63.09	25 g	
	(90.09)		Douglas
Only in extemporaneously compounded codeine linctus.			
COLLODION FLEXIBLE			
Note: This product is no longer being manufactured by the su	pplier and will be	delisted fror	n the Schedule at a date to be
determined. Collodion flexible	10.00	1001	
		100 ml	✓ PSM
COMPOUND HYDROXYBENZOATE – Only in combination			
Only in extemporaneously compounded oral mixtures. Soln	20.00	100 ml	✓ Midwest
		100 111	• midwest
GLYCERIN WITH SODIUM SACCHARIN – Only in combination	music and louvid (Standard Fa	mulaa
Only in combination with Ora-Plus or when used in the vancor Suspension		473 ml	✓ Ora-Sweet SF
		475111	• Ola-Sweet Si
GLYCERIN WITH SUCROSE – Only in combination Only in combination with Ora-Plus or when used in the vancor	music and launid (Standard Ea	rmulaa
Suspension		473 ml	✓ Ora-Sweet
GLYCEROL		470111	
KOLICEROL KOLICEROL	3 23	500 ml	healthE Glycerol BP
Only in extemporaneously compounded oral liquid prepar		500 m	
METHADONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
 c) Safety medicine; prescriber may determine dispensing free 	quency		
d) Extemporaneously compounded methadone will only be re		ate of the ch	neapest form available
(methadone powder, not methadone tablets).			
Powder	7.84	1 g	✓ AFT
(AFT Powder to be delisted 1 July 2024)			
METHYL HYDROXYBENZOATE			
Powder	8.98	25 g	 Midwest
METHYLCELLULOSE			
Powder		100 g	 MidWest
Suspension – Only in combination		473 ml	 Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHA			6 a b b b a
Suspension		473 ml	 Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - Only			
Suspension		473 ml	 Ora-Blend
PHENOBARBITONE SODIUM			4 • • • • • • •
Powder – Only in combination		10 g	 MidWest
Only in children up to 10 years	325.00	100 g	 MidWest
Only in children up to 12 years			
PROPYLENE GLYCOL	ata 100/		
Only in extemporaneously compounded methyl hydroxybenzo Lig		500 ml	✓ Midwest
Lid	11.20	500 mi	• Miuwest

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Pric \$	e) Si Per	Fully ubsidised	Brand or Generic Manufacturer
SODIUM BICARBONATE	Ŷ	1.01		Manufacturer
Powder BP – Only in combination Only in extemporaneously compounded omeprazole and		500 g pension.	🗸 N	lidwest
SYRUP (PHARMACEUTICAL GRADE) – Only in combination Only in extemporaneously compounded oral liquid preparatio	ns.			
Liq	14.95	500 ml	🗸 N	lidwest
WATER				
Tap – Only in combination	0.00	1 ml	🗸 Т	ap water

SECTION D: SPECIAL FOODS

Fully

Subsidy (Manufacturer's Price)

\$

Subsidised Per ✓ Brand or Generic Manufacturer

Nutrient Modules

Carbohydrate

⇒SA1930 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Initial application — (Inborn errors of metabolism)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism. **Renewal — (Cystic fibrosis or renal failure)** only from a dietitian, relevant specialist, vocationally registered general

practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

. Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT - Special Authority see SA1930 above - Hospital pharmacy [HP3]

Powder6.72	400 g OP	 Polycal
------------	----------	-----------------------------

Carbohydrate And Fat

⇒SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

Subsidy		Fully	Brand or	
(Manufacturer's F	Price) S	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT S	SUPPLEMENT – Special Author	ity see SA1376 on	the previous pag	je -	Hospital pharmacy [HP3]
Powder (neutral)			400 g OP	1	Duocal Super
			-		Soluble Powder

Fat

⇒SA2204 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has an inborn error of metabolism. Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 10 ascites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Indications other than inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Authority see SA2204 on the	ne previous page – Hos	spital pharmacy	[HP3]
Emulsion (neutral)		200 ml OP	 Calogen
	38.44	500 ml OP	 Calogen
Emulsion (strawberry)		200 ml OP	 Calogen
Oil		500 ml OP	 MCT oil (Nutricia)
MCT Emulsion, 250 ml		4 OP	 Liquigen

Protein

⇒SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT - Specia	al Authority see SA1524 above – Hospital ph	armacy [HP3]	
Powder		227 g OP	 Resource
			Beneprotein
	13.82	225 g OP	 Protifar

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

Oral and Enteral Feeds

Diabetic Products

⇒SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authorit Liquid	•	500 ml OP	 Glucerna Select Nutrison Advanced
(Nutrison Advanced Diason Liquid to be delisted 1 July 202	24)		Diason
	,		
DIABETIC ORAL FEED 1KCAL/ML – Special Authority se	e SA1095 above – Ho	spital pharmacy	[HP3]
Liquid (strawberry)		200 ml OP	 Diasip
Liquid (vanilla)	1.50	200 ml OP	✓ Diasip
	2.10		 Nutren Diabetes

Fat Modified Products

⇒SA2205 Special Authority for Subsidy

Initial application — (**Inborn errors of metabolism**) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has an inborn error of metabolism. **Initial application** — (**Indications other than errors of inborn metabolism**) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient has a chyle leak; or
- 2 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Monogen

Subsidy			
(Manufacturer's Price)	Subsidised		Generic
\$	Per	✓	Manufacturer

Paediatric Products For Children Awaiting Liver Transplant

⇒SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Paediatric Products For Children With Chronic Renal Failure

⇒SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see	SA1099 above – Hos	oital pharmacy	[HP3]
Powder	64.26	400 g OP	 Kindergen

Paediatric Products

⇒SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for

	Subsidy		Fully	Brand or
	(Manufacturer's Price \$	e) Sub Per	sidised ✓	Generic Manufacturer
ontinued				
pplications meeting the following criteria: Both:				
 The treatment remains appropriate and the patient is benuezed. General Practitioners must include the name of the dietitian practitioner and date contacted. 			onally re	egistered general
AEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority Liquid		e <mark>previous </mark> 500 ml OP	✓ F	Hospital pharmacy [HP3 Frebini Energy Iutrini Energy RTH
AEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority s Liquid		previous pa 500 ml OP	✓ F ✓ N	spital pharmacy [HP3] Pediasure RTH Nutrini RTH Frebini Original
AEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Sp harmacy [HP3]	-	SA1379 on	the prev	vious page – Hospital
Liquid	7.00 § 7.14	500 ml OP		rebini Energy Fibre lutrini Energy Multi Fibre
PAEDIATRIC ENTERAL FEED WITH FIBRE 1KCAL/ML - Spectharmacy [HP3]	cial Authority see SA	A1379 on th	e previc	ous page – Hospital
Liquid	7.00 §	500 ml OP	✓ F	rebini Original Fibre
AEDIATRIC ORAL FEED 1.5KCAL/ML - Special Authority see				
Liquid (strawberry)		200 ml OP		ortini
Liquid (vanilla)		200 ml OP	-	ortini
		500 ml OP		Pediasure Plus
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see S				
Liquid (chocolate)		200 ml OP	-	Pediasure
Liquid (strawberry)		200 ml OP		Pediasure
Liquid (vanilla)		200 ml OP	-	Pediasure
		250 ml OP	-	Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special harmacy [HP3]	Authority see SA1	379 on the	previous	s page – Hospital
Liquid (unflavoured)		200 ml OP	🖌 F	Fortini Multi Fibre
Liquid (chocolate)		200 ml OP		ortini Multi Fibre
Liguid (strawberry)		200 ml OP	-	ortini Multi Fibre
	100 0	200 ml OP	🗸 F	Fortini Multi Fibre
Liquid (vanilla)				
Liquid (vanilla) PEPTIDE-BASED ORAL FEED – Special Authority see SA1379		ge – Hospi	tal pharr	nacy [HP3]

Renal Products

■ SA1101 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✔	
continued recommendation of a dietitian, relevant specialist or vocationally applications meeting the following criteria: Both:	registered general pra	actitioner. Appr	ovals valid for 3 years for
 The treatment remains appropriate and the patient is ben General Practitioners must include the name of the dietitic practitioner and date contacted. 	0		registered general
RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority see Liquid			bital pharmacy [HP3] Nepro HP RTH
RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see SA1 Liquid		0 ml OP	pharmacy [HP3] Nepro HP (strawberry) Nepro HP (vanilla)
RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA110 Liquid, 200 ml bottle		<mark>ge</mark> – Hospital pł 4 OP	narmacy [HP3]
Liquid (apricot) 125 ml Liquid (caramel) 125 ml	(13.24) 13.72		NovaSource Renal Renilon 7.5 Renilon 7.5

Specialised And Elemental Products

⇒SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Any of the following:
 - 1 malabsorption; or
 - 2 short bowel syndrome; or
 - 3 enterocutaneous fistulas; or
 - 4 eosinophilic oesophagitis; or
 - 5 inflammatory bowel disease; or
 - 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Sp Liquid		e SA1377 abov 1,000 ml OP	
ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority se Liquid (grapefruit), 250 ml carton		– Hospital phar 18 OP	macy [HP3] ✓ Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton Liquid (summer fruits), 250 ml carton	179.46	18 OP 18 OP	 ✓ Elemental 028 Extra ✓ Elemental 028 Extra

	Subsidy (Manufacturer's Pri \$	ice) Subs Per	Fully sidised	Brand or Generic Manufacturer
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see S Powder (unflavoured)		vious page – 80 g OP		
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Auth [HP3]	ority see SA1377	on the previo	us page	 Hospital pharmacy
Liquid	7.47	500 ml OP		utrison Advanced Peptisorb
	9.60			urvimed OPD

Paediatric Products For Children With Low Energy Requirements

⇒SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML	- Special Authority	see SA1196	above ·	- Hospital pharmacy [HP3]
Liquid	6.27	500 ml OP	1	Nutrini Low Energy
				Multi Fibre

Standard Supplements

⇒SA1859 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on

Subsidy	Fully	Brand or	_
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal - (Children - exclusive enteral nutrition for Crohn's disease) from any relevant practitioner on the

recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Initial application — (Adults) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

Patient is Malnourished

- 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
- 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 1.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:

Patient has not responded to first-line dietary measures over a 4 week period by:

- 2.1 Increasing their food intake frequency (eg snacks between meals); or
- 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
- 2.3 Using over the counter supplements (e.g. Complan); and

3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:

Subsidy	Full	y Brand or	_
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🖌	Manufacturer	

continued...

- 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
- 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
- 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) from any relevant practitioner. Approvals valid without further renewal unless notified for applications

meeting the following criteria:

Any of the following:

1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or

SPECIAL FOODS

	Subsidy (Manufacturer's F		Fully Subsidised	Brand or Generic
	\$	Per		Manufacturer
ontinued				
2 Cystic Fibrosis; or				
3 Liver disease; or				
4 Chronic Renal failure; or				
5 Inflammatory bowel disease; or				
6 Chronic obstructive pulmonary disease with hypercapnia; of	or			
7 Short bowel syndrome; or				
8 Bowel fistula; or				
9 Severe chronic neurological conditions.				
NTERAL FEED 1.5KCAL/ML – Special Authority see SA1859 o	1 0		, .	
Liquid		250 ml (Ensure Plus HN
	8.68	1,000 ml	OP 🗸	Ensure Plus HN RTH
	9.00			Nutrison Energy
	9.60		1	Fresubin HP Energy
NTERAL FEED 1KCAL/ML – Special Authority see SA1859 on	page 278 – Hos	spital pharr	nacy [HP3]
Liquid	1.24	250 ml (OP 🗸	Isosource Standard
	6.50	1,000 ml	OP 🗸	Fresubin Original
	6.56			Osmolite RTH
	6.90		✓	Nutrison RTH
NTERAL FEED WITH FIBRE 0.83 KCAL/ML - Special Authority	/ see <mark>SA1859</mark> c	n page 27	8 – Hospit	al pharmacy [HP3]
Liquid	9.05	1,000 ml	OP 🗸	Nutrison
				800 Complete
				Multi Fibre
NTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority se	e SA1859 on p	age 278 -	Hospital p	harmacy [HP3]
Liquid	6.56	1,000 ml	OP 🗸	Jevity RTH
	7.00		✓	Fresubin Original
				Fibre
	7.21		~	Nutrison Multi Fibre
NTERAL FEED WITH FIBRE 1.2KCAL/ML – Special Authority s				
Liquid	7.87	1,000 ml	OP 🗸	Jevity Plus RTH
NTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority s				
Liquid	8.68	1,000 ml	-	Jevity HiCal RTH
			1	Nutrison Energy
				Multi Fibre
	9.80		1	Fresubin HP Energy
				Fibre
NTERAL FEED WITH PROTEIN 1.2KCAL/ML – Special Author	ity see SA1859	on page 2		
Liquid	9.60	500 ml (OP 🗸	Fresubin Intensive
RAL FEED (POWDER) – Special Authority see SA1859 on pag	e 278 – Hospita	al pharmac	y [HP3]	
Powder (chocolate)	14.00	່ 840 g C		Sustagen Hospital
. ,		5		Formula
	26.00	850 g C	DP 🗸	Ensure
Powder (vanilla)		840 g C		Sustagen Hospital
· · · /		5 -		Formula Active
	26.00	850 g C	P 🗸	Ensure
	_0.00			

	Subsidy		ully Brand or
	(Manufacturer's Pr \$	ice) Subsidis Per	sed Generic Manufacturer
	Ŧ		
ORAL FEED 1.5KCAL/ML – Special Authority see SA1859 on pa			
Additional subsidy by endorsement is available for patients b			
epidermolysis bullosa, or as exclusive enteral nutrition in child disease, or for patients with COPD and hypercapnia, defined			
endorsed accordingly.	as CO2 value ex		g. The prescription must be
Liquid (banana) – Higher subsidy of up to \$1.56 per 200 ml with Endorsement	0.70	200 ml OP	
	0.72 (1.26)	200 MI OP	Fortisip
	(1.26)		Ensure Plus
Liquid (abaaalata) Higher subsidy of up to \$1.56 per 200 m	· /		LIISUIE FIUS
Liquid (chocolate) – Higher subsidy of up to \$1.56 per 200 m with Endorsement		200 ml OP	
	0.72 (1.26)	200 111 0F	Fortisip
	(1.26)		Ensure Plus
Liquid (fruit of the forest) – Higher subsidy of \$1.56 per 200 i	· /		
with Endorsement		200 ml OP	
	(1.56)	200 III OF	Ensure Plus
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with	()		Ensure Flus
Endorsement		200 ml OP	
	(1.26)	200 111 01	Fortisip
Liquid (vanilla) – Higher subsidy of up to \$1.65 per 237 ml w	· · ·		i onop
Endorsement		200 ml OP	
	(1.26)	200 111 01	Fortisip
	0.85	237 ml OP	i onioip
	(1.65)		Ensure Plus
	0.72	200 ml OP	
	(1.56)		Ensure Plus
ORAL FEED WITH FIBRE 1.5 KCAL/ML - Special Authority see	,	278 – Hospital r	
Additional subsidy by endorsement is available for patients b			
epidermolysis bullosa. The prescription must be endorsed a		ough a recurry t	abo, or who have severe
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with			
Endorsement		200 ml OP	
	(1.26)	200 111 01	Fortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with	()		
Endorsement		200 ml OP	
	(1.26)		Fortisip Multi Fibre
Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with	(
Endorsement	0.72	200 ml OP	
	(1.26)		Fortisip Multi Fibre
	· -/		- p
High Calorie Products			
•			

► SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML - Special Authority see SA1195 on	the previous pa	<mark>age</mark> – Hospital p	harmacy [HP3]
Liquid	6.50	500 ml OP	 Fresubin 2kcal HP
	6.82		 Nutrison Concentrated
	13.64	1,000 ml OP	 Ensure Two Cal HN RTH
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the Additional subsidy by endorsement is available for patients be epidermolysis bullosa. The prescription must be endorsed are Liquid (vanilla) – Higher subsidy of \$2.34 per 200 ml with	eing bolus fed tl		
Endorsement	0.96	200 ml OP	
	(2.34)		Two Cal HN

Food Thickeners

SA1106 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for

continued...

applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FOOD THICKENER	- Special Authority see SA1106 on the previous page - H	ospital pharmacy	/ [HP3]
Powder		300 g OP	 Nutilis
	24.00	380 g OP	 Aptamil Feed
			Thickener

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by Pharmac from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

⇒SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist. Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

GLUTEN FREE BAKING MIX – Special Authority see SA1729 above – Hosp Powder		
(5.15)	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX - Special Authority see SA1729 above - Hospit	tal pharmacy [HP3]	
Powder	1,000 g OP	
(7.32)	NZB Low Gluten Bread Mix
3.51		
(10.87)	Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1729 above - Hospital ph	narmacy [HP3]	
Powder	2,000 g OP	
(18.10)	Horleys Flour

	Subsidy		Fully	Brand or
	(Manufacturer's Pri \$	ice) Sul Per	osidised ✓	Generic Manufacturer
GLUTEN FREE PASTA - Special Authority see SA1729 on the	previous page - H	lospital phar	macy [H	P3]
Buckwheat Spirals		250 g OP		
	(3.11)		C	Drgran
Corn and Vegetable Shells	2.00	250 g OP		
	(2.92)		C	Drgran
Corn and Vegetable Spirals	2.00	250 g OP		
	(2.92)		C	Drgran
Rice and Corn Lasagne Sheets	1.60	200 g OP		
	(3.82)		C	Drgran
Rice and Corn Macaroni		250 g OP		•
	(2.92)	•	C	Drgran
Rice and Corn Penne		250 g OP		•
	(2.92)	-	C	Drgran
Rice and Maize Pasta Spirals	2.00	250 g OP		-
	(2.92)	-	C	Drgran
Rice and Millet Spirals	2.00	250 g OP		-
	(3.11)	•	C	Drgran
Rice and corn spaghetti noodles	2.00	375 g OP		-
	(2.92)	-	C	Drgran
Vegetable and Rice Spirals		250 g OP		•
	(2.92)	•	C	Drgran
Italian long style spaghetti		220 g OP		-
	(3.11)	•	C	Drgran

Foods And Supplements For Inherited Metabolic Disease

⇒SA2300 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Dietary management of inherited metabolic disease; or
- 2 For use as a supplement to a Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE -	Special Authority see SA2300	above - He	ospital pharmacy [HP3]
Powder, 12.5 g sachets		30	HCU Explore 5
Powder, 25 g sachets	1,048.95	30	HCU Express 15
Powder		500 g OP	 XMET Maxamum

Supplements For MSUD and short chain enoyl coA hydratase deficiency

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA2300 above – Hospital pharmacy [HP3]

Powder, 12.5 g sachets		30	MSUD Explore 5
Powder, 25 g sachets	1,048.95	30	 MSUD Express 15
Powder		500 g OP	 MSUD Maxamum

	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Supplements For PKU				
MINOACID FORMULA WITHOUT PHENYLALANINE – Spectarracy [HP3]	cial Authority see SA2	2300 on	the previo	<mark>us page</mark> – Hospital
Tabs	99 00	75 OF	. .	Phlexy 10
Powder (Lemon), 34 g sachets		30		PKU Express 20
Powder (Neutral), 12.5 g sachets		30		PKU Explore 5
Powder (Neutral), 34 g sachets		30		PKU Express 20
Powder (Orange), 25 g sachets		30		PKU Explore 10
Powder (Orange), 34 g sachets		30		PKU Express 20
Powder (Raspberry), 25 g sachets		30		PKU Explore 10
Powder (Tropical), 34 g sachets		30		PKU Express 20
Powder (berry) 28 g sachets		30		PKU Lophlex
		00	-	Powder
Powder (chocolate) 36 g sachet	303.00	30	1	PKU Anamix Junior
		50	•	Chocolate
Dourder (noutral) 00 a cochata	026.00	30		PKU Lophlex
Powder (neutral) 28 g sachets		30	v	Pro Lopniex Powder
		~~		
Powder (neutral) 36 g sachets		30		PKU Anamix Junior
Powder (orange) 28 g sachets		30	•	PKU Lophlex
				Powder
Powder (orange) 36 g sachet		30	~	PKU Anamix Junior
				Orange
Powder (vanilla) 36 g sachet		30	✓	PKU Anamix Junior
				Vanilla
Infant formula	174.72	400 g C	DP 🗸	PKU Anamix Infant
Powder (neutral)		400 g C		PKU Start
Powder (orange)		500 g C	DP 🗸	XP Maxamum
Powder (unflavoured)		500 g C	DP 🗸	XP Maxamum
Liquid (berry)		125 ml (OP 🗸	PKU Anamix Junior
				LQ
Liquid (orange)		125 ml (OP 🗸	PKU Anamix Junior
				LQ
Liquid (unflavoured)		125 ml (OP 🗸	PKU Anamix Junior
(LQ
Liquid (forest berries), 250 ml carton	540.00	18 OF		Easiphen Liquid
Liquid (juicy tropical) 125 ml		30 OF		PKU Lophlex LQ 20
Oral semi-solid (berries) 109 g		36 OF		PKU Lophlex
		00 01	-	Sensation 20
Liquid (juicy berries) 62.5 ml	030 00	60 OF	. .	PKU Lophlex LQ 10
Liquid (juicy bernes) 62.5 ml		60 OF		PKU Lophlex LQ 10
Liquid (juicy crange) 62.5 ml		60 OF		PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml		30 OF		PKU Lophlex LQ 20
		30 OF		
Liquid (juicy orange) 125 ml		30 OF	•	PKU Lophlex LQ 20

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
LYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOM	ME PHENYLALANINE	– Spe	cial Autho	ority see SA2300 on
age 285 – Hospital pharmacy [HP3]				
Powder (Banana) 35 g sachets	930.00	30	1	PKU
				sphere20 Banana
Powder (Berry), 20 g sachets		60	✓	PKU Restore
				Powder
Powder (Chocolate) 32 g Sachets		30	✓	PKU Build
				20 Chocolate
Powder (Chocolate) 35 g sachets		30	1	PKU
				sphere20 Chocolate
Powder (Lemon) 35 g sachets	930.00	30	1	PKU
		00		sphere20 Lemon
Powder (Lemonade) 33.4 g sachets	936.00	30	1	PKU GMPro Ultra
		00	•	Lemonade
Powder (Neutral), 16 g sachets	449.28	30	1	PKU Build 10
Powder (Orange), 20 g sachets		60		PKU Restore
		00	•	Powder
Powder (Raspberry Lemonade) 32 g Sachets	898 56	30	1	PKU Build
		00		20 Raspberry
				Lemonade
Powder (Smooth) 32 g Sachets	898 56	30	1	PKU Build
		00		20 Smooth
Powder (Vanilla) 32 g Sachets	898.56	30	1	PKU Build 20 Vanilla
Powder (neutral), 40 g sachets		30		Camino Pro
· • · · · · · · · · · · · · · · · · · ·				Bettermilk
Powder (Red Berry) 35 g sachets	930.00	30	1	PKU sphere20 Red
		00	-	Berry
Powder (Vanilla) 35 g sachets	930.00	30	1	PKU
		00	•	sphere20 Vanilla
Liquid (Coffee Mocha), 250 ml carton	684.45	30 OF	· ·	PKU Glytactin RTD
		00 01	•	15 Lite
Liquid (chocolate), 250 ml carton	684 45	30 OF		PKU Glytactin RTD
בוקטוט (טוטטטומוש), בטט וווו טמונטוו		50 Or	•	15
Liquid (neutral), 250 ml carton	684 45	30 OF		PKU Glytactin RTD
בוקטוט (ווכטוומו), בטט וווו טמונטוו		50 Or	•	15
Liquid (vanilla), 250 ml carton	694 45	30 OF		
Liquiu (vanilia), 200 mii Ganon	004.40	30 OF	v	PKU Glytactin RTD 15 Lite

Foods

LOW PROTEIN BAKING MIX – Special Authority see SA2300 or Powder			y [HP3] ✓ Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA2300 on page	e 285 – Hospital	pharmacy [HP:	3]
Animal shapes		500 g OP	 Loprofin
Lasagne	6.19	250 g OP	 Loprofin
Low protein rice pasta		500 g OP	 Loprofin
Macaroni	6.19	250 g OP	 Loprofin
Penne		500 g OP	 Loprofin
Spaghetti		500 g OP	 Loprofin
Spirals		500 g OP	 Loprofin

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Supplements for Tyrosinaemia				
AMINOACID FORMULA WITHOUT PHENYLALANINE AND TYR pharmacy [HP3]	OSINE – Special Au	thority	/ see <mark>SA2</mark>	300 on page 285 – Hospita
Powder (Neutral), 12.5 g sachets		30		TYR Explore 5
GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME SA2300 on page 285 – Hospital pharmacy [HP3]	TYROSINE AND PH	ENYL	ALANINE	 Special Authority see
Powder (Red Berry), 35 g sachets	1,398.60	30	1	TYR Sphere 20
Powder (Vanilla), 35 g sachets		30		TYR Sphere 20
Supplements for Organic Acidaemias				
AMINOACID FORMULA WITHOUT METHIONINE, THREONINE Hospital pharmacy [HP3]		cial Aı	uthority se	e SA2300 on page 285 –
Powder, 12.5 g sachets		30	-	MMA/PA Explore 5
Powder, 25 g sachets	1,048.95	30	•	MMA/PA Express 15
Supplements for Glutaric Aciduria type 1				
AMINOACID FORMULA WITHOUT LYSINE - Special Authority s				
Powder, 12.5 g sachets	349.65	30	v	GA Explore 5
Supplements for Glycogen Storage Disease				
HIGH AMYLOPECTIN CORN-STARCH – Special Authority see S Powder. 60 g sachets		– Hos 30		macy [HP3] Glycosade
Fowder, 60 g sachets	241.02	30	•	diycosade
Single dose amino acids				
ARGININE – Special Authority see SA2300 on page 285 – Hospit Powder, 4 g sachets	211.45	30	•	Arginine2000
CITRULLINE – Special Authority see SA2300 on page 285 – Hos Powder, 4 g sachets] 30	~ (Citrulline1000
ISOLEUCINE – Special Authority see SA2300 on page 285 – Hos Powder, 4 g sachets		3] 30	✓	Isoleucine50
LEUCINE – Special Authority see SA2300 on page 285 – Hospita Powder, 4 g sachets		30	✓	Leucine100
PHENYLALANINE – Special Authority see SA2300 on page 285 - Powder, 4 g sachets		[HP3] 30		Phenylalanine50
TYROSINE – Special Authority see SA2300 on page 285 – Hospi Powder, 4 g sachets		30	1	Tyrosine1000
VALINE – Special Authority see SA2300 on page 285 – Hospital Powder, 4 g sachets		30	~	Valine50

S	Subsidy		Fully	Brand or
(Manufa	cturer's Price)	Sub	sidised	Generic
	\$	Per	1	Manufact

Generic Manufacturer

Infant Formulae

For Williams Syndrome

⇒SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 vear where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see	SA1110 above – Ho	spital pharmad	y [HP3]
Powder		400 g OP	 Locasol

Gastrointestinal and Other Malabsorptive Problems

AMINO ACID FORMULA - Special Authority see SA2092 below - Hospital phan	macy [HP3]	
Powder	400 g OP	 ✓ Alfamino ✓ Alfamino Junior
Powder (unflavoured)55.61	400 g OP	 Neocate Gold Neocate Junior Unflavoured
65.72		 ✓ Neocate SYNEO ✓ Elecare ✓ Elecare LCP
Powder (vanilla)55.61	400 g OP	 Neocate Junior Vanilla
65.72		 Elecare

■ SA2092 Special Authority for Subsidy

Initial application — (Infants under 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 History of anaphylaxis to cow's milk protein formula or dairy products; or
- 2 Eosinophilic oesophagitis: or
- 3 Ultra-short gut; or
- 4 Severe Immune deficiency: or
- 5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
- 6 Both:
 - 6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and

6.2 Fither:

- 6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
- 6.2.2 Patient has IgE mediated allergy.

Initial application — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric

continued...

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsid	ised	Generic
\$	Per	✓	

immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Fither:

- 1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or
- 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
- 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 2.6.2.2 Patient has IgE mediated allergy.

Renewal — (Infants up to 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has IgE mediated allergy; and
 - 1.2 All of the following:
 - 1.2.1 Patient remains allergic to cow's milk; and
 - 1.2.2 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy or extensively hydrolysed infant formula has been undertaken; and
 - 1.2.3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 1.2.4 Amino acid formula is required for a nutritional deficit; and
 - 1.2.5 It has been more than three months from the previous approval; or
- 2 Both:
 - 2.1 Patient has non IgE mediated severe gastrointestinal intolerance (including eosinophilic oesophagitis, ultra-short gut and severe immune deficiency); and
 - 2.2 All of the following:
 - 2.2.1 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
 - 2.2.2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 2.2.3 Amino acid formula is required for a nutritional deficit; and
 - 2.2.4 It has been more than three months from the previous approval.

Renewal — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or

Subsidy	Fully Subsidised		Brand or	
(Manufacturer's Price)			Generic	
\$	Per	✓	Manufacturer	

- 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
- 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 2.6.2.2 Patient has IgE mediated allergy.

Initial application — (for patients who have a current funding under Special Authority form SA1557) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a valid Special Authority approval for extensively hydrolysed formula (SA1557); and
- 2 Extensively hydrolysed formula (Aptamil Gold+ Pepti Junior, AllerPro SYNEO 1 and 2) is unable to be supplied at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Special Authority form SA1557. There is no renewal criteria under this restriction.

ENTERAL LIQUID PEPTIDE FORMULA	 Special Authority see SA1953 below 	 Hospital pharm 	nacy [HP3]
Linuial di Longi /mai	10.14		All student Dariet

Liquid 1 kcal/ml	12.44	500 ml OP	Nutrini Peptisorb
Liquid 1.5 kcal/ml	18.66	500 ml OP	 Nutrini Peptisorb
			Energy

⇒SA1953 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
- 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or

2.10 Both:

2.10.1 The patient is currently receiving funded amino acid formula; and

continued...

Subsidy	Fully		Brand or
(Manufacturer's Price)	Price) Subsidised		Generic
 \$	Per	1	

- 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula; and
- 3 General practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

EXTENSIVELY HYDROLYSED FORMULA	- Special Authority see SA1557 be	low – Hospital pl	narmacy [HP3]
Powder		450 g OP	 Pepti-Junior
	36.20	900 g OP	 Allerpro Syneo 1
		-	Allerpro Syneo 2

⇒SA1557 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 All of the following:
 - 11.1 For step down from Amino Acid Formula; and
 - 11.2 The infant is currently receiving funded amino acid formula; and
 - 11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
 - 11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Fluid Restricted

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML	- Special Authority see SA1698	below	– Hospita	al pharmacy [HP3]
Liquid				 Infatrini

⇒SA1698 Special Authority for Subsidy

Initial application only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
- 2 Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
- 2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

➡SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA - S	pecial Authority see SA1197	above - Retail	pharmacy
Powder (unflavoured)		300 g OP	 KetoCal 4:1
			 Ketocal 3:1
Powder (vanilla)		300 g OP	 KetoCal 4:1

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
Vaccinations			
 BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm] For infants at increased risk of tuberculosis. Increased risk i 1) living in a house or family with a person with current or 2) having one or more household members or carers who equal to 40 per 100,000 for 6 months or longer; or 3) during their first 5 years will be living 3 months or longer Note a list of countries with high rates of TB are available at www.bcgatlas.org/index.php. Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent 	past history of TB; or within the last 5 year er in a country with a r www.health.govt.nz/tu	rs lived in a count ate of TB > or eq uberculosis (sear	ual to 40 per 100,000
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE a) Only on a prescription b) No patient co-payment payable c)			
 A) Funded for any of the following criteria: A single dose for pregnant women in the sect A single dose for parents or primary caregiver Specialist Care Baby Unit for more than 3 day 14 days prior to birth; or A course of up to four doses is funded for chil full primary immunisation; or An additional four doses (as appropriate) are stem cell transplantation or chemotherapy; pr dialysis and other severely immunosuppressi A single dose for vaccination of patients aged A single dose for vaccination of patients aged For vaccination of previously unimmunised or For revaccination following immunosuppressi For the patients with tetanus-prone w Notes: Please refer to the Immunisation Handbool Contractors will be entitled to claim payment from the vaccine to patients eligible under the above criteria for subsidised immunisation, and they may only do listed in the Pharmaceutical Schedule. Contractors may only claim for patient populations a sub-set of the population described in paragraphs Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous 	rs of infants admitted t vs, who had not been dren from age 7 up to funded for (re-)immun e or post splenectomy ve regimens; or from 65 years old; or from 45 years old wh partially immunised p on; or bounds. a for appropriate scheo he Funder for the sup pursuant to their cont so in respect of the di within the criteria that	to a Neonatal Inte exposed to mate the age of 18 ye isation for patien r; pre- or post sol to have not had 4 vatients; or dule for catch up ply of diphtheria, tract with Health I iphtheria, tetanus	nsive Care Unit or rnal vaccination at least ars inclusive to complete ts post haematopoietic id organ transplant, renal previous tetanus doses; or programmes. tetanus and pertussis New Zealand (Health NZ) and pertussis vaccine

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c) A) Funded for any of the following:
 - 1) A single dose for children up to the age of 7 who have completed primary immunisation; or
 - A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
 - 3) An additional four doses (as appropriate) are funded for (re-)immunisation for people post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
 - 4) Five doses will be funded for children requiring solid organ transplantation.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis and polio vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis and polio vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg

pertussis toxoid, 25 mcg pertussis filamentous

haemagglutinin, 8 mcg pertactin and 80 D-antigen units

poliomyelitis virus in 0.5ml syringe0.00 10

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE

a) Only on a prescription

I

- b) No patient co-payment payable
- c) A) Funded for children meeting any of the following criteria
 - 1) Up to four doses for children up to and under the age of 10 for primary immunisation; or
 - 2) An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
 - 3) Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

nj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg		
pertussis toxoid, 25 mcg pertussis filamentous		
haemagglutinin, 8 mcg pertactin, 80 D-Ag U polio virus,		
10 mcg hepatitis B surface antigen in 0.5 ml syringe0.00	10	Infanrix-hexa

	Subsidy	Fully	Brand or
	(Manufacturer's Price) \$	Subsidised Per ✓	Generic Manufacturer
HAEMOPHILUS INFLUENZAE TYPE B VACCINE			
a) Only on a prescription			
b) No patient co-payment payable			
c) A) One dose for people meeting any of the followin	g:		
1) For primary vaccination in children; or	•		
2) An additional dose (as appropriate) is fund	led for (re-)immunisatio	n for people pos	t haematopoietic stem cell
transplantation, or chemotherapy; function	al asplenic; pre or post	splenectomy; p	re- or post solid organ
transplant, pre or post cochlear implants, r	enal dialysis and other	severely immun	osuppressive regimens; or
For use in testing for primary immunodefic	iency diseases, on the	recommendation	n of an internal medicine
physician or paediatrician.			
 B) Contractors will be entitled to claim payment from 			
vaccine to people eligible under the above criter			
for subsidised immunisation, and they may only listed in the Pharmaceutical Schedule.	do so in respect of the	Haemophilus in	nuenzae type o vaccine
C) Contractors may only claim for populations withi	n the criteria that are co	overed by their c	contract which may be a
sub-set of the population described in paragraph			onitiaet, which may be a
	Trabove.		
Haemophilus Influenzae type B polysaccharide 10 mcg			
conjugated to tetanus toxoid as carrier protein 20-40 m	cg;		
prefilled syringe plus vial 0.5 ml	0.00	1 🖌	Hiberix
HEPATITIS A VACCINE – [Xpharm]			
Funded for patients meeting any of the following criteria:			
1) Two vaccinations for use in transplant patients; or			
2) Two vaccinations for use in children with chronic liver	disease; or		
3) One dose of vaccine for close contacts of known hepa	atitis A cases.		
Inj 1440 ELISA units in 1 ml syringe	0.00	1 🖌	Havrix

Inj 1440 ELISA units in 1 mi syringe	0.00	1	• Havrix
Inj 720 ELISA units in 0.5 ml syringe	0.00	1	 Havrix Junior

	Subsidy	0	Fully	Brand or
	(Manufacturer's Price) \$	Per	sidised	Generic Manufacturer
	Ψ	1.01	-	Manalastaron
HEPATITIS B RECOMBINANT VACCINE – [Xpharm]	0.00			n martin D
Inj 10 mcg per 0.5 ml prefilled syringe		1	♥ E	ngerix-B
Funded for patients meeting any of the following criteria:				
 for household or sexual contacts of known acute h 				s; or
for children born to mothers who are hepatitis B su				
for children up to and under the age of 18 years in				achieved a positive
serology and require additional vaccination or requ	ire a primary course c	of vaccina	tion; or	
for HIV positive patients; or				
5) for hepatitis C positive patients; or				
for patients following non-consensual sexual intercontent	ourse; or			
for patients following immunosuppression; or				
for solid organ transplant patients; or				
for post-haematopoietic stem cell transplant (HSC⁻	Γ) patients; or			
following needle stick injury.				
Inj 20 mcg per 1 ml prefilled syringe		1	✓ <u>E</u>	ngerix-B
Funded for patients meeting any of the following criteria:				
 for household or sexual contacts of known acute h 				s; or
for children born to mothers who are hepatitis B su				
for children up to and under the age of 18 years in				achieved a positive
serology and require additional vaccination or requ	ire a primary course c	of vaccina	tion; or	
for HIV positive patients; or				
for hepatitis C positive patients; or				
for patients following non-consensual sexual intercontent	ourse; or			
for patients following immunosuppression; or				
8) for solid organ transplant patients; or				
9) for post-haematopoietic stem cell transplant (HSC	F) patients; or			
10) following needle stick injury; or				
11) for dialysis patients; or				
12) for liver or kidney transplant patients.				
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 5	8) VACCINE [HPV]			
 Maximum of 1 inj per prescription 				
 b) Only on a prescription 				
 No patient co-payment payable 				
d)				
 A) Any of the following: 				
 Maximum of two doses for children aged 				
Maximum of three doses for patients me		ring criteri	a:	
 People aged 15 to 26 years inclusion 	ve; or			
2) Either:				
People aged 9 to 26 years inclusiv	e			
 Confirmed HIV infection; or 				
2) Transplant (including stem ce				
3) Maximum of four doses for people aged				
 B) Contractors will be entitled to claim payment f 				
to patients eligible under the above criteria pu				()
subsidised immunisation, and they may only o	to so in respect of the	Human p	apilloma	avirus vaccine listed in the
Pharmaceutical Schedule.				
C) Contractors may only claim for patient populat			covered	by their contract, which
may be a sub-set of the population described				
Inj 270 mcg in 0.5 ml syringe	0.00	10	✓ <u>G</u>	ardasil 9

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
INFLUENZA VACCINE Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)		10	✔ Ir	nfluvac Tetra (2024 formulation)

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

- a) Maximum of 1 inj per prescription
- b) Only on a prescription
- c) No patient co-payment payable
- d)

A) INFLUENZA VACCINE

is available each year for patients who meet the following criteria, as set by Pharmac:

- a) all people 65 years of age and over; or
- b) people under 65 years of age who:
 - i) have any of the following cardiovascular diseases:
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebo-vascular disease; or
 - ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
 - iii) have diabetes; or
 - iv) have chronic renal disease; or
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) Down syndrome, or
 - vii) are pregnant; or
- c) children 4 years of age and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or
- d) people under 65 years of age who:
 - i) have any of the following serious mental health conditions:
 - a) schizophrenia, or
 - b) major depressive disorder, or
 - c) bipolar disorder, or
 - d) schizoaffective disorder, or
 - ii) are currently accessing secondary or tertiary mental health and addiction services; or

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

MEASLES, MUMPS AND RUBELLA VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- C)

A) Measles, mumps and rubella vaccine

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella; or
- 4) A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes. Although a price is listed for the vaccine, doctors can still order measles mumps and rubella vaccine free of charge, as with other Schedule vaccines.

- B) Contractors will be entitled to claim payment for the supply of measles, mumps and rubella vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the measles, mumps and rubella vaccine listed in the Pharmaceutical Schedule.
- C) Contractors can only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.
- Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50,

10 Y Priorix

MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- C)
- A) Any of the following:
 - Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
 - 2) One dose for close contacts of meningococcal cases of any group; or
 - 3) One dose for person who has previously had meningococcal disease of any group; or
 - 4) A maximum of two doses for bone marrow transplant patients; or
 - 5) A maximum of two doses for person pre- and post-immunosuppression*; or
- B) Both:
 - 1) Person is aged between 13 and 25 years, inclusive; and
 - 2) Either:
 - One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences, or prisons; or
 - 2) One dose for individuals who turn 13 years of age while living in boarding school hostels.
- C) Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal A, C, Y and W-135 vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal A, C, Y and W-135 vaccine listed in the Pharmaceutical Schedule.
- D) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-B above.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days. Ini 10 mcg of each meningococcal polysaccharide conjugated

300

Sub	sidy	Fully I	Brand or
(Manufactu	irer's Price) Su	ubsidised (Generic
	B Per	 I 	Manufacturer

MENINGOCOCCAL B MULTICOMPONENT VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c) Any of the following:
 - A) Three doses for children up to 12 months of age (inclusive) for primary immunisation; or
 - B) Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to
 - 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025; or
 - C) Both:
 - 1) Person is one year of age or over; and
 - 2) Any of the following:
 - i) up to two doces and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
 - ii) up to two doses for close contacts of meningococcal cases of any group; or
 - iii) up to two doses for person who has previously had meningococcal disease of any group; or
 - iv) up to two doses for bone marrow transplant patients; or
 - v) up to two doses for person pre- and post-immunosuppression*; or
 - D) Both:
 - 1) Person is aged between 13 and 25 years (inclusive); and
 - 2) Either:
 - Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences or prisons; or
 - ii) Two doses for individuals who turn 13 years of age while living in boarding school hostels.
 - E) Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal B multicomponent vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal B multicomponent vaccine listed in the Pharmaceutical Schedule.
 - F) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-D above.

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 175 mcg per 0.5 ml prefilled syringe	0.00	1	 Bexsero
		10	Bexsero

MENINGOCOCCAL C CONJUGATE VACCINE - [Xpharm]

Both:

- 1) The child is under 12 months of age; and
- 2) Any of the following:
 - 1) Up to three doses for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
 - 2) Two doses for close contacts of meningococcal cases of any group; or
 - 3) Two doses for child who has previously had meningococcal disease of any group; or
 - 4) A maximum of two doses for bone marrow transplant patients; or
 - 5) A maximum of two doses for child pre- and post-immunosuppression*.

Note: children under 12 months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 10 mcg in 0.5 ml syringe......0.00 1 🗸 Neisvac-C

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE - [Xpha	rm]			
1) A primary course of three doses for previously unvace	cinated individuals up to	the age o	of 59 m	onths inclusive
Note: please refer to the Immunisation Handbook for the a	ppropriate schedule for	catch up	prograr	nmes
Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5,	6B,			
7F, 9V, 14 and 23F; 3 mcg of pneumococcal				
polysaccharide serotypes 4, 18C and 19F in 0.5 ml				
prefilled syringe	0.00	10	🗸 🗸 S	vnflorix

Subsidy Fu Manufacturer's Price) Subsidis		Brand or Generic
\$	Per 🗸	Manufacturer

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c) A) Any of the following:
 - 1) A course of three doses for previously unvaccinated children up to the age of 59 months inclusive; or
 - Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10; or
 - 3) Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high risk children aged under 5 years with any of the following:
 - a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - b) primary immune deficiencies; or
 - c) HIV infection; or
 - d) renal failure, or nephrotic syndrome; or
 - e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - f) cochlear implants or intracranial shunts; or
 - g) cerebrospinal fluid leaks; or
 - receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - i) chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - j) pre term infants, born before 28 weeks gestation; or
 - k) cardiac disease, with cyanosis or failure; or
 - I) diabetes; or
 - m) Down syndrome; or
 - n) who are pre-or post-splenectomy, or with functional asplenia; or
 - 4) Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency; or
 - 5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Pneumococcal (PCV13) conjugate vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Pneumococcal (PCV13) conjugate vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4,

5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml		
syringe0.00	10	Prevenar 13
	1	Prevenar 13

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Either:	[Xpharm]		
 Up to three doses (as appropriate) for patients with HI chemotherapy; pre- or post-splenectomy or with functi complement deficiency (acquired or inherited), cochle All of the following: 	onal asplenia, pre- or p	oost-solid organ t	ransplant, renal dialysis,
a) Patient is a child under 18 years for (re-)immunisb) Treatment is for a maximum of two doses; andc) Any of the following:	sation; and		
 i) on immunosuppressive therapy or radiation immune response; or ii) with primary immune deficiencies; or iii) with HIV infection; or iv) with renal failure, or nephrotic syndrome; ov who are immune-suppressed following org 	r		
or vi) with cochlear implants or intracranial shunt vii) with cerebrospinal fluid leaks; or viii) receiving corticosteroid therapy for more th prednisone of 2 mg/kg per day or greater, v 20 mg or greater; or	an two weeks, and wh		
 ix) with chronic pulmonary disease (including x) pre term infants, born before 28 weeks ges xi) with cardiac disease, with cyanosis or failu xii) with diabetes; or xiii) with Down syndrome; or xiv) who are pre-or post-splenectomy, or with finance 	tation; or re; or	gh-dose corticost	eroid therapy); or
Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) POLIOMYELITIS VACCINE – [Xpharm] Up to three doses for patients meeting either of the following 1) For partially vaccinated or previously unvaccinated ind 2) For revaccination following immunosuppression. Note: Please refer to the Immunisation Handbook for appro Inj 80D antigen units in 0.5 ml syringe	g: lividuals; or ppriate schedule for cat	_	

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	✓	Manufacturer	

ROTAVIRUS ORAL VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c) A) Maximum of two doses for people meeting the following:
 - 1) first dose to be administered in infants aged under 14 weeks of age; and
 - 2) no vaccination being administered to children aged 24 weeks or over.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Rotavirus oral vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Rotavirus oral vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Oral susp live attenuated human rotavirus			
1,000,000 CCID50 per dose, squeezable tube	0.00	10	 Rotarix
Oral susp live attenuated human rotavirus			
1,000,000 CCID50 per dose, prefilled oral applicator	0.00	10	 Rotarix

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	Subsidised	Generic	
\$	Per	~	Manufacturer	

VARICELLA VACCINE [CHICKENPOX VACCINE]

- a) Only on a prescription
- b) No patient co-payment payable
- c) A) Either:
 - 1) Maximum of one dose for primary vaccination for either:
 - a) Any infant born on or after 1 April 2016; or
 - b) For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox), or
 - 2) Maximum of two doses for any of the following:
 - a) Any of the following for non-immune individuals:
 - i) with chronic liver disease who may in future be candidates for transplantation; or
 - ii) with deteriorating renal function before transplantation; or
 - iii) prior to solid organ transplant; or
 - iv) prior to any elective immunosuppression*; or
 - v) for post exposure prophylaxis who are immune competent inpatients; or
 - b) For individuals at least 2 years after bone marrow transplantation, on advice of their specialist; or
 - c) For individuals at least 6 months after completion of chemotherapy, on advice of their specialist; or
 - For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
 - e) For individuals with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
 - f) For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
 - g) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Varicella vaccine [Chickenpox vaccine] vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Varicella vaccine [Chickenpox vaccine] listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A above.

* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Inj 1350 PFU prefilled syringe	0.0
--------------------------------	-----

✓	Varivax
✓	Varivax

1

10

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE]

- a) Only on a prescription
- b) No patient co-payment payable
- C)
- A) Funded for patients meeting the following criteria:
 - 1) Two doses for all people aged 65 years
- B) Contractors will be entitled to claim payment from the Funder for the supply of Varicella zoster vaccine (Shingles vaccine) to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Varicella zoster vaccine [Shingles vaccine] listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Inj 50 mcg per 0.5 ml vial plus vial	0.00	1	 Shingrix
		10	 Shingrix

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
Diagnostic Agents				
TUBERCULIN PPD [MANTOUX] TEST – [Xpharm] Inj 5 TU per 0.1 ml, 1 ml vial	0.00	1	✓ <u>⊺</u>	ubersol

- Symbols -

3TC112
3TC112 7 MED NSHA Silver/Copper
Short
- A -
A-Scabies
Abacavir sulphate
Abacavir sulphate with
lamivudine 112
Abacavir/Lamivudine Viatris
Abilify Maintena
Abiraterone acetate 173
Acarbose11
Accarb
Accuretic 1047
Accuretic 2047
Acetazolamide262
Acetec46
Acetic acid with hydroxyquinoline and
ricinoleic acid
Acetylcysteine
Aci-Jel81
Aciclovir
Infection107
Sensory260
Acidex
Acipimox54
Acitretin74
Actemra
Actinomycin D160
Actrapid10
Actrapid Penfill10
Acupan
Adalimumab (Amgevita)
Adalimumab (Humira - Alternative
brand) 192
Adapalene
Adapaiene
ADR Cartridge 1.823
Adrenaline Cardiovascular
Respiratory
Advantan
Advate
Adynovate
Afinitor
Aflibercept199
AFT-Pyrazinamide106
After Hours Med Mgmt 15 min 265
After Hours Med Mgmt 30 min 265
After Hours Med Mgmt 45 min 265
Agents Affecting the
Renin-Angiotensin System 46
Agents for Parkinsonism and Related

Disorders Agents Used in the Treatment of	. 123
Agents Used in the Treatment of	
Poisonings	. 265
Agrylin	159
Albendazole	95
Albey249	-250
Albustix	83
Alchemy Oxaliplatin	155
Alchemy Oxybutynin	83
Aldurazyme	28
Alecensa	167
Alectinib	167
Alendronate sodium	117
Alendronate sodium with	
colecalciferol	. 117
Alfacalcidol	
Alfamino	289
Alfamino Junior	
Alginic acid	6
Alglucosidase alfa	26
Alkeran	155
Alkeran S29	
Allerfix	262
Allerpro Syneo 1	292
Allerpro Syneo 2	
Allersoothe	250
Allmercap	
Allopurinol	
Alpha-Adrenoceptor Blockers	46
Alpha-Keri Lotion	72
Alphamox	98
Alphamox 125	98
Alphamox 250	
Alprolix	
Alu-Tab	
Aluminium hydroxide	6
Alvogen	50
Amantadine hydrochloride	123
Ambrisentan	57
Ambrisentan Viatris	57
Amgevita	184
Amiloride hydrochloride	52
Amiloride hydrochloride with	
furosemide	53
Amilarida hydrochlarida with	
hydrochlorothiazide	53
Aminophylline Amiodarone hydrochloride	256
Amiodarone hydrochloride	48
Amisulpride	
Amitriptyline	129
Amlodipine	
Amorolfine	
Amoxicillin	
Amoxicillin with clavulanic acid	<mark>98</mark>

Amphotericin B	32
Amsacrine	. 159
AmsaLyo	. 159
Amsidine	. 159
Amzoate	30
Anaesthetics	. 124
Anafranil	. 129
Anafranil Anagrelide hydrochloride	. 159
Analgesics	. 125
Anastrozole	. 176
Anatrole	. 176
Androderm	86
Anoro Ellipta	.254
Antabuse	. 151
Antacids and Antiflatulents	6
Anthelmintics	95
Antiacne Preparations	68
Antiallergy Preparations	249
Antianaemics	
Antiandrogen Oral	
Contraceptives	81
Antiarrhythmics	
Antibacterials	95
Antibacterials Topical	
Anticholinergic Agents	
Anticholinesterases	116
Antidepressants	129
Antidiarrhoeals	
Antiepilepsy Drugs	121
Antifibrinolytics, Haemostatics and	
Local Sclerosants	37
Antifibrotics	255
Antifungals	102
Antifungals Topical	60
Antihistamines	250
Antihypotensives	<u>200</u>
Antimalarials	104
Antimigraine Preparations	134
Antinausea and Vertigo Agents	134
Antipruritic Preparations	70
Antipsychotics	136
Antiretrovirals	110
Antirheumatoid Agents	117
Antispasmodics and Other Agents	
Altering Gut Motility	8
Antithrombotic Agents	40
Апшинопроце Адения	40
Antithymocyte alohulin	18/
Antithymocyte globulin	104
(equine)	
(equine) Antitrichomonal Agents	
(equine) Antitrichomonal Agents Antituberculotics and	105
(equine) Antitrichomonal Agents Antituberculotics and Antileprotics	
(equine) Antitrichomonal Agents Antituberculotics and Antileprotics Antiulcerants	9
(equine) Antitrichomonal Agents Antituberculotics and Antileprotics	9 107

Anxiolytics140
Anzatax
Apidra
Apidra SoloStar11
APO-Atomoxetine 145
APO-Atomoxetine S29 145
Apo-Azithromycin
Apo-Bicalutamide 174
APO-Candesartan HCTZ
16/12.5
APO-Candesartan HCTZ
32/12.5
Apo-Temozolomide 165
Apo-Terbinafine 104
Apomorphine hydrochloride123
Aprepitant134
Apresoline57
Aptamil Feed Thickener284
Aqueous cream72
Aratac
Arava117
Arginine
Arginine2000
Aripiprazole136–137
Aripiprazole Sandoz
Aristocort
Arrotex-Prazosin S29
Arrow - Clopid
Arrow - Lattim
Arrow-Amitriptyline
Arrow-Bendrofluazide
Arrow-Brimonidine
Arrow-Diazepam
Arrow-Doxorubicin
Arrow-Fluoxetine
Arrow-Losartan & Hydrochlorothiazide
Hydrochlorothlazide
Arrow-Norfloxacin
Arrow-Ornidazole
Arrow-Quinapril 1047
Arrow-Quinapril 2047
Arrow-Quinapril 547
Arrow-Roxithromycin
Arrow-Timolol
Arrow-Topiramate133
Arrow-Tramadol129
Arsenic trioxide 159
Asacol7
Asacol S297
Ascend Aripiprazole136
Ascend-Cefuroxime
Ascorbic acid32
Aspen Adrenaline56
Aspirin
Blood40
Nervous125

Asthalin253
Atazanavir Mylan 112
Atazanavir sulphate 112
Atazanavir Viatris112
Atenolol
Atenolol AFT
Atenolol AFT S29
Atenolol Viatris
Atezolizumab
ATGAM
Ativan
Atnahs Olsalazine
Atomoxetine
Atorvastatin
Atropine sulphate
Cardiovascular
Sensory263
Atropt
Atrovent
Aubagio141
Augmentin
Aurorix
AutoSoft 3023
AutoSoft 9023
Avallon126
Avelox100
Avonex141
Avonex Pen 141
Azacitidine
Azacitidine Dr Reddy's 155
Azamun
Azathioprine
Azilect
Azithromycin
Azopt
AZOpt
-B-
- р - B-D Micro-Fine15
B-D Ultra Fine
B-D Ultra Fine II16 Bacillus Calmette-Guerin (BCG)
Bacilius Calmette-Guerin (BCG)
vaccine
Bacillus Calmette-Guerin
vaccine
Baclofen121
Bactroban68
Balance
Barrier Creams and Emollients71
BCG Vaccine 294
Beclazone 100251
Beclazone 250251
Beclazone 50251
Beclomethasone dipropionate
Bedaquiline105
Bee venom allergy treatment249
Bendamustine hydrochloride 153
•

Bendrofluazide	53
Bendroflumethiazide	
[Bendrofluazide]	
Benralizumab	
Benzathine benzylpenicillin	
Benzatropine mesylate	123
Benzbromaron AL 100	120
Benzbromarone	
Benztrop	
Benzydamine hydrochloride	31
Benzylpenicillin sodium [Penicillin	
G]	
Beta Cream	
Beta Ointment	
Beta Scalp	76
Beta-Adrenoceptor Agonists	252
Beta-Adrenoceptor Blockers	49
Betadine	73
Betadine Skin Prep	73
Betaferon	141
Betahistine dihydrochloride	134
Betaine	
Betamethasone dipropionate	70
Betamethasone dipropionate with	
calcipotriol	74
Betamethasone sodium phosphat	е
with betamethasone acetate	85
Betamethasone valerate	70, 76
Betamethasone valerate with sodi	um
fusidate [fusidic acid]	71
fusidate [fusidic acid] Betaxolol	71 262
fusidate [fusidic acid] Betaxolol Betnovate	71 262 70
fusidate [fusidic acid] Betaxolol Betnovate Betoptic	71 262 70 262
fusidate [fusidic acid] Betaxolol Betnovate Betoptic Betoptic S	71 262 70 262 262
fusidate [fusidic acid] Betaxolol Betnovate Betoptic Betoptic S Bexsero	71 262 70 262 262 301
fusidate [fusidic acid] Betaxolol Betnovate Betoptic Betoptic S Bexsero Bezafibrate	71 262 70 262 262 301 54
fusidate [fusidic acid] Betaxolol Betnovate Betoptic Betoptic S Bexsero Bezafibrate Bezalip	71 262 70 262 262 301 54 54
fusidate [fusidic acid] Betaxolol Betoptic. Betoptic S Bexsero Bezafibrate Bezalip. Bezalip Retard.	71 262 70 262 262 301 54 54 54
fusidate [fusidic acid] Betaxolol Betoptic. Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide	71 262 70 262 262 301 54 54 54 54
fusidate [fusidic acid] Betaxolol Betoptic. Betoptic S Bexsero Bezafibrate Bezalip Retard. Bicalutamide Bicillin LA	71 262 70 262 301 54 54 54 174 98
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicillin LA BiCNU	71 262 70 262 301 54 54 54 174 98 154
fusidate [fusidic acid] Betaxolol Betnovate Betoptic. Betoptic S Bezafibrate Bezalip Retard Bicalutamide Bicalutamide BicNU Bile and Liver Therapy	71 70 262 262 301 54 54 174 98 154 10
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicillin LA BiCNU Bile and Liver Therapy Biltricide	71 262 262 262 301 54 54 54 174 98 154 95
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicillin LA Bile and Liver Therapy Biltricide Bimatoprost	71 262 262 262 301 54 54 54 174 98 154 10 95 95 952
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicillin LA Bile and Liver Therapy Biltricide Bimatoprost Multichem	71 262 70 262 301 54 54 54 174 98 154 98 154 95 262 262
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bezafibrate Bezalip Bezalip Bezalip Bezalip Bezalip Bezalip Bezalip Bezalip Bezalip Bezalip Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bitricide Bimatoprost Bimatoprost Multichem Binarex	71 262 70 262 301 54 54 54 54 174 98 154 95 262 262 262 174
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bezafibrate Bezalip. Bezalip Retard Bicalutamide Bicillin LA Bile and Liver Therapy Biltricide Bimatoprost Multichem Binarex Binocrit	71 262 70 262 301 54 54 54 54 174 98 154 95 262 262 262 262 262 301
fusidate [fusidic acid]BetaxololBetopticBetoptic SBetoptic SBexseroBezafibrateBezalip.RetardBicalutamideBicalutamideBicNUBile and Liver TherapyBiltricideBimatoprost MultichemBinarexBinocritBiodone	
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bezafibrate Bezalip Bezalip Bezalip Retard Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Binarex Binarex Binocrit Biodone Biodone Extra Forte	
fusidate [fusidic acid] Betaxolol Betoptic. Betoptic S Bexsero Bezafibrate Bezalip Retard. Bicalutamide Bicillin LA BiCNU. Bile and Liver Therapy. Biltricide Bimatoprost Bimatoprost Multichem Binarex Biodone Extra Forte. Biodone Forte	
fusidate [fusidic acid]Betaxolol Betaxolol Betoptic Betoptic S Bezafibrate Bezafibrate Bezalip Retard Bicalutamide Bicalutamide Bicalutamide BicNU Bile and Liver Therapy Biltricide Bimatoprost Multichem Binatoprost Multichem Binarex Biodone Biodone Extra Forte Biodone Forte Bisacodyl	
fusidate [fusidic acid]Betaxolol Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicalutamide Bicalutamide BicAlutamide Binacon Biodone Extra Forte Bisacodyl Bisacodyl Viatris	
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bisacodyl Bisacodyl Viatris Bisoprolol fumarate	
fusidate [fusidic acid]Betaxolol Betaxolol Betoptic Betoptic S Bezafibrate Bezafibrate Bezalip Retard Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bile and Liver Therapy Bile and Liver Therapy Binatoprost Binatoprost Biodone Extra Forte Bisacodyl Viatris Bisoprolol fumarate BK Lotion	
fusidate [fusidic acid] Betaxolol Betoptic Betoptic S Bexsero Bezafibrate Bezalip Retard Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bicalutamide Bisacodyl Bisacodyl Viatris Bisoprolol fumarate	

Factors43
Blood glucose diagnostic test
meter 14
Blood glucose diagnostic test
strip
Blood glucose test strips (visually
impaired)15
Blood Ketone Diagnostic Test
Strip 13
Sup
Bonjela
Bortezomib
Bosentan60
Bosentan Dr Reddy's60
Bplex
Brentuximab Vedotin
Breo Ellipta252
Brevinor 1/28 80
Brevinor-1 28 Day80
Bricanyl Turbuhaler253
Brilinta40
Brimonidine tartrate263
Brimonidine tartrate with timolol
maleate 263
Brinzolamide262
Brown & Burk 130
Brufen SR 116
BSF Max Health265
BSF Methylphenidate ER -
Teva
BSF Noumed Dexamfetamine
Buccastem135
Budesonide
Alimentary
Respiratory251, 258
Budesonide Te Arai
Budesonide with eformoterol
Bumetanide
Buprenorphine Naloxone BNM 150
Buprenorphine with naloxone
Bupropion hydrochloride
Burel
Burinex
Burinex S29
Buscopan
Buspirone hydrochloride140
Buspirone Viatris140
Busulfan154
- C - Cabergoline93
Caffeine citrate
Calamine
Calci-Tab 500
Calcipotriol
Calcitonin
Calcitriol

Calcitriol-AFT	33
Calcium 500 mg Hexal	34
Calcium carbonate6,	34
Calcium carbonate PAI	. 6
Calcium Channel Blockers	51
Calcium Disodium Versenate	967
Calcium folinate 1	
Calcium Folinate Ebewe1	56
Calcium Folinate Sandoz1	56
Calcium Folinate Sandoz S29	
Calcium gluconate	
Calcium Homeostasis	84
Calcium polystyrene sulphonate	
Calcium Resonium	44
Calogen	
Camber	
Camino Pro Bettermilk2	987
Candesartan cilexetil	47
Candesartan cilexetil with	
hydrochlorothiazide	47
Candestar	47
Canesten	
Capecitabine1	
Capecitabine Viatris1	
Capsaicin	00
Musculoskeletal1	17
Nervous1	
Captopril	
Carafate	10
Carbaccord 1	
Carbamazepine1	
Carbimazole	
Carbomer	
Carboplatin 1	54
Carboplatin Ebewe 1	54
Carbosorb-X	880
Cardinol LA	
Cardizem CD	
CareSens Dual	14
CareSens N 14-	
CareSens N POP	14
CareSens N Premier	14
CareSens PRO	15
Carmellose sodium with gelatin and	10
pectin	31
Carmustine1	
Carnitor	
Carvedilol	
Carvedilol Sandoz	
Casirivimab and imdevimab	
Catapres1	52
Cofaclor monohydrato	55
Cefaclor monohydrate	55 95
Cefaclor monohydrate Cefalexin	55 95 95
Cefaclor monohydrate	55 95 95 95

	_
Cefazolin-AFT	95
Ceftriaxone	95
Ceftriaxone-AFT	
Cefuroxime axetil	95
Celapram 13	30
Celebrex11	16
Celecoxib11	
Celecoxib Pfizer11	16
Celestone Chronodose	35
Cellcept17	77
Centrally-Acting Agents	51
Cephalexin ABM	95
Cetirizine hydrochloride 25	50
Cetomacrogol	72
Cetomacrogol with glycerol	72
Cetomacrogol-AFT	72
Cetuximab20	
Charcoal	
Chemotherapeutic Agents 15	
Chickenpox vaccine)6
Chlorambucil15	54
Chloramphenicol26	
Chlorothiazide	
Chlorpheniramine maleate25	
Chlorpromazine hydrochloride13	36
Chlorsig	50
Chlortalidone [Chlorthalidone]	
Chlorthalidone	53
Chlorvescent	
Chlorvescent Choice 380 7med Nsha Silver/copper	14
Chlorvescent Choice 380 7med Nsha Silver/copper Short	14 79
Chlorvescent Choice 380 7med Nsha Silver/copper Short	14 79 79
Chlorvescent Choice 380 7med Nsha Silver/copper Short7 Choice Load 3757 Choice TT380 Short7	14 79 79 79
Chlorvescent Choice 380 7med Nsha Silver/copper Short	14 79 79 79
Chlorvescent Choice 380 7med Nsha Silver/copper Short	14 79 79 79 79
Chlorvescent Choice 380 7med Nsha Silver/copper Short	14 79 79 79 79
Chlorvescent	14 79 79 79 79 79 32
Chlorvescent	44 79 79 79 79 32 45
Chlorvescent	44 79 79 79 79 79 79 79 79 79 79 79 79 79
Chlorvescent	44 79 79 79 79 79 32 45 46 99 34
Chlorvescent	44 79 79 79 79 32 45 46 99 34
Chlorvescent	44 79 79 79 79 32 45 46 99 34
Chlorvescent	14 79 79 79 79 32 15 16 99 34 34 00
Chlorvescent	 44 79 <
Chlorvescent	14 79 79 79 32 15 16 99 34 34 00 00 60
Chlorvescent	14 79 79 79 79 32 15 16 99 34 34 00 50 50
Chlorvescent	14 79 79 79 79 32 15 16 99 34 34 00 50 00 50
Chlorvescent	14 79 70 70
Chlorvescent	14 79 79 79 79 325 469 340 500 500 500 545
Chlorvescent	14 79 79 79 79 79 325 469 345 39 345 345 345 345 345 345 345 345 345 345 345 345 345 345 345 345 345 346 346 347 348 349 340 350 350 354 354 357 358 359 350 350 350 350 350 350 350 350 350 350 350 350 350 350
Chlorvescent	144 79 79 79 79 32 15 6 99 34 15 6 99 34 46 99 34 46 99 93 4 45 60 00 00 00 00 00 00 00 00 00 00 00 00
Chlorvescent	144 79 79 79 79 32 15 6 99 34 15 6 99 34 46 99 34 46 99 93 4 45 60 00 00 00 00 00 00 00 00 00 00 00 00
Chlorvescent	14 79 79 79 79 32 15 60 99 34 34 00 00 00 00 00 00 00 00 00 00 00 00 00
Chlorvescent	14 79 79 79 79 32 15 6 99 34 34 00 00 00 00 00 00 00 00 00 00 00 00 00
Chlorvescent	14 79 79 79 32 15 16 99 34 34 30 00 00 00 00 00 00 00 00 00 00 00 00

Clexane Forte41
Climara87
Clindamycin100
Clinicians
Clinicians Renal Vit
Clobazam
Clobetasol propionate
Clobetasone butyrate
Clofazimine
Clomazol
Dermatological
Genito-Urinary81
Clomifene citrate94
Clomipramine - Teva 129
Clomipramine hydrochloride129
Clomipramine Teva 129
Clonazepam 131, 140
Clonidine
Clonidine hydrochloride
Clonidine Teva
Clopidogrel
Clopine
Clopixol
Clotrimazole
Dermatological
Genito-Urinary81
Clozapine
Clozaril
Clustran
Co-trimoxazole
Coal tar
Coal tar with allantoin, menthol,
phenol and sulphur75
Coal tar with salicylic acid and
sulphur75
Cobal-B12
Cobalin-H32
Coco-Scalp75
Codeine phosphate
Extemporaneous269
Nervous
Coenzyme Q1027
Colchicine
Colecalciferol
Colestid
Colestipol hydrochloride
Colestyramine
Colectivering Mulen E4
Colestyramine - Mylan
Colgout
Colifoam
Colistin sulphomethate
Colistin-Link100
Collodion flexible
Colloidal bismuth subcitrate9
Colofac8
Coloxyl

Combigan	263
Compliance Packaging	265
Compound electrolytes	. 44
Compound electrolytes with glucose	
[Dextrose]	. 44
Compound hydroxybenzoate	269
Comtan	
Concerta	
Condoms	78
Condyline	
Contraceptives - Hormonal	79
Contraceptives - Non-hormonal	77
Copaxone	
Cordarone-X	. 48
Corticosteroids and Related Agents	
for Systemic Use	. 85
Corticosteroids Topical	70
Cosentyx	
Cosmegen	
Coumadin	43
Country Life	
Coversyl	
Creon 10000	
Creon 25000	
Creon Micro	
Crotamiton	
Crystaderm	68
Curam	
Curam Duo 500/125	
Cvite	
Cyclizine hydrochloride	
Cyclizine lactate	
Cyclogyl	
Cyclonex	
Cyclopentolate hydrochloride	263
Cyclophosphamide	
Cyclorin	
Cycloserine	
Cyklokapron	
Cyproterone acetate	
Cyproterone acetate with	00
ethinyloestradiol	Q1
Cystadane	01
Cytarabine	156
Cytotec	
Cytoxan	
- D -	104
D-Penamine	117
	117
Dabigatran	
Dacarbazine Dacarbazine APP	100
Dactinomycin [Actinomycin D]	100
Daivobet	
Daivonex	
Daktarin	
Dalacin C	100

Dantrium 1	21
Dantrium S291	
Dantrolene 1	21
Daonil	11
Dapa-Tabs	53
Dapsone	06
Daraprim1	01
Darunavir1	13
Darunavir Viatris1	13
Dasatinib1	
Daunorubicin1	60
Daunorubicin Zentiva1	
David One Step Cassette Pregnancy	00
Test	80
DBL Adrenaline	56
DBL Aminophylline2	
DBL Bleomycin Sulfate1	
DBL Bortezomib1	
DBL Carboplatin1	04
DBL Cisplatin1	
DBL Dacarbazine1	60
DBL Desferrioxamine Mesylate for Inj	~~
BP2	
DBL Docetaxel1	60
DBL Ergometrine	81
DBL Gemcitabine1	5/
DBL Gentamicin1	00
DBL Heparin Sodium	42
DBL Leucovorin Calcium 1	56
DBL Methotrexate Onco-Vial1	
DBL Pethidine Hydrochloride1	28
DBL Vincristine Sulfate1	
Decozol	32
Deferasirox2	66
Deferiprone	66
Deferoxamine Pfizer S292	66
Denosumab1	17
Deolate 1	04
Deoxycoformycin 1	
Depo-Medrol	86
Depo-Provera	
Depo-Testosterone	86
Deprim 1	02
Dermol70,	76
Desferrioxamine mesilate2	
Desmopressin	93
Desmopressin acetate	
Desmopressin-PH&T	
Desuric1	20
Detection of Substances in	
Urine	83
Dexamethasone	
Hormone	85
Sensory2	
Dexamethasone phosphate	85
Dexamethasone with framycetin and	

gramicidin 260
Dexamethasone with neomycin
sulphate and polymyxin B
sulphate 261
Dexamfetamine sulfate
Dexmethsone
Dextrochlorpheniramine
maleate
Dextrose
DHC Continus127
Diabetes 10
Diabetes Management13
Diacomit133
Diagnostic Agents
Diamide Relief6
Diamox
Diasip274
Diazepam 131, 140
Diazoxide10
Dibenzyline
Diclofenac Sandoz116
Diclofenac sodium
Musculoskeletal
Sensory
Differin
Difflam
Diflucan
Digestives Including Enzymes
Digoxin
Dihydrocodeine tartrate 127
Dilantin132
Dilantin Infatab132
Dilantin Paediatric132
Diltiazem CD Clinect51
Diltiazem hydrochloride51
Dimethicone71, 73
Dimethyl fumarate 141
Dipentum8
Diphtheria, tetanus and pertussis
vaccine
Diphtheria, tetanus, pertussis and
polio vaccine
Diphtheria, tetanus, pertussis, polio,
hepatitis B and haemophilus
influenzae type B vaccine
Diprosone
Diprosone OV
Dipyridamole
Disopyramide phosphate
Disulfiram151
Diuretics
Docetaxel160
Docetaxel Accord 160
Docetaxel Sandoz 160
Docusate sodium24
Docusate sodium with

sennosides 25
Dolutegravir 113
Dolutegravir with lamivudine113
Domperidone 135
Domperidone Viatris 135
Donepezil hydrochloride 149
Donepezil-Rex149
Dornase alfa256
Dortimopt
Dorzolamide with timolol
Dostinex
Dosulepin [Dothiepin]
hydrochloride
Dosulepin Mylan
Dosulepin Viatris
Dothiepin
Dovato
Doxazosin
Doxazosin Clinect
Doxazosin Cilinect
Doxorubicin Ebewe
Doxorubicin Ebewe
Doxorubiciii nyurochionde
Doxycycline
DP Lotin HC
DP-Allopurinol
DP-Captopril
Dr Reddy's Omeprazole
Di neuuy s Omepiazoie
Drofoto
Drofate
Drugs Affecting Bone
Drugs Affecting Bone Metabolism 117
Drugs Affecting Bone Metabolism
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 diagnostic test meter 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 DuoResp Spiromax 252
Drugs Affecting Bone Metabolism
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 Duordes Spiromax 252 Durde 56 Durvalumab 241
Drugs Affecting Bone Metabolism
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 diagnostic test meter 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 252 Duride 56 Durvalumab 241 - E - e-chamber La Grande 259 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 diagnostic test meter 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 DuoResp Spiromax 252 Duride 56 Durvalumab 241 - E - e-chamber La Grande 259 e-chamber Mask 258 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10 Ear Preparations 260
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 252 Duride 56 Durvalumab 241 - E - - e-chamber La Grande 259 e-chamber Mask 258 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10 Ear Preparations 260 Ear/Eye Preparations 260
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 Durde 56 Durvalumab 241 - E - - e-chamber La Grande 259 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10 Ear Preparations 260 Ear/Eye Preparations 260 Easiphen Liquid 286
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 Durkesp Spiromax 252 Duride 56 Durvalumab 241 - E - - e-chamber La Grande 259 E-Mycin 97 e5 Pharma 10 Ear /Peparations 260 Easiphen Liquid 286 Econazole nitrate 69
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 Durde 56 Durvalumab 241 - E - - e-chamber La Grande 259 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10 Ear Preparations 260 Ear/Eye Preparations 260 Ear/Eye Preparations 260 Eaconazole nitrate 69 Efavirenz 111
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcoal SP Drop 26 Duccal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 252 Durde 56 Durvalumab 241 - E - - e-chamber La Grande 259 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10 Ear Preparations 260 Ear/Eye Preparations 260 Easiphen Liquid 286 Econazole nitrate 69 Efavirenz 111
Drugs Affecting Bone 117 Metabolism 117 Dual blood glucose and blood ketone 14 Dulaglutide 12 Dulcolax SP Drop 26 Duocal Super Soluble Powder 272 Duolin 253 Duolin HFA 253 Duolin Respules 253 Durde 56 Durvalumab 241 - E - - e-chamber La Grande 259 e-chamber Turbo 259 E-Mycin 97 e5 Pharma 10 Ear Preparations 260 Ear/Eye Preparations 260 Ear/Eye Preparations 260 Eaconazole nitrate 69 Efavirenz 111

Eformoterol fumarate dihydrate	251
Eftrenonacog alfa [Recombinant factor IX]	27
Efudix	
Egopsoryl TA	
Elaprase	
Elecare	289
Elecare LCP	
Electral	
Elelyso	30
Elemental 028 Extra	277
Elexacaftor with tezacaftor, ivacaftor	or
and ivacaftor	257
Elidel	75
Elocon	
Elocon Alcohol Free	71
Eltrombopag	
Eltroxin	
EMB Fatol	
Emend Tri-Pack	
Emicizumab	
EMLA	
Empagliflozin	13
Empagliflozin with metformin	10
hydrochloride	13
Emtricitabine	110
Emtricitabine with tenofovir	112
disoproxil	100
Emtriva	
Emulsifying ointment	
Emulsifying Ointment ADE	72
Enalapril maleate	
Enbrel	177
Endocrine Therapy	173
Endoxan	154
Engerix-B	
Enlafax XR	
Enoxaparin sodium	
Enstilar	
Ensure	
Ensure Plus	282
Ensure Plus HN	281
Ensure Plus HN RTH	281
Ensure Two Cal HN RTH	283
Entacapone	
Entecavir	
Entecavir (Rex)	107
Entresto 24/26	48
Entresto 49/51	
Entresto 97/103	
Entyvio	
Epilim	
Epilim Crushable	
Epilim IV	
Epilim S/F Liquid	133
Epilim Syrup	

Epipen
Epipen Jr
Epirubicin Ebewe160
Epirubicin hydrochloride 160
Eplerenone52
Epoetin alfa
Epoprostenol
Eptacog alfa [Recombinant factor
VIIa]
Erbitux
Ergometrine maleate
Erlotinib168
Erythrocin IV97
Erythromycin (as lactobionate)97
Erythromycin ethyl succinate97
Esbriet
Escitalopram130
Escitalopram (Ethics)
Eskazole
Essential Ethosuximide
Essential Generics
Essential Prednisolone8
Estraderm MX87
Estradiol Sandoz87
Estradiol TDP Mylan87
Estradiol Viatris
Estradot
Estrofem
Etanercept
Ethambutol hydrochloride
Ethics Aspirin
Ethics Aspirin EC40
Ethics Lisinopril46
Ethinyloestradiol with
desogestrel79
Ethinyloestradiol with
levonorgestrel
Ethinyloestradiol with
norethisterone
Ethosuximide
Etopophos
Etoposide
Etoposide phosphate160
Etravirine 111
Eumovate70
Eurofolic156
Evara
EVARA White Soft Paraffin72
Everet 132
Everolimus
Evista
Evrysdi
Evusheld
Exelon Patch 10
Exelon Patch 5 149
Exemestane176

Exjade266
Extemporaneously Compounded
Preparations and
Galenicals
Eve Bronarationa 200
Eye Preparations
Eylea
Ezemibe Viatris56
Ezetimibe
Ezetimibe Sandoz56
Ezetimibe with simvastatin56
- F -
Factor eight inhibitor bypassing
fraction
Famotidine9
Famotidine Hovid9
Fasenra200
Faslodex174
Fatty Cream AFT72
Febuxostat121
Febuxostat (Teva)
Febuxostat multichem
FEIBA NF
Felo 10 ER51
Felo 5 ER51
Felo 5 ER
Felodipine51
Fenpaed 100 mg per 5 ml 116
Fentanyl
Fentanyl Sandoz 127
Ferinject34
Ferodan
Ferriprox
Ferro-F-Tabs34
Ferro-Liquid34
Ferro-tab34
Ferrograd34
Ferrosig35
Ferrous fumarate
Ferrous fumarate with folic acid34
Ferrous sulfate34
Fexofenadine hydrochloride250
Fibro-vein
Filgrastim43
Finasteride
Fingolimod141
Firazyr
Flagyl
FlagyI-S 105
•••
Flamazine
Flecainide acetate
Flecainide BNM
Flecainide Controlled Release
Teva
Flecatab
Fleet Phosphate Enema25
Flixonase Hayfever & Allergy
Flixotide251

Flixotide Accuhaler	
Florinef	
Fluanxol	
Flucil	99
Flucloxacillin	
Flucloxacillin-AFT	
Flucloxin	
Flucon	
Fluconazole	102
Fludara Oral	
Fludarabine Ebewe	156
Fludarabine phosphate	156
Fludrocortisone acetate	85
Fluids and Electrolytes	
Flumetasone pivalate	260
Fluocortolone caproate with	
fluocortolone pivalate and	
cinchocaine	8
Fluorometholone	261
Fluorouracil	157
Fluorouracil Accord	
Fluorouracil sodium	76
Fluox	
Fluoxetine hydrochloride	130
Flupenthixol decanoate	138
Flutamide	174
Flutamin	174
Fluticasone	251
Fluticasone furoate with	
umeclidinium and vilanterol	254
Fluticasone furoate with	
vilanterol	252
Fluticasone propionate	258
Fluticasone with salmeterol	
Flynn	95
FML	
Foban	<mark>69</mark>
Folic acid	37
Folic Acid multichem	37
Folic Acid Viatris	37
Food Thickeners	283
Foods And Supplements For	
Inherited Metabolic Disease	285
Forteo	
Fortini	
Fortini Multi Fibre	276
Fortisip	282
Fortisip Multi Fibre	282
Fosamax	117
Fosamax Plus	
Framycetin sulphate	117
i i danij oo din o dipilato initilitii ili	260
Frebini Energy	260 276
Frebini Energy Frebini Energy Fibre	260 276 276
Frebini Energy Frebini Energy Fibre Frebini Original	260 276 276 276
Frebini Energy Frebini Energy Fibre	260 276 276 276 276

INDEX: Generic Chemicals and Brands

Fresubin HP Energy281
Fresubin HP Energy Fibre
Fresubin Intensive
Fresubin Original
Fresubin Original Fibre
Frisium131
Frumil53
Frusemide52
Fucicort71
Fucidin 101
Fucithalmic260
Fulvestrant174
Fungilin32
Furosemid-Ratiopharm52
Furosemide [Frusemide]52
Furosemide-Baxter
fusidic acid
Dermatological 69, 71
Infection
Sensory260
- G -
GA Explore 5
Gabapentin131
Gacet
Galsulfase27
Galvumet12
Galvus12
Gardasil 9
Gastrodenol9
Gaviscon Extra Strength6
Gaviscon Infant6
Gazyva212
Gefitinib169
GEM Aqueous Cream72
Gemcitabine Ebewe 157
Gemcitabine hydrochloride157
Gemtuzumab ozogamicin203
Gentamicin sulphate 100
Gilenya141
Ginet81
Glatiramer acetate 141
Glecaprevir with pibrentasvir 109
Glibenclamide11
Gliclazide11
Glipizide11
Glizide11
Glucagen Hypokit 10
Glucagon hydrochloride10
Glucerna Select 274
Glucose [Dextrose]43
Gluten Free Foods284
Glycerin with sodium saccharin 269
Glycerin with sucrose269
Glycerol
Alimentary25
Extemporaneous269

Glyceryl trinitrate	
Alimentary	8
Cardiovascular	56
Glycopyrronium	
Glycopyrronium bromide	
Glycopyrronium with	
indacaterol	254
Glycosade	
Gold Knight	78
Gold Knight XL	
Goserelin	
Gynaecological Anti-infectives	
-H-	
Habitrol	151
Haemophilus influenzae type B	
vaccine	296
Haldol	
Haldol Concentrate	138
Haldol Decanoas	
Haloperidol	
Haloperidol decanoate	138
Harvoni	
Havrix	
Havrix Junior	
Haylor syrup	
HCU Explore 5	285
HCU Express 15	285
healthE Aqueous Cream SLS	
Free	72
healthE Calamine Aqueous	
healthE Dimethicone 10%	71
healthE Dimethicone 4% Lotion	73
healthE Dimethicone 5%	71
healthE Glycerol BP	
healthE Urea Cream	
Healtheries Simple Baking Mix	.284
Hemastix	
Hemlibra	
Heparin sodium	
Heparin Sodium Panpharma	
Heparinised saline	
Heparon Junior	
Hepatitis A vaccine	.296
Hepatitis B recombinant	
vaccine	. 297
Herceptin	
Herzuma	
Hiberix	
Hiprex	. 115
Histaclear	
Histafen	
Holoxan	
Horleys Bread Mix	
Horleys Flour	
Hormone Replacement Therapy -	
Systemic	
0,0001110	

HPV	297
Humalog	. 11
Humalog Mix 25	. 11
Humalog Mix 50	
Human papillomavirus (6, 11, 16, 18,	
31, 33, 45, 52 and 58) vaccine	
[HPV]	297
Humatin	
Humira	
HumiraPen	
Humulin 30/70	
Humulin NPH	
Humulin R	
Hyaluronic acid	264
Hydralazine	
Hydralazine hydrochloride	
Hydralyte - Lemonade	
Hydrocortisone	
Dermatological	70
Hormone	
Hydrocortisone acetate	
Hydrocortisone acetate with	•••••
pramoxine hydrochloride	7
Hydrocortisone and paraffin liquid	
and lanolin	71
Hydrocortisone butyrate71	76
Hydrocortisone with cinchocaine	
Hydrocortisone with miconazole	
Hydrocortisone with natamycin and	
neomycin	
	. 71
Hvdrogen peroxide	. 71 . 68
Hydrogen peroxide	. 68
Hydrogen peroxide Hydroxocobalamin	68 32
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma	. 68 . 32 . 32
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide	68 32 32 160
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma	68 32 32 160
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea	68 32 32 160 117
Hydrogen peroxide Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea [hydroxycarbamide]	68 32 32 160 117 160
Hydrogen peroxide Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea [hydroxycarbamide] Hygroton	68 32 160 117 160 53
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh	68 32 160 117 160 53 264
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh Hymenoptera	68 32 160 117 160 53 264 -250
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxycarbamide Hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh Hymenoptera	68 32 32 160 117 160 53 264 250 8
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh Hymoptera Hyoscine butylbromide Hyoscine hydrobromide Hyoscine hydrobromide	68 32 160 117 160 53 264 250 8 135 120
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxychloroquine Hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh Hymoptera Hyoscine butylbromide Hyoscine hydrobromide Hyoscine hydrobromide	68 32 160 117 160 53 264 250 8 135 120
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Panpharma hydroxycarbamide Hydroxycarbamide Hydroxyurea [hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh Hymenoptera	68 32 160 1177 160 53 264 250 8 135 120 263
Hydrogen peroxide	68 32 32 160 117 160 53 264 250 8 135 120 263 263
Hydrogen peroxide Hydroxocobalamin Hydroxocobalamin Hydroxycarbamide Hydroxycarbamide Hydroxyurea [hydroxyurea [hydroxycarbamide] Hygroton Hylo-Fresh Hymoptera 249- Hyoscine butylbromide Hyoscine hydrobromide Hyperuricaemia and Antigout Hypromellose Hypromellose with dextran	68 32 32 160 117 160 53 264 250 8 135 120 263 263
Hydrogen peroxide	68 32 32 160 117 160 53 264 250 8 135 120 263 263 98
Hydrogen peroxide	68 32 160 117 160 53 264 250 8 135 120 263 263 263 263 170 160
Hydrogen peroxide	68 32 160 117 160 53 264 250 8 135 120 263 263 263 263 170 160 116
Hydrogen peroxide	68 32 32 160 117 160 53 264 250 8 135 120 263 263 120 263 170 160 116 249
Hydrogen peroxide	68 32 32 160 117 160 53 264 250 8 135 120 263 263 120 263 170 160 116 249
Hydrogen peroxide	68 32 160 117 160 53 264 250 8 135 120 263 263 170 160 116 249 161 28
Hydrogen peroxide	68 32 160 117 160 53 264 250 8 135 120 263 263 263 98 170 160 116 249 161 28 154
Hydrogen peroxide	68 32 32 160 117 160 53 264 250 8 135 120 263 263 263 170 160 116 249 161 28 154 262

Imatinib mesilate169
Imatinib-Rex169
Imbruvica160
Imfinzi
Imipramine Crescent 129
Imipramine hydrochloride 129
Imiguimod
Immune Modulators113
Immunisation Administration
Immunisation
Co-administration
Immunosuppressants
Incruse Ellipta
Indacaterol
Indapamide
Infanrix IPV
Infanrix-hexa
Infant Formulae
Infatrini
Infliximab
Influenza vaccine
Influvac Tetra
(2024 formulation) 298
Inhaled Corticosteroids251
Inhaled Long-acting
Beta-adrenoceptor Agonists 251
Inresa35
Inspra52
Instillagel Lido 124
Insulin aspart11
Insulin aspart with insulin aspart
protamine10
Insulin glargine11
Insulin glulisine11
Insulin isophane10
Insulin isophane with insulin
neutral
Insulin lispro11
Insulin lispro with insulin lispro
protamine
Insulin neutral
Insulin pen needles
Insulin pump
Insulin pump cartridge
Insulin pump infusion set (steel
cannula)21
Insulin pump infusion set (steel
cannula, straight insertion) 21
Insulin pump infusion set (teflon
cannula)22
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device) 23
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device) 23

nsulin pump reservoir	23
nsulin syringes, disposable with	
attached needle	16
ntelence	
nterferon beta-1-alpha	
nterferon beta-1-beta	141
ntra-uterine device	79
nvega Sustenna	138
nvega Trinza	139
pca-Allopurinol	120
pca-Bisoprolol	49
pca-Donepezil	1/0
pca-Escitalopram	
PCA-Frusemide	100
PCA-Metoprolol	
PCA-Propranolol	
POL	
pratropium bromide253	
), ∠00 100
ressa	
rinotecan Actavis 100 rinotecan hydrochloride	15/
rinotecan nyarochioride	15/
rinotecan-Rex	15/
ron (as ferric carboxymaltose)	
ron polymaltose	35
sentress	113
sentress HD	113
smo 20	56
smo 40 Retard	56
soleucine50	288
soniazid	106
soniazid with rifampicin	
soptin	51
soptin Retard	51
soptin SR	51
sopto Carpine	
sosorbide mononitrate	56
sosource Standard	281
sotretinoin	68
spaghula (psyllium) husk	24
tch-Soothe	70
traconazole	103
trazole	
vacaftor	257
vermectin	73
- J -	
Jadelle	80
Jakavi	
Jardiamet	
Jardiance	
Jaydess	
Jevity HiCal RTH	281
Jevity Plus RTH	
Jevity RTH	281
Jinarc	
Juno Pemetrexed	158
- K -	

Kadcyla236
Kalydeco257
Kemadrin 123
Kenacomb260
Kenacort-A 1086
Kenacort-A 4086
Kenalog in Orabase
Ketocal 3:1
KetoCal 4:1
Ketoconazole
Dermatological
Infection
Ketogenic Diet
Ketoprofen 116
KetoSens13
Keytruda
Kindergen
•
Klacid
Alimentary9
Infection
Kliogest
Kliovance
Kogenate FS
Konakion MM40
Konsyl-D24
Kuvan 29
-L-
Labetalol50
Lacosamide 131
Lactulose25
Laevolac25
Lagevrio110
Lamictal
Lamivudine 107, 112
Lamivudine Viatris 112
Lamivudine/Zidovudine Viatris112
Lamotrigine
Lamprene 105
Lanoxin
Lanoxin Paediatric Elixir
Lanoxin PG48
Lanoxin S2948
Lansoprazole9
Lantus
Lantus SoloStar11
Lanvis 159
Lanzol Relief9
Largactil
Laronidase
Lasix
Latanoprost
Latanoprost with timolol
Lax-Suppositories
Lax-suppositories Glycerol
Lax-suppositones Gryceror
Laxauves
Langel

Ledipasvir with sofosbuvir 109
Leflunomide 117
Lenalidomide 161
Letrole176
Letrozole176
Leucine100288
Leukeran FC 154
Leukotriene Receptor
Antagonists
Leuprorelin93
Leustatin 156
Levetiracetam 132
Levetiracetam-AFT132
Levocabastine
Levocarnitine
Levodopa with benserazide123
Levodopa with carbidopa123
Levomepromazine 136
Levomepromazine
hydrochloride 137
Levonorgestrel
Genito-Urinary80-81
Hormone
Levonorgestrel BNM
Levothyroxine
Lidocaine [Lignocaine]
Lidocaine [Lignocaine] hydrochloride
hydrochloride
Lidocaine [Lignocaine] with
Lidocaine [Lignocaine] with prilocaine
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 124 Life Extension 30 30 Lignocaine 124-125 124 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 121
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 124–125 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 12 12
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Lidocaine-Baxter 124 125 Lignocaine 124-125 126 Linezolid 106 106 Lioresal Intrathecal 121 121 Liquigen 273 54 Liquigen 121 12 Lisnopril 46 46
Lidocaine [Lignocaine] with 125 prilocaine 124 Lidocaine-Baxter 124 Life Extension 30 Lignocaine 124–125 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 Lisinopril 46 Litak 156
Lidocaine [Lignocaine] with 125 prilocaine 124 Lide Extension 30 Lignocaine 124-125 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 Lisinopril 46 Litak 156 Lithium carbonate 137
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124–125 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 Lisinopril 46 Litak 156 Lithium carbonate 137 Livostin 261
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124-125 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 Litak 156 Lithium carbonate 137 Livostin 261 LMX4 125
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124-125 Linezolid 106 Lioresal Intrathecal 121 Lingen 273 Liraglutide 12 Lisinopril 46 Litak 156 Lithium carbonate 137 Livostin 261 LMX4 125 Lo-Oralcon 20 ED 80
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124-125 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 Litak 156 Lithium carbonate 137 Livostin 261 LMX4 125 Lo-Oralcon 20 ED 80 Locacorten-Viaform ED's 260
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124-125 Linezolid 106 Lioresal Intrathecal 121 Lingen 273 Liraglutide 12 Lisinopril 46 Litak 156 Lithium carbonate 137 Livostin 261 LMX4 125 Lo-Oralcon 20 ED 80
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 121 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 124 Lizinopril 124 125 Litak 156 137 Litvostin 261 144 LMX4 125 260 Locacorten-Viaform ED's 260 260 Local preparations for Anal and Rectal Disorders 88 289
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 121 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 124 Ligaigen 273 127 Liraglutide 12 125 Litak 156 137 Livostin 261 137 Livostin 261 80 Locacorten-Viaform ED's 260 Local preparations for Anal and 8 Locasol 289 Loccoid Locasol 289 Locoid
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 121 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 124 Ligaigen 273 127 Liraglutide 12 125 Lisinopril 46 46 Litak 156 137 Livostin 261 137 Livostin 261 80 Locacorten-Viaform ED's 260 260 Local preparations for Anal and Rectal Disorders 88 Locasol 289 Locoid 71, 76 Locoid Crelo 71 71 71
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 124–125 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 124 Liraglutide 121 121 Liraglutide 121 123 Liraglutide 122 124 Litak 156 115 Lithium carbonate 137 125 Lo-Oralcon 20 ED 80 100 Locacorten-Viaform ED's 260 260 Local preparations for Anal and Rectal Disorders 8 Locasol 289 1000 289 Locoid Crelo 71 76 100 71
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124-125 Linezolid 106 Lioresal Intrathecal 121 Lignotifying Agents 54 Liquigen 273 Liraglutide 12 Lisinopril 46 Litak 156 Lithium carbonate 137 Livostin 261 LMX4 125 Lo-Oralcon 20 ED 80 Locacorter-Viaform ED's 260 Locaid 71, 76 Locoid Crelo 71 Locoid Crelo 71 Locorten-Vioform 260
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 124–125 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 124 Liquigen 273 124 Lisinopril 46 126 Litak 156 137 Livostin 261 137 Livostin 261 100 Locacorten-Viaform ED's 260 Locacorten-Viaform Sfor Anal and 8 Locasol 289 10 Locoid Crelo 71 76 Locoid Crelo 71 71 Locorten-Vioform 260 10 Locoxid Lipocream 71 71 Locoxid Crelo 71 71 Locoxid Crelo 71 71
Lidocaine [Lignocaine] with 125 prilocaine 124 Life Extension 30 Lignocaine 124 Life Extension 30 Lignocaine 124 Life Extension 30 Lignocaine 124 Linezolid 106 Lioresal Intrathecal 121 Lipid-Modifying Agents 54 Liquigen 273 Liraglutide 12 Lisinopril 46 Litak 156 Lithium carbonate 137 Livostin 261 LMX4 125 Lo-Oralcon 20 ED 80 Locacorten-Viaform ED's 260 Locasol 289 Locoid 71 Locoid Crelo 71 Locoid Crelo 71 Locoid Crelo 71 Locoid Lipocream 71 Lodoxamide 261 Logem 132
Lidocaine [Lignocaine] with prilocaine 125 Lidocaine-Baxter 124 125 Life Extension 30 30 Lignocaine 124–125 124–125 Linezolid 106 106 Lioresal Intrathecal 121 121 Lipid-Modifying Agents 54 124 Liquigen 273 124 Lisinopril 46 126 Litak 156 137 Livostin 261 137 Livostin 261 100 Locacorten-Viaform ED's 260 Locacorten-Viaform Sfor Anal and 8 Locasol 289 10 Locoid Crelo 71 76 Locoid Crelo 71 71 Locorten-Vioform 260 10 Locoxid Lipocream 71 71 Locoxid Crelo 71 71 Locoxid Crelo 71 71

Loniten57
Loperamide hydrochloride6
Lopinavir with ritonavir113
Lopinavir/Ritonavir Mylan 113
Loprofin
Loprofin Mix
Lorafix
Loratadine
Lorazepam140
Lorstat
Losartan Actavis
Losartan potassium
Losartan potassium with
hydrochlorothiazide
Lovir
Lucrin Depot 1-month
Lucrin Depot 3-month
Lyrica
- M -
m-Eslon
Mabthera
Macrobid115
Macrogol 3350 with potassium
chloride, sodium bicarbonate and
sodium chloride
Madopar 125 123
Madopar 250 123
Madopar 62.5 123
Madopar HBS123
Madopar Rapid
Magnesium hydroxide
Magnesium sulphate
Mantoux
MAR-Midodrine
Marevan43
Marine Blue Lotion SPF 50+76
Martindale Pharma265
Mask for spacer device258
Maviret
Maxidex
Maxitrol261
MCT oil (Nutricia)273
Measles, mumps and rubella
vaccine
Mebendazole95
Mebeverine hydrochloride8
Med Mgmt 15 min265
Med Mgmt 30 min265
Med Mgmt 45 min265
Medicine Delivery
Medrol85
Medroxyprogesterone acetate
Genito-Urinary80
Hormone

Mefenamic acid	
Megval	
Melatonin	. 143
Melpha	. 155
Melphalan	. 155
Meningococcal (groups A, C, Y and	
W-135) conjugate vaccine	
Meningococcal B multicomponent	
vaccine	301
Meningococcal C conjugate	
wassing	201
vaccine	
MenQuadfi	
Menthol	
Mepolizumab	
Mercaptopurine	
Mercilon 28	79
Mesalazine	7
Mesna	. 162
Mestinon	. 116
Metabolic Disorder Agents	
Metformin hydrochloride	
Metformin Viatris	
Methadone BNM	
Methadone hydrochloride	
Extemporaneous	260
Nervous	
Methenamine (hexamine)	. 121
hippurate	115
Methopt	
Methotrexate	. 158
Methotrexate DBL Onco-Vial	. 158
Methotrexate DBL S29	
Methotrexate Ebewe	
Methotrexate Sandoz	. 158
Methyl hydroxybenzoate	. 269
Methylcellulose	. 269
Methylcellulose with glycerin and	
sodium saccharin	. 269
Methylcellulose with glycerin and	
sucrose	. 269
Methyldopa	
Methyldopa Mylan	
Methyldopa Mylan S29	
Methyldopa Viatris	
Methylnaltrexone bromide	
Methylphenidate ER - Teva	
Methylphenidate hydrochloride	
Methylphenidate hydrochloride	
extended-release	
Methylprednisolone	
Methylprednisolone (as sodium	00
succinate)	05
Methylprednisolone aceponate	
Methylprednisolone acetate	
Methylxanthines	.256
Metoclopramide Actavis 10	. 135

Metoclopramide hydrochloride 135
Metolazone53
Metopirone94
Metoprolol IV Mylan50
Metoprolol IV Viatris
Metoprolol succinate
Metoprolol tartrate
Metrogyl105
Metronidazole 105
Metyrapone94
Mexiletine hydrochloride
Miacalcic
Micolette
Micolette-S2925
Miconazole
Miconazole nitrate
Dermatological
Genito-Urinary
Micreme
Micreme H
Microgynon 30
Microlut
Midazolam
Midazolam-Baxter
Midodrine
Mifegyne
Mifepristone
Milpharm
Minerals
Mini-Wright AFS Low Range
Minidiab
MiniMed 3.0 Reservoir
MMT-332A
MiniMed 770G
MiniMed Mio MMT-921A 22
MiniMed Mio MMT-923A
MiniMed Mio MMT-925A
MiniMed Mio MMT-941A 22
MiniMed Mio MMT-943A
MiniMed Mio MMT-945A22
MiniMed Mio MMT-965A22
MiniMed Mio MMT-975A 22
MiniMed Quick-Set MMT-386A23
MiniMed Quick-Set MMT-387A22
MiniMed Quick-Set MMT-396A22
MiniMed Quick-Set MMT-397A22
MiniMed Quick-Set MMT-398A 22
MiniMed Quick-Set MMT-399A22
MiniMed Silhouette MMT-368A22
MiniMed Silhouette MMT-377A 22
MiniMed Silhouette MMT-378A22
MiniMed Silhouette MMT-381A22
Willinivied Silliouelle Wilvi I-38TA
MiniMed Silhouette MMT-382A 22
MiniMed Silhouette MMT-381A22 MiniMed Silhouette MMT-382A22 MiniMed Silhouette MMT-383A22 MiniMed Silhouette MMT-384A22

MiniMed Sure-T MMT-864A	21
MiniMed Sure-T MMT-866A	21
MiniMed Sure-T MMT-874A	21
MiniMed Sure-T MMT-876A	21
MiniMed Sure-T MMT-884A	21
MiniMed Sure-T MMT-886A	21
Minims Cyclopentolate	263
Minims Pilocarpine	263
Minims Prednisolone	262
Minipress	
Minipless	
Minirin Melt	
Mino-tabs	99
Minocycline hydrochloride	99
Minomycin	99
Minor Skin Infections	
Minoxidil	
Minoxidil Roma	
Mirena	88
Miro-Amoxicillin	98
Mirtazapine	.130
Misoprostol	9
Mitomycin C	. 162
Mitozantrone	
Mitozantrone Ebewe	
Mixtard 30	
MMA/PA Explore 5	
MMA/PA Express 15	288
Moclobemide	130
Modafinil	148
Modavigil	
Moduretic	52
Molaxole	
Molnupiravir	
Moments	/8
Mometasone furoate	
Monogen	274
Montelukast	
Montelukast Viatris	.256
Moroctocog alfa [Recombinant factor	or
VIII]	39
Morphine hydrochloride	
Morphine sulphate	. 128
Motetis	. 124
Mouth and Throat	31
Мочаро	. 123
Moxifloxacin	. 100
MSUD Explore 5	.285
MSUD Express 15	.285
MSUD Maxamum	
Mucolytics	
Mucosoothe	
Multiple Sclerosis Treatments	
Multivitamin renal	
Multivitamins	
Mupirocin	

Muscle Relaxants	
Mvite	33
Myambutol	
Mycobutin	107
MycoNail	<mark>69</mark>
Mycophenolate mofetil	177
Mydriacyl	263
Mylan (24 hr release)	51
Mylan Atenolol	49
Mylan Clomiphen	94
Mylan Italy (24 hr release)	51
Myleran	154
Myloc CR	50
Mylotarg	203
Myometrial and Vaginal Hormone	
Preparations	81
Myozyme	26
- N -	
Nadolol	50
Nadolol BNM	50
Naglazyme	27
Naloxone hydrochloride	265
Naltraccord	151
Naltrexone AOP	151
Naltrexone hydrochloride	151
Naphazoline hydrochloride	
Naphcon Forte	264
Naprosyn SR 1000	116
Naprosyn SR 750	116
Naproxen	
Narcaricin mite	
Nasal Preparations	
Natalizumab	
Natulan	
Nausafix	135
Nausafix - S29	135
Nausicalm	
Navelbine	
Navelbine S29	167
Nefopam hydrochloride	
Neisvac-C	301
Neo-Cytamen S29	
Neo-Mercazole	
Neocate Gold	
Neocate Junior Unflavoured	289
Neocate Junior Vanilla	289
Neocate SYNEO	
Neoral	245
Neostigmine metilsulfate	. 116
Nepafenac	262
Nepro HP (strawberry)	277
Nepro HP (vanilla)	277
Nepro HP RTH	277
Neulactil	
Neuraxpharm	
NeuroTabs	34

Maximum data data
Nevirapine112
Nevirapine Alphapharm112
Nevirapine Viatris 112
Nicorandil
Nicotine
Nicourie
Nifedipine51
Nifedipine Viatris51
Nifuran 115
Nilotinib169
Nilstat
Alimentary32
Alimentary
Genito-Urinary81
Infection 103
Nintedanib255
Nipent 165
Niraparib162
Nirmatrelvir with ritonavir
Nitrates56
Nitroderm TTS56
Nitrofurantoin115
Nitrolingual Pump Spray56
Nivestim
Nivolumab242
Nodia6
Noflam 250 116
Noflam 500 116
Non-Steroidal Anti-Inflammatory
Drugs
Nanagag gamma [Decembinant
Nonacog gamma, [Recombinant
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX]
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary. 81 Hormone 88 Norflex. 122 Norfloxacin. 115 Noriday 28 81 Norimin. 80 Norimin-1 28 Day. 80 Norpress. 129 Nortriptyline hydrochloride. 129 Norvir. 113 Noured Dexamfetamine. 146
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Norpress 129 Nortriptyline hydrochloride 129 Norvir 113 Nourmed Dexamfetamine 146 Nourmed Paracetamol 126
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Norpress 129 Nortriptyline hydrochloride 129 Norvir 113 Nourmed Dexamfetamine 146 Nourmed Paracetamol 126
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Norrison 143 Norpress 129 Nortriptyline hydrochloride 129 Norvir 113 Noured Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary. 81 Hormone 88 Norflex. 122 Norfloxacin. 115 Noriday 28 81 Norimin. 80 Norimin.1 28 Day. 80 Normison 143 Norpress 129 Nortriptyline hydrochloride. 129 Norvir. 113 Noured Dexamfetamine. 146 Noumed Paracetamol. 126 Noumed Pethidine. 128 Noumed Pethidine. 128 Noumed Pethidine. 128 Noumed Pethidine. 128
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary. 81 Hormone 88 Norflex. 122 Norfloxacin. 115 Noriday 28 81 Norimin. 80 Norimin.1 28 Day. 80 Norrison 143 Norpress 129 Nortvir. 113 Noured Dexamfetamine. 146 Noumed Paracetamol. 126 Noumed Pethidine. 128 Noumed Pethidine. 132 NovaSource Renal 277
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Norrison 143 Norpress 129 Nortriptyline hydrochloride 129 Noured Dexamfetamine 146 Noumed Dexamfetamine 126 Noumed Pethidine 128 Noumed Pethidine 128 Noured Pethidine 132 NovaSource Renal 277 Novatretin 74
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin-1 28 Day Norrinion 80 Norrinion 143 Norpress 129 Nortriptyline hydrochloride 129 Norivir 113 Noured Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 Noumed Pethidine 127 NovaSource Renal 277 Novatretin 74 Novitium Sugar Free 28
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Norrison 143 Norpress 129 Nortriptyline hydrochloride 129 Norivir 113 Noured Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 Noured Petholarbitone 128 NovaSource Renal 277 Novatretin 74 Novitium Sugar Free 28 NovoMix 30 FlexPen 10
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin-1 28 Day Norrinion 80 Norrinion 143 Norpress 129 Nortriptyline hydrochloride 129 Norivir 113 Noured Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 Noumed Pethidine 127 NovaSource Renal 277 Novatretin 74 Novitium Sugar Free 28
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day Norrison 143 Norpress 129 Nortriptyline hydrochloride 129 Norivir 113 Noumed Dexamfetamine 146 Noumed Paracetamol 126 Noumed Phenobarbitone 122 Novatretin 74 Novittium Sugar Free 28 NovoMix 30 FlexPen 10 NovoRapid 11
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Normison 143 Norpress 129 Nortriptyline hydrochloride 129 Norivir 113 Noumed Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 NovaGource Renal 277 NovaSource Renal 277 Novatretin 74 Novitium Sugar Free 28 NovoRapid 11 NovoRapid 11
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary. 81 Hormone 88 Norflex 122 Norfloxacin. 115 Noriday 28 81 Norimin 80 Norimin. 80 Norrison 143 Norpress 129 Nortriptyline hydrochloride 129 Norvir 113 Noumed Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 Novasource Renal 277 Novatretin 74 Novitium Sugar Free 28 NovoRapid 11 NovoRapid FlexPen 11 NovoRapid FlexPen 11 NovoRapid Penfill 11
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary 81 Hormone 88 Norflex 122 Norfloxacin 115 Noriday 28 81 Norimin 80 Norimin-1 28 Day 80 Norrison 143 Norpress 129 Norvir 113 Noumed Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 Novasource Renal 277 Novastretin 74 Novitium Sugar Free 28 NovoRapid 11 NovoRapid FlexPen 11 NovoRapid Penfill 11 NovoRapid Penfill 11
Nonacog gamma, [Recombinant Factor IX] 39 Norethisterone 81 Genito-Urinary. 81 Hormone 88 Norflex 122 Norfloxacin. 115 Noriday 28 81 Norimin 80 Norimin. 80 Norrison 143 Norpress 129 Nortriptyline hydrochloride 129 Norvir 113 Noumed Dexamfetamine 146 Noumed Paracetamol 126 Noumed Pethidine 128 Novasource Renal 277 Novatretin 74 Novitium Sugar Free 28 NovoRapid 11 NovoRapid FlexPen 11 NovoRapid FlexPen 11 NovoRapid Penfill 11

Nozinan S29	137
Nucala	211
Nuelin	256
Nuelin-SR	256
Nupentin	131
Nusinersen	144
Nutilis	284
Nutren Diabetes	
Nutrient Modules	071
Nutrini Energy Multi Fibre	270
Nutrini Energy RTH	276
Nutrini Low Energy Multi Fibre	278
Nutrini Peptisorb	291
Nutrini Peptisorb Energy	291
Nutrini RTH	276
Nutrison 800 Complete Multi	
Fibre	
Nutrison Advanced Diason	274
Nutrison Advanced Peptisorb	278
Nutrison Concentrated	283
Nutrison Energy	281
Nutrison Energy Multi Fibre	281
Nutrison Multi Fibre	281
Nutrison RTH	281
Nyefax Retard	51
Nystatin	
Alimentary	20
	01
Genito-Urinary	81
Infection	103
Infection NZB Low Gluten Bread Mix	103
Infection NZB Low Gluten Bread Mix - O -	103 284
Infection NZB Low Gluten Bread Mix - O - Obinutuzumab	103 284 212
Infection NZB Low Gluten Bread Mix • O - Obinutuzumab Obstetric Preparations	103 284 212 83
Infection NZB Low Gluten Bread Mix - O - Dbinutuzumab Dbstetric Preparations Dcicure	.103 .284 .212 83 9
Infection VZB Low Gluten Bread Mix - O - Dbinutuzumab Dstetric Preparations Dcicure Dcrelizumab	.103 .284 .212 83 9 .141
Infection NZB Low Gluten Bread Mix - O - Dbinutuzumab Dbstetric Preparations Dcicure	.103 .284 .212 83 9 .141
Infection NZB Low Gluten Bread Mix - O - Dbinutuzumab Dbstetric Preparations Dcicure Dcrelizumab Dcrevus	.103 .284 .212 83 9 .141
Infection NZB Low Gluten Bread Mix - O - Dbinutuzumab Dostetric Preparations Diccure Dcrelizumab Dcrevus Dcrevos Dctocog alfa [Recombinant factor	103 284 212 83 9 141 141
Infection NZB Low Gluten Bread Mix O - Dbinutuzumab Dostetric Preparations Distetric Preparations Distetric Preparations Disterve .	103 284 212 83 9 141 141
Infection	103 284 .212 83 9 .141 .141 39
Infection	103 284 212 83 9 141 141 39 39
Infection	103 284 212 83 9 141 141 39 39 175
Infection	103 284 212 9 141 141 39 39 175 175
Infection	103 284 212 83 9 141 .141 39 39 .175 .175 .175
Infection	103 284 212 83 9 .141 141 39 39 .175 .175 .175 .175
Infection	103 284 212 83 9 141 141 39 39 175 175 175 87
Infection	103 284 212 9 141 141 39 175 175 175 87 87
Infection	103 284 212 9 141 141 39 175 175 175 87 87
Infection	103 284 212 83 9 141 .141 39 175 175 175 175 87 87 87
Infection	103 284 212 83 9 141 141 39 39 175 175 175 175 87 87 88 81
Infection	103 284 212 83 9 141 141 39 39 175 175 175 87 87 87 88 81 88
Infection	103 284 212 83 9 141 141 39 39 175 175 175 175 87 87 87 88 81 88 81
Infection	103 284 212 83 9 141 141 39 39 175 175 175 87 87 88 81 88 81 88 87 255
Infection	103 284 212 83 9 141 141 39 39 175 175 175 175 87 87 88 81 88 81 88 87 255 72
Infection	103 284 212 83 9 141 141 39 39 175 175 175 175 87 87 88 81 88 81 88 87 255 72
Infection	103 284 212 83 9 141 141 39 175 175 175 175 87 87 88 81 88 81 88 72 138
Infection	103 284 212 83 9 141 141 39 175 175 175 175 87 88 88 81 88 81 72 -138 163

Olbetam S29	54
Olopatadine	264
Olopatadine Teva	
Olsalazine	8
Omalizumab	213
Omeprazole	9
Omeprazole actavis 10	9
Omeprazole actavis 20	9
Omeprazole actavis 40	9
Omnitrope	89
Omnitrope S29	89
Onbrez Breezhaler	251
Oncaspar LYO	164
OncoTICE	184
Ondansetron	135
One-Alpha	33
One-Alpha S29	33
Opdivo	
Ora-Blend	
Ora-Blend SF	
Ora-Plus	269
Ora-Sweet	
Ora-Sweet SF	269
Orabase	
Oral and Enteral Feeds	274
Oralcon 30 ED	
Oramorph	128
Oratane	
Ordine	
Orgran	
Ornidazole	105
Orphenadrine citrate	122
Ortho-tolidine	
Oruvail SR	
Osmolite RTH	
Other Endocrine Agents	
Other Oestrogen Preparations	88
Other Breggetegen	
Preparations	88
Other Skin Preparations	76
Otodex	
Ovestin	
Genito-Urinary	81
Hormone	
Oxaliplatin	155
Oxaliplatin Accord	155
Oxaliplatin Actavis 100	155
Oxaliplatin Ebewe	
Oxis Turbuhaler	
Oxpentifylline	.57
Oxybutynin	.83
Oxycodone hydrochloride	128
Oxycodone Sandoz	128
Oxycodone Sandoz S29	
OxyContin	
OxyNorm	
, ·	

Oxytocin	82
Oxytocin BNM	82
Oxytocin GH	82
Oxytocin Panpharma	
Oxytocin with ergometrine	02
maleate	00
Ozurdex	260
	~
Pacifen1	
Pacimol1	
Paclitaxel1	
Paclitaxel Actavis1	
Paclitaxel Ebewe 1	
Paediatric Seravit	
Palbociclib1	
Paliperidone1	
Paliperidone palmitate 1	39
Pamidronate disodium1	
Pamisol1	
Pamol 1	
Pancreatic enzyme	
Pantoprazole	. 9
Panzop Relief	9
Papaverine hydrochloride	
Para-amino salicylic acid1	
Paracetamol1	
Paracetamol (Ethics) 1	26
Paracetamol + Codeine	
(Relieve) 1	28
Paracetamol with codeine1	
Paraffin	
Paraffin liquid with wool fat	264
Parasiticidal Preparations	
Parnate 1	
Paromomycin1	
Paroxetine 1	
Paser 1	
Paxam 1	
Paxlovid 1	
Pazopanib1	
Peak flow meter	
Pediasure	276
Pediasure Plus2	
Pediasure RTH2	
Pegaspargase1	64
Pegasys1	
Pegfilgrastim	
Pegylated interferon alfa-2a1	13
Pembrolizumab2	
Pemetrexed1	
Penicillamine1	
Penicillin G	98
PenMix 30	11
PenMix 50	
Pentasa	
Pentostatin [Deoxycoformycin] 1	65

Pentoxifylline [Oxpentifylline]	57
Peptamen Junior	276
Pepti-Junior	292
Perhexiline maleate	
Pericyazine	
Perindopril	47
Periset	135
Periset ODT	135
Perjeta	
Permethrin	213
Perrigo	79
Pertuzumab	215
Peteha	
Pethidine hydrochloride	100
Pevaryl	. 120
Pexsig	
Pfizer Exemestane	
Pfizer S29	156
Pharmacy Services	
Pheburane	
Phenasen	
Phenobarbitone	132
Phenobarbitone sodium	
Extemporaneous	269
Nervous	143
Phenoxybenzamine	
hydrochloride	46
Phenoxymethylpenicillin (Penicillin	
V)	
Phenylalanine50	288
Phenytoin sodium131	-132
Phillips Milk of Magnesia	35
Phlexy 10	286
Phosphate Phebra	44
Phosphorus	
Phytomenadione	
Pilocarpine hydrochloride	
Pilocarpine nitrate	263
Pimafucort	
Pimecrolimus	
Pine tar with trolamine laurilsulfate	
and fluorescein	75
Pinetarsol	
Pioglitazone	
Pirfenidone	256
Pizotifen	12/
PKU Anamix Infant	
PKU Anamix Junior	
PKU Anamix Junior Chocolate	
PKU Anamix Junior LQ	
PKU Anamix Junior Orange	
PKU Anamix Junior Vanilla	
PKU Build 10	
PKU Build 20 Chocolate	287
PKU Build 20 Raspberry	
Lemonade	. 287

PKU Build 20 Smooth	.287
PKU Build 20 Vanilla	
PKU Explore 10	
PKU Explore 5	286
PKU Express 20	286
PKU Glytactin RTD 15	287
PKU Glytactin RTD 15 Lite	
PKU GMPro Ultra Lemonade	
PKU Lophlex LQ 10	
PKU Lophlex LQ 20	
PKU Lophlex Powder	
PKU Lophlex Sensation 20	
PKU Restore Powder	
PKU sphere20 Banana	
PKU sphere20 Chocolate	
PKU sphere20 Lemon	.287
PKU sphere20 Red Berry	.287
PKU sphere20 Vanilla	.287
PKU Start	
Plaquenil	
Plendil ER	
PMS-Salbutamol	.253
Pneumococcal (PCV10) conjugate	
vaccine	. 302
Pneumococcal (PCV13) conjugate	
vaccine	. 303
Pneumococcal (PPV23)	
polysaccharide vaccine	. 304
Pneumovax 23	.304
Podophyllotoxin	76
Polaramine	.250
Poliomyelitis vaccine	.304
Poloxamer	25
Poly-Gel	.264
Poly-Tears	
Poly-Visc	.264
Polycal	.271
Polyethylene glycol 400 and	
propylene glycol	264
Ponstan	.116
Posaconazole	
Posaconazole Juno	
Potassium chloride4	3-44
Potassium citrate	
Potassium iodate	
Povidone iodine	
Pradaxa	
Pramipexole hydrochloride	123
Pravastatin	
Praziguantel	
Prazosin	
Prazosin Mylan	
Pred Forte	40 060
Prednisolone	
Prednisolone acetate	
Prednisolone acetate	
	X

Prednisolone sodium

phosphate262
Prednisolone-AFT262
Prednisone86
Prednisone Clinect
Pregabalin132
Pregabalin Pfizer
Pregnancy Tests - hCG Urine
Premarin
Prevenar 13
Priadel
Primaquine104
Primidone132
Primidone Clinect
Primolut N88
Priorix
Probenecid121
Probenecid-AFT 121
Procarbazine hydrochloride
Prochlorperazine
Prochlorperazine Brown &
Burk 135
Proctofoam
Proctosedyl
Procyclidine hydrochloride123
Progesterone
Proglicem
Proglycem10
Progynova
Prolia
Promethazine hydrochloride
Propafenone hydrochloride
Propranolol
Propylene glycol
Propylthiouracil
Prostacur
Protaphane 10
Protaphane Penfill
Protifar
Protionamide
Provera
Provera HD
Deariasis and Ference
Preparations
PTU
Pulmicort Turbuhaler
Pulmozyme
Puri-nethol 157
Puritan's Pride Vitamin
B-2 100 mg 29
Pyrazinamide
Pyridostigmine bromide
Pyridoxine hydrochloride
Pyridoxine multichem
Pyrimethamine101
Pytazen SR40
1 ytuzon OI t

- 0 -Quantalan sugar free......54 Quetapel......137 Quinapril47 Quinapril with hydrochlorothiazide 47 - R -RA-Morph127 Ralicrom8 Raloxifene hydrochloride118 Raltegravir potassium......113 Ramipex123 Ramipril47 Ranbaxy-Cefaclor.....95 Rapamune.....246 Rasagiline.....123 Reandron 1000......86 Recombinant factor IX 37, 39 Rectogesic.....8 Redipred......86 Relieve.....116 Resonium-A......45 Resource Beneprotein......273 Respigen253 Respiratory Stimulants259 Retinol palmitate......264 Revlimid......161 Riboflavin......29 Ribomustin......153 Rifabutin107 Rifadin107 Rifadin Sanofi 107 Rifampicin.....107 Rifaximin......10 Rifinah106 Riluzole.....123 Risdiplam.....144 Risedronate Sandoz 119 Risedronate sodium......119 Risperdal Consta 139 Risperidone 137, 139

Risperidone (Teva)	137
Risperon	137
Ritalin	. 147
Ritalin LA	
Ritonavir	
Rituximab (Mabthera)	
Rituximab (Riximyo)	
Rivaroxaban	
Rivastigmine	
Rivastigmine Patch BNM 10	149
Rivastigmine Patch BNM 5	
Rivotril	
Riximvo	
RIXUBIS	
Rizamelt	134
Rizatriptan	134
Robinul	
Ronapreve	
Ropin	
Ropinirole hydrochloride	123
Rosuvastatin	
Rosuvastatin Viatris	
Rotarix	
Rotavirus oral vaccine	
Roxane-Propranolol	
Roxithromycin	
Rubifen	
Rubifen SR	
Rugby Capsaicin Topical Cream	
Musculoskeletal	. 117
Nervous	
Rurioctocog alfa pegol [Recombina	
factor VIII]	
Ruxolitinib	
Rythmodan	
Rythmodan - Cheplafarm	
Rytmonorm	
- S -	
Sabril	133
Sacubitril with valsartan	
Sagent	
SalAir	
Salazopyrin	
Salazopyrin EN	
Salbutamol252	-253
Salbutamol Cipla	253
Salbutamol with ipratropium	
bromide	253
Salicylic acid	
Salmeterol	
Sandomigran	
Sandostatin LAR	
Sanofi Primaquine	
Sapropterin dihydrochloride	
Scalp Preparations	
ooup i iopaialloilð	10
Scopoderm TTS	

Scopolamine - Mylan 13	5
Scopolamine - Mylan S29 13	5
Sebizole	6
Secukinumab22	
Sedatives and Hypnotics14	3
Seebri Breezhaler	
Senna	
Senokot	
SensoCard1	
Serc	
Serenace	
Seretide	
Seretide Accuhaler	
Serevent	
Serevent Accuhaler	
Sertraline	
Setrona13	
Sevredol	8
Sex Hormones Non	
Contraceptive	
Shingles vaccine	
Shingrix	6
SII-Onco-BCG 18	
Sildenafil6	
Siltuximab23	
Simvastatin5	6
Simvastatin Mylan	6
Simvastatin Viatris	6
Sinemet 12	
Sinemet CR 12	3
Sirolimus24	6
Sirturo 10	5
Siterone8	6
Slow-Lopresor	0
Smith BioMed Rapid Pregnancy	
Test	2
Sodibic4	
Sodium acid phosphate2	5
Sodium alginate	6
Sodium benzoate	0
Sodium bicarbonate	
Blood4	4
Extemporaneous27	
Sodium calcium edetate	
Sodium chloride	
Blood4	4
Respiratory25	8
Sodium citrate with sodium lauryl	Ĩ
sulphoacetate	5
Sodium citro-tartrate	
Sodium cromoglicate	`
Alimentary	8
Sensory	
Sodium Fusidate [fusidic acid]	-
Dermatological	۵
	J

Infection	
Sensory	260
Sodium hyaluronate [Hyaluronic	
acid]	264
Sodium phenylbutyrate	30
Sodium picosulfate	20
Sodium polystyrene sulphonate	45
Sodium tetradecyl sulphate	39
Sodium valproate	133
Sodium valproate Sofradex	260
Soframycin	260
Solgar	26 20
Solifenacin succinate	00-00
Solifenacin Viatris	83
Solu-Cortef	85
Solu-Medrol	85
Solu-Medrol-Act-O-Vial	85
Somatropin (Omnitrope)	89
Sotalol	50
Spacer device	250
	209
Span-K	44
Spazmol	8
Spinal Muscular Atrophy	144
Spinraza	144
Spiolto Respimat	254
Spiractin	53
Spiriva	254
Spiriva Respimat	204
	204
Spironolactone	53
Sporanox	103
Sprycel	167
Stelara	237
Stemetil	135
Steril-Gene	
SteroClear	258
Stesolid	101
	101
Stimulants/ADHD Treatments	145
Stiripentol	
Stocrin	111
Stomahesive	31
Strides Shasun	103
Stromectol	73
Sucralfate	10
Sulfadiazine Silver	60
Sulfadiazine sodium	101
Sulfasalazine	8
Sulphur	75
Sulprix	136
Sumagran	134
Sumatriptan	134
Sunitinib	170
Sunitinib Pfizer	170
	172
Sunscreens	/6
Sunscreens, proprietary	76
Survimed OPD	278

Sustagen Hospital Formula	281
Sustagen Hospital Formula	
Active	281
Sustanon Ampoules	86
Sylvant	230
Symbicort Turbuhaler 100/6	252
Symbicort Turbuhaler 200/6	252
Symbicort Turbuhaler 400/12	252
Symmetrel	123
Sympathomimetics	<mark>56</mark>
Synacthen	<mark>86</mark>
Synacthen Depot	<mark>86</mark>
Synacthene Retard	<mark>86</mark>
Synflorix	302
Synthroid	88
Syntometrine	
Syrup (pharmaceutical grade)	
Systane Unit Dose	
-T-	
Tacrolimus	
Dermatological	75
Oncology	247
Tacrolimus Sandoz	<u>2</u> 77
Taliglucerase alfa	<u>2</u> 47 20
Tambocor	
Tamoxifen citrate	
Tamoxifen Sandoz	170
Tamoxileri Sanuoz	170
Tamsulosin hydrochloride	
Tamsulosin-Rex	82
Tandem Cartridge	21
Tandem t:slim X2 with Basal-IQ	16
Tap water	
Taro	
Taro-Testosterone	
Tasigna	169
Tasmar	
Taurine	
Tecentriq	
Tecfidera	
Tegretol	131
Tegretol CR	
Telfast	250
Teligent	100
Temaccord	165
Temazepam	
Temozolomide	165
Tenofovir disoproxil	
Tenofovir Disoproxil Emtricitabine	
Viatr	. 109
Tenofovir Disoproxil Viatris	
Tenoxicam	
Tensipine MR10	
Tepadina	
Terbinafine	104
Terbutaline sulphate	
Teriflunomide	

Teriparatide119
Teriparatide - Teva 119
Testogel
Testosterone86
Testosterone cipionate
Testosterone esters
Testosterone undecanoate
Tetrabenazine
Tetrabromophenol
Tetracosactrin
Tetracycline
Teva Lisinopril
Teva-Ketoconazole
Teva-Salbutamol Sterinebs
P.F253
Thalidomide165
Thalomid165
Theophylline
Theophylline
Thiamine hydrochloride
Thiamine multichem
THIO-TEPA
Thioguanine
Thiotepa155 Thyroid and Antithyroid Agents
Ticagrelor
Ticagrelor Sandoz40
Tilcotil
Timolol
Tiotronium bromide 254
Tiotropium bromide254
Tiotropium bromido with
Tiotropium bromide with olodaterol
Tiotropium bromide with olodaterol254 Tivicay
Tiotropium bromide with olodaterol
Tiotropium bromide with olodaterol 254 Tivicay 113 Tixagevimab with cilgavimab 230 TMP 102 Tobramycin 102 Infection 102 Sensory 260 Tobramycin (Viatris) 102
Tiotropium bromide with olodaterol
Tiotropium bromide with olodaterol
Tiotropium bromide with olodaterol
Tiotropium bromide with olodaterol 254 Tivicay 113 Tixagevimab with cilgavimab 230 TMP 102 Tobramycin 102 Infection 102 Sensory 260 Tobramycin (Viatris) 102 Tobramycin BNM 102 Tobrac 260 Tobramycin BIM 102 Tobrac 260 Tocilizumab 230 Tofranil 129
Tiotropium bromide with olodaterol

Tranexamic acid40
Franylcypromine sulphate129
Frastuzumab (Herceptin)234
Frastuzumab (Herzuma)235
Frastuzumab emtansine
Fravatan262
Fravoprost262
Freatments for Dementia149
Freatments for Substance
Dependence 150
Frelegy Ellipta254
Frental 400 57
Fretinoin
Dermatological 68
Oncology166
Trexate
Triamcinolone acetonide
Alimentary32
Dermatological71
Hormone86
Friamcinolone acetonide with
gramicidin, neomycin and nystatin
Dermatological71
Sensory260
Trientine30
Trientine Waymade30
Trikafta257
Trimethoprim102
Trimethoprim with
sulphamethoxazole
[Co-trimoxazole] 102
Trisequens88
Trisul
Frophic Hormones89
Frophic Hormones
Frophic Hormones
Frophic Hormones
Frophic Hormones 88 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47
Frophic Hormones 88 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307
Frophic Hormones 88 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307
Frophic Hormones 86 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 Fwo Cal HN 283
Frophic Hormones 86 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 Fwo Cal HN 283 FYR Explore 5 286
Frophic Hormones 86 Fropicamide 260 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 Two Cal HN 283 FYR Explore 5 286 FYR Sphere 20 286
Frophic Hormones 86 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 Fwo Cal HN 283 FYR Explore 5 288 FYR Sphere 20 286 Fyrosine1000 286
Frophic Hormones 86 Fropicamide 263 Frulicity 12 TruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 Fyr Saphere 5 286 FYR Sphere 20 286 Fyrosine 1000 286 Fyrosine 1000 286
Frophic Hormones 86 Fropicamide 263 Frulicity 12 TruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 FVR Cal HN 286 FYR Explore 5 286 FVR Sphere 20 286 Fysabri 141 - U - -
Frophic Hormones 86 Fropicamide 263 Frulicity 12 TruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 FWR Cal HN 286 TYR Explore 5 286 Tyrosine 1000 286 Tysabri 141 - U - 365
Frophic Hormones 86 Fropicamide 263 Frulicity 12 TruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fuberculin PPD [Mantoux] test 307 Five Cal HN 283 FYR Explore 5 286 Fyrsine 1000 286 Fysabri 141 JK Synacthen 86 Jltibro Breezhaler 254
Frophic Hormones 89 Fropicamide 263 Frulicity 12 FruSteel 21 Tryzan 47 Fuberculin PPD [Mantoux] test 307 Fuberculin PPD [Mantoux] test 307 Frwo Cal HN 283 FYR Explore 5 286 Fyrosine 1000 286 Fysabri 141 JK Synacthen 86 Jltibro Breezhaler 254
Frophic Hormones 89 Fropicamide 263 Frulicity 12 FruSteel 21 Tryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 FVR Explore 5 286 Fyrsphere 20 286 Fysabri 141 Jtibro Breezhaler 254 Jltiaproct 254
Frophic Hormones 86 Fropicamide 263 Frulicity 12 FruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 FWR Sphere 20 286 Fyrosine 1000 286 Fysabri 141 Jtibro Breezhaler 254 Jtraproct 254 Jmeclidinium 254
Frophic Hormones 86 Fropicamide 263 Frulicity 12 Frulicity 12 Frusteel 21 Frusteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fubersol 307 Fwo Cal HN 263 FYR Sphere 20 286 Fyrosine1000 286 Fysabri 141 - U - JK JK Synacthen 86 Jithoro Breezhaler 254 Jitraproct 26 Jmeclidinium 254 Jnivent 253, 256
Frophic Hormones 86 Fropicamide 260 Frulicity 12 FruSteel 21 FruSteel 21 Fruberculin PPD [Mantoux] test 307 Fubersol 307 Fwo Cal HN 283 FYR Explore 5 286 FYR Sphere 20 286 Fysosine 1000 286 Fysabri 141 - U - 307 JK Synacthen 306 Jitraproct 254 Jmeclidinium 254 Jnivent 253, 255 Jpadacitinib 246
Frophic Hormones 86 Fropicamide 260 Frulicity 12 TruSteel 21 Frusterel 21 Frusterel 21 Frusterel 21 Frusterel 21 Frusterel 307 Fubersol 307 Fwo Cal HN 283 FYR Explore 5 286 FYR Sphere 20 286 Fysabri 141 - U - 307 JK Synacthen 86 Jitraproct 254 Jmeclidinium with vilanterol 254 Jnivent 253, 256 Jpadacitinib 244 Jral 86
Frophic Hormones 86 Fropicamide 263 Frulicity 12 TruSteel 21 Frusteel 21 Frusteel 21 Frusterel 21 Frusterel 307 Fubersol 307 Fubersol 307 Fwo Cal HN 283 FYR Sphere 20 286 Fyrosine 1000 286 Fysabri 141 - U - 307 JK Synacthen 36 Just Synacthen 36 Just Synacthen 254 Jitraproct 254 Jnivent 253, 256 Jpadacitinib 244 Jral 36 Jrea 72
Frophic Hormones 86 Fropicamide 263 Frulicity 12 TruSteel 21 Fryzan 47 Fuberculin PPD [Mantoux] test 307 Fuberculin PPD [Mantoux] test 307 Five Cal HN 283 FYR Explore 5 286 Fyrsine 1000 286 Fysabri 141 JK Synacthen 86 Jltibro Breezhaler 254

Urinary Agents	82
Urinary Tract Infections	115
Urinorm	
Uromitexan	. 162
Ursodeoxycholic acid	
Ursosan	
Ustekinumab	
litrogestan	207
Utrogestan	
Vaccinations	
Vaclovir	
Valaciclovir	
Valganciclovir	
Valganciclovir Viatris	107
Valine50	107 000
Vancomycin	100
Vancomycin	102
Vannair	202
Varenicline Pfizer	151
Varenicline tartrate	151
Varicella vaccine [Chickenpox	
vaccine]	. 306
Varicella zoster vaccine [Shingles	
vaccine]	. 306
Various	
Varivax	
Vasodilators	
Vasopressin Agonists	93
Vasorex	51
Vebulis	65
Vedafil	
Vedolizumab	239
Veletri	63
Venclexta	
Venetoclax	
Venlafaxine	
Venomil249	-250
VENOX	249
Ventolin252	-253
Ventolin Nebules	253
Vepesid	160
Verapamil hydrochloride	100
Vermox	
Versacloz	
Vesanoid	
Vexazone	
Vfend	۲۵ ۱۵۸
Viederm KC	. 104
Viaderm KC	
Victoza	
Vigabatrin	
Vigisom	
Vildagliptin	12
Vildagliptin with metformin	
hydrochloride	
Vimpat	
Vinblastine sulphate	
Vincristine sulphate	167

Vinorelbine167
Vinorelbine Ebewe167
Vinorelbine Te Arai167
Viramune Suspension112
ViruPOS260
Vit.D333
Vita-B1232
VitA-POS
Vitabdeck33
Vital
Vitamin B complex32
Vitamin B6 25 32
Vitamins
Vitarubin Depot Injection32
Vivonex TEN
Voltaren 116
Voltaren D116
Voltaren Ophtha261
Voltaren SR 116
Volumatic259
Voriconazole104
Votrient170
Vttack104
- W -
Warfarin sodium
Wart Preparations76
Wasp venom allergy treatment250
Water
Blood44
Extemporaneous 270
Extemporaneous
Blood
Extemporaneous270 White Soft Liquid Paraffin AFT72 Wool fat with mineral oil72 - X -
Extemporaneous
Extemporaneous270 White Soft Liquid Paraffin AFT72 Wool fat with mineral oil72 - X -
Extemporaneous
Extemporaneous
Extemporaneous
Extemporaneous 270 White Soft Liquid Paraffin AFT 72 Wool fat with mineral oil 72 - X - Xarelto Xarelto 42 Xifaxan 10 XMET Maxamum 285 Xolair 213 XP Maxamum 286 Xylocaine 124
Extemporaneous 270 White Soft Liquid Paraffin AFT 72 Wool fat with mineral oil 72 - X - Xarelto Xarelto 42 Xifaxan 10 XMET Maxamum 285 Xolair 213 XP Maxamum 124 Xylocaine 124
Extemporaneous
Extemporaneous 270 White Soft Liquid Paraffin AFT 72 Wool fat with mineral oil 72 - X - Xarelto Xarelto 42 Xifaxan 10 XMET Maxamum 285 Xolair 213 XP Maxamum 124 Xylocaine 124
Extemporaneous
Extemporaneous 270 White Soft Liquid Paraffin AFT 72 Wool fat with mineral oil 72 - X - Xarelto Xarelto 42 Xifaxan 10 XMET Maxamum 285 Xolair 213 XP Maxamum 286 Xylocaine 124 Xylocaine 2% Jelly 124 Xylocaine 500 124 Xyntha 39
Extemporaneous

Zimybe	56
Zinc and castor oil	71
Zinc sulphate	35
Zincaps	35
Ziprasidone1	37
Zista2	50
Zithromax	96
Zoladex	93
Zoledronic acid	
Hormone	
Musculoskeletal1	20
Zoledronic acid Viatris	
Hormone	85
Musculoskeletal1	20
Zopiclone 1	
Zopiclone Actavis1	44
Zostrix1	
Zostrix HP1	25
Zuclopenthixol decanoate1	39
Zuclopenthixol hydrochloride1	37
Zusdone1	37
Zyban1	50
Zypine1	
Zypine ODT 1	37
Zyprexa Relprevv1	38
Zytiga1	73
Zyvox1	06













